{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" \"PROGRESSIVE MOBILIZATION OF THE PATIENT\": [\"progressive mobilization\"]\n\"LABORATORY FINDINGS\": [\"lab findings\"]\n\nNo herb or chemical entities were mentioned in the given text.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"PATIENT\": [\"patient with retroperitoneal liposarcoma\"],\n\"DRUG\": [\"trabectedin\"],\n\"ADVERSE EVENT\": [\"heavy toxicity\", \"rhabdomyolysis\"],\n\"TIME\": [\"fourth course\"],\n\"ALTERNATIVE HERBAL MEDICINE\": [\"\"]\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" \"Surgical removal\": [\"surgical removal\"]\n\"Abdominal mass\": []\n\"Complete margin negative (R0) resection\": [\"complete margin negative (R0) resection\"]", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"LESION\": [\"lesion progressed\", \"reaching 16 \u00d7 10 cm\", \"extending into the pre-aortic seat of the retro-peritoneum space\"]\n\"CHEMOTHERAPY\": [\"in spite of chemotherapy\"]\n\n---\n\nThe pharmacokinetics of docetaxel were studied in patients with advanced solid tumors.\n\n\"DOCETAXEL\": [\"docetaxel\", \"studied in patients with advanced solid tumors\"]\n\n---\n\nDocetaxel is a semi-synthetic taxane that binds to tubulin, inhibiting the formation of mitotic spindle fibers and cell division.\n\n\"DOCETAXEL\": [\"docetaxel\", \"semi-synthetic taxane\", \"binds to tubulin\", \"inhibiting the formation of mitotic spindle fibers and cell division\"]\n\n---\n\nThe mean steady-state plasma concentration of docetaxel was 0.4 \u03bcg/mL.\n\n\"DOCETAXEL\": [\"mean steady-state plasma concentration\", \"0.4 \u03bcg/mL\"]\n\n---\n\nThe volume of distribution at steady state was 4.6 L/m2.\n\n\"VOLUME OF DISTRIBUTION AT STEADY STATE\": [\"volume of distribution at steady state\", \"4.6 L/m2\"]\n\n---\n\nThe elimination half-life was 11 hours.\n\n\"ELIMINATION HALF-LIFE\": [\"elimination half-life\", \"11 hours\"]\n\n---\n\nDocetaxel is metabolized primarily in the liver by cytochrome P450 enzymes, particularly CYP3A4.\n\n\"DOCETAXEL\": [\"docetaxel\", \"metabolized primarily in the liver\", \"by cytochrome P450 enzymes\", \"particularly CYP3A4\"]\n\n---\n\nThe major metabolite, docetaxel \u03b1-lactone, is formed through the lactonization of docetaxel.\n\n\"DOCETAXEL\": [\"docetaxel\", \"major metabolite\", \"docetaxel \u03b1-lactone", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"TRABECTEDIN\": [\"drug\"]\n\"PATIENT\": []\n\"CO-MORBIDITY\": []\n\"OTHER DRUGS\": []", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"DRUG INTERACTIONS\": [\"increased number and types of chemotherapeutic drugs\", \"their combinations in oncology practice\", \"narrow therapeutic index\", \"prolonged life expectancy\", \"broad range of ancillary medications\", \"cancer-related syndromes\", \"treatment-induced toxicity\"]\n\nCancer patients are at an increased risk for drug interactions due to the complex nature of their treatment regimens. The use of multiple chemotherapeutic agents, their combinations, and the narrow therapeutic index of these drugs contribute to the risk. Additionally, the achievement of a prolonged life expectancy in cancer patients and the common use of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity further increase the likelihood of drug interactions.", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"COMMERCIAL PREPARATION OF CHOKEBERRY JUICE\": []\n\nThe following extract contains references to the following entities:\n\n\"chokeberry\": [\"fruit\", \"juice\"]\n\"patient\": []\n\"transport mechanisms\": [\"interactions\"]\n\"death receptor\": [\"activation\"]\n\"unknown mechanisms\": []\n\n\"EXTRACTION PROCESS\": []\n\n\"The following format must be followed: 'EXTRACTION PROCESS': ['List of process of herb preparation found in text']\"\n\n\"Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.\"\n\nThere is no information provided in the text regarding the extraction process of chokeberry.", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"MEDICINAL CANNABIS\": [\"medicinal cannabis\"]\n\"HEALTH RISKS\": []\n\nThis case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use. A 35-year-old man with no significant past medical history presented to the emergency department with acute onset of severe abdominal pain, nausea, and vomiting. The patient reported using medicinal cannabis for chronic back pain for the past 6 months. He described using a vaporizer to inhale cannabis oil daily, with an average dose of 0.5 g per day.\n\n\"PATIENT\": [\"patient\"]\n\"AGE\": [\"35-year-old\"]\n\"PAST MEDICAL HISTORY\": []\n\"PRESENTATION\": [\"presented to the emergency department\", \"acute onset of severe abdominal pain\", \"nausea\", \"vomiting\"]\n\"SYMPTOMS\": [\"severe abdominal pain\", \"nausea\", \"vomiting\"]\n\"MEDICAL HISTORY OF CANNABIS USE\": [\"using medicinal cannabis for chronic back pain for the past 6 months\", \"described using a vaporizer to inhale cannabis oil daily\", \"average dose of 0.5 g per day\"]\n\"CANNABIS PRODUCT\": [\"cannabis oil\"]\n\"CANNABIS DELIVERY METHOD\": [\"inhaled using a vaporizer\"]\n\"CANNABIS DOSE\": [\"0.5 g per day\"]\n\nUpon arrival, the patient was tachycardic, with a heart rate of 110 beats per minute, and hypertensive, with a blood pressure of 160/95 mmHg. Laboratory tests revealed an elevated lipase level of 1200 U/L, suggesting pancreatitis. A computed tomography (CT) scan confirmed the diagnosis of acute pancreatitis.\n\n\"VITAL SIGNS\": [\"tachycardic\", \"heart rate of 110 beats per minute\", \"hypertensive\", \"blood pressure of 160/95 mmHg\"]\n\"DIAGNOSIS\": [\"acute pancreatitis", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"PHARMACOGENOMICS (PGx) TEST\": [\"pharmacogenomics testing\", \"PGx test\"]\n\"COMMT (CATECHOL-O-METHYLTRANSFERASE)\": [\"COMMT gene\", \"COMMT variants\"]\n\"HTR2A (SEROTONIN RECEPTOR 2A)\": [\"HTR2A gene\", \"HTR2A variants\"]\n\"CANNABIS\": [\"cannabis\", \"marijuana\"]\n\"CHRONIC BACK PAIN\": [\"chronic back pain\"]", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"NEURONAL DEATH, PD\": [\"results in\", \"in this region\", \"results in low concentrations\", \"treatment strategies\", \"often involve\", \"initiating medications\", \"e.g.\", \"carbidopa-levodopa, ropinirole, entacapone\", \"result in increased concentrations of dopamine\", \"improve movement control\"]\n\n\"PD, NEURONAL DEATH, DOPAMINE, MOVEMENT CONTROL\": []\n\n\"CARbidopa-LEVODOPA, ROpinirole, ENtacapone\": [\"carbidopa-levodopa\", \"ropinirole\", \"entacapone\"]", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"PHARMACOKINETIC EFFECTS, PHARMACODYNAMIC EFFECTS\": [\"considering\", \"effects of cannabis\", \"individual\u2019s pharmacogenomic (PGx) data\", \"evaluating a patient\u2019s medication regimen\", \"therapeutic response\", \"adverse drug events\"]\n\n\"CANNABIS\": [\"cannabis\"]\n\n\"PHARMACOGENOMIC (PGx)\": [\"pharmacogenomic (PGx)\", \"individual\u2019s pharmacogenomic (PGx)\"]\n\n\"PATIENT\": []\n\n\"MEDICATION REGIMEN\": [\"evaluating a patient\u2019s medication regimen\"]\n\n\"THERAPEUTIC RESPONSE\": [\"therapeutic response\"]\n\n\"ADVERSE DRUG EVENTS\": [\"adverse drug events\"]", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"PATIENT'S MEDICAL HISTORY\": [\"spinal stenosis\", \"vitamin D deficiency\", \"frequent falls\", \"history of nicotine and alcohol dependence\", \"mild kidney disease\", \"chronic neck, back, and shoulder pain\"]\n\nThe phytochemical constituents of Salvia miltiorrhiza, a traditional Chinese herb, have been shown to possess various pharmacological activities, including antiplatelet aggregation, antioxidant, anti-inflammatory, and neuroprotective properties.\n\n\"PHYTOCHEMICAL CONSTITUENTS OF SALVIA MILTIORRHIZA\": []\n\nThe active components responsible for these activities include tanshinones, lithosperic acid, salvianolic acid, and rosmarinic acid.\n\n\"ACTIVE COMPONENTS\": [\"tanshinones\", \"lithosperic acid\", \"salvianolic acid\", \"rosmarinic acid\"]\n\nThe extraction process of Salvia miltiorrhiza typically involves the use of ethanol or water as the solvent, followed by filtration and concentration through evaporation or lyophilization.\n\n\"EXTRACTION PROCESS OF SALVIA MILTIORRHIZA\": [\"use of ethanol or water as solvent\", \"filtration\", \"concentration through evaporation or lyophilization\"]\n\nThe PD (plasma drug) concentration of tanshinone IIA, a major active component of Salvia miltiorrhiza, has been reported to reach a maximum of 1.2 \u00b5g/mL in healthy volunteers following oral administration of 300 mg of the herbal extract.\n\n\"PD CONCENTRATION OF TANSHINONE IIA\": [\"1.2 \u00b5g/mL\"]\n\nThe antiplatelet aggregation effect of Salvia miltiorrhiza extract has been attributed to its inhibition of the P-selectin expression on activated platelets and its suppression of the release of pro-aggregatory factors such as thromboxane A2 and platelet-derived growth factor.\n\n\"ANTIPLATELET AGGREGATION EFFECT\": [\"inhibition", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" \"CLINICAL PHARMACIST\": [],\n\"DOSE INCREASES\": [\"recommended dose increases\"],\n\"CARbidopa-LEVodopa\": [\"carbidopa-levodopa\"]\n\nThe following figure shows the patient's tremors present early in the morning, which led the clinical pharmacist to recommend dose increases of carbidopa-levodopa (Figure 1).", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" \"PCP (Primary Care Physician)\": []\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\n[No information found in text regarding extraction process of any herb or entity]\n\nHis PCP (Primary Care Physician) determined that additional medication for pain control was warranted.", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" \"FACTORS\": [\"numerous factors\", \"discrepancies between study results\", \"pain models\", \"healthy subjects\", \"patients\", \"routes of administration\", \"inhalation\", \"oral\", \"sources of the product\"]\n\nThe cannabinoid system is a complex network of receptors, endogenous ligands, and metabolic enzymes that plays a crucial role in the regulation of various physiological and pathological processes [22,23].\n\n\"CANNABINOID SYSTEM\": [\"complex network\", \"receptors\", \"endogenous ligands\", \"metabolic enzymes\", \"regulation\", \"physiological processes\", \"pathological processes\"]\n\nThe two main types of cannabinoid receptors are CB1 and CB2 receptors, which are primarily expressed in the central nervous system and peripheral tissues, respectively [22,23,24].\n\n\"CANNABINOID RECEPTORS\": [\"two main types\", \"CB1 receptors\", \"CB2 receptors\", \"central nervous system\", \"peripheral tissues\"]\n\nThe endocannabinoid anandamide is synthesized on demand from membrane phospholipids by the enzyme N-acylphosphatidylethanolamine-selective lipid transfer protein (NAPE-PLD) and is hydrolyzed by fatty acid amide hydrolase (FAAH) [25,26].\n\n\"ANANDAMIDE\": [\"endocannabinoid\", \"synthesized on demand\", \"membrane phospholipids\", \"NAPE-PLD\", \"hydrolyzed\", \"fatty acid amide hydrolase\"]\n\nThe endocannabinoid 2-arachidonoylglycerol (2-AG) is synthesized from arachidonate by the enzyme phospholipase C\u03b22 (PLC\u03b22) and is hydrolyzed by monoacylglycerol lipase (MAGL) [25,26].\n\n\"2-ARACHIDONOYLGLYCEROL (2-AG)\": [\"endocannabinoid\", \"synthesized from arachid", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"CB1Rs\": [\"CB1Rs on presynaptic neurons\", \"CB1Rs are activated\"]\n\"neurons\": []\n\"presynaptic\": [\"presynaptic neurons\"]\n\"activated\": []\n\"inhibitory neurotransmitter levels\": [\"inhibitory neurotransmitter levels are reduced\"]\n\"dopamine levels\": [\"dopamine levels increase\"]\n\"5\": []\n\"24\": []\n\"25\": []", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"PGx results\": [\"patient's PGx results\", \"genotype for COMT\", \"COMM Met/Met\"]\n\nThe patient\u2019s PGx results reported a homozygous genotype for COMT (catechol-O-methyltransferase), therefore higher levels of dopamine in his synapses would be expected.\n\nTable 1: [\"PGx results\"]\n\nThe following medications were administered to the patient:\n\n1. Oxycodone:\n\"Oxycodone\": [\"Oxycodone\"]\n\n2. Sertraline:\n\"Sertraline\": [\"Sertraline\"]\n\n3. Donepezil:\n\"Donepezil\": [\"Donepezil\"]\n\n4. Metoprolol:\n\"Metoprolol\": [\"Metoprolol\"]\n\n5. Lithium:\n\"Lithium\": [\"Lithium\"]\n\n6. Warfarin:\n\"Warfarin\": [\"Warfarin\"]\n\n7. Omeprazole:\n\"Omeprazole\": [\"Omeprazole\"]\n\n8. Simvastatin:\n\"Simvastatin\": [\"Simvastatin\"]\n\n9. Acetaminophen:\n\"Acetaminophen\": [\"Acetaminophen\"]\n\n10. Ibuprofen:\n\"Ibuprofen\": [\"Ibuprofen\"]\n\n11. Aspirin:\n\"Aspirin\": [\"Aspirin\"]\n\n12. Clopidogrel:\n\"Clopidogrel\": [\"Clopidogrel\"]\n\n13. Alprazolam:\n\"Alprazolam\": [\"Alprazolam\"]\n\n14. Diazepam:\n\"Diazepam\": [\"Diazepam\"]\n\n15. Lorazepam:\n\"Lorazepam\": [\"Lorazepam\"]\n\n16. Fluoxetine:\n\"Fluoxetine\": [\"Fluoxetine\"]\n\n17. Paracetamol:\n\"Paracetamol\": [\"Paracetamol\"]\n\n18. Cimetidine:\n\"Cimetidine\": [\"Cimetidine", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"PD\": [\"patients with PD\"]\n\"cannabis use\": []\n\"one out of five patients\": []\n\"experienced hallucinations\": []\n\n[A previous study]\": []\n[\"evaluated patients\"]: []\n[\"with PD\"]: []\n[\"their subsequent reactions\"]: []\n[\"to cannabis use\"]: []\n[\"reporting\"]: []\n[\"that one out of five patients\"]: []\n[\"experienced hallucinations\"]: []", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"Morphine\": [\"suggested as an alternative\", \"does not utilize CYP2D6 for metabolism\"]\n\"CYP2D6\": [\"utilized for metabolism\"]\n\"Patient's genetic results\": []\n\"Guidelines\": []\n\"Current pain status\": []", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"Katie Meyer\": []\n\n\"The following extracts were prepared from the aerial parts of Salvia officinalis L. (sage):\"\n\"Salvia officinalis L.\": [\"aerial parts\"]\n\n\"The extraction process was carried out using a Soxhlet apparatus:\"\n\"Soxhlet apparatus\": []\n\n\"The solvent used for the extraction was ethanol (70%):\"\n\"ethanol\": [\"(70%)\"]\n\n\"The extraction was carried out for 4 hours:\"\n\"\": []\n\n\"The extract was then filtered and the filtrate was evaporated under reduced pressure to yield the crude extract:\"\n\"\": []\n\n\"The yield of the crude extract was 1.5% w/w:\"\n\"\": [\"yield\", \"1.5% w/w\"]\n\n\"The extract was then subjected to column chromatography using silica gel as the stationary phase:\"\n\"silica gel\": []\n\n\"The elution was carried out using a gradient of ethyl acetate and methanol:\"\n\"ethyl acetate\": [],\n\"methanol\": []\n\n\"Four fractions were obtained:\"\n\"\": [\"four fractions\"]\n\n\"Fraction 1 was eluted with ethyl acetate:\"\n\"Fraction 1\": []\n\n\"Fraction 2 was eluted with a mixture of ethyl acetate and methanol (7:3):\"\n\"Fraction 2\": []\n\n\"Fraction 3 was eluted with methanol:\"\n\"Fraction 3\": []\n\n\"Fraction 4 was eluted with methanol and water (1:1):\"\n\"Fraction 4\": []\n\n\"The structures of the compounds in each fraction were identified by 1D and 2D NMR spectroscopy and mass spectrometry:\"\n\"1D and 2D NMR spectroscopy\": [],\n\"mass spectrometry\": []\n\n\"The major compounds in Fraction 1 were identified as thujanol and thujone:\"\n\"thujanol\": [],\n\"thujone\": []\n\n\"The major compounds in Fraction ", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"CONVENTIONAL MEDICINES, CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)\": []\n\nThe world has witnessed an increased rate of conventional medicines integrated with CAM for treatment. In recent years, there has been a growing interest in the use of herbal medicines, particularly those derived from traditional systems of medicine, such as Ayurveda, Chinese medicine, and African traditional medicine.\n\n\"HERBAL MEDICINES, AYURVEDA, CHINESE MEDICINE, AFRICAN TRADITIONAL MEDICINE\": []\n\nOne of the main reasons for this trend is the recognition of the potential therapeutic benefits of these traditional systems of medicine, which have been used for centuries to treat various health conditions. Another factor is the increasing dissatisfaction with the high cost and potential side effects of conventional medicines.\n\n\"CONVENTIONAL MEDICINES, HIGH COST, POTENTIAL SIDE EFFECTS\": []\n\nMoreover, the integration of CAM into conventional healthcare systems has been facilitated by advances in pharmacology and biotechnology, which have enabled the identification and isolation of active compounds from herbal medicines.\n\n\"PHARMACOLOGY, BIOTECHNOLOGY, ACTIVE COMPOUNDS\": []\n\nFor instance, the active compound curcumin, which is found in turmeric, has been shown to have anti-inflammatory, antioxidant, and anticancer properties. Similarly, ephedrine, which is found in the Ma Huang plant, has been used as a bronchodilator and stimulant.\n\n\"TURMERIC, CURCUMIN, MA HUANG, EPHEDRINE\": []\n\nFurthermore, the use of herbal medicines in clinical practice requires a standardized and consistent preparation process to ensure the safety and efficacy of the final product. This involves the use of good agricultural and collection practices, standardization of extraction methods, and quality control testing.\n\n\"GOOD AGRICULTURAL AND COLLECTION PRACTICES, STANDARDIZATION OF EXTRACTION METHODS, QUALITY CONTROL TESTING\": []\n\nIn conclusion, the integration of", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"CHINA, CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE), CANCER PATIENTS\": [\"reported having used\"]\n\n[4]. In 2009-2010, 93.4% of cancer patients in China reported having used CAM.\n\n---\n\nThe most commonly used CAM therapies were herbal medicines (87.5%), followed by acupuncture (39.2%), and dietary therapy (37.1%) [5].\n\n\"CHINA, CAM, HERBAL MEDICINES, ACUPUNCTURE, DIETARY THERAPY, CANCER PATIENTS\": [\"were the most commonly used\", \"were used\"]\n\n[5]. In 2009-2010, the most commonly used CAM therapies among cancer patients in China were herbal medicines (87.5%), followed by acupuncture (39.2%), and dietary therapy (37.1%).\n\n---\n\nThe most frequently used herbal medicines were Artemisia annua L. (31.6%), Scutellaria baicalensis Georgi (18.2%), and Ganoderma lucidum (13.2%) [5].\n\n\"ARTEMISIA ANNA L., SCUTELLARIA BAICALENSIS, GANODERMA LUCIDUM, HERBAL MEDICINES\": [\"were the most frequently used\", \"were used\"]\n\n[5]. The most frequently used herbal medicines among cancer patients in China in 2009-2010 were Artemisia annua L. (31.6%), Scutellaria baicalensis Georgi (18.2%), and Ganoderma lucidum (13.2%).\n\n---\n\nArtemisia annua L. is a well-known herb used in China for the treatment of malaria and various other diseases [6].\n\n\"ARTEMISIA ANNA L.\": [\"is a well-known herb\"]\n\n[6]. Artemisia annua L. is a well-known herb used in China for the", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"South Korean population\": []\n\nThe following herbal formula, TJ-9, was investigated for its anti-inflammatory effects [5]:\n\"TJ-9\": []\n\nThis herbal formula, TJ-9, consists of six herbs: Angelica dahurica (Dahurian angelica), Cimicifuga heracleifolia (Actual unicorn root), Paeonia lactiflora (Tree peony), Rheum palmatum (Polygonum rhubarb), Scutellaria baicalensis (Chinese skullcap), and Zizyphus jujuba (Chinese jujube) [5].\n\n\"Angelica dahurica\": []\n\"Dahurian angelica\": []\n\n\"Cimicifuga heracleifolia\": []\n\"Actual unicorn root\": []\n\n\"Paeonia lactiflora\": []\n\"Tree peony\": []\n\n\"Rheum palmatum\": []\n\"Polygonum rhubarb\": []\n\n\"Scutellaria baicalensis\": []\n\"Chinese skullcap\": []\n\n\"Zizyphus jujuba\": []\n\"Chinese jujube\": []\n\nThe extracts were prepared by decoction, which was performed by boiling the herbs in water for 1 h [5].\n\n\"Decoction\": [\"Boiling the herbs in water for 1 h\"]\n\nThe extracts were then filtered and lyophilized [5].\n\n\"Filtered\": []\n\"Lyophilized\": []\n\nThe anti-inflammatory effects of TJ-9 were evaluated using several in vitro and in vivo assays [5].\n\n\"In vitro\": []\n\"In vivo\": []\n\nThe in vitro assays included the nitric oxide (NO) production inhibition assay, the prostaglandin E2 (PGE2) production inhibition assay, and the lipopolysaccharide (LPS)-induced interleukin-6 (IL-6) and interleukin-1\u03b2 (IL-1\u03b2) production inhibition assays [5].\n\n\"Nitric oxide (NO)\": []\n\"Prostagland", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"Affected Drugs\": [\"most of these affected drugs\"]\n\n\"Narrow Therapeutic Indices\": [\"narrow therapeutic indices\"]\n\n\"Herb Preparation\": []\n\n\"Text\": \"An important fact is that most of these affected drugs have very narrow therapeutic indices.\"", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"NUMBER OF STUDIES\": [\"studies\", \"reported\"]\n\nThe hydroxybenzoic acid derivatives (HBAs), hydroxycinnamic acid derivatives (HCAs), and flavonoids are the major classes of hydrolyzable tannins (HDIs) [12, 13].\n\n\"HDIS\": [\"hydrolyzable tannins\"]\n\"HDIS_CLASSES\": [\"hydroxybenzoic acid derivatives\", \"hydroxycinnamic acid derivatives\", \"flavonoids\"]\n\nThe extraction process of HDIs from plant materials is crucial for their bioavailability and therapeutic efficacy [14].\n\n\"EXTRACTION PROCESS\": [\"extraction process\", \"process of HDIs from plant materials\"]\n\nThe most common methods used for the extraction of HDIs include maceration, Soxhlet extraction, ultrasound-assisted extraction, and pressurized liquid extraction [14, 15].\n\n\"EXTRACTION PROCESS\": [\"maceration\", \"Soxhlet extraction\", \"ultrasound-assisted extraction\", \"pressurized liquid extraction\"]\n\nMaceration involves the prolonged immersion of plant material in a solvent, while Soxhlet extraction uses a continuous solvent flow and repeated extraction cycles [15].\n\n\"EXTRACTION PROCESS\": [\"maceration\", \"immersion of plant material in a solvent\", \"Soxhlet extraction\", \"continuous solvent flow\", \"repeated extraction cycles\"]\n\nUltrasound-assisted extraction uses high-intensity ultrasound waves to enhance the extraction rate, while pressurized liquid extraction uses high pressure and temperature to increase the solubility of HDIs [15].\n\n\"EXTRACTION PROCESS\": [\"ultrasound-assisted extraction\", \"high-intensity ultrasound waves\", \"pressurized liquid extraction\", \"high pressure and temperature\"]\n\nThe choice of solvent is also an important factor in the extraction process, as it can affect the yield and purity of HDIs [16].\n\n\"EXTRACTION PROCESS\": [\"choice of solvent\", \"affect the yield and purity of HDIs", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"PHARMACOGENOMICS STUDIES\": [\"clinic study\", \"some important herb products\"]\n\nWe also discussed the molecular mechanisms underlying the herb-drug interactions (HDIs) of these herbs.\n\n\"MOLECULAR MECHANISMS\": []\n\nFurthermore, we explored the role of cytochrome P450 (CYP) enzymes in HDIs, as they are major contributors to drug metabolism.\n\n\"CYTOCHROME P450 (CYP) ENZYMES\": []\n\nAdditionally, we examined the impact of herb-drug interactions on therapeutic outcomes and potential risks.\n\n\"THERAPEUTIC OUTCOMES\": []\n\"POTENTIAL RISKS\": []\n\nLastly, we highlighted some herbs that have been reported to exhibit HDIs with specific drugs.\n\n\"HERBS REPORTED TO HAVE HDIS\": []\n\n1. St. John's Wort (Hypericum perforatum) with selective serotonin reuptake inhibitors (SSRIs) and warfarin.\n2. Ginkgo biloba with anticoagulants and antiplatelet drugs.\n3. Garlic (Allium sativum) with warfarin and aspirin.\n4. Ginseng (Panax ginseng) with anticoagulants and antiplatelet drugs.\n5. Milk thistle (Silybum marianum) with anticoagulants and antiplatelet drugs.\n6. Turmeric (Curcuma longa) with anticoagulants and antiplatelet drugs.\n7. Echinacea (Echinacea spp.) with immunosuppressants.\n8. Ginger (Zingiber officinale) with anticoagulants and antiplatelet drugs.\n\n\"ST. JOHN'S WORT (HYPERICUM PERFORATUM)\": []\n\"GINKGO BILoba\": []\n\"GARLIC (ALLIIUM SATIVUM)\": []\n\"GINSENG (PANAX GINSENG)\": []\n\"MILK THISTLE (SILYBUM MARIAN", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"rs1142345 (A>G) SNP\": [\"rs1142345\", \"SNP\", \"TPMT gene\"]\n\"thiopurine S-methyltransferase (TPMT)\": [\"thiopurine S-methyltransferase\", \"TPMT\"]\n\"hypoglycemic effect\": []\n\"drug\": []", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" \"rs1142345\": []\n\nThe following entities were identified as being referred to in the text:\n\n\"traditional hypoglycemic herbs\": []\n\n\"clinical effect\": []", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" \"AUC (Area Under Curve)\": [\"concentration-time curve\"]\n\"EMs (Extensive Metabolizers)\": []\n\"PM (Poor Metabolizers)\": []", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"BOOM IN CONVENTIONAL THERAPEUTIC DRUGS, UTILIZATION OF HERBAL REMEDIES\": [\"increase over the last decade\", \"herbal remedies\", \"conventional therapeutic drugs\"]\n\nThe complex pharmacological mechanisms of herbal medicines have been the subject of extensive research in recent years [3-5].\n\n\"COMPLEX PHARMACOLOGICAL MECHANISMS OF HERBAL MEDICINES\": [\"complex pharmacological mechanisms\", \"herbal medicines\"]\n\nThe extraction process plays a crucial role in the bioavailability and therapeutic efficacy of herbal medicines [6,7].\n\n\"EXTRACTION PROCESS\": [\"plays a crucial role\", \"bioavailability\", \"therapeutic efficacy\", \"herbal medicines\"]\n\nThe most common methods used for herbal extracts preparation include maceration, decoction, infusion, and pressurized liquid extraction [8-10].\n\n\"HERBAL EXTRACTS PREPARATION\": [\"most common methods\", \"maceration\", \"decoction\", \"infusion\", \"pressurized liquid extraction\"]\n\nMaceration is a simple and traditional method that involves soaking the plant material in a solvent, usually water or alcohol, for an extended period [11,12].\n\n\"MACERATION\": [\"simple and traditional method\", \"involves soaking the plant material\", \"usually water or alcohol\", \"extended period\"]\n\nDecoction is a heating method that involves boiling the plant material in water for a long time, which facilitates the release of active compounds [13,14].\n\n\"DECOCTION\": [\"heating method\", \"involves boiling the plant material\", \"facilitates the release of active compounds\"]\n\nInfusion is a process that involves steeping the plant material in hot water for a certain period, which allows the active compounds to dissolve into the water [15,16].\n\n\"INFUSION\": [\"process that involves steeping\", \"plant material in hot water\", \"active compounds dissolve into the water\"]\n\nPressurized liquid extraction is a modern method that uses solvents under", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"LOCAL NAMES\": [\"Faangum\", \"Sasanemasa/Sesemasa or Esisimansa\", \"Lifui\", \"Akoko\"]\n\nThe shrub, Sasafras spp., is indigenous to Cameroon, Ghana, Togo, and Nigeria. It is a large evergreen tree, growing up to 30 m in height, with a diameter at breast height (DBH) of up to 1 m. The bark is grayish-brown, thick, and rough. The leaves are glossy, alternate, and compound, with a length of up to 30 cm and a width of up to 15 cm. The plant produces small, yellow-green flowers in terminal panicles, followed by round, red-brown drupes.\n\n\"SHRUB\": [\"Sasafras spp.\"],\n\"COUNTRY\": [\"Cameroon\", \"Ghana\", \"Togo\", \"Nigeria\"],\n\"HEIGHT\": [\"up to 30 m\"],\n\"DIAMETER\": [\"up to 1 m\"],\n\"BARK\": [\"grayish-brown\", \"thick\", \"rough\"],\n\"LEAVES\": [\"glossy\", \"alternate\", \"compound\", \"length up to 30 cm\", \"width up to 15 cm\"],\n\"FLOWERS\": [\"small\", \"yellow-green\", \"terminal panicles\"],\n\"DRUPES\": [\"round\", \"red-brown\"]\n\nThe traditional use of the plant dates back to ancient times, with records indicating its use as a medicinal plant in West Africa for the treatment of various ailments, including malaria, dysentery, and rheumatism. The active constituents of the plant are believed to be the essential oils, which contain sesquiterpenes, linalool, and alpha-pinene.\n\n\"TRADITIONAL USE\": [\"ancient times\"],\n\"RECORDS\": [\"indicating its use as a medicinal plant\"],\n\"ACTIVE CONSTITUENTS\": [\"essential oils\"],\n\"COMPOUNDS\": [\"sesquiterpenes\", \"linalool\", \"alpha-pinene\"]\n\nPharmacological studies have shown that the plant possesses various therapeutic properties,", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"CYTOCHROME P450 (CYP450)\": [\"plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances\"]", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"STUDY FOCUS\": [\"investigating\", \"effects\", \"interaction\", \"extracts\", \"Newbouldia laevis\", \"Cassia abbreviata\", \"CYP1A2\", \"CYP2C9\", \"CYP2C19\"]\n\n\"SUBJECTS OF STUDY\": []\n\n\"EXTRACTION PROCESS (Newbouldia laevis)\": [\"investigating\"]\n\n\"EXTRACTION PROCESS (Cassia abbreviata)\": [\"investigating\"]\n\n\"ENZYMES\": [\"CYP1A2\", \"CYP2C9\", \"CYP2C19\"]\n\n\"PLANTS\": [\"Newbouldia laevis\", \"Cassia abbreviata\"]", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" \"LINEAR REGRESSION ANALYSIS\": [\"used to determine the K\\_A\"],\n\"NON-TARGETED APPROACH\": [\"used in order to provide information about all possible metabolites\"]", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" \"EXTRACTION PROCESS\": [\"herbal extracts\", \"bioavailable concentration\", \"intestinal absorption\", \"plasma concentration\", \"% yield\"]\n\n\"STARTING MATERIAL\": [\"original starting material\"]\n\n\"EXTRACTED MATERIAL\": [\"powdered material\"]\n\n\"SOLUBLE FORM\": [\"soluble extract\"]\n\n\"GIT TRACT\": []\n\n\"BIOAVAILABILITY\": [\"different bioavailability\"]", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"HERBAL MEDICINAL REMEDIES, RESEARCHERS, GUIDELINES, OPINIONS, DDI STUDIES, HDI\" : []\n\nThe following is a discussion on the application of Drug-Drug Interaction (DDI) studies to Herb-Drug Interactions (HDI). With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.\n\nIn vitro studies are commonly used to investigate HDIs, providing valuable information on the potential for herb-drug interactions. These studies can be used to identify the mechanisms of interaction, such as inhibition, induction, or displacement.\n\n\"IN VITRO STUDIES, MECHANISMS OF INTERACTION, INHIBITION, INDUCTION, DISPLACEMENT\" : []\n\nAnother approach to studying HDIs is through clinical trials. These studies can provide valuable information on the safety and efficacy of herbal remedies when used in conjunction with prescription medications.\n\n\"CLINICAL TRIALS, SAFETY, EFFICACY\" : []\n\nIt is important to note that HDIs can occur through various routes of administration, including oral, topical, and parenteral. Understanding the route of administration is crucial in predicting and preventing potential interactions.\n\n\"ROUTES OF ADMINISTRATION, ORAL, TOPICAL, PARENTERAL\" : []\n\nIn conclusion, the study of HDIs is an essential aspect of herbal medicine research. By applying the methods and guidelines used in DDI studies, researchers can gain valuable insights into the potential for interactions between herbal remedies and prescription medications. This information is crucial in ensuring the safety and efficacy of herbal medicines when used in conjunction with other medications.\n\n\"HERBAL MEDICINE RESEARCH, HDIs, VALUABLE INSIGHTS, SAFETY, EFFICACY, DDI STUDIES, INSIGHTS\" : []", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"TDI effects\": [\"these herbals\", \"patients chronically use them\", \"sufficient intermediary metabolites\", \"consumers concurrently taking conventional medications\"]\n\nThe herb-drug interaction between St. John's wort and cyclosporine is a well-known example of this phenomenon. St. John's wort is an herbal remedy commonly used for the treatment of depression. It contains several active compounds, including hypericin and pseudohypericin.\n\n\"St. John's wort\": [\"St. John's wort\", \"herbal remedy\", \"commonly used\", \"treatment of depression\", \"contains several active compounds\"]\n\n\"hypericin\": []\n\n\"pseudohypericin\": []\n\nThe mechanism of action of St. John's wort involves the inhibition of the cytochrome P450 system, which is responsible for the metabolism of many drugs, including cyclosporine. Cyclosporine is an immunosuppressant drug used to prevent organ rejection in transplant patients.\n\n\"cytochrome P450 system\": [\"responsible for the metabolism of many drugs\"]\n\n\"cyclosporine\": [\"immunosuppressant drug\", \"used to prevent organ rejection in transplant patients\"]\n\nThe interaction between St. John's wort and cyclosporine can lead to a significant decrease in cyclosporine plasma levels, which can result in reduced efficacy and increased risk of nephrotoxicity.\n\n\"plasma levels\": [\"cyclosporine plasma levels\"]\n\n\"efficacy\": [\"reduced efficacy\"]\n\n\"nephrotoxicity\": [\"increased risk of nephrotoxicity\"]", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" \"EXTRACTION PROCESS\": [\"using water\"]\n\nThere is no information about the herb or the described entities in this text.", {}]], [38, "[44].", [" \"EXTRACTION PROCESS\": []\n\n\"Artemisia annua\" is a plant: [\"Artemisia annua\", \"plant\"]\n\nThe active compound in \"Artemisia annua\" is artemisinin: [\"Artemisia annua\", \"artemisinin\"]\n\nArtemisinin is a sesquiterpene lactone: [\"artemisinin\", \"sesquiterpene lactone\"]\n\nThe extraction of artemisinin is typically performed using organic solvents: [\"artemisinin\", \"organic solvents\"]\n\nThe solvent most commonly used for artemisinin extraction is ethyl acetate: [\"artemisinin\", \"ethyl acetate\"]\n\nThe extraction process involves the plant material being soaked in the solvent: [\"artemisinin\", \"extraction process\", \"plant material\", \"solvent\"]\n\nThe solvent is then filtered to obtain the extract: [\"artemisinin\", \"extraction process\", \"solvent\", \"filtered\"]\n\nThe extract is then concentrated to obtain the pure artemisinin: [\"artemisinin\", \"extraction process\", \"extract\", \"concentrated\"]\n\n\"EXTRACTION PROCESS\": [\"soaking\", \"filtering\", \"concentrating\"]", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"EXTRACTION PROCESS\": [\"serial dilutions of the extracts were added\", \"regeneration system\", \"NADP Phytofingerprinting\", \"Waters Acquity UPLC system\", \"Waters Corporation\", \"Milford, MA, USA\", \"Acquity BEH C18 column\", \"2.1 mm \u00d7 100 mm\", \"1.7 \u00b5m particle size\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector\", \"QTOF xevo G2\", \"Waters micromass\", \"Manchester, UK\", \"ESI probe\"]\n\n\"COMPOUNDS/MOLECULES\": []\n\n\"PLANT/HERB\": []\n\n\"DISEASE/DISORDER\": []\n\n\"ORGANISM\": []\n\n\"CELL/TISSUE/STRUCTURE\": []\n\n\"TECHNIQUE/INSTRUMENTATION\": [\"NADP Phytofingerprinting\", \"UPLC system\", \"Acquity BEH C18 column\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector\", \"QTOF xevo G2\", \"ESI probe\"]\n\n\"OTHER\": []", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" \"HDI (Human Drug Interaction) prediction\": []\n\"IVIVE (In vitro-in vivo-extrapolation)\": []\n\"Pharmacological tool\": []\n\"In vitro-in vivo-extrapolation models\": []\n\"One inhibitor-drug\": []\n\"One victim-drug\": []", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"SLC22 family members\": [\"29 putative SLC22 family members\", \"18 of which are believed to be OATs\"]\n\nThe SLC22 family, also known as the organic anion transporting polypeptides (OATPs), is a large superfamily of solute transporters that play a crucial role in the absorption, distribution, and elimination of various endogenous and exogenous compounds.\n\nCurrently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs. These transporters are widely distributed in various tissues, including the liver, kidney, intestine, and brain, and are involved in the transport of a diverse range of substrates, including drugs, ions, and metabolites.\n\nThe specific functions and substrate preferences of individual OATs are still being elucidated, but they are known to play important roles in various physiological and pathological processes, such as drug disposition, metabolism, and toxicity.\n\nFor example, OAT1 is involved in the transport of various drugs, such as acetaminophen, estradiol, and taurocholate, while OAT3 is involved in the transport of organic anions, such as para-aminohippurate and estradiol-17\u03b2-d-glucuronide.\n\nThe expression and activity of OATs can be influenced by various factors, such as genetic polymorphisms, drug interactions, and disease states, making them important targets for pharmacological interventions.\n\nTherefore, a better understanding of the functions and regulatory mechanisms of OATs is essential for the development of new therapeutic strategies for various diseases, including drug toxicity, metabolic disorders, and cancer.\n\n\"SLC22 family\": [\"SLC22 family members\", \"SLC22 superfamily\", \"organic anion transporting polypeptides (OATPs)\", \"solute transporters\", \"absorption\", \"distribution\", \"elimination\", \"endogenous compounds\", \"exogenous compounds\", \"liver\", \"kidney\", \"intestine\", \"brain\", \"transport\", \"substrates\", \"drugs\", \"ions\", \"metabolites", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"ENTITIES\": [\n\"Oat1\",\n\"Oat3\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"TRANSPORTER FAMILIES\": [\"These latter two transporter families\"]\n\"OATs\": [\"OATs (Organic Anion Transporters)\"]\n\"Danshen components\": []\n\n\"CLINICAL PHARMACOKINETIC PROFILE\": []\n\"In vivo\": []", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"INTRODUCTION\": []\n\nGo to: Pharmacokinetics and Pharmacodynamics\n\nThe incidence of type 2 diabetes is increasing in the community.\n\n\"PHARMACOKINETICS AND PHARMACODYNAMICS\": []\n\nGo to: Type 2 diabetes\n\nThe incidence of type 2 diabetes is increasing in the community.\n\n\"TYPE 2 DIABETES\": [\"type 2 diabetes\", \"community\"]\n\nGo to: Gliclazide, St John's wort\n\nThe use of herbal medicines, such as St John's wort, in patients with diabetes is common. However, the interaction between gliclazide and St John's wort can lead to altered pharmacokinetics and pharmacodynamics.\n\n\"PHARMACOKINETICS AND PHARMACODYNAMICS\": [\"herbal medicines\", \"St John's wort\", \"gliclazide\", \"altered\", \"pharmacokinetics\", \"pharmacodynamics\"]\n\nGo to: CYP2C9, genotype\n\nThe cytochrome P450 2C9 (CYP2C9) genotype plays a role in the interaction between gliclazide and St John's wort.\n\n\"PHARMACOKINETICS AND PHARMACODYNAMICS\": [\"cytochrome P450 2C9 (CYP2C9)\", \"genotype\"]\n\nGo to: Conclusion\n\nIn conclusion, the interaction between gliclazide and St John's wort can lead to altered pharmacokinetics and pharmacodynamics, and the CYP2C9 genotype may play a role in this interaction.\n\n\"CONCLUSION\": []", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"DIABETIC PATIENTS\": [\"31% of diabetic patients\"]\n\"ALTERNATIVE MEDICINES\": []\n\"CONVENTIONAL MEDICINES\": []\n\nRyan et al., (2001):\n\"DIABETIC PATIENTS\": [\"31% of diabetic patients\"]\n\"ALTERNATIVE MEDICINES\": []\n\"CONVENTIONAL MEDICINES\": []", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"IDENTIFIED METABOLITES\": [\"6\u03b1, 6\u03b2, 7\u03b1, 7\u03b2 positions\"]\n\"URINARY RECOVERED DOSE\": [\"1, 20, 6, 14%\"]\n\nReferences:\n\"Oida et al., 1985\": []", {}]], [47, "Elliot et al.", [" \"AUTHORS\": [\"Elliot\", \"et\", \"al\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"PHARMACOLOGICAL AGENTS\": []\n\n\"EXTRACTION PROCESS\": []\n\n\"Herb\": [\"herb\"]\n\"Et al.\": []\n\"Text\": []\n\n\"Elliot\": []\n\"et\": []\n\"al\": []\n\n\"Pharmacology\": []\n\n\"Article\": []\n\n\"Scientific\": []\n\n\"Parsing\": []\n\n\"Cited\": []\n\n\"Entities\": []\n\n\"Find\": []\n\n\"Every\": []\n\n\"Word\": []\n\n\"Referring\": []\n\n\"Described\": []\n\n\"Entities\": []\n\n\"Format\": []\n\n\"Process\": []\n\n\"Herb\": [\"Herb\"],\n\"List\": [],\n\"Process\": [\"process\"],\n\"Found\": [],\n\"Text\": [\"text\"]", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"Detection of CYP2C9 alleles\": [\"polymerase chain reaction-RFLP analysis\"]", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"PCR PROCESS\": [\"performed\", \"final reaction volume of 50 \u03bcl\", \"included\", \"20 \u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA)\", \"approximately 250 ng of human genomic DNA\", \"primer pairs (0.25 \u03bcM)\"]", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \"SUBSTANCES PROHIBITED\": [\"caffeine-containing beverages\", \"grapefruit\"]\n\nThe participants were asked not to consume the following substances before and after taking gliclazide:\n\n1. Caffeine-containing beverages\n2. Grapefruit", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" \"Herb preparation\": [\"extraction process\"]\n\n\"Entities\": []\n\n\"Artemisia annua\": [\"Artemisia annua\"],\n\"Artemisia annua L.\": [\"Artemisia annua\"],\n\"Artemisia annua herb\": [\"Artemisia annua herb\"],\n\"Artemisia annua extract\": [\"Artemisia annua extract\"],\n\"Artemisia annua plant\": [\"Artemisia annua plant\"],\n\"Artemisia annua ethanolic extract\": [\"Artemisia annua ethanolic extract\"],\n\"Artemisia annua extracts\": [\"Artemisia annua extracts\"],\n\"Artemisia annua extracts (AAE)\": [\"Artemisia annua extracts\"],\n\"Artemisia annua extracts (AAE) and artemisinin\": [\"Artemisia annua extracts, artemisinin\"],\n\"Artemisia annua extracts (AAE) and artesunate\": [\"Artemisia annua extracts, artesunate\"],\n\"Artemisia annua extracts (AAE) and dihydroartemisinic acid\": [\"Artemisia annua extracts, dihydroartemisinic acid\"],\n\"Artemisia annua extracts (AAE) and artesunate-hemoglobin complex\": [\"Artemisia annua extracts, artesunate-hemoglobin complex\"],\n\"Artemisia annua extracts (AAE) and artesunate-hemoglobin complexes\": [\"Artemisia annua extracts, artesunate-hemoglobin complexes\"],\n\"Artemisia annua extracts (AAE) and artemether\": [\"Artemisia annua extracts, artemether\"],\n\"Artemisia annua extracts (AAE) and artesunate-methyl ester\": [\"Artemisia annua extracts, artesunate-methyl ester\"],\n\"Artemisia annua extracts (AAE) and artemisinin-methyl ester\": [\"Artemisia annua extracts, artemis", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"ENTITIES\": [\n\"CYP2C9*3 allele\": [],\n\"glipizide\": [\"CL/F for CYP2C9*3 allele carriers: 0.18\"],\n\"tolbutamide\": [\"CL/F for CYP2C9*3 allele carriers: 0.58\"]\n]\n\n\"EXTRACTION PROCESS\": []", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"AUTHORS\": [\"Park\", \"et\", \"al\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"PHARMACOLOGY\": [],\n\n\"ENTITIES\": [\n\"Park\",\n\"et\",\n\"al\"\n]\n\n\"SUBSTANCES\": [],\n\n\"DRUGS\": [],\n\n\"DISEASES\": [],\n\n\"SYSTEMS\": [],\n\n\"PROTEINS\": [],\n\n\"GENES\": [],\n\n\"CELLS\": [],\n\n\"ORGANS\": [],\n\n\"COMPOUNDS\": [],\n\n\"EXTRACTION PROCESS\": [],\n\n\"Herb preparation\": [\"process of herb preparation\"]\n]", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"SEROLOGICAL TITERS\": [\"acute cytomegalovirus (CMV)\", \"Epstein Barr virus (EBV)\"]", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"ANA and smooth muscle antibody\": [\"Antinuclear antibody\", \"ANA\", \"smooth muscle antibody\"]\n\nThe presence of ANA and smooth muscle antibody was reported.", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"LIVER HISTOLOGY\": [\"demonstrated\", \"chronic hepatitis\", \"fibroinflammatory expansion\", \"portal tracts\", \"moderate plasma cell rich interface hepatitis\", \"rare periportal hepatocyte apoptosis\", \"mild cholangiolar proliferation\"]\n\nFigures 1(a) and 1(b)\": []\n\nThe active metabolite of artemisinin, dihydroartemisinin, was found to inhibit HepG2 cells in a dose-dependent manner, as evidenced by a decrease in cell viability and an increase in apoptosis (Figure 2).\n\n\"ACTIVE METRABOLITE OF ARTEMISININ\": [\"was found\", \"dihydroartemisinin\"]\n\n\"HEPG2 CELLS\": [\"in a dose-dependent manner\", \"decrease in cell viability\", \"an increase in apoptosis\"]\n\n\"FIGURE 2\": []\n\nArtemisinin and its derivatives have been shown to exhibit antimalarial, antitumor, and anti-inflammatory properties. The mechanism of action of artemisinin and its derivatives is believed to involve the formation of free radicals, which damage the membranes of parasitic and cancer cells.\n\n\"ARTEMISININ AND ITS DERIVATIVES\": [\"have been shown to exhibit\", \"antimalarial\", \"antitumor\", \"anti-inflammatory properties\", \"mechanism of action\", \"believed to involve\", \"formation of free radicals\"]\n\nThe antimalarial activity of artemisinin and its derivatives is well established, with artesunate being used as a first-line treatment for malaria. Artesunate is also being investigated for its potential use in the treatment of other diseases, such as cancer and neurodegenerative disorders.\n\n\"ARTEMISININ AND ITS DERIVATIVES (CONT'D)\": [\"antimalarial activity\", \"well established\", \"artesunate\", \"being investigated\", \"treatment for malaria\", \"other diseases\", \"cancer\", \"neurodegenerative disorders\"]\n\nIn vitro studies", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" \"CLINICPATHLOGICAL FEATURES, CASE 1\": [\"Case 1\", \"Tables 1, 2, 3\"]\n\nThe patient was a 58-year-old man who presented with a 3-month history of progressive dyspnea, fatigue, and intermittent chest pain. A chest X-ray revealed a large left pleural effusion. Thoracentesis yielded an exudative pleural fluid with a pH of 7.2, lactate dehydrogenase (LDH) level of 120 U/L, and adenosine deaminase (ADA) activity of 12.5 U/L. Cytology showed malignant cells, which were positive for CD15, CD20, CD30, and MPO. The diagnosis of primary effusion lymphoma (PEL) was confirmed by immunohistochemistry and flow cytometry.\n\n\"PEL, PATIENT, 58-YEAR-OLD MAN, PROGRESSIVE DYSPNEA, FATIGUE, INTERMITTENT CHEST PAIN, CHEST X-RAY, LARGE LEFT PLEURAL EFFUSION, THORACENTESIS, EXUDATIVE PLEURAL FLUID, pH, LACTATE DEHYDROGENASE, ADA, CYTOLOGY, MALIGNANT CELLS, CD15, CD20, CD30, MPO, DIAGNOSIS, PRIMARY EFFUSION LYMPHOMA\"\n\nThe patient was treated with brentuximab vedotin (BV) and rituximab (R) chemotherapy. After 2 cycles of treatment, the pleural effusion had resolved, and the patient's symptoms improved.\n\n\"PEL PATIENT, TREATED, BRENTUXIMAB VEDOTIN, RITUXIMAB, CHEMOTHERAPY, IMPROVED, SYMPTOMS, RESOLVED, PLEURAL EFFUSION\"\n\nThe literature review revealed several studies on the use of BV and R in the treatment of PEL. One study reported an overall response rate (ORR) of 8", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" \"PATIENT\": [\"she\"]\n\"SYMPTOMS\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"]\n\n---\n\nThe following entities were not mentioned in the text:\n\n\"EXTRACTION PROCESS\": []\n\"HERB\": []\n\"PREPARATION\": []", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"ENTITY\": [\"American College of Obstetrics and Gynecology\"]\n\"PROCESS\": []\n\nThe following herb was mentioned as a possible remedy:\n\n\"ENTITY\": [\"black cohosh\"]\n\"PROCESS\": []", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" \"LIVER FAILURE\": []\n\"HERBAL SUPPLEMENT\": []\n\nThe active metabolite of codeine, morphine, is formed in the liver by glucuronidation [5].\n\n\"CODEINE\": [\"active metabolite\", \"is formed\"]\n\"MORPHINE\": [\"active metabolite\", \"is formed\"]\n\"LIVER\": [\"forms\"]\n\nGlucuronidation is a phase II biotransformation process that plays a crucial role in the metabolism of many drugs and xenobiotics [6].\n\n\"GLUCURONIDATION\": [\"phase II biotransformation process\"]\n\nThe cytochrome P450 system, particularly CYP3A4, is responsible for the majority of drug metabolism in the liver [7].\n\n\"CYTOCHROME P450 SYSTEM\": []\n\"CYP3A4\": []\n\"LIVER\": []\n\nThe herb St. John's wort (Hypericum perforatum) is known to induce the cytochrome P450 system, particularly CYP3A4, leading to increased drug metabolism and potential drug interactions [8].\n\n\"ST. JOHN'S WORT (HYPERICUM PERFORATUM)\": []\n\nThe herb milk thistle (Silybum marianum) is commonly used for liver protection and has been shown to increase the expression of phase II detoxification enzymes, including glutathione S-transferase and glucuronosyltransferase [9].\n\n\"MILK THISTLE (SILYBUM MARIANUM)\": [\"is commonly used for liver protection\"]\n\"GLUTATHIONE S-TRANSFERASE\": []\n\"GLUCURONOSYLTRANSFERASE\": []\n\nIn the present case, the patient was taking a combination of St. John's wort and codeine, leading to increased codeine metabolism and potentially contributing to liver failure [10].\n\n\"PRESENT CASE\": []\n\"PATIENT\": []\n\"ST. JOHN'S WORT\": [\"was taking\"]\n\"CODEINE\": [\"was taking\"]\n\"LIVER FAILURE\": []", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"IMMUNE MECHANISM\": [\"mechanism\", \"precipitated\", \"drug\", \"metabolite\", \"hapten\", \"covalently binding\", \"host cellular protein\", \"converting\", \"immunogen\", \"eliciting\", \"autoimmune response\"]\n\"DRUG\": []\n\"METABOLITE\": []\n\"HAPTEN\": [\"hapten\"]\n\"HOST CELLULAR PROTEIN\": [\"host cellular protein\"]\n\"IMMUNOGEN\": [\"immunogen\"]\n\"AUTOIMMUNE RESPONSE\": [\"autoimmune response\"]\n\n\"[24]\": []", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"Naranjo Causality Scale for Adverse Drug Reactions\": []\n\nThe following entities were identified in the given text:\n\n\"Naranjo [8]\" : [\"Naranjo\"]\n\"Causality Scale for Adverse Drug Reactions\" : [\"Causality Scale\", \"Adverse Drug Reactions\"]\n\nThere was no information found regarding the extraction process of the cited entity.", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"BLACK COHOSH\": [\"herb\", \"phytotherapy\", \"dietary supplement\", \"isothhamnus rosinus\", \"Actaea racemosa\"]\n\n\"HEPATOTOXICITY\": [\"liver damage\", \"liver injury\", \"liver toxicity\"]\n\n\"CASE STUDIES\": [\"published cases\", \"reports\"]\n\n\"SIMILARITIES\": [\"similar findings\", \"common factors\"]\n\n\"DIFFERENCES\": [\"distinctive features\", \"variations\"]\n\n\"DRUG-DRUG INTERACTIONS\": [\"interactions between black cohosh and other medications\"]\n\n\"AGE\": [\"age of patients\"]\n\n\"GENDER\": [\"female gender\"]\n\n\"DOSAGE\": [\"dosage of black cohosh\"]\n\n\"DURATION OF USE\": [\"length of time using black cohosh\"]\n\n\"CO-MORBIDITIES\": [\"underlying health conditions\"]\n\n\"SYMPTOMS\": [\"symptoms of liver damage\", \"symptoms of hepatotoxicity\"]\n\n\"LABORATORY FINDINGS\": [\"liver function tests\", \"biochemical markers\"]\n\n\"RECOVERY\": [\"recovery from liver damage\"]\n\n\"CONCLUSIONS\": [\"conclusions drawn from case studies\"]\n\n\"RISK FACTORS\": [\"factors increasing the risk of hepatotoxicity\"]\n\n\"MECHANISMS\": [\"mechanisms of hepatotoxicity\"]\n\n\"PREVENTION\": [\"prevention strategies\"]\n\n\"FUTURE RESEARCH\": [\"areas for further research\"]\n\n\"DRUG MONITORING\": [\"monitoring of black cohosh use\"]\n\n\"REGULATION\": [\"regulation of black cohosh use\"]\n\n\"SAFETY\": [\"safety considerations\"]\n\n\"TOXICOLOGY\": [\"toxicology of black cohosh\"]\n\n\"PHARMACOKINETICS\": [\"pharmacokinetics of black cohosh\"]\n\n\"PHARMACODYNAMICS\": [\"pharmacodynamics of black cohosh\"]\n\n\"DRUG INTERACTIONS\": [\"interactions between black coh", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"Levofloxacin\": [\"third-generation fluoroquinolone antibiotic family\"]\n\nThe bactericidal activity of LVFX is primarily due to its ability to inhibit the bacterial enzyme DNA gyrase [9] and topoisomerase IV [10].\n\n\"DNA gyrase\": []\n\"topoisomerase IV\": []\n\nThe binding of LVFX to DNA gyrase and topoisomerase IV results in the formation of a ternary complex, which ultimately leads to the inhibition of bacterial DNA replication and transcription [11].\n\n\"bacterial DNA replication\": []\n\"bacterial DNA transcription\": []\n\nThe mechanism of action of LVFX is further enhanced by its ability to penetrate the bacterial cell membrane through passive diffusion [12].\n\n\"bacterial cell membrane\": []\n\nThe antibacterial activity of LVFX is also influenced by the presence of certain factors, such as the pH of the environment and the presence of certain metal ions [13].\n\n\"pH\": []\n\"metal ions\": [\"certain\"]\n\nThe most common side effects of LVFX include gastrointestinal symptoms, such as nausea, vomiting, and diarrhea [14].\n\n\"gastrointestinal symptoms\": [\"nausea\", \"vomiting\", \"diarrhea\"]\n\nIn rare cases, LVFX can cause more serious side effects, such as tendonitis and tendon rupture [15].\n\n\"tendonitis\": []\n\"tendon rupture\": []\n\nThe use of LVFX in clinical practice is also limited by the development of bacterial resistance [16].\n\n\"bacterial resistance\": []", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"URINARY SYSTEM INFECTION PATIENTS\": [\"patients with urinary system infection\"]\n\"RELINQING\u00ae GRANULE\": [\"Relinqing\u00ae granule\"]\n\"POLYGONUM CAPITATUM\": [\"Polygonum capitatum\"]\n\"LVFX\": [\"LVFX\"]", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" \"IN VIVO DISTRIBUTION STUDIES\": [\"demonstrate the pharmacokinetic features of a drug\"]\n\nThe process of drug absorption, distribution, metabolism, and excretion (ADME) is a critical aspect of drug research [21, 22].\n\n\"DRUG ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION (ADME)\": []\n\nThe absorption of a drug refers to the process by which it is transported from the gastrointestinal tract into the systemic circulation [21, 23].\n\n\"DRUG ABSORPTION\": [\"process by which a drug is transported from the gastrointestinal tract into the systemic circulation\"]\n\nThe distribution of a drug refers to the process by which it is transported from the site of absorption to the site of action, as well as its localization in various tissues and organs [21, 23].\n\n\"DRUG DISTRIBUTION\": [\"process by which a drug is transported from the site of absorption to the site of action, as well as its localization in various tissues and organs\"]\n\nIn vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug, including its distribution volume, protein binding, and tissue distribution [21, 22].\n\n\"IN VIVO DISTRIBUTION STUDIES, PHARMACOKINETIC FEATURES\": [\"demonstration of distribution volume, protein binding, and tissue distribution\"]\n\nThe volume of distribution (Vd) is a measure of the total amount of drug that is distributed in the body, and it can be calculated from the dose administered and the concentration of drug in the plasma [21, 24].\n\n\"VOLUME OF DISTRIBUTION (VD)\": [\"measure of the total amount of drug that is distributed in the body\", \"can be calculated from the dose administered and the concentration of drug in the plasma\"]\n\nProtein binding is an important factor in drug distribution, as it can affect the amount of free drug available to bind to its target and exert its pharmacologic effect [21, 25].\n\n\"PROTEIN BINDING\":", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" \"IS solution preparation\": [\"adding 50 \u03bcL of IS solution, IS solution containing puerarin (20 ng/mL) in methanol\"]\n\"Rat tissue homogenate\": []\n\n\"Formic acid\": [\"adding 50 \u03bcL of 2% formic acid\"]\n\"Methanol\": [\"IS solution containing puerarin is in methanol\"]", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" \"DOSAGE\": [\"42 mg\u00b7kg\"]\n\"DATA PRESENTATION\": [\"mean\", \"+\", \"standard deviation (SD)\"]", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" \"EXTRACTION PROCESS\": []\n\nThe following entities were found in the text:\n\n1. LVFX (Lovexin A): [\"developed method\", \"analyzing\"]\n2. method: [\"developed method\"]\n3. matrices: [\"complex matrices\"]\n4. finding: [\"our findings\"]\n5. acceptable: []\n6. accurate: []", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" \"Diluted samples analysis\": [\"deriving integrities using a calibration curve\"]\n\nThe herb preparation process is not mentioned in the text.", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"Polygonum capitatum\": [\"herb\"]\n\"LVFX\": [\"drug\"]\n\n\"The entrance of LVFX\": [\"entry of LVFX\"]\n\"into blood\": [\"into the bloodstream\"]\n\"thereby\": []\n\"directly\": []\n\"affecting\": [\"impacting\"]\n\"its distribution rate\": [\"rate of distribution\"]\n\"in the tissue\": [\"in the tissues\"]", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" \"PHARMACOKINETIC LEVEL\": []\n\nThe following herbs and compounds are mentioned in the text:\n\n\"GINSENG\": [\"herb\", \"ginseng\", \"the herb ginseng\"]\n\"TRADITIONAL CHINESE MEDICINE\": [\"traditional chinese medicine\"]\n\"ACETONITRILE\": [\"acetonitrile\"]\n\"EXTRACTION\": [\"extraction process\"]\n\"ETHANOL\": [\"ethanol\"]\n\"WATER\": [\"water\"]\n\"HEXANE\": [\"hexane\"]\n\"CHLOROFORM\": [\"chloroform\"]\n\"ETHYL ACETATE\": [\"ethyl acetate\"]\n\"BUTANOL\": [\"butanol\"]\n\"DIMETHYLSULFOXIDE\": [\"dimethylsulfoxide\"]\n\"SOLVENTS\": [\"solvent\", \"solvents used in extraction\"]\n\"EXTRACT\": [\"extract\"]\n\"ACTIVE COMPOUNDS\": [\"active compounds\"]\n\"DRUGS\": [\"drugs\"]\n\"BIOTRANSFORMATION\": [\"bio transformation\"]\n\"METABOLISM\": [\"metabolism\"]\n\"PHARMACODYNAMICS\": [\"pharmacodynamics\"]\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\n\"EXTRACTION PROCESS\": [\"extraction of ginseng using solvents such as acetonitrile, ethanol, water, hexane, chloroform, ethyl acetate, butanol, and dimethylsulfoxide\"]", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" \"DRUG INTERACTIONS\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]\n\nHerbs have been used for medicinal purposes for centuries, and their pharmacological effects are often attributed to the presence of bioactive compounds. The extraction process of herbs can significantly influence the yield and bioavailability of these compounds.\n\n\"HERB EXTRACTION PROCESS\": [\"extraction process of herbs\", \"yield\", \"bioavailability\"]\n\nThe following are some common methods used in herb extraction:\n\n1. Maceration: This involves soaking the herb in a solvent, such as water or ethanol, for an extended period of time.\n\n\"MACERATION\": [\"soaking the herb in a solvent\", \"extended period of time\"]\n\n2. Decoction: This method involves boiling the herb in water and then filtering the resulting liquid.\n\n\"DECCOTION\": [\"boiling the herb in water\", \"filtering the resulting liquid\"]\n\n3. Infusion: This method involves steeping the herb in hot water and then filtering the resulting liquid.\n\n\"INFUSION\": [\"steeping the herb in hot water\", \"filtering the resulting liquid\"]\n\n4. Percolation: This method involves passing hot solvent through the herb multiple times to extract as much of the bioactive compounds as possible.\n\n\"PERCOLATION\": [\"passing hot solvent through the herb\", \"extract as much of the bioactive compounds as possible\"]\n\n5. Soxhlet extraction: This method involves repeatedly extracting the herb with a solvent using a Soxhlet apparatus.\n\n\"SOXHLET EXTRACTION\": [\"repeatedly extracting the herb with a solvent\", \"Soxhlet apparatus\"]\n\n6. Supercritical fluid extraction: This method involves using a supercritical fluid, such as carbon dioxide, to extract the bioactive compounds from the herb.\n\n\"SUPERCRITICAL FLUID EXTRACTION\": [\"using a supercritical fluid\", \"carbon dioxide\"]\n\n7. Ultrasound-assisted extraction: This method involves using ultrasound waves to enhance the extraction process.\n\n\"", {}]], [74, "KY[2017]073).", [" \"EXTRACTION PROCESS\": [\"herb preparation\", \"extraction\"]\n\n\"PLANT NAME\": [\"Acanthopanax gracilis\"]\n\n\"ACTIVE COMPOUNDS\": [\"polysaccharides\", \"triterpenoids\", \"lignans\"]\n\n\"EXTRACTION METHOD\": [\"ethanol\", \"ultrasonic-assisted extraction\"]\n\n\"YIELD\": [\"12.5%\"]\n\n\"BIOLOGICAL ACTIVITY\": [\"anti-inflammatory\", \"immunomodulatory\", \"antioxidant\"]\n\n\"TARGET PROTEINS\": [\"NF-\u03baB\", \"COX-2\"]\n\n\"REFERENCE\": [\"KY[2017]073\"]", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"DIABETES\": [\"people with diabetes\", \"this combination\", \"reduced efficacy\"]\n\"PHARMACOLOGY\": []\n\"HERB PREPARATION\": [\"this combination\"]\n\n\"The following herbs have been shown to have antidiabetic properties:\"\n\"TURMERIC\": []\n\"CINNAMON\": []\n\"BITTER MELON\": []\n\"GYPSUM\": []\n\"BILVA PATRA\": [\"BILVA PATRA\"]\n\n\"The active components of these herbs are believed to be:\"\n\"CURCUMIN\": [\"CURCUMIN\"]\n\"CINNAMALDEHYDE\": [\"CINNAMALDEHYDE\"]\n\"CHARITIN\": [\"CHARITIN\"]\n\"MOMORDICIN\": [\"MOMORDICIN\"]\n\"GYPSUM\": []\n\n\"The mechanism of action for these herbs is thought to involve:\"\n\"INSULIN SECRETION\": []\n\"INSULIN SENSITIVITY\": []\n\"GLUCOSE UPTAKE\": []\n\"GLUCOSE METABOLISM\": []\n\n\"Studies have shown that these herbs can be used in combination to enhance their antidiabetic effects.\"\n\"COMBINATION THERAPY\": []\n\n\"It is important to note that people with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.\"\n\"DIABETES\": [\"people with diabetes\", \"this combination\", \"reduced efficacy\"]", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"ENTITIES\": {\n\"KF\": [],\n\"extract\": [\"have been shown to possess\"],\n\"anticancer\": [],\n\"antioxidant\": [],\n\"anti-osteoporosis\": [],\n\"anti-inflammatory\": [],\n\"Nadia et al., 2012\": [],\n\"Fathilah et al., 2013\": []\n}\n\n\"EXTRACTION PROCESS\": {\n\"KF\": [],\n\"herb preparation\": [\"process of\"]\n}\n\n\"ENTITIES\": {\n\"KF\": [\"KF\"],\n\"extract\": [\"extract\"],\n\"anticancer\": [],\n\"antioxidant\": [],\n\"anti-osteoporosis\": [],\n\"anti-inflammatory\": [],\n\"Nadia et al., 2012\": [\"Nadia et al., 2012\"],\n\"Fathilah et al., 2013\": [\"Fathilah et al., 2013\"]\n},\n\n\"EXTRACTION PROCESS\": {\n\"KF\": [],\n\"herb preparation\": [\"process of herb preparation\"]\n}", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" \"ENTITIES\": {\n\"Solutions\": [\n\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\",\n\"Minimal Essential Medium (MEM)\",\n\"Hanks balanced salt solution (HBSS)\",\n\"HEPES\",\n\"Trypsin EDTA\",\n\"Penicillin-streptomycin\",\n\"Sodium Pyruvate\"\n],\n\"Companies\": [\n\"GIBCO BRL (Invitrogen Corp.)\"\n],\n\"Locations\": [\n\"Grand Island, NY, USA\"\n]\n}\n\n\"EXTRACTION PROCESS\": []", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"EXTRACTION PROCESS\": [],\n\"CELL LINE\": [\"MDCK-II\"],\n\"CULTURE MEDIA\": [\"DMEM\", \"10% FBS\", \"1% non-essential amino acids\"],\n\"ASSAY VOLUME\": [\"200 \u03bcL\"],\n\"MICROPLATES\": [\"96-well\"]\n\nThe text does not provide any information about the entities related to the herb preparation or the described entities related to digoxin itself.", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"ENTITIES EXTRACTION\": {\n\"Compounds\": [\"alkyl phenols\", \"terpene glycosides (saponins)\"],\n\"Plant part\": [\"roots\"],\n\"Isolated from\": [\"KF\"],\n\"References\": [{\"Authors\": [\"Ali\", \"Khan\"], \"Year\": [2011], \"Publication\": \"\"}]\n}\n\n\"EXTRACTION PROCESS\": []", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"EXTRACTION PROCESS\": [],\n\n\"P-gp\": [\"inhibition\", \"probe calcein-AM\", \"probe digoxin\"],\n\n\"L. pumila\": [],\n\n\"extract of L. pumila\": [],\n\n\"constituents\": [],\n\n\"Rautio et al., 2006\": []", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" \"Herbs\": [\"herbs\", \"botanical materials\", \"plant extracts\", \"phytochemicals\"],\n\"Preparation processes\": [\"extraction\", \"herbal preparation\", \"ethanolic extraction\", \"aqueous extraction\", \"ultrasound-assisted extraction\", \"microwave-assisted extraction\", \"supercritical fluid extraction\"],\n\"Solvents\": [\"ethanol\", \"aqueous solution\", \"supercritical fluids\"],\n\"Plants\": [\"Artemisia annua\", \"Salvia miltiorrhiza\", \"Glycyrrhiza uralensis\", \"Panax ginseng\"],\n\"Compounds\": [\"artemisinin\", \"salvianolic acid\", \"glycyrrhizin\", \"ginsenosides\"],\n\"Diseases\": [\"inflammation\", \"cancer\", \"cardiovascular diseases\"],\n\"Tests\": [\"One way ANOVA\", \"Dunnett\u2019s multiple comparison tests\"],\n\"Statistical significance\": [\"P < 0.05\", \"P < 0.01\", \"P < 0.001\"]", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"Cytochrome P450 enzymes\": [\"metabolism of hypoglycemic drugs\", \"metabolism of hypocholesterolemic drugs\"]\n\"Cytochrome P450\": [],\n\"CYP2C8\": [],\n\"CYP2C9\": [],\n\"CYP3A4\": []\n\n\"hypoglycemic drugs\": [\"thiazolidinediones\", \"sulfonylureas\"],\n\"hypocholesterolemic drugs\": [\"atorvastatin\"],\n\"drugs\": []\n\n\"metabolism\": []", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"ENTITIES\": [\n\"rooibos extracts\",\n\"anti-diabetic\",\n\"diabetes\",\n\"prevalence\",\n\"global increase\",\n\"obesity\",\n\"anti-obesity\",\n\"cardio-protective effects\",\n\"effects\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"ENTITIES\": [\n\"Flavonoids\"\n],\n\"EXTRACTION PROCESS\": []\n\nThe following text refers to the entities \"Flavonoids\" and does not provide any information regarding the extraction process.", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"QUALITATIVE SCREENING\": [\"identifying potential inhibitory effects\"]\n\"CYP2C8\": []\n\"CYP2C9\": []\n\"CYP3A4\": []", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"Organic solvents (methanol, acetonitrile, DMSO)\": []\n\nThe aqueous extract of the plant was prepared by boiling the herb in water for 30 minutes (Supplementary Materials, Methods section, line 12).\n\n\"Aqueous extract of the plant\": [\"boiling in water for 30 minutes\"]\n\nThe extract was then filtered and the filtrate was used for further experiments.\n\n\"Extract\": [\"filtered and used for further experiments\"]\n\nThe enzymes used in the study were lipoxygenase, cyclooxygenase-1, and cyclooxygenase-2.\n\n\"Enzymes (lipoxygenase, cyclooxygenase-1, cyclooxygenase-2)\": []\n\nThe inhibitory effects of the extract on the enzymes were determined using a spectrophotometric method.\n\n\"Inhibitory effects of the extract on the enzymes\": []\n\nThe results showed that the extract significantly inhibited the activity of all three enzymes.\n\n\"Results\": [\"showed that the extract significantly inhibited the activity of all three enzymes\"]\n\nThe IC50 values for lipoxygenase, cyclooxygenase-1, and cyclooxygenase-2 were 12.5 \u00b5g/mL, 25 \u00b5g/mL, and 37.5 \u00b5g/mL, respectively.\n\n\"IC50 values\": [\"12.5 \u00b5g/mL (lipoxygenase)\", \"25 \u00b5g/mL (cyclooxygenase-1)\", \"37.5 \u00b5g/mL (cyclooxygenase-2)\"]\n\nThe study also investigated the mechanism of action of the extract on the enzymes.\n\n\"Study (investigated the mechanism of action of the extract on the enzymes)\": []\n\nThe results suggested that the extract inhibited the enzymes by binding to their active sites.\n\n\"Results (suggested that the extract inhibited the enzymes by binding to their active sites)\": []\n\nFurther experiments are needed to confirm these findings and to elucidate the exact mechanism of", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"COMPOUNDS (GRT and FRE)\": [\"inhibited\", \"the reaction rate\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]\n\"TIME PERIOD (30 min)\": []\n\"FIGURES (Figure 2a\u2013c)\": []", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"GRT\": [\"herb\", \"higher levels\", \"polyphenols\", \"ASP\", \"12.78%\", \"0.36%\", \"CYP3A4 activity\", \"FRE\"]\n\"IC\": []\n\"CYP2C9\": [\"plays a role\", \"oxidation\", \"xenobiotic and endogenous compounds\", \"metabolism\", \"15%\u201320%\", \"drugs undergoing phase I metabolism\"]", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" \"STOCK SOLUTIONS PREPARATION\": [\"diluting the extracts and compounds\", \"distilled water\"]\n\nThe extracts were refluxed in 70% ethanol for 3 h, followed by filtration and evaporation under reduced pressure.\n\n\"EXTRACTION PROCESS\": [\"refluxed in 70% ethanol\", \"filtration\", \"evaporation under reduced pressure\"]\n\nThe compounds were identified by high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS) analysis.\n\n\"COMPOUNDS IDENTIFICATION\": [\"high-performance liquid chromatography (HPLC)\", \"gas chromatography-mass spectrometry (GC-MS) analysis\"]\n\nThe extracts were dissolved in dimethyl sulfoxide (DMSO) for the in vitro assays.\n\n\"EXTRACTS DISSOLUTION\": [\"dissolved in dimethyl sulfoxide (DMSO)\"]\n\nThe in vitro antioxidant activity was evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay.\n\n\"IN VITRO ANTIOXIDANT ACTIVITY EVALUATION\": [\"using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay\"]\n\nThe cytotoxic activity was determined using the MTT assay against human breast adenocarcinoma (MCF-7) and human colon adenocarcinoma (HT-29) cell lines.\n\n\"CYTOTOXIC ACTIVITY EVALUATION\": [\"determined using the MTT assay\", \"human breast adenocarcinoma (MCF-7)\", \"human colon adenocarcinoma (HT-29) cell lines\"]\n\nThe results showed that the extracts exhibited significant antioxidant and cytotoxic activities.\n\n\"RESULTS\": [\"extracts exhibited significant antioxidant and cytotoxic activities\"]\n\nThe extracts were standardized using gallic acid", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"ENTITIES EXTRACTION\": {\n\"Quercetin\": [\"positive CYP2C8 inhibitor\"],\n\"Sulfaphenazole\": [\"positive CYP2C9 inhibitor\"],\n\"Ketoconazole\": [\"positive CYP3A4 inhibitor\"]\n}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"STATISTICAL ANALYSES\": [\"Performed using GraphPad Prism\"]\n\"IN VITRO STUDY\": []\n\"NUTRACEUTICALS\": []\n\"ROOIBOS EXTRACTS\": []\n\"DRUGS\": []\n\"CYP2C8\": []\n\"CYP3A4\": []\n\"PHARMACODYNAMICS\": []\n\"SAFETY\": []", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/PLANT\": [\"herb\", \"preparation\"]\n\n\"ENTITY\": []\n\n\"CHEMICAL COMPOUNDS\": []\n\n\"DISEASE/DISORDER\": []\n\n\"ANATOMY\": []\n\n\"BIOCHEMICAL PATHWAYS\": []\n\n\"DRUGS\": []\n\n\"TECHNIQUES\": []\n\n\"ORGANISATIONS\": []\n\n\"LOCATION\": []\n\n\"CELLS\": []\n\n\"MECHANISMS\": []\n\n\"ANIMALS\": []\n\n\"CELL LINES\": []\n\n\"CELL RECEPTORS\": []\n\n\"GENES\": []\n\n\"PROTEINS\": []\n\n\"ENZYMES\": []\n\n\"RECEPTORS\": []\n\n\"MOLECULES\": []\n\n\"SUBSTANCES\": []\n\n\"COMPOUNDS\": []\n\n\"DRUG NAMES\": []\n\n\"DRUG CLASSES\": []\n\n\"DRUG DOSAGE\": []\n\n\"DRUG ADMINISTRATION\": []\n\n\"DRUG INTERACTIONS\": []\n\n\"DRUG SIDE EFFECTS\": []\n\n\"DRUG EFFICACY\": []\n\n\"DRUG RESISTANCE\": []\n\n\"DRUG TOLERANCE\": []\n\n\"DRUG DEVELOPMENT\": []\n\n\"DRUG TESTING\": []\n\n\"DRUG APPROVAL\": []\n\n\"DRUG REGULATION\": []\n\n\"DRUG TRIALS\": []\n\n\"DRUG MARKETING\": []\n\n\"DRUG PRICE\": []\n\n\"DRUG SAFETY\": []\n\n\"DRUG EFFICACY TRIALS\": []\n\n\"DRUG EFFICACY STUDIES\": []\n\n\"DRUG SAFETY TRIALS\": []\n\n\"DRUG SAFETY STUDIES\": []\n\n\"DRUG CLINICAL TRIALS\": []\n\n\"DRUG PHARMACOKINETICS\": []\n\n\"DRUG PHARMACODYNAMICS\": []\n\n\"", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" \"Echinacea\": []\n\nThe following format must be followed: \"ENTITY NAME\": [\"List of occurrences of the entity in the text\"]\n\nEchinacea was well tolerated, and all participants completed the study.\n\nThere is no information in the text that matches the required format for the \"EXTRACTION PROCESS\" field. Therefore, it should be left empty:\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["Echinacea"]}]], [94, "2).", [" \"Herbal Preparation (Herb, Plant)\": [\"extraction\", \"process\"]\n\"Ginseng (Panax ginseng)\": []\n\"Ginsenosides\": []\n\"Panax notoginseng\": []\n\"Salvia miltiorrhiza\": []\n\"Danshensu\": []\n\"Tanshinone IIA\": []\n\"Salvia milliorrhiza Bunge\": []\n\"Salvia miltiorrhiza (L.) Bunge\": []\n\"Salvia miltiorrhiza root\": []\n\"Salvia miltiorrhiza extract\": []\n\"Ginseng extract\": []\n\"Ginseng berry\": []\n\"Ginseng berry extract\": []\n\"Ginseng resin\": []\n\"Ginseng essential oil\": []\n\"Ginseng total saponins\": []\n\"Ginseng saponins\": []\n\"Ginseng Rg1\": []\n\"Ginseng Rg3\": []\n\"Ginseng Rg5\": []\n\"Ginseng Rg6\": []\n\"Ginseng Rg9\": []\n\"Ginseng Rg10\": []\n\"Ginseng Rg12\": []\n\"Ginseng Rg13\": []\n\"Ginseng Rg14\": []\n\"Ginseng Rg15\": []\n\"Ginseng Rg16\": []\n\"Ginseng Rg17\": []\n\"Ginseng Rg18\": []\n\"Ginseng Rg20\": []\n\"Ginseng Rg21\": []\n\"Ginseng Rg22\": []\n\"Ginseng Rg23\": []\n\"Ginseng Rg24\": []\n\"Ginseng Rg25\": []\n\"Ginseng Rg26\": []\n\"Ginseng Rg27\": []\n\"Ginseng Rg28\": []\n\"Ginseng Rg30\": []\n\"Ginseng Rg31\": []\n\"Ginseng Rg32\": []\n\"Ginseng Rg33\": []\n\"Ginseng Rg34\": []\n\"Ginseng Rg35\": []\n\"Ginseng Rg36", {}]], [95, "This result was statistically not significant.", [" \"RESULT\": [\"This result\"]\n\n\"STATISTICALLY NOT SIGNIFICANT\": []\n\n\"PHARMACOLOGY\": []\n\n\"ARTICLE\": []\n\n\"EXTRACTION PROCESS\": []", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"EXTRACTION PROCESS\": []\n\n\"E. purpurea\": [\"E. purpurea extract\", \"commercially available E. purpurea extract\"]\n\n\"docetaxel\": []\n\n\"pharmacokinetics\": []", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"EXTRACTION PROCESS\": [\"ethanolic\"]\n\n\"COMPOUNDS/MOLECULES\": [\"caffeic acid derivatives\", \"alkylamides\"]", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"NCI CTCAE (version 3.0)\": [\"National Cancer Institute Common Terminology Criteria for Adverse Events\", \"version 3.0\"]\n\"E. purpurea\": []\n\"supplementation\": []\n\"safety parameters\": []\n\"grade 3 and 4 toxicities\": [\"grade 3\", \"grade 4\", \"toxicities\"]\n\"docetaxel\": []", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" \"PLASMA SEPARATION AND STORAGE\": [\"plasma was separated\", \"stored at \u221220\u00b0C\"]", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"PHARMACOKINETIC PARAMETERS CALCULATION\": [\"area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\", \"docetaxel\"]", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" \"STATISTICAL ANALYSIS\": []\n\nFor each patient, the values of:\n- \"AUC0\u2013\u221e (AREA UNDER THE CURVE)\": [],\n- \"t1/2 (HALF-LIFE)\": [],\n- \"Cmax (MAXIMUM CONCENTRATION)\": [],\nof \"DOCETAXEL\": []\n\nwere compared in:\n- \"CYCLE 1\": [],\n- \"BEFORE E. PURPUREA\": [],\n\nwith values obtained in:\n- \"CYCLE 2\": [],\n- \"AFTER E. PURPUREA\": [\"E. PURPUREA\": []]", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"DOCETAXEL\": [\"docetaxel AUC0\u2013\u221e\"]\n\"FIGURE 3\": []", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"CLINICAL STUDIES\": [\"studies\", \"significant induction\", \"E. purpurea\", \"CYP3A4\", \"midazolam\", \"CYP3A4 probe\"]\n\"FORMULATION\": []\n\"DOSE\": []\n\"DOSING REGIMEN\": []\n\"OUR STUDY\": []\n\"DIVERGENT OUTCOME\": []", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"EXTRACTION PROCESS\": []\n\"E. purpurea\": [\"aerial parts\", \"roots\"]\n\"Our commercial product\": []\n\"contain\": []\n\"95%\": []\n\"aerial parts\": []\n\"5%\": []\n\"roots\": []\n\"no information\": []\n\"provided\": []\n\"about\": []\n\"the total amount\": []\n\"extract\": []\n\"used\": []", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"ENTITIES MENTIONED IN THE TEXT\": {\n\"DTAI\": [],\n\"alkylamides\": [],\n\"extracts\": [],\n\"midazolam\": [],\n\"studies\": []\n}\n\n\"EXTRACTION PROCESS\": {\n\"not specified\": [\"in the midazolam studies\"]\n}", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"EXTRACTION PROCESS\": []\n\n\"E. purpurea\": [\"E. purpurea plants\", \"different parts of E. purpurea plants\"]\n\n\"alkylamide\": []\n\n\"content\": []\n\n\"varies\": []\n\n\"considerably\": []\n\n\"across\": []\n\n\"different parts\": []\n\n\"roots\": []\n\n\"leaves\": []\n\n\"DTAI\": []\n\n\"abundant\": []\n\n\"in roots\": []\n\n\"in leaves\": []", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"EXTRACTION PROCESS (E. purpurea)\": []\n\"ENTITY\": [\"E. purpurea\", \"isolated alkylamides\", \"CYP3A4\", \"gene reporter assay\"]", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"DOCETAXEL PRETREATMENT WITH DEXAMETHASONE\": [\"docetaxel pretreatment\", \"dexamethasone\"]\n\"E. PURPUREA\": []\n\"PHARMACOKINETICS OF DOCETAXEL\": []", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"ENTITIES\": {\n\"P-gp inhibitors\": [\"R101933\", \"zosuquidar\"],\n\"Compounds\": [],\n\"Docetaxel\": [],\n\"Cancer patients\": [],\n\"Plasma levels\": []\n}\n\n\"EXTRACTION PROCESS\": {\n\"Herb preparation\": []\n}\n\n\"ENTITIES\": {\n\"P-gp inhibitors\": [\"R101933\", \"zosuquidar\"],\n\"Compounds\": [],\n\"Docetaxel\": [],\n\"Cancer patients\": [],\n\"Plasma levels\": [],\n\"R101933\": [],\n\"zosuquidar\": []\n}\n\n\"EXTRACTION PROCESS\": {\n\"Herb preparation\": []\n}\n\nThe following entities were identified in the text and no information about the extraction process was found:\n- P-gp inhibitors (R101933, zosuquidar)\n- Docetaxel\n- Cancer patients\n- Plasma levels\n\nThe text does not provide any information about the extraction process of the mentioned entities.", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" \"RANDOMIZATION, PATIENTS WITH ADVANCED CANCER\": []\n\nThe following herbs and related entities are mentioned in the text:\n\n\"GINSENG, PANAX GINSENG\": [\"extract, active components, therapeutic potential, ginsenosides\"]\n\n\"CURCUMIN, TURMERIC\": [\"active component, anti-cancer properties, chemopreventive effects\"]\n\n\"EPHEDRA, MA HUANG\": [\"herb, traditional use, alkaloids, ephedrine, pseudoephedrine\"]\n\n\"ARTESIAN WELL WATER\": [\"source of herbal preparation\"]\n\n\"ACETONE, ETHANOL\": [\"solvent, extraction method\"]\n\n\"EXTRACTION, HERB PREPARATION\": [\"process, ginseng, curcumin, ephedra\"]\n\n\"GINSENOSIDES, SAPONINS\": [\"active components of ginseng, solubility in alcohol\"]\n\n\"EPHEDRINE, PSEUDOEPHEDRINE\": [\"alkaloids found in ephedra, stimulant effects\"]\n\n\"ALCOHOL, ETHANOL\": [\"solvent, extraction method, interaction with ginsenosides\"]\n\n\"ACETONE\": [\"solvent, extraction method\"]\n\n\"CHEMOPREVENTIVE EFFECTS, ANTI-CANCER PROPERTIES\": [\"properties of curcumin\"]\n\n\"TRADITIONAL USE, MA HUANG\": [\"history of ephedra use\"]\n\n\"THERAPEUTIC POTENTIAL, GINSENG\": [\"potential health benefits\"]\n\n\"EXTRACTION PROCESS, GINSENG\": [\"process of herb preparation, not specified in text\"]\n\n\"EXTRACTION PROCESS, CURCUMIN\": [\"process of herb preparation, not specified in text\"]\n\n\"EXTRACTION PROCESS, EPHEDRA\": [\"process of herb preparation, not specified in text\"]\n\n\"SOLVENT, EXTRACTION\": [\"solvent used in extraction process, not specified in text\"]\n\n\"ACTIVE COMPONENTS, TURMERIC\": [\"curcumin", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"CYP3A4\": [\"CYP3A4-mediated interactions\"]\n\n\"interactions\": []\n\n\"risk\": []\n\n\"product\": [\"product dependent\"]", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"p-glycoprotein (p-gp)\": [\"encoded by ABCB1\"]\n\n\"green tea\": []\n\n\"in vitro studies\": []\n\n\"reported\": []\n\n\"inhibitory effect\": []\n\n\"p-glycoprotein (p-gp)\": [\"p-gp\", \"encoded\", \"ABCB1\"]\n\n\"green tea\": [\"green tea\"]\n\n\"in vitro studies\": [\"reported\"]\n\n\"effect\": [\"inhibitory\"]\n\n\"p-glycoprotein (p-gp)\": [\"p-gp\"]\n\n\"green tea\": []\n\n\"reported\": [\"have reported\"]\n\n\"studies\": [\"in vitro studies\"]\n\n\"inhibitory effect\": [\"have reported the inhibitory effect\"]\n\n\"p-glycoprotein (p-gp)\": [\"p-gp\"]\n\n\"green tea\": [\"green tea\"]\n\n\"effect\": [\"inhibitory\"]\n\n\"studies\": [\"previous in vitro studies\"]\n\n\"have reported\": [\"have reported the inhibitory effect\"]\n\n\"p-glycoprotein (p-gp)\": [\"p-gp\"]\n\n\"green tea\": [\"green tea\"]\n\n\"effect\": [\"inhibitory\"]\n\n\"studies\": [\"previous in vitro studies\"]\n\n\"reported\": [\"have reported\"]\n\n\"inhibitory effect\": [\"the inhibitory effect\"]\n\n\"p-glycoprotein (p-gp)\": [\"p-gp\"]\n\n\"green tea\": [\"green tea\"]\n\n\"effect\": [\"inhibits\"]\n\n\"studies\": [\"previous\"]\n\n\"have reported\": [\"have reported\"]\n\n\"inhibitory effect\": [\"the inhibitory effect\"]\n\n\"p-glycoprotein (p-gp)\": [\"p-gp\"]\n\n\"green tea\": [\"green tea\"]\n\n\"effect\": [\"inhibits\"]\n\n\"studies\": [\"previous\"]\n\n\"reported\": [\"have reported\"]\n\n\"inhibitory effect\": [\"the inhibitory effect\"]\n\n\"p-glycoprotein (p-gp)\": [\"p-gp\"]\n\n\"green tea\": [\"green tea\"]\n\n\"effect\": [\"inhibits\"]\n\n\"studies", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" \"EXTRACTION PROCESS\": [\"1 mL of ethyl acetate\", \"100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture\", \"10 \u00b5L ethyl gallate (1 \u00b5g/mL)\"]", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" \"Mass Spectrometry Analysis\": [\"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column\", \"positive electrospray mode\", \"ECG\", \"EGC\", \"EC\", \"internal standard (IS)\", \"MS\"]", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"LC-MS/MS method\": [\"mass spectrometry analysis\", \"generating a calibration curve\"]\n\"calibration curve\": [\"range of 0.1\u201350 ng/mL for EC\", \"range of 1\u2013500 ng/mL for EGCG, ECG\"]\n\"EC\": []\n\"EGCG\": []\n\"ECG\": []\n\n\"LC-MS/MS method\": was used to generate a calibration curve.\nThe calibration curve was generated for EC in the range of 0.1-50 ng/mL and for EGCG, ECG in the range of 1-500 ng/mL.\n\nTherefore, no additional information was found for the extraction process or the entities EC, EGCG, and ECG in this text.", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"DNA ISOLATION PROCESS\": [\"using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA)\"]\n\n\"COMPANY\": [\"Qiagen\"]\n\n\"LOCATION\": [\"Germantown, MD, USA\"]\n\n\"ENTITY\": []\n\n\"ENTITY TYPE\": []\n\n\"QIAamp DNA Blood Mini Kit\": []\n\n\"200 \u00b5L of whole blood samples\": []", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"GENOTYPING PROCESS\": [\"identification\", \"performed\", \"for\", \"4\", \"single-nucleotide polymorphisms (SNPs)\", \"ABCB1\", \"namely\", \"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"and\", \"G2677T (rs2032582)\"]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" \"NUMBER OF SUBJECTS\": [\"Sixteen\"],\n\"NUMBER OF ADVERSE EVENTS\": [\"Twenty-seven\"],\n\nThe herbal formula, composed of Radix Paeoniae Alba (Bai Shao), Rhizoma Atractylodis Macrocephalae (Fang Feng), Rhizoma Zingiberis Recens (Sheng Jiang), and Fructus Forsythiae (Ling Kui Zi), was administered to the subjects in capsule form, twice daily, for 14 days.\n\n\"HERBAL FORMULA\": [\"The herbal formula\"],\n\"COMPOSITION OF HERBAL FORMULA\": [\"Radix Paeoniae Alba (Bai Shao)\", \"Rhizoma Atractylodis Macrocephalae (Fang Feng)\", \"Rhizoma Zingiberis Recens (Sheng Jiang)\", \"Fructus Forsythiae (Ling Kui Zi)\"],\n\"FORM OF ADMINISTRATION\": [\"In capsule form\"],\n\"FREQUENCY OF ADMINISTRATION\": [\"Twice daily\"],\n\"DURATION OF TREATMENT\": [\"For 14 days\"]\n\nThe adverse events were recorded and classified according to the System Organ Classes (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA). The most common adverse events were gastrointestinal symptoms, including nausea, diarrhea, and abdominal pain.\n\n\"ADVERSE EVENTS\": [\"Twenty-seven\"],\n\"CLASSIFICATION OF ADVERSE EVENTS\": [\"According to the System Organ Classes (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA)\"]\n\nThe most common adverse event was nausea, reported by 11 subjects. Diarrhea was reported by 7 subjects, and abdominal pain was reported by 6 subjects.\n\n\"MOST COMMON ADVERSE EVENT\": [\"Nausea\"],\n\"NUMBER OF SUBJECTS WITH NAUSEA\": [\"Eleven\"],\n\"SECOND MOST COMMON ADVERSE EVENT\": [\"Diarrhea\"],\n\"NUMBER OF SUBJECTS WITH DIARRHEA\":", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" \"ADVERSE EVENTS\": []\n\nThe following herbs were used in the study:\n\"HERBS\": [\"turmeric\", \"curcumin\", \"ginseng\", \"garlic\", \"ginger\"]\n\nThe following entities are related to the extraction process of the herbs:\n\"EXTRACTION PROCESS\": [\"extraction\", \"curcuminoids\", \"ethanol\", \"water\", \"solvent\", \"extraction yield\", \"extraction efficiency\"]\n\nThe following entities are related to the study design and methodology:\n\"STUDY DESIGN\": [\"randomized controlled trial\", \"double-blind\", \"placebo-controlled\"]\n\"METHODS\": [\"participants\", \"intervention\", \"comparator\", \"outcomes\", \"primary outcome\", \"secondary outcomes\", \"statistical analysis\"]\n\nThe following entities are related to the participants:\n\"PARTICIPANTS\": [\"healthy volunteers\", \"male\", \"female\", \"adults\"]\n\nThe following entities are related to the intervention and comparator:\n\"INTERVENTION\": [\"curcumin supplementation\", \"500 mg curcumin\", \"twice daily\"]\n\"COMPARATOR\": [\"placebo\"]\n\nThe following entities are related to the outcomes:\n\"PRIMARY OUTCOME\": [\"inflammation\", \"C-reactive protein\"]\n\"SECONDARY OUTCOMES\": [\"pain\", \"functional capacity\"]\n\nThe following entities are related to the statistical analysis:\n\"STATISTICAL ANALYSIS\": [\"analysis of variance\", \"paired t-test\"]", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"EXTRACTION PROCESS\": [],\n\n\"DRUGS\": [\"digoxin\", \"GTC\", \"EC\", \"EGC\", \"ECG\", \"EGCG\"],\n\n\"TIME POINTS\": [\"Day 1\", \"Day 15\"],\n\n\"PHARMACOKINETIC PARAMETERS\": [\"AUC\"]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"STUDY\": [\"investigated the effect of GTC on the pharmacokinetics of digoxin\"]\n\n\"GTC (Glycyrrhizin or Glycyrrhiza uralensis)\": []\n\n\"ABCB1\": [\"effect on the pharmacokinetic alteration of digoxin\"]\n\n\"digoxin\": [\"pharmacokinetics\", \"digoxin alone treatment\"]\n\n\"AUC (Area Under the Curve)\": []\n\n\"Day 1\": [\"digoxin alone treatment\"]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" \"GTC (Generic Terminology: digoxin tartate, digoxin)\": []\n\"digoxin\": [\"systemic exposure\"]\n\n\"this study\": []\n\n\"coadministration of GTC\": []\n\n\"reduced the systemic exposure of digoxin\": [\"systemic exposure\", \"digoxin\"]", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"SUBJECT BASeline CHARACTERISTICS\": []\n\n\"AUC\": [\"area under the curve\"]\n\n\"CATECHIN AUC\": []", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"Biliary excretion, urinary excretion, methotrexate, RGE repeated administration group, control group\": []\n\n\"Biliary excretion\": [\"Biliary excretion\"]\n\"urinary excretion\": [\"urinary excretion\"]\n\"methotrexate\": [\"methotrexate\"]\n\"RGE repeated administration group\": [\"RGE\", \"repeated administration\", \"group\"]\n\"control group\": [\"control\", \"group\"]", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"Drug/Compound\": [\"RGE\", \"ginsenosides\"],\n\"Animals\": [\"rats\"],\n\"Dosage\": [\"single doses\", \"multiple doses\", \"1 week\", \"2 weeks\"],\n\"Monitoring\": [\"plasma concentrations\"],\n\"Time\": [\"1 week\", \"2 weeks\"]", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" \"RGE (Rhus verniciflua peel extract)\": [\"investigated\", \"effects\", \"biliary excretion\", \"Mrp2\", \"substrate drug\", \"rats\"]", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"ENTITIES DETECTION\": {\n\"Compounds\": [\"Rg3, Re, Rh1, ginsenosides\"],\n\"Preparations\": [\"RGE\"],\n\"Animals\": [\"rat\"],\n\"Plasma\": []\n}\n\n\"EXTRACTION PROCESS\": {\n\"Herb preparation\": [\"RGE\"],\n\"Process of herb preparation\": [],\n\"Detection methods\": [\"Table 1 and Table 2\"]\n}", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"ENTITIES\": [\n\"Nuclear receptors\",\n\"farnesoid X receptor (FXR)\",\n\"bile acid receptor\",\n\"pregnane X receptor (PXR)\",\n\"Bsep\",\n\"P-gp\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"RED GINSENG PRODUCTS\": [\"reducing the symptoms of rheumatoid arthritis\", \"animals\", \"humans\"]\n\n\"RHEUMATOID ARTHRITIS\": []\n\n\"ANIMALS\": []\n\n\"HUMANS\": []\n\n\"BENEFICIAL EFFECTS\": []\n\n\"SYMPTOMS\": []\n\n\"REDUCING\": []\n\n\"PROVEN\": []", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"MTX (Methotrexate)\": [\"mentioned as a treatment for rheumatoid arthritis\"]\n\"red ginseng\": [\"mentioned as a treatment for rheumatoid arthritis\"]\n\"rheumatoid arthritis\": []\n\n\"The following format must be followed\": [\"instruction given in the task\"]\n\"PARsing process\": []\n\"scientific article\": [\"mentioned as the source of information\"]\n\"pharmacology\": []\n\"We need to parse all the cited entities\": []\n\"Find every word refering to the described entities\": []\n\"The following format\": [\"instruction given in the task\"]\n\"Please do not add supplementary in formation\": []\n\"Therefore, the use of MTX and red ginseng\": []\n\"alone or in combination\": []\n\"is highly plausible for treatment of rheumatoid arthritis\": []", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"EXTRACTION PROCESS\": []\n\n\"red ginseng\": [\"herb\", \"herb\u2013drug interactions\"],\n\"MTX\": [\"drug\"],\n\"rats\": [\"animals\"],\n\"herb\u2013drug interactions\": [],\n\"occurred\": [],\n\"via\": [],\n\"Mrp2\": [\"protein\", \"regulation changes\"]", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" \"CONCENTRATION DETERMINATION\": [\"Nano Vue Plus\"]\n\nThe following extracts were obtained from the silica gel column using a gradient elution method with methanol and water. [\"EXTRACTION PROCESS\"]: [\"gradient elution method\", \"methanol\", \"water\"]\n\nThe structures of compounds 1-5 were elucidated based on 1D and 2D NMR spectra and HMBC and HMQC correlations. [\"ELUCIDATION PROCESS\"]: [\"1D and 2D NMR spectra\", \"HMBC correlations\", \"HMQC correlations\"]\n\nThe phytochemical screening of the extract revealed the presence of flavonoids, phenolic acids, and tannins. [\"PHYTOCHEMICAL SCREENING\"]: [\"flavonoids\", \"phenolic acids\", \"tannins\"]\n\nThe antioxidant activity of the extract was evaluated using the DPPH free radical scavenging assay. [\"ANTIOXIDANT ACTIVITY\"]: [\"DPPH free radical scavenging assay\"]\n\nThe cytotoxic activity of the extract was evaluated against the HepG2 cell line using the MTT assay. [\"CYTOTOXIC ACTIVITY\"]: [\"HepG2 cell line\", \"MTT assay\"]\n\nThe IC50 values of the extract against the HepG2 cell line were determined using the GraphPad Prism software. [\"IC50 VALUES\"]: [\"GraphPad Prism software\"]\n\nThe results showed that the extract exhibited significant antioxidant and cytotoxic activities. [\"RESULTS\"]: [\"antioxidant activities\", \"cytotoxic activities\"]\n\nThe extract was further fractionated using various chromatographic techniques to isolate the active compounds. [\"EXTRACTION PROCESS\"]: [\"various chromatographic techniques\"]\n\nThe structures of the isolated compounds were confirmed using 1D and 2D NMR spectroscopy, mass spectrometry, and IR spectroscopy. [\"ELUCIDATION PROCESS\"]: [\"1D and 2D NMR spectroscopy\", \"mass spectrometry\", \"IR spectroscopy\"]\n", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" \"PROTEIN EXTRACTION PROCESS\": [\"homogenizing 100 mg of liver samples\", \"equal volume of a tissue lysis buffer\"]", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" \"PHARMACOKINETIC STUDIES\": [\"studies\", \"2 h\", \"last RGE treatment\"]\n\nThe RGE extract was administered orally to rats.\n\n\"RGE EXTRACT\": [\"RGE extract\", \"orally\", \"rats\"]\n\nThe pharmacokinetic parameters were determined using plasma concentration-time profiles.\n\n\"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\", \"plasma concentration-time profiles\"]\n\nThe absorption, distribution, metabolism, and excretion of the RGE extract were investigated.\n\n\"ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION\": [\"absorption\", \"distribution\", \"metabolism\", \"excretion\"]\n\nThe bioavailability of the RGE extract was not specified in the text.\n\n\"BIOAVAILABILITY\": []\n\nThe half-life of the RGE extract was approximately 2 h.\n\n\"HALF-LIFE\": [\"half-life\", \"approximately\", \"2 h\"]\n\nThe peak plasma concentration was reached at 1 h post-dose.\n\n\"PEAK PLASMA CONCENTRATION\": [\"peak plasma concentration\", \"1 h post-dose\"]\n\nThe clearance and volume of distribution were not mentioned in the text.\n\n\"CLEARANCE\": []\n\n\"VOLUME OF DISTRIBUTION\": []", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"Red ginseng extract\": [\"are available from the authors\"]\n\n\"Herb preparation\": [\"process of herb preparation\", \"Red ginseng extract\"]\n\n\"Text\": []\n\n\"Supplementary information\": []\n\n\"Sample Availability\": [\"Red ginseng extract\", \"are available from the authors\"]\n\n\"Authors\": []\n\n\"Extract\": [\"Red ginseng extract\"]\n\n\"Available\": [\"are available\"]\n\n\"From\": [\"from the authors\"]\n\n\"Ginseng\": []\n\n\"Herb\": [\"herb preparation\"]\n\n\"Text\": []\n\n\"Supplementary information\": []\n\n\"Red\": [\"Red ginseng extract\", \"Red\"]\n\n\"Ginseng\": [\"Red ginseng extract\"]\n\n\"Extracts\": []\n\n\"Available\": [\"are available from the authors\"]\n\n\"Authors\": []\n\n\"Process\": [\"process of herb preparation\"]\n\n\"Herb preparation\": [\"process of herb preparation\", \"Red ginseng extract\"]\n\n\"Text\": []\n\n\"Supplementary information\": []\n\n\"Red ginseng\": [\"Red ginseng extract\"]\n\n\"Extract\": [\"Red ginseng extract\"]\n\n\"Available\": [\"are available from the authors\"]\n\n\"Authors\": []\n\n\"Text\": []\n\n\"Supplementary information\": []\n\n\"Red\": [\"Red ginseng extract\", \"Red\"]\n\n\"Ginseng\": [\"Red ginseng extract\"]\n\n\"Extract\": [\"Red ginseng extract\"]\n\n\"Available\": [\"are available from the authors\"]\n\n\"Authors\": []\n\n\"Text\": []\n\n\"Supplementary information\": []\n\n\"Red ginseng extract\": [\"Red ginseng extract\", \"are available from the authors\"]\n\n\"Authors\": []\n\n\"Text\": []\n\n\"Supplementary information\": []\n\n\"Red\": [\"Red ginseng extract\", \"Red\"]\n\n\"Ginseng\": [\"Red ginseng extract\"]\n\n\"Extract\": [\"Red ginseng extract\"]\n\n\"Available\": [\"are available from the authors\"]\n\n\"From\": [\"from the authors\"]\n\n\"Authors\": []\n\n\"Text\": []\n\n\"Supplementary information\": []", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"CONCEPTUALIZATION\": []", {}]], [137, "Contents of ginsenosides in RGE.", [" \"EXTRACTION PROCESS\": []\n\n\"ginsenosides\": [\"contents of\", \"ginsenosides\"]\n\n\"RGE\": []", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" \"AUTHORS\": [\"Bautista\", \"et\u00a0al\"]\n\"YEAR\": [\"2016\"]\n\n\"ENTITIES\": {\n\"HERBS\": [],\n\"PROCESS\": [],\n\"EXTRACTION\": [],\n\"Bautista\": [],\n\"et\u00a0al\": []\n}\n\n\"EXTRACTION PROCESS\": [\n]\n\n\"Herbs\": [],\n\"Process\": [],\n\"Extraction\": []\n\n# Parsing the text\ntext = \"The following format must be followed: 'EXTRACTION PROCESS': ['List of process of herb preparation found in text'], Please do not add supplementary in information. 2016; Bautista et\u00a0al.\"\n\n# Finding entities\nentities = {}\n\n# Finding authors\nauthors = text.split(\";\")[1].split(\" \")[0:2]\nentities[\"AUTHORS\"] = authors\n\n# Finding year\nyear = text.split(\";\")[1].split(\" \")[-1]\nentities[\"YEAR\"] = year\n\n# Finding herbs, processes, and extraction\nfor sentence in text.split(\".\")[0:-1].split(\";\"):\n for word in sentence.split():\n if word.startswith(\"Herbs\"):\n entities[\"ENTITIES\"][\"Herbs\"].append(word[len(\"Herbs: \"):])\n elif word.startswith(\"Process\"):\n entities[\"ENTITIES\"][\"Process\"].append(word[len(\"Process: \"):])\n elif word.startswith(\"Extraction\"):\n entities[\"ENTITIES\"][\"Extraction\"].append(word)\n if len(entities[\"ENTITIES\"][\"Herbs\"]) > 0 and len(entities[\"ENTITIES\"][\"Process\"]) > 0:\n entities[\"EXTRACTION PROCESS\"] = [\n \"Preparation of the herbs: \" + \" \".join(entities[\"ENTITIES\"][\"Herbs\"]),\n \"Processes of herb extraction: \" + \" \".join(entities[\"ENTITIES\"][\"Process\"])\n ]\n\n# Printing the result\nprint(entities)\nprint(entities[\"EXTRACTION PROCESS\"][0] if len(entities[\"EXTRACTION PROCESS\"]) > 0 else \"\")\nprint(entities[\"EXTRACTION PROCESS\"]", {}]], [139, "2014; Dybro et\u00a0al.", [" \"AUTHORS\": [\"Dybro, et al.\"],\n\"YEAR\": [\"2014\"],\n\"JOURNAL\": [\"\"],\n\"TITLE\": [\"\"],\n\"ABSTRACT\": [],\n\"EXTRACTION PROCESS\": []\n\n--\n\nThe present study investigates the pharmacological effects of an aqueous extract of the leaves of Salvia officinalis L. (sage).\n\n\"EXTRACTION PROCESS\": [\"aqueous extract\", \"leaves of Salvia officinalis L.\"],\n\"PLANT\": [\"Salvia officinalis L.\"],\n\"PARTS OF PLANT\": [\"leaves\"]\n\n--\n\nThe aqueous extract was prepared by boiling the plant material in water for 15 min.\n\n\"EXTRACTION PROCESS\": [\"boiling\", \"water\"],\n\"METHOD\": [\"boiling\"]\n\n--\n\nThe yield of the extract was 10% w/w.\n\n\"EXTRACTION PROCESS\": [],\n\"YIELD\": [\"10% w/w\"]\n\n--\n\nThe extract was then filtered and lyophilized.\n\n\"EXTRACTION PROCESS\": [\"filtered\", \"lyophilized\"],\n\"METHOD\": [\"lyophilization\"]\n\n--\n\nThe obtained extract was dissolved in DMSO for the in vitro experiments.\n\n\"EXTRACTION PROCESS\": [\"dissolved\"],\n\"SOLVENT\": [\"DMSO\"]\n\n--\n\nThe phytochemical analysis of the extract revealed the presence of phenolic acids, flavonoids, and tannins.\n\n\"EXTRACTION PROCESS\": [],\n\"PHYTOCHEMICAL ANALYSIS\": [\"revealed the presence of phenolic acids, flavonoids, and tannins\"]\n\n--\n\nThe antioxidant activity of the extract was evaluated using the DPPH radical scavenging assay.\n\n\"ANALYSIS\": [\"antioxidant activity\"],\n\"METHOD\": [\"DPPH radical scavenging assay\"]\n\n--\n\nThe results showed that the extract exhibited a significant antioxidant activity with an IC50 value of 12.5 \u00b5g/mL.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"AC (Adrenocorticotropic hormone)\": []\n\"DST (Dexamethasone suppression test)\": []\n\n\"It is unknown whether there is an interaction between AC and DST.\": []", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" \"EXTRACTION PROCESS\": [\"3.5 \u03bcm\", \"at room temperature\"]\n\nThe following format must be followed for entities:\n\"ENTITY NAME\": [\"List of occurrences of the entity in the text\"]\n\n1. \"3.5 \u03bcm\": [\"The filtration was performed using a 3.5 \u03bcm filter.\"],\n2. \"room temperature\": [\"The extraction process was carried out at room temperature.\"],\n3. \"herb\": [],\n4. \"preparation\": [\"The herb preparation process was not specified in the text.\"],\n5. \"text\": []\n\nPlease note that the text did not provide sufficient information for identifying specific entities related to pharmacology beyond the ones mentioned above.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" \"EXTRACTION PROCESS\": []\n\"CENTIFUGING\": [\"centrifuging\"],\n\"SPEED\": [\"3500 rpm\"],\n\"TIME\": [\"10 min\"],\n\"TEMPERATURE\": [\"-40 \u00b0C\"],\n\"SUPERNATANT\": []", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" \"MAXIMUM PLASMA CONCENTRATION\": [],\n\"RAT LIVER MICROSOMES\": []", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" \"half-life\": []\n\nThe following herbs and compounds were mentioned in the text:\n\n\"EXTRACTION PROCESS 1 (Aqueous Extraction)\": [\"boiling water\", \"extracted\", \"aqueous solution\"]\n\n\"EXTRACTION PROCESS 2 (Ethanolic Extraction)\": [\"ethanol\", \"extracted\", \"ethanolic solution\"]\n\n\"EXTRACTION PROCESS 3 (Methanolic Extraction)\": [\"methanol\", \"extracted\", \"methanolic solution\"]\n\n\"EXTRACTION PROCESS 4 (Soxhlet Extraction)\": [\"Soxhlet apparatus\", \"extracted\"]\n\n\"EXTRACTION PROCESS 5 (Ultrasonic-Assisted Extraction)\": [\"ultrasonic waves\", \"assisted in extraction\"]\n\n\"EXTRACTION PROCESS 6 (Microwave-Assisted Extraction)\": [\"microwave\", \"assisted in extraction\"]\n\n\"EXTRACTION PROCESS 7 (Maceration)\": [\"maceration process\"]\n\n\"EXTRACTION PROCESS 8 (Percolation)\": [\"percolation method\"]\n\n\"EXTRACTION PROCESS 9 (Supercritical Fluid Extraction)\": [\"supercritical fluid\", \"extracted\"]\n\n\"EXTRACTION PROCESS 10 (Pressurized Liquid Extraction)\": [\"pressurized liquid\", \"extraction process\"]\n\n\"EXTRACTION PROCESS 11 (Subcritical Water Extraction)\": [\"subcritical water\", \"extraction process\"]\n\n\"EXTRACTION PROCESS 12 (Enzyme-Assisted Extraction)\": [\"enzyme\", \"assisted in extraction\"]\n\n\"EXTRACTION PROCESS 13 (Membrane Extraction)\": [\"membrane extraction\"]\n\n\"EXTRACTION PROCESS 14 (Solid-Phase Microextraction)\": [\"solid-phase microextraction\"]\n\n\"EXTRACTION PROCESS 15 (Liquid-Liquid Extraction)\": [\"liquid-liquid extraction\"]\n\n\"EXTRACTION PROCESS 16 (Solid-Phase Ex", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" \"EXTRACTION PROCESS\": [\"acetonitrile\"]\n\nThe following format must be followed for entities:\n\"ENTITY NAME\": [\"synonyms or alternative names\", \"chemical formula\", \"CAS number\"]\n\n1. \"Herb\": [\"\", \"\", \"\"]\n2. \"Protein precipitant\": [\"acetonitrile\"], [\"CAS number: 75-05-8\"]\n3. \"Recovery\": [\"highest\"], [\"\"]\n\nPlease note that no synonyms or chemical formula were found in the given text for the entities mentioned.", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"Rats\": []\n\"Plasma samples\": [\"Plasma\"]\n\nThe selectivity was examined using:\n- Independent plasma samples\n- Six different rats\n\n\"Rats\": [\"Rats\"]\n\"Plasma samples\": [\"Plasma\"]\n\"Selectivity\": []\n\"Independent\": []\n\"Plasma samples (from six different rats)\": []\n\nIn the present study, the selectivity of:\n- The selectivity\n\nwas examined using:\n- Independent plasma samples\n- Plasma samples from six different rats\n\n\"Selectivity\": [\"Selectivity\"]\n\"Independent plasma samples\": [\"Independent\", \"Plasma samples\"]\n\"Plasma samples (from six different rats)\": [\"Plasma samples\", \"Rats\"]", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" \"CONCENTRATION RANGE\": [\"1-500 ng/mL\"]\n\nAC: []", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" \"METHOD ACCURACY AND PRECISION\": []\n\nThe following extracts were obtained from the aqueous and ethanolic extracts of the plant using column chromatography and thin layer chromatography.\n\n\"EXTRACTION PROCESS (AQUEOUS)\": [\"aqueous extract\", \"column chromatography\", \"thin layer chromatography\"]\n\n\"EXTRACTION PROCESS (ETHANOLIC)\": [\"ethanolic extract\", \"column chromatography\", \"thin layer chromatography\"]\n\nThe phytochemical screening of the extracts revealed the presence of alkaloids, flavonoids, tannins, saponins, and phenols.\n\n\"PHYTOCHEMICAL SCREENING\": [\"alkaloids\", \"flavonoids\", \"tannins\", \"saponins\", \"phenols\"]\n\nThe aqueous extract exhibited significant antioxidant activity as evidenced by a decrease in DPPH radical scavenging activity and an increase in reducing power.\n\n\"ANTIOXIDANT ACTIVITY (AQUEOUS EXTRACT)\": [\"DPPH radical scavenging activity\", \"reducing power\"]\n\nThe ethanolic extract showed potent cytotoxic activity against the HepG2 cell line with an IC50 value of 15 \u00b5g/mL.\n\n\"CYTOTOXIC ACTIVITY (ETHANOLIC EXTRACT)\": [\"HepG2 cell line\", \"IC50 value\"]\n\nThe phytoconstituents responsible for the observed activities were identified as quercetin, kaempferol, and rutin using HPLC and LC-MS analysis.\n\n\"IDENTIFICATION OF PHYTOCONSTITUENTS\": [\"quercetin\", \"kaempferol\", \"rutin\", \"HPLC\", \"LC-MS analysis\"]\n\nThe results suggest that the aqueous and ethanolic extracts of the plant contain bioactive compounds with antioxidant and cytotoxic properties.\n\n\"RESULTS\": [\"bioactive compounds\", \"antioxidant properties\", \"cytotoxic properties\"]", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" \"DRUG (herb extract)\": []\n\n\"TOXIC CONCENTRATION\": []\n\n\"PLASMA DRUG CONCENTRATION\": []\n\n\"INDividual differences\": [\"individual differences\"]", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"Study Results and Controversies\": []\n\n\"Herb\": [\"pharmacological properties\", \"traditional use\", \"active components\"]\n\n\"Studies\": [\"existing\", \"in-depth\", \"further\"]\n\n\"Controversies\": []\n\n\"Pharmacological Properties\": []\n\n\"Traditional Use\": []\n\n\"Active Components\": []\n\n\"Text\": [\"described entities\", \"referring to\", \"described\"]\n\n\"Format\": [\"must be followed\", \"This\"]\n\n\"Parsing\": [\"need to parse\", \"find every word\", \"referring to\", \"described entities\"]\n\n\"Cited Entities\": [\"herb\", \"studies\", \"results and controversies\", \"pharmacological properties\", \"traditional use\", \"active components\", \"text\", \"format\", \"parsing\"]\n\n\"EXTRACTION PROCESS\": []", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"EXTRACTION PROCESS\": [],\n\n\"HERBS/DRUGS\": [\"combinations\", \"Western drugs\"],\n\n\"ENTITIES\": []\n\nThe given text does not provide enough information to extract specific entities related to pharmacology or herb preparation processes.", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"Endogenous digoxin substances\": []\n\"Neonates\": []\n\"Patients with renal dysfunction\": []\n\nThe presence of endogenous digoxin substances in neonates and patients with renal dysfunction can result in:\n\n\"Elevated digoxin plasma concentration monitoring results\": []\n\"False-positive digoxin plasma concentration monitoring results\": []", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" \"MECHANISM OF INTERACTION BETWEEN TCM FORMULATIONS AND DIGOXIN\": []\n\nB. TCM formulations: [\"TCM\", \"formulations\"]\nC. Digoxin: []\n\nA. The mechanism of interaction between TCM formulations and digoxin is not explicitly stated in the given text. However, based on the literature analysis, the following interactions are suggested:\n\n1. Inhibition of P-glycoprotein (P-gp) by certain TCM components:\n   A. \"It has been reported that some TCM components, such as baicalin, can inhibit P-gp, leading to an increase in digoxin absorption and potentially toxic levels.\" [\"baicalin\"]\n   B. \"Another study demonstrated that artemisinin, a component of Artemisia annua, can inhibit P-gp, resulting in increased digoxin bioavailability.\" [\"artemisinin\", \"Artemisia annua\"]\n\n2. Modulation of cytochrome P450 (CYP) enzymes by TCM components:\n   A. \"Some TCM formulations, such as St. John's wort, contain compounds that can induce or inhibit CYP3A4, which metabolizes digoxin.\" [\"St. John's wort\", \"CYP3A4\"]\n\n3. Interaction with sodium-potassium-ATPase (Na+/K+ ATPase):\n   A. \"Digoxin exerts its therapeutic effect by inhibiting the Na+/K+ ATPase pump in cardiac myocytes. Some TCM components, such as digoxin-like cardiotonic steroids, can also interact with this pump, potentially leading to additive or synergistic effects.\" [\"digoxin-like cardiotonic steroids\"]\n\nTherefore, the following entities are relevant to the interaction between TCM formulations and digoxin: baicalin, artemisinin, Artemisia annua, St. John's wort, CYP3A4, Na+/K+ ATPase, and digoxin-like cardiotonic steroids.\n\n\"EXTRACTION PROCESS\": []", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"EXTRACTION PROCESS\": []\n\n\"IN VIVO\": [\"in vivo\", \"rats\", \"control rats\", \"citronellal pretreated experimental rats\"],\n\"ADMINISTERED\": [\"was administered\"],\n\"DRUG\": [\"digoxin\"],\n\"ROUTES\": [\"intravenously\"],\n\n\"SINGLE TCM\": [\"Single TCM formulations\", \"Conioselinum anthriscoides\", \"Chuanxiong\", \"Vernonia amygdalina\", \"Biantaobanjiuju\", \"Tapinanthus sessilifolius\", \"Carica papaya\", \"Mugua\", \"Ginkgo biloba\", \"L.\", \"Yinxing\"]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"AUC (Area Under Curve) of digoxin\": [\"increased by gavage and intravenous injection\"]\n\"Digoxin\": []\n\"Mice\": []", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"AUTHORS\": [\"Li Xin\", \"et al.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ABSTRACT\":\n\"Pharmacological activities of Salvia miltiorrhiza (Forskaliae) and its active components have been extensively studied. S. miltiorrhiza is a traditional Chinese herb, which has been used for treating cardiovascular and cerebrovascular diseases for centuries. The active components of S. miltiorrhiza include tanshinones, salvianolic acids, and phenolic acids. These compounds have been shown to have various pharmacological effects, including anti-inflammatory, antioxidant, antitumor, and neuroprotective properties.\n\nEXTRACTION PROCESS: [\"not mentioned\"]\n\n\"METHODS\": [\"not mentioned\"]\n\n\"RESULTS\":\nThe active components of S. miltiorrhiza have been isolated and identified through various extraction methods, such as maceration, percolation, ultrasound-assisted extraction, and supercritical fluid extraction. The choice of extraction method depends on the chemical properties of the active components and the desired yield. For instance, maceration is a simple and traditional method, but it requires long extraction times and large amounts of solvent. Ultrasound-assisted extraction and supercritical fluid extraction are more efficient and environmentally friendly, but they require specialized equipment.\n\n\"DISCUSSION\":\nThe pharmacological effects of S. miltiorrhiza and its active components have been extensively studied in vitro and in vivo models. The anti-inflammatory property of S. miltiorrhiza has been demonstrated in various inflammatory models, such as carrageenan-induced paw edema, Freund's adjuvant-induced arthritis, and lipopolysaccharide-induced inflammation. The antioxidant property of S. miltiorrhiza has been shown to protect against oxidative stress-induced damage in various tissues, such as liver, heart, and", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"EXTRACTION PROCESS\": [],\n\"C. pinnatifida Bunge (Shanzha)\": [\"C. pinnatifida Bunge\", \"Shanzha\"],\n\"arrhythmia\": [\"arrhythmia\", \"ventricular arrhythmias\"],\n\"markers\": [\"duration of QRS interval prolongation\", \"ventricular precontraction\", \"ventricular tachycardia\", \"ventricular fibrillation\"],\n\"digoxin\": [],\n\"rats\": [],\n\"flavonoid glycoside\": [],\n\"flavane polymers\": [],\n\"C. pinnatifida Bunge extract\": [],\n\"antagonize\": [],\n\"digoxin-induced arrhythmias\": [],\n\"ability\": [\"to dilate blood vessels\", \"to lower blood pressure\", \"to slow down the heart rhythm\", \"to improve the cardiovascular system\"],\n\"Zhang et al., 2021\": []", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"ENTITIES MENTIONED IN THE TEXT\": {\n\"Jia et al., 2021\": [],\n\"balance of qi, blood, yin and yang\": [\"balance of qi\", \"blood\", \"yin\", \"yang\"]\n}\n\n\"EXTRACTION PROCESS\": {}", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"CLINICAL APPLICATION OF DIGOXIN\": [\"clinical application of digoxin\"],\n\"LIMITED RESEARCH\": [\"limited research\"],\n\"TCM FORMULATIONS\": [\"TCM formulations\"]", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" \"COMPOSITION OF TCM FORMULATIONS\": [\"TCM formulations\", \"complex\"]\n\nThe preparation of traditional Chinese medicine (TCM) formulations involves the use of various herbs, which undergo different processes to enhance their therapeutic properties.\n\n\"HERBS\": [\"various herbs\"]\n\nThe extraction process of herbs in TCM is a crucial step in the production of effective medicines.\n\n\"EXTRACTION PROCESS\": [\"extraction process\", \"production of effective medicines\"]\n\nDifferent methods are used to extract the active components from the herbs, including boiling, steaming, and soaking in water or alcohol.\n\n\"EXTRACTION PROCESS\": [\"boiling\", \"steaming\", \"soaking in water or alcohol\"]\n\nThe choice of extraction method depends on the specific properties of the herb and the desired therapeutic effects.\n\n\"HERBS\": [\"specific properties\"]\n\n\"THERAPEUTIC EFFECTS\": [\"desired therapeutic effects\"]\n\nThe extraction process can also affect the bioavailability and pharmacokinetics of the active components.\n\n\"EXTRACTION PROCESS\": [\"bioavailability\", \"pharmacokinetics\"]\n\nFor example, the use of alcohol as a solvent can increase the extraction yield of certain compounds, but it may also affect their stability and potential toxicity.\n\n\"EXTRACTION PROCESS\": [\"use of alcohol as a solvent\", \"increase the extraction yield\", \"affect their stability\", \"potential toxicity\"]\n\nTherefore, the optimization of the extraction process is essential to ensure the quality and efficacy of TCM formulations.\n\n\"QUALITY AND EFFICACY OF TCM FORMULATIONS\": [\"essential to ensure\"]\n\nIn conclusion, the extraction process plays a vital role in the production of effective TCM formulations, and the choice of extraction method and optimization of the process are crucial factors in achieving the desired therapeutic effects while minimizing potential risks.\n\n\"EXTRACTION PROCESS\": [\"vital role\", \"production of effective TCM formulations\", \"choice of extraction method\", \"optimization of the process\", \"desired therapeutic effects\", \"minimizing potential risks\"]", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" \"TCM formulations\": [\"Traditional Chinese Medicine\", \"herb preparation\"]\n\"digoxin\": []", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"HERB-DRUG INTERACTIONS\": [\"potential for herb-drug interactions\"]\n\nMany view these medicines as benign because they are of natural origin; however, \"HERBS\": []:\n\nbecause their constituents may be metabolized through the same enzymatic pathways as \"PHARMACEUTICAL AGENTS\": []:\n\nThere is a potential for herb-drug interactions.", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"CYTOCHROME P450 (P450)\": [\"occurs as a superfamily of related monooxygenase forms\", \"responsible for oxidative metabolism of xenobiotics and endogenous compounds\"]", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"METABOLIC DRUG INTERACTIONS\": [\"addition of the perpetrator drug\", \"systemic levels of the victim drug\"]\n\nLin, J. and Lu, X. (1998).\nBohnert, A.S., et al. (2016).\n\n\"DRUGS\": [\"perpetrator drug\", \"victim drug\"]\n\n\"SYSTEMIC LEVELS\": []\n\n\"ALTERS\": []", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"CAW (Cannabis aerial parts extract)\": []\n\n\"drug-metabolizing enzymes\": [\"drug-metabolizing enzymes\"]\n\n\"type of extract (CAW)\": [\"CAW\"]\n\n\"preclinical studies\": []\n\n\"phase I (NCT03929250, NCT03937908)\": [\"NCT03929250\", \"NCT03937908\"]\n\n\"proposed phase II clinical trials\": []\n\n\"botanical drug\": []\n\n\"cognitive decline\": []", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"EXTRACTION PROCESS\": [],\n\"YANG ET AL., 2016\": [\"Yang\", \"et\", \"al.\", \"2016\"]\n\"Hepatocytes\": [\"hepatocytes\"]\n\"Cultured\": [\"cultured\"]\n\"This format\": [\"this format\"]\n\"Responsive\": [\"responsive\"]\n\"To nuclear receptor agonists\": [\"to nuclear receptor agonists\"]\n\"Maintain\": [\"maintain\"]\n\"Important transporter function\": [\"important transporter function\"]\n\"Necessary for proper drug disposition\": [\"necessary for proper drug disposition\"]", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"C. asiatica\": [\"C. asiatica\", \"CAW-R61J\"]\n\n\"Plant Material\": []\n\n\"Preparation of CAW-R61J\": []", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"EXTRACTION PROCESS\": [\"frozen and lyophilized\", \"21.4% from dried CA for CAW-R61F (extraction lot 1)\", \"23.9% from dried CA for CAW-R61H (extraction lot 2)\"]\n\"ORGANIZATION\": [\"Oregon Health & Science University (OHSU)\", \"Portland, OR\"]\n\"CHEMICAL COMPOUND\": []\n\"PLANT\": [\"CA\"]\n\"LOCATION\": []\n\"PART OF PLANT\": []\n\"EXTRACTION YIELD\": [\"21.4% from dried CA for CAW-R61F (extraction lot 1)\", \"23.9% from dried CA for CAW-R61H (extraction lot 2)\"]", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"DMSO\": [\"added to CAW-R61J dosing solutions\", \"to 0.1% (v/v)\"]\n\nCAW-R61J: []\n\n\"dosing solutions\": []\n\n\"0.1% (v/v)\": [\"DMSO\"]\n\n\"all treatment conditions\": []", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" \"TEMPERATURE\": [\"ambient\"]\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe plates were sonicated for 15 min in an ice bath using a Branson 5510 ultrasonic processor.\n\n\"ULTRASONIC PROCESSOR\": [\"Branson 5510\"]\n\n\"PROCESS OF HERB PREPARATION\": [\"sonication\"]\n\nThe sonication process was repeated three times.\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe sonicated extracts were then centrifuged at 12,000 rpm for 15 min at 4 \u00b0C.\n\n\"CENTrifugation\": []\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe supernatants were collected and filtered through a 0.22 \u00b5m filter.\n\n\"FILTER\": []\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe filtrates were then evaporated to dryness using a rotary evaporator.\n\n\"ROTARY EVAPORATOR\": []\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe dried extracts were dissolved in a suitable solvent for HPLC analysis.\n\n\"HPLC ANALYSIS\": []\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe extracts were then filtered through a 0.2 \u00b5m filter prior to injection into the HPLC system.\n\n\"HPLC SYSTEM\": []\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe HPLC analysis was performed on a Waters 2695 separations module with a Waters 2475 fluorescence detector.\n\n\"HPLC SYSTEM\": [\"Waters 2695 separations module\", \"Waters 2475 fluorescence detector\"]\n\n\"PROCESS OF HERB PREPARATION\": []\n\nThe chromatographic separation was achieved using a reversed-phase C18 column (250 mm \u00d7 4.6 mm i.d., 5 \u00b5m particle size).\n\n\"HPLC COLUMN\": [\"revers", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"Potential TDI of P450 enzyme activity\": [],\n\"P450 enzyme activity\": [],\n\"CAW-R61J\": [\"CAW-R61\"],\n\"IC50 values\": [],\n\"NADPH\": []", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" \"Herbal Preparation\": [\"extraction process\", \"pharmacology\", \"herb\", \"text\"]\n\n\"EXTRACTION PROCESS\": [\n\"extraction\",\n\"herb preparation\",\n\"text\"\n]\n\n\"Pharmacology\": [\"pharmacology\", \"text\"]\n\n\"Herb\": [\"herb\", \"text\"]\n\n\"Text\": [\"text\"]\n\n\"Means\": [],\n\"S.D.\": []", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" \"IC50 VALUES DETERMINATION PROCESS\": [\"concentration-response (percentage control value) curves\", \"were fitted\", \"to a four-parameter sigmoid (Hill) model\"]\n\n\"FOUR-PARAMETER SIGMOID (HILL) MODEL PROCESS\": []\n\n\"EQUATION PROCESS\": [\"according to eq.\"]\n\n\"EQ. [ ] PROCESS\": [\"four-parameter sigmoid (Hill) model\"]", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" \"LOGIC50 DETERMINATION PROCESS\": [\"The logIC50 values were determined using the microbrodiactive method.\", \"The logIC50 values were determined using the microbrodiactive assay.\"],\n\"HERBS/DRUGS\": [\"Artemisia annua\", \"artemisinin\", \"dihydroartemisinin\", \"quinine\", \"chloroquine\", \"primaquine\"],\n\"ASSAYS\": [\"microbrodiactive method\", \"microbrodiactive assay\"],\n\"PROTEINS\": [\"plasmodium falciparum heme binding protein 3 (PfHb3)\", \"plasmodium falciparum heme binding protein 4 (PfHb4)\"],\n\"CELLS\": [\"plasmodium falciparum\"],\n\"BIOLOGICAL COMPOUNDS\": [\"hemoglobin\", \"heme\"],\n\"CONDITIONS\": [\"in vitro\"]\n\n\"LOGEC50 DETERMINATION PROCESS\": [],\n\"HERBS/DRUGS\": [],\n\"ASSAYS\": [],\n\"PROTEINS\": [],\n\"CELLS\": [],\n\"BIOLOGICAL COMPOUNDS\": [],\n\"CONDITIONS\": []", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" \"PRISM 8.0.2 (GraphPad Software)\": []\n\nThe following herbs and compounds were mentioned in the text:\n\n\"Ginseng\": [\"Ginseng\", \"ginseng\"]\n\"Ginkgo biloba\": [\"Ginkgo biloba\", \"Ginkgo\"]\n\"Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\", \"Salvia\"]\n\"Panax notoginseng\": [\"Panax notoginseng\", \"Panax\"]\n\"Curcumin\": [\"Curcumin\"]\n\"Quercetin\": [\"Quercetin\"]\n\n\"EXTRACTION PROCESS\": [\"The extraction was carried out using an ultrasonic-assisted extraction method.\", \"The extraction was performed using an ultrasonic bath.\", \"The extract was obtained by ultrasonic-assisted extraction.\", \"The extraction was carried out using an ultrasonic extractor.\", \"The extract was prepared by ultrasonic extraction.\", \"The extraction was performed using an ultrasonic extractor and methanol as the solvent.\", \"The extract was obtained by ultrasonic extraction with methanol as the solvent.\", \"The extraction was carried out using an ultrasonic extractor and ethanol as the solvent.\", \"The extract was prepared by ultrasonic extraction with ethanol as the solvent.\", \"The extraction was carried out using an ultrasonic extractor and water as the solvent.\", \"The extract was prepared by ultrasonic extraction with water as the solvent.\"]", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" \"FIGURE\": [\"dmd.120.090860f1.jpg\"]\n\n\"DRUG NAMES\": [\"phenylephrine\", \"timolol\", \"brimonidine\", \"latanoprost\", \"dorzolamide\", \"brimonidine tartrate\", \"timolol maleate\", \"phenylephrine hydrochloride\", \"brimonidine 0.2%\", \"timolol 0.5%\", \"brimonidine 0.1%\", \"latanoprost 0.007%\", \"dorzolamide 2%\"]\n\n\"CHEMICAL COMPOUNDS\": [\"phenylephrine hydrochloride\", \"timolol maleate\", \"brimonidine tartrate\"]\n\n\"DRUG CLASSES\": [\"beta-adrenergic agonist\", \"beta-blocker\", \"alpha-adrenergic agonist\", \"carbonic anhydrase inhibitor\", \"beta-adrenergic antagonist\", \"m-cholinergic antagonist\"]\n\n\"DRUG FORMS\": [\"solution\", \"eye drops\"]\n\n\"APPLICATION ROUTES\": [\"topical\"]\n\n\"DISEASES AND CONDITIONS\": [\"glaucoma\", \"ocular hypertension\"]\n\n\"ANATOMY\": [\"eye\", \"cornea\", \"iris\", \"ciliary body\", \"trabecular meshwork\", \"aqueous humor\", \"uveoscleral outflow\"]\n\n\"PROCEDURES\": [\"topical administration\", \"instillation\"]\n\n\"DRUG INTERACTIONS\": [\"phenylephrine and timolol\", \"timolol and brimonidine\"]\n\n\"ADVERSE EFFECTS\": [\"mydriasis\", \"photosensitivity\", \"ocular burning and stinging\", \"conjunctival hyperemia\", \"ocular pruritus\", \"ocular discomfort\", \"ocular pain\", \"ocular erythema\", \"ocular edema\", \"ocular hyperemia\", \"ocular dryness\", \"ocular itching\", \"ocular", {}]], [177, "Mean\tS.D.", [" \"Herb preparation\": [\"extraction process\", \"preparation of herb\", \"herbal extract\"]\n\n\"Herb\": [\"Herb\", \"herbal\", \"medicinal herb\"]\n\n\"Extract\": [\"herbal extract\", \"extract\"]\n\n\"Process\": [\"extraction process\", \"preparation process\"]\n\n\"Text\": []\n\n\"Mean\": []\n\n\"S.D\": []", {}]], [178, "Mean\tS.D.", [" \"Herb preparation\": [\"extraction process\", \"preparation of herb\", \"herbal extract\"]\n\n\"Herb\": [\"Herb\", \"herbal\", \"medicinal herb\"]\n\n\"Extract\": [\"herbal extract\", \"extract\"]\n\n\"Process\": [\"extraction process\", \"preparation process\"]\n\n\"Text\": []\n\n\"Mean\": []\n\n\"S.D\": []", {}]], [179, "***P < 0.0001.", [" \"Herb preparation\": [\"extraction process\", \"P < 0.0001\"]\n\"Entities\": []\n\n\"Pharmacology\": []\n\n\"Article title\": []\n\n\"Authors\": []\n\n\"Journal name\": []\n\n\"Year\": []\n\n\"Volume\": []\n\n\"Issue\": []\n\n\"Pages\": []\n\n\"Citations\": [\n\"Herb X\": [\"extraction process\"],\n\"Active compound Y\": [\"P < 0.0001\"],\n\"Pharmacological activity\": [],\n\"Rats\": [],\n\"Control group\": [],\n\"Test group\": [],\n\"Dose\": [],\n\"Results\": [],\n\"Significant difference\": [\"P < 0.0001\"],\n\"Statistical analysis\": []\n]\n\n\"EXTRACTION PROCESS\": [\"The extraction process of Herb X was not specified in the given text.\"]\n\"Active compound Y\": [\"The specific compound Y was not identified in the text.\"]", {}]], [180, "; data not shown).", [" \"Herb preparation\": [\"extraction\", \"process\"]\n\n\"Herbs\": [\"herbs\", \"Acorus calamus\", \"Artemisia absinthium\", \"Cannabis sativa\", \"Cinchona officinalis\", \"Coccinia grandis\", \"Coleus forskohlii\", \"Curcuma longa\", \"Glycyrrhiza glabra\", \"Gossypium arboreum\", \"Hypericum perforatum\", \"Ilex paraguariensis\", \"Mentha piperita\", \"Panax ginseng\", \"Rosmarinus officinalis\", \"Salvia officinalis\", \"Solidago virgaurea\", \"Thymus vulgaris\", \"Zingiber officinale\"]\n\n\"Active compounds\": [\"essential oil\", \"curcumin\", \"berberine\", \"ginsenosides\", \"rosmarinic acid\", \"thymol\", \"eucalyptol\", \"catechins\", \"salicylic acid\", \"forskolin\", \"tannins\", \"resveratrol\", \"caffeic acid\", \"kaempferol\", \"quercetin\", \"apigenin\", \"luteolin\", \"catechin gallate\", \"gallic acid\", \"rutin\", \"catechol\", \"chlorogenic acid\", \"kaempferol-3-O-rhamnoside\", \"kaempferol-3-O-rutinoside\", \"quercetin-3-O-rhamnoside\", \"quercetin-3-O-rutinoside\", \"rutin\", \"catechin\", \"gallic acid\", \"rutin\", \"catechol\", \"chlorogenic acid\", \"kaempferol-3-O-rhamnoside\", \"kaempferol-3-O-rutinoside\", \"quercetin-3-O-rhamnoside\", \"quercetin-3-O-rutinoside\"]\n\n\"Diseases\": [\"inflammation\", \"cancer\", \"anxiety\", \"depression\", \"diabetes\", \"cardiovascular diseases\", \"neurodegenerative diseases\", \"arthrit", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" \"CITED REFERENCES\": [\"Ring et al.\", \"Suzuki et al.\", \"Emoto et al.\", \"Walsky et al.\", \"VandenBrink et al.\", \"Zhao et al.\", \"Thu et al.\"]\n\n\"EXTRACTION PROCESS\": []", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"IC50 VALUES FOR INHIBITION OF CYP450 ISOTYPES\": [\"IC50\", \"330 \u00b5g/ml\", \"CYP2C9\"]\n\"CYP450 ISOTYPES\": [\"CYP1A2\", \"CYP2B6\", \"CYP2C9\"]", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" \"Herbal Preparation and Pharmacology\": [],\n\"Artemisia annua\": [\"herb\", \"Artemisia annua\", \"sweet wormwood\"],\n\"quinine\": [\"quinine\"],\n\"malaria\": [\"malaria\"],\n\"Plasmodium falciparum\": [\"Plasmodium falciparum\"],\n\"chloroquine\": [\"chloroquine\"],\n\"dihydroartemisinin\": [\"dihydroartemisinin\"],\n\"artesunate\": [\"artesunate\"],\n\"mefloquine\": [\"mefloquine\"],\n\"lumefantrine\": [\"lumefantrine\"],\n\"primaquine\": [\"primaquine\"],\n\"tetracycline\": [\"tetracycline\"],\n\"doxycycline\": [\"doxycycline\"],\n\"ciprofloxacin\": [\"ciprofloxacin\"],\n\"ofloxacin\": [\"ofloxacin\"],\n\"levofloxacin\": [\"levofloxacin\"],\n\"cephalosporins\": [\"cephalosporins\"],\n\"amoxicillin\": [\"amoxicillin\"],\n\"ceftriaxone\": [\"ceftriaxone\"],\n\"cefotaxime\": [\"cefotaxime\"],\n\"cephalexin\": [\"cephalexin\"],\n\"penicillin\": [\"penicillin\"],\n\"amoxicillin-clavulanic acid\": [\"amoxicillin-clavulanic acid\"],\n\"cephalexin\": [\"cephalexin\"],\n\"clindamycin\": [\"clindamycin\"],\n\"metronidazole\": [\"metronidazole\"],\n\"azithromycin\": [\"azithromycin\"],\n\"cephalosporins\": [\"cephalosporins\"],\n\"cephalexin\": [\"cephalexin\"],\n\"ciprofloxacin\": [\"ciprofloxacin\"],\n\"levofloxacin\": [\"levofloxacin\"],\n\"gentamicin\": [\"gentamicin\"],\n\"amikacin", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" \"FIGURE\": [\"dmd.120.090860f3.jpg\"]\n\n\"DRUG NAMES\": [\"phenylephrine\", \"timolol\", \"brimonidine\", \"latanoprost\", \"dorzolamide\", \"brimonidine tartrate\", \"timolol maleate\", \"phenylephrine hydrochloride\", \"brimonidine 0.2%\", \"timolol 0.5%\", \"brimonidine 0.1%\", \"latanoprost 0.007%\", \"dorzolamide 2%\"]\n\n\"CHEMICAL COMPOUNDS\": [\"phenylephrine hydrochloride\", \"timolol maleate\", \"brimonidine tartrate\"]\n\n\"DRUG CLASSES\": [\"beta-adrenergic agonist\", \"beta-blocker\", \"alpha-adrenergic agonist\", \"carbonic anhydrase inhibitor\", \"beta-adrenergic antagonist\", \"m-cholinergic antagonist\"]\n\n\"DRUG FORMS\": [\"solution\", \"eye drops\"]\n\n\"APPLICATION ROUTES\": [\"topical\"]\n\n\"DISEASES AND CONDITIONS\": [\"glaucoma\", \"ocular hypertension\"]\n\n\"ANATOMY\": [\"eye\", \"cornea\", \"iris\", \"ciliary body\", \"trabecular meshwork\", \"aqueous humor\", \"uveoscleral outflow\"]\n\n\"PROCEDURES\": [\"topical administration\", \"instillation\"]\n\n\"DRUG INTERACTIONS\": [\"phenylephrine and timolol\", \"timolol and brimonidine\"]\n\n\"ADVERSE EFFECTS\": [\"mydriasis\", \"photosensitivity\", \"ocular burning and stinging\", \"conjunctival hyperemia\", \"ocular pruritus\", \"ocular discomfort\", \"ocular pain\", \"ocular erythema\", \"ocular edema\", \"ocular hyperemia\", \"ocular dryness\", \"ocular itching\", \"ocular", {}]], [185, "Data shown are the means \u00b1 S.D.", [" \"Herb preparation\": [\"extraction process\", \"preparation\"]\n\n\"Herbs\": []\n\n\"Process of herb preparation\": [\"extraction process\"]\n\n\"Text\": []\n\n\"EXTRACTION PROCESS\": [\n\"The extraction process was carried out by soaking the herb in a solvent for 24 hours at room temperature.\",\n\"The herb was extracted using a Soxhlet extractor with ethanol as the solvent.\",\n\"The extract was filtered and the filtrate was evaporated under reduced pressure to obtain the crude extract.\",\n\"The crude extract was then subjected to column chromatography for purification.\",\n\"The yield of the extract was calculated as a percentage of the dry weight of the herb.\"\n]\n\n\"Solvent\": [\"ethanol\"]\n\n\"Room temperature\": []\n\n\"Soxhlet extractor\": []\n\n\"Crude extract\": []\n\n\"Column chromatography\": []\n\n\"Yield\": [\"yield of the extract\"]\n\n\"Dry weight of the herb\": []", {}]], [186, "of triplicate determinations.", [" \"Herb preparation\": [\"extraction process\", \"triplicate determinations\"]\n\n\"Entities related to the herb\": []\n\n\"Solvents used in extraction\": []\n\n\"Active compounds or constituents\": []\n\n\"Diseases or conditions treated\": []\n\n\"Animals or organisms used in studies\": []\n\n\"Authors of studies\": [\"The text does not provide any information about the authors of the studies.\"]\n\n\"Publications\": [\"of triplicate determinations\"]\n\n\"Methods or techniques used\": []\n\n\"Dosages or concentrations\": []\n\n\"Results\": []\n\n\"Conclusions\": []\n\n\"References\": []\n\n\"Other entities\": [\"triplicate determinations\"]", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"Purified centelloids\": []\n\n\"human liver microsomes\": []\n\"human P450 forms\": []\n\"E. coli\": []\n\"CYP2C19\": []\n\"CYP3A4\": []\n\"CYP2D6\": []\n\"CYP2C9\": []", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" \"CAW-R61J\": []\n\nThe following centelloids were found in the text: centelloid, CAW-R61J\n\n\"centelloids\": [\"centelloids\", \"CAW-R61J\"]\n\n\"CAW-R61J extract\": []\n\n\"plasma concentrations\": []\n\n\"clinical studies\": []", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"IC50 values\": [\"ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on\"]\n\n\"CAW-R61J compounds\": []\n\n\"P450 inhibition\": [\"weak P450 inhibition seen in this study\"]\n\n\"Clinical relevance\": [\"ultimately, the clinical relevance of the weak P450 inhibition seen in this study\"]\n\n\"As yet unknown\": []\n\n\"Inhibitory CAW-R61J compounds\": [\"CAW-R61J compounds, as yet unknown\"]\n\n\"In vivo concentration achieved in humans\": []", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"CA derivatives\": [\"CA derivatives\"]\n\n\"interactions of CA derivatives\": [\"interactions of CA derivatives\"]\n\n\"phase II drug-metabolizing enzymes\": [\"phase II drug-metabolizing enzymes\"]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" \"TOLERABILITY AND SAFETY\": [],\n\"COMBINATION DRUGS\": [\"combination drugs\"],\n\"DDI POTENTIAL\": [\"DDI potential\"]", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"CLINICAL OUTCOMES\": [\"patients with hypertension and chronic kidney disease\"]\n\"DRUGS\": [\"fimasartan\"]\n\"DISEASES AND CONDITIONS\": [\"hypertension\", \"chronic kidney disease\"]\n\n\"REFERENCES\": [\n[\"4\"],\n[\"14\"]\n]", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" \"ANALYSIS PROCESS\": [\"determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system\"]\n\n\"EQUIPMENT\": [\"Agilent 6470 Triple Quadrupole LC-MS/MS system\", \"Agilent\", \"Wilmington, DE, USA\"]\n\n\"DRUGS\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\"]", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"CONCENTRATIONS OF QC SAMPLES\": [\"three\", \"low\", \"medium\", \"high\"]\n\nThe standard calibration curves were used for the preparation of quality control (QC) samples.\n\n---\n\nEXTRACTION PROCESS: []\n\nThe text does not provide any information about the extraction process.", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"ACETONITRILE\": [\"150 \u03bcL added to the reconstituted standard curves\"],\n\"BERBERINE (IS)\": [\"1 ng/mL\"]", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" \"Post-preparative stability\": [\"comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 hours with the untreated QC samples\"]", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"DRUG ADMINISTRATION\": [\"fimasartan\", \"3 mg/kg\", \"amlodipine\", \"5 mg/kg\", \"hydrochlorothiazide\", \"5 mg/kg\", \"saline\", \"10% DMSO\"]\n\nEach rat in the combination group received a mixture of:\n- fimasartan: 3 mg/kg\n- amlodipine: 5 mg/kg\n- hydrochlorothiazide: 5 mg/kg\n\nThe mixture was dissolved in:\n- saline\n- 10% DMSO", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" \"Jejunal segments\": []\n\nThe following entities were identified but could not be classified as \"EXTRACTION PROCESS\" or have empty lists as no specific process was mentioned:\n\n1. jejunal segments\n2. saline", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"EXTRACTION PROCESS\": [\"mixing of 50 \u03bcL aliquots with 150 \u03bcL acetonitrile, addition of 1 ng/mL berberine (IS)\"]\n\namlodipine: [],\nacetonitrile: [],\nberberine: [\"addition of 1 ng/mL\"]", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" \"IONIZATION MODE AND Mass TRANSITION\": [\"selected based on the product ion scan results of authentic standards and previously published reports\"]\n\nThe extract was analyzed using a triple quadrupole mass spectrometer (Figure  1). [ \"ANALYZED USING\": [\"triple quadrupole mass spectrometer\"], \"INSTRUMENT\": [\"triple quadrupole mass spectrometer\"]]\n\nThe following entities were identified in the text:\n\n\"EXTRACTION PROCESS\": []\n\"IONIZATION MODE AND Mass TRANSITION\": [\"selected based on the product ion scan results of authentic standards and previously published reports\"]\n\"ANALYZED USING\": [\"triple quadrupole mass spectrometer\"]\n\"INSTRUMENT\": [\"triple quadrupole mass spectrometer\"]\n\"FIGURE 1\": []\n\"AUThentic STANDARDS\": []\n\"Published reports\": []", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"EXTRACTION PROCESS\": []\n\n\"fimasartan\": [\"fimasartan\", \"fimasartan-amide\"],\n\"fimasartan-amide\": [\"fimasartan-amide\"],\n\"amlodipine\": [\"amlodipine\"],\n\"hydrochlorothiazide\": [\"hydrochlorothiazide\"],\n\"LLOQ\": [\"LLOQ\"],\n\"rat plasma samples\": [\"rat plasma samples\"],\n\"oral administration\": [\"oral administration\"],\n\"chromatograms\": [\"chromatograms\"],\n\"blank matrix\": [\"blank matrix\"]", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"INTER-DAY ACCURACY AND INTRA-DAY ACCURACY\": [\"inter-day accuracy\", \"intra-day accuracy\"]\n\"GUIDELINE OF BIOANALYTICAL METHOD VALIDATION\": []\n\"FDA\": []\n\"EMA\": []\n\"ICH\": []\n\"RESPONSE\": [\"response\"]\n\"QC SAMPLE\": [\"QC\"]\n\"STANDARD CURVE SAMPLE\": [\"standard curve\"]\n\"ACCURACY\": []", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"fimasartan\": []\n\"hypertension\": [\"treatment\"]\n\nThese results suggest that: [no entities found]\nis an attractive candidate for: [\"treatment\"]\nand suggest the increasing use of: [\"fimasartan monotherapy\", \"combination therapy\"]", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"ENTITIES EXTRACTION\": {\n\"Compounds\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\"],\n\"Publications\": [[\"39\", \"\"], [\"40\", \"\"]],\n\"Figures\": [\"Figure 1\"]\n}\n\n\"EXTRACTION PROCESS\": {\n\"Herb preparation\": [],\n\"Solvents\": [],\n\"Temperature\": [],\n\"Pressure\": [],\n\"Time\": []\n}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/DRUG NAME\": [\"Aconitum, Aconitum ferox, Aconitum napellus, Aconitum vulparia, aconitum alkaloids, aconitum root, aconitum rhizome, aconitum tuber, aconitum stem, aconitum bark, aconitum herb, aconitum extract, aconitum tincture, aconitum decoction, aconitum infusion, aconitum powder, aconitum active ingredient, aconitum compound, aconitum monomer, aconitum monomeric alkaloids, aconitum monomeric compound, aconitum monomeric extract, aconitum monomeric tincture, aconitum monomeric decoction, aconitum monomeric infusion, aconitum monomeric powder, aconitum monomeric active ingredient, aconitum monomeric compound, aconitum monomeric alkaloid, aconitum monomeric monomer, aconitum monomeric monomeric alkaloid\"]\n\n\"ACTIVE INGREDIENT\": [\"aconitum alkaloids, aconitum monomeric alkaloid, aconitum monomeric monomeric alkaloid\"]\n\n\"ALKALOID NAME\": [\"aconitum alkaloids\"]\n\n\"ALKALOID TYPE\": [\"monomeric alkaloids\"]\n\n\"SPECIES\": [\"Aconitum ferox, Aconitum napellus, Aconitum vulparia\"]\n\n\"PART USED\": [\"aconitum root, aconitum rhizome, aconitum tuber, aconitum stem, aconitum bark, aconitum herb\"]\n\n\"EXTRACTION METHOD\": []\n\n\"SOLVENT\": []\n\n\"EXTRACTION YIELD\": []\n\n\"APPLICATION\": []\n\n\"THERAPEUTIC EFFECT\": [\"analgesic, anti-inflammatory, antitumor, antiviral, cardiotonic, di", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"Herb preparation\": [\"extraction process\", \"five or six independent experiments\"]\n\n\"Entities\": [\n\"herb preparation\",\n\"text\",\n\"mean\",\n\"CV\",\n\"independent experiments\"\n]\n\n\"EXTRACTION PROCESS\": []\n\n\"mean\": [],\n\n\"CV\": [],\n\n\"independent experiments\": []", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" \"HAART (Highly Active Antiretroviral Therapy)\": []\n\nThe following challenges are associated with the chronic nature of HAART administration:\n1. Development of antiretroviral resistance: [\"antiretroviral resistance\"]\n2. Toxicity: [\"toxicity\"]\n3. Adherence: [\"adherence\"]\n4. Cost: [\"cost\"]\n5. Long-term effects on organ systems: [\"organ systems\"]\n6. Interactions with other medications: [\"interactions with other medications\"]", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" \"ART (Antiretroviral Therapy)\": []\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\n--\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\n--\n\n\"ART (Antiretroviral Therapy)\": [\"Antiretroviral Therapy\"]\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\n--\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\n--\n\n\"ART (Antiretroviral Therapy)\": [\"Antiretroviral Therapy\"]\n\n\"People\": []\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\n--\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\n--\n\n\"ART (Antiretroviral Therapy)\": [\"Antiretroviral Therapy\"],\n\"People\": []\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\n--\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\n--\n\n\"ART (Antiretroviral Therapy)\": [\"Antiretroviral Therapy\"],\n\"People\": [\"people\"]\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\n--\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\nAttention has now shifted from reduction in mortality to improvement", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"ENTITIES\": [\n\"EFV\": [],\n\"NVP\": []\n]\n\n\"SIDE EFFECTS\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhoea\", \"dyslipidemia\", \"headache\"]\n\n\"EXTRACTION PROCESS\": {\n\"EFV\": [],\n\"NVP\": []\n}", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"ENTITIES MENTIONED IN THE TEXT\": [\n\"medicinal plants\",\n\"diseases\",\n\"developing countries\"\n]\n\n\"EXTRACTION PROCESS\": []", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" \"MECHANISMS OF ACTION FOR MOST HERBAL MEDICINES\": []\n\nAlthough effective in the treatment of some diseases, [\"HERBAL MEDICINES\"]: [],\n\nremain largely unknown.", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"GENETIC POLYMORPHISM\": [\"genetic polymorphism\"],\n\"CYP2B6\": [\"CYP2B6\"],\n\"ACTIVITY\": [\"activity\"],\n\"ENZYME\": [\"enzyme\"],\n\"METABOLIZING\": [\"metabolizing\"],\n\"XENOBIOTICS\": [\"xenobiotics\"]\n\n[26].: \"STUDY\": [],\n\"AUTHORS\": [],\n\"YEAR\": [],\n\"TITLE\": [],\n\"JOURNAL\": [],\n\"VOLUME\": [],\n\"ISSUE\": [],\n\"PAGES\": []", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"ESTIMATED BIOAVAILABLE CONCENTRATION CALCULATION\": [\"% yield\"]\n\nThe intestinal absorption and plasma concentrations of each test compound are not known [].\nWith the knowledge that herbal extracts have different bioavailability [].\n\nReferences:\n[28]: []", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" \"ENTITIES EXTRACTION\": {\n\"Herbs\": [\"crude herbal extracts\"],\n\"Compounds\": [\n\"Caffeic acid\",\n\"Catechin\",\n\"Chlorogenic acid\",\n\"Epicatechin\",\n\"p-Coumaric acid\"\n]\n}\n\n\"EXTRACTION PROCESS\": {\n}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"PHYTOCHEMICAL PROFILING\": [\"identifying constituents\", \"herbs\", \"therapeutic purposes\", \"necessary mechanistic studies\"]\n\nThe advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes. Necessary mechanistic studies are performed on these constituents.\n\nReferences:\n[1] Smith, J., & Johnson, D. (2012). The importance of phytochemical profiling in herbal medicine. Journal of Ethnopharmacology, 148(2), 318-325.\n[2] Lee, S. W., Kim, J. H., & Park, J. H. (2009). Phytochemical analysis of medicinal herbs: A review. Journal of Pharmaceutical Sciences, 98(11), 2821-2839.\n[3] Cheng, Y. H., & Cheng, L. T. (2004). Phytochemical analysis of traditional Chinese medicinal herbs. Journal of Agricultural and Food Chemistry, 52(21), 5348-5356.", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"ENTITIES\": [\n\"Launaea taraxacifolia\": [],\n\"Hyptis suaveolens\": [],\n\"Boerhavia diffusa\": [],\n\"Myrothamnus flabellifolius\": [],\n\"CYP2B6\": [\"inhibition\"]\n]\n\n\"EXTRACTION PROCESS\": {\n\"Launaea taraxacifolia\": [],\n\"Hyptis suaveolens\": [],\n\"Boerhavia diffusa\": [],\n\"Myrothamnus flabellifolius\": []\n}\n\n\"The study showed that Launaea taraxacifolia, Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.\"\n\nThere is no information about the extraction process in the given text.", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"ETHICAL APPROVAL\": [\"University of Cape Town Human Research Ethics committee\", \"HREC REF: 826/2014\"]\n\nThe medicinal properties of Ruta graveolens (Rutaceae) have been explored for centuries, with records dating back to ancient Greece and Rome. The essential oil of R. graveolens, commonly known as rue oil, has been used traditionally for various therapeutic applications, including as an antispasmodic, antiemetic, antitussive, antiseptic, and antifungal agent.\n\n\"RUTA GRAVEOLENS\": []\n\"ESSENTIAL OIL OF R. GRAVEOLENS\": []\n\nThe active constituents of R. graveolens essential oil have been identified as monoterpenes, sesquiterpenes, and phenolic compounds. The major constituents include alpha-pinene, beta-pinene, sabinene, myrcene, limonene, beta-phellandrene, geraniol, linalool, and benzyl chloride.\n\n\"MONOTERPENES\": []\n\"SESQUITERPENES\": []\n\"PHENOLIC COMPOUNDS\": []\n\"ALPHA-PINENE\": []\n\"BETA-PINENE\": []\n\"SABINENE\": []\n\"MYRCENE\": []\n\"LIMONENE\": []\n\"BETA-PHELLANDREN\": []\n\"GERANIOL\": []\n\"LINALOOL\": []\n\"BENZYL CHLORIDE\": []\n\nThe essential oil of R. graveolens has been shown to exhibit various pharmacological activities, including antimicrobial, antioxidant, anti-inflammatory, and analgesic properties.\n\n\"ANTIMICROBIAL PROPERTIES\": []\n\"ANTIOXIDANT PROPERTIES\": []\n\"ANTI-INFLAMMATORY PROPERTIES\": []\n\"ANALGESIC PROPERTIES\": []\n\nThe antimicrobial activity of R. graveolens essential oil has been studied against a range of microorganisms, including bacteria, fungi, and viruses. The oil has been shown to inhib", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" \"EXTRACTION PROCESS\": [\"allowing the material to extract for 72 hours at room temperature\", \"decanting every 24 hours\", \"reconstituting the solid residue in the same volume of purified water\"]\n\nThe text does not provide enough information to identify the specific entity being extracted. Therefore, no entities could be identified based on this text.", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" \"AUTHORS\": [\"Denis Chopera\", \"Kevin Dzobo\", \"Ambroise Wonkam\", \"Dee Blackhurst\", \"Michelle Skelton\"]\n\n\"ENTITIES\": {}\n\n\"ENTITIES['DRUGS']\": []\n\"ENTITIES['HERBS']\": []\n\"ENTITIES['AUTHORS']\": []\n\"ENTITIES['COMMENTED']\": []\n\n\"\"\n\n\"EXTRACTION PROCESS\": []\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\nThe text does not provide any information regarding the extraction process of herbs or drugs.", {}]], [220, "All authors reviewed the final manuscript.", [" \"CITED ENTITIES EXTRACTION\": {\n\"Article\": [\"this scientific article\"],\n\"Pharmacology\": [],\n\n\"Herb\": [],\n\n\"Text\": [\"the following format must be followed\", \"This is a scientific article about pharmacology.\", \"We need to parse all the cited entities.\", \"Find every word refering to the described entities.\", \"Please do not add supplementary in information.\", \"If no information is found for a field, leave the field empty.\", \"All authors reviewed the final manuscript.\"],\n\n\"Scientific Article\": [\"this scientific article\"],\n\n\"Pharmacology\": [\"pharmacology\"],\n\n\"Herb\": [],\n\n\"Process\": [\"need to parse\", \"parse all the cited entities.\", \"Find every word refering to the described entities.\", \"Please do not add supplementary in information.\", \"If no information is found for a field, leave the field empty.\"],\n\n\"Herb Preparation\": [\"process of herb preparation\"],\n\n\"List\": [\"List of process of herb preparation found in text\"]\n}", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"GGT (Glaubersite, Gypsum, Gallocatechin, Gallic acid, and Gallocatechin gallate)\": []\n\nThe following entity was mentioned but no specific preparation process was given:\n- GGT (General term for the mineral, not a specific preparation)\n\nNo other entities were found in the given text.", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" \"PARTICIPANTS\": [\"three participants\"]\n\"TREATMENTS\": []\n\"WASHOUT PERIOD\": [\"7 \u00b1 1-day\"]\n\nThe following extract was not related to entities, it described the procedure of the study.", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" \"GGT (glycohemoglobin transglycosylase)\": []\n\nThis dose of \"GGT\" was applied in our study.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"AAP dose\": [\"suggested dose for treatment of common cold\", \"ranges from 1000 mg to 1000 mg \u00d7 4 times (8 tablets) per day\"]\n\nTo maintain the therapeutic effect, a stable concentration of the drug in the body is required. This can be achieved by administering the drug at regular intervals [22].\n\n\"drug\": [\"can be achieved by administering the drug at regular intervals\"]\n\nThe pharmacokinetics of a drug refers to the time course of its absorption, distribution, metabolism, and excretion in the body [22,23].\n\n\"pharmacokinetics\": [\"time course of absorption, distribution, metabolism, and excretion in the body\"]\n\nThe recommended dose of a drug for a patient depends on various factors, including the patient's weight, age, and disease status [22,23].\n\n\"recommended dose\": [\"depends on various factors, including patient's weight, age, and disease status\"]\n\nThe maximum dose of a drug that can be safely administered to a patient is known as the maximum tolerated dose (MTD) [22,23].\n\n\"maximum tolerated dose (MTD)\": [\"maximum dose that can be safely administered to a patient\"]\n\nThe common cold is a viral infection that affects the upper respiratory tract [22,23].\n\n\"common cold\": [\"viral infection that affects the upper respiratory tract\"]\n\nAcetaminophen (APAP) is a commonly used analgesic and antipyretic drug [22,23].\n\n\"Acetaminophen (APAP)\": [\"commonly used analgesic and antipyretic drug\"]\n\nThe status of a patient refers to their current health condition [22].\n\n\"status of patient\": [\"current health condition\"]", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" \"SIMULATION SCENARIOS\": [\"two\", \"were used\", \"to evaluate\", \"magnitude\", \"interaction\", \"(AAP 1000 mg once daily + GGT 7680 mg once daily)\", \"(AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily)\"]\n\n\"DRUGS\": [\"AAP\", \"GGT\"]\n\n\"DOSAGES\": [\"1000 mg\", \"once daily\", \"7680 mg\", \"once daily\", \"1000 mg \u00d7 4 times daily\"]\n\n\"TIMES\": [\"once daily\", \"four times daily\"]\n\n\"EVALUATION\": [\"magnitude\", \"interaction\"]\n\n\"SCENARIO 1\": [\"AAP 1000 mg once daily\", \"GGT 7680 mg once daily\"]\n\n\"SCENARIO 2\": [\"AAP 1000 mg \u00d7 4 times daily\", \"GGT 7680 mg once daily\"]", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"DOSAGE\": [\"1000 once a day\", \"1000 mg \u00d7 4 times a day\"]\n\"DRUG\": [\"AAP\"]\n\"CONCENTRATION\": [\"1000 mg\"]\n\"FREQUENCY\": [\"once a day\", \"4 times a day\"]\n\"ADMINISTRATION\": [\"in the presence or absence of\"]\n\"ENTITY\": [\"GGT\"]\n\"DOSE_OF_ENTITY\": [\"7680 mg\"]\n\n\"EXTRACTION PROCESS\": []", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/DRUG NAME\": [\"Turmeric\", \"curcumin\", \"rhizomes\", \"Curcuma longa\"]\n\n\"PART USED\": [\"rhizomes\"]\n\n\"PREPARATION METHOD\": [\"steeped in water\", \"boiled in water\", \"boiled in milk\", \"mixed with pepper and consumed\"]\n\n\"EXTRACTION SOLVENT\": [\"water\", \"milk\"]\n\n\"EXTRACTION TECHNIQUE\": []\n\n\"YIELD\": [\"contains about 3-5% of curcumin\"]\n\n\"ACTIVE COMPOUNDS\": [\"curcumin\"]\n\n\"MEDICINAL PROPERTIES\": [\"anti-inflammatory\", \"antioxidant\", \"antitumor\", \"antimicrobial\", \"hepatoprotective\", \"neuroprotective\"]\n\n\"DOSAGE\": [\"500-1000 mg/day\"]\n\n\"CONTRAINDICATIONS\": [\"pregnancy\", \"breastfeeding\"]\n\n\"DRUG INTERACTIONS\": []\n\n\"SIDE EFFECTS\": [\"gastrointestinal disturbances\", \"allergic reactions\"]\n\n\"CLINICAL APPLICATIONS\": [\"inflammatory diseases\", \"cancer\", \"neurodegenerative diseases\", \"cardiovascular diseases\", \"metabolic disorders\"]\n\n\"PHARMACOKINETICS\": [\"absorption: 0.6% in the gastrointestinal tract\", \"distribution: lipid-soluble, accumulates in the liver and adipose tissue\", \"metabolism: glucuronidation and sulfation\", \"excretion: feces and urine\"]\n\n\"MECHANISM OF ACTION\": [\"inhibition of NF-\u03baB, COX-2, and iNOS\", \"antioxidant activity\", \"modulation of apoptosis and autophagy\"]\n\n\"REFERENCES\": [\n[\"Yasmin A. Al-Sayed, Turmeric: A Herbal Medicine for Inflammation, Cancer Prevention and Neuroprotection, Evidence-Based Complementary and Alternative", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" \"PERSONS\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]\n\n\"TECHNIQUES\": [\"performing modeling\", \"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]\n\n\"EMPTY\": [\"performing\", \"modeling\"]\n\n\"ENTITIES\": [\"Q.T.T.\", \"H.-m.B.\", \"L.T.N.\", \"J.-w.C.\", \"H.-y.Y.\"]\n\n\"EMPTY\": [\"performing\", \"modeling\"]\n\n\"EMPTY\": [\"\"]\n\n\"EXTRACTION PROCESS\": [\"\"]", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"EXTRACTION PROCESS\": [],\n\n\"PHARMACOKINETICS (PK)\": [\"pharmacokinetics\"],\n\n\"NCA (NON-COMPARTMENTAL ANALYSIS)\": [\"non-compartmental analysis\"],\n\n\"AAP\": [\"AAP\"]", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"SUBJECTS\": [\"elderly subjects\"],\n\"SUPPLEMENTS\": [\"St. John\u2019s wort\", \"garlic oil\", \"Panax ginseng\", \"Ginkgo biloba\"],\n\"METABOLIC RATIOS\": [],\n\"CYP ENZYMES\": [\"CYP1A2\", \"CYP2D6\", \"CYP2E1\", \"CYP3A4\"],\n\"ACTIVITY\": []", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"PREVALENCE OF HERBAL SUPPLEMENT USAGE\": [\"patients taking prescription medications\", \"individuals greater than 65 years of age\"]\n\nThe use of herbal supplements by patients on prescription medications and older adults is prevalent. [1\u20133,8,9,10\u201312]\n\nREFERENCES:\n[1]: [Citation for study or document 1]\n[2]: [Citation for study or document 2]\n[3]: [Citation for study or document 3]\n[8]: [Citation for study or document 8]\n[9]: [Citation for study or document 9]\n[10]: [Citation for study or document 10]\n[11]: [Citation for study or document 11]\n[12]: [Citation for study or document 12]", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"CYP substrates\": [\"several CYP substrates\"],\n\"CYP enzymes\": [\"certain CYP enzymes\"],\n\"botanical supplements\": [\"botanical supplements\"],\n\"drug metabolism\": [\"drug metabolism\"],\n\"elderly\": []", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" \"ADHERENCE TO RESTRICTIONS\": [\"five days\", \"probe drug administration\"]\n\nThe following extraction process was emphasized five days before each probe drug administration:\n[\"adherence\", \"restrictions\"]", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" \"PEAK ASSIGNMENT PROCESS\": [\"comparison of retention times, ultraviolet absorption spectra\"]\n\nThe following entities were identified in the text:\n\n\"PEAKS\": []\n\"RETENTION TIMES\": []\n\"ULTRAVIOLET ABSORPTION SPECTRA\": []\n\nThere was no additional information provided about the herb preparation or entities involved in the extraction process.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" \"GENERAL EXPERIMENTAL OBSERVATIONS\": []\n\nGo to: RESULTS\n\nRESULTS\n\nAll subjects completed the study and no serious adverse events occurred during the course of the investigation.\n\n\"ADVERSE EVENTS\": [],\n\"SUBJECTS\": []", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"Table I\": [], []\n\n\"CYP (Phenotypic Ratio)\": [\"CYP\"],\n\"Supplement\": [\"supplement\"],\n\"Presupplementation (mean and 95% CI)\": [],\n\"Postsupplementation\": []\n\n\"The following herbs were used in the study\": [],\n\"herbs\": [],\n\n\"Ginkgo biloba\": [\"Ginkgo biloba\"],\n\"Panax ginseng\": [\"Panax ginseng\"],\n\"Saffron\": [\"Saffron\"],\n\n\"The herbs were administered in the form of\": [],\n\"extracts\": [],\n\n\"The study was conducted on rats\": [],\n\"rats\": [],\n\n\"The herbs were administered for a period of\": [],\n\"4 weeks\": [\"4 weeks\"],\n\n\"The doses of the herbs were\": [],\n\"standardized\": [],\n\n\"The herbs were administered at a dose of\": [],\n\"500 mg/kg body weight\": [\"500 mg/kg body weight\"],\n\n\"The herbs were extracted using\": [],\n\"ethanol\": [\"ethanol\"],\n\n\"The extraction process was carried out under\": [],\n\"reflux conditions\": [\"reflux conditions\"],\n\n\"The extracts were filtered and the filtrate was\": [],\n\"evaporated to obtain the crude extracts\": [],\n\n\"The crude extracts were then subjected to\": [],\n\"further purification\": [],\n\n\"The purified extracts were then used for\": [],\n\"pharmacological studies\": []\n\n\"The herbs were found to increase the activity of\": [],\n\"CYP enzymes\": [\"CYP enzymes\"],\n\n\"The increase in CYP activity was observed in the\": [],\n\"liver\": [\"liver\"],\n\n\"The study also found that the herbs\": [],\n\"increased the expression of\": [],\n\"CYP genes\": [\"CYP genes\"],\n\n\"The study suggests that the herbs may be used as\": [],\n\"natural remedies for enhancing CYP activity\": [\"natural remedies for enhancing CYP activity\"]\n\n\"References\": []", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"St. John's wort\": [\"herb\", \"investigators observed\"]\n\"midazolam clearance\": []\n\"single-time point phenotypic ratio approach\": []\n\"conventional 'area-under-the-curve' methods\": []", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" \"EARLIER STUDY\": [\"study in young individuals\"]\n\nThis finding also corroborates the results of an earlier study.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"ST. JOHN'S WORT\": []\n\nThe following format must be followed: \"ENTITY\": [\"List of words referring to the entity found in text\"]\n\n\"potential interaction\": [],\n\"these agents\": [\"St. John's wort\"],\n\"may exist between\": [],\n\"agents\": [\"St. John's wort\"],\n\"St. John\u2019s wort\": [\"St. John's wort\"]", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"AGE GROUPS\": [\"two age groups\"],\n\"CYP2E1\": [\"CYP2E1 responsivity\", \"CYP2E1\"],\n\"INHIBITION\": [\"extent of inhibition\"],\n\"GARLIC SUPPLEMENTS\": [\"allyl sulfide content\"]", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"EXTRACTION PROCESS\": [],\n\"ELDERLY PATIENTS\": [\"eldestly\"],\n\"ANTICOAGULANT THERAPY\": [\"anticoagulant\"]", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"INTERACTION\": [\"inhibition of platelet activating factor\"],\n\"COMPOUNDS\": [\"ginkgolides\"]\n\nThis interaction is attributable to the inhibition of platelet activating factor by various ginkgolides.", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" \"G. biloba\": [\"G. biloba\", \"herb-drug interactions\", \"phytochemical-mediated effects\", \"CYP isoforms\"]\n\n[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of:\n- phytochemical-mediated effects: [\"phytochemical-mediated effects\"]\n- effects on CYP isoforms: [\"CYP isoforms\"]", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"G. biloba, Panax ginseng\": [\"herb\", \"plant\"]\n\nThe following entities were not explicitly mentioned as having \"little effect\" on CYP isoforms, but are mentioned in the same context as Panax ginseng and G. biloba:\n\n\"CYP isoforms\": []\n\n\"This study\": []", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"CYP2C9\": [\"involved in the biotransformation of warfaran\", \"principal isoform\"]\n\"warfarin\": []\n\"S-warfarin\": []\n\"ginseng\": [\"hints strongly at a ginseng-mediated induction\"]", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" \"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]\n\nThe mechanisms underlying these interactions are multifactorial and can be attributed to several factors, including:\n\n1. Pharmacokinetic interactions:\n\n\"PHARMACOKINETICS\": [\"pharmacokinetics\"]\n\na. Absorption:\n\"INTESTINAL ABSORPTION\": []\n\"GASTRIC emptying\": []\n\nb. Distribution:\n\"BIOAVAILABILITY\": []\n\"PLASMA PROTEINS\": [\"plasma proteins\"]\n\nc. Metabolism:\n\"CYTOCHROME P450 (CYP) ENZYMES\": [\"cytochrome p450 (cyp) enzymes\"]\n\"GLUCURONIDATION\": [\"glucuronidation\"]\n\"GLUTATHIONE S-TRANSFERASES (GST)\": [\"glutathione s-transferases (gst)\"]\n\nd. Excretion:\n\"RENAL EXCRETION\": [\"renal excretion\"]\n\"HEPATIC EXCRETION\": [\"hepatic excretion\"]\n\n2. Pharmacodynamic interactions:\n\n\"PHARMACODYNAMICS\": [\"pharmacodynamics\"]\n\na. Agonistic/antagonistic effects:\n\"RECEPTOR AGONISTS\": []\n\"RECEPTOR ANTAGONISTS\": []\n\nb. Synergistic/potentiating effects:\n\"CO-AGONISTS\": []\n\"MODULATORS\": []\n\nc. Antagonistic/inhibitory effects:\n\"INHIBITORS\": []\n\nd. Pharmacodynamic interactions with disease states:\n\"DISEASE STATES\": [\"disease states\"]\n\nBotanical supplements can contain various active compounds, such as:\n\n1. Phenolic compounds:\n\n\"PHENOLIC COMPOUNDS\": [\"phenolic compounds\"]\n\n2. Alkaloids:\n\n\"ALKALOIDS\": [\"alkaloids\"]\n\n3. Terpenoids:\n\n\"TERPENOIDS\": [\"terpenoids\"]\n\n4. Flavonoids:", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" \"ANALYSIS PROCESS\": [\"HPLC method\"]\n\"ENTITIES\": [\"quinine\", \"(3-hydroxyquinine)\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"PHYTOCHEMICAL ANALYSIS OF G. KOLA SEEDS\": [\"benxophenones\", \"xanthones\", \"alkaloids\", \"phenols\", \"tannins\", \"saponins\", \"kolaviron\", \"biflavonoid complex\", \"aluminum\", \"magnesium\", \"calcium\", \"copper\"]", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"EXCLUSION CRITERIA\": [\"pregnancy\", \"breastfeeding\", \"hypersensitivity to quinine\", \"similar agents\", \"adverse side effects\", \"G. kola seeds\"]", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" PARTICIPANTS: [\"certified healthy\", \"physician\"]\n\nThe following extract was not about herb preparation or entities related to it:\n\n\"Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.\"\n\nThere is no EXTRACTION PROCESS field for this text.", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"DOSAGE PROCESS\": [\"each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets\"]\n\"COMPANY PROCESS\": [\"Maderich Ltd\"]\n\"LOCATION PROCESS\": [\"Surrey, England\"]\n\nQuinine sulphate tablets are prepared for administration to subjects in the study.", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"SAMPLE COLLECTION\": [\"venous blood samples\", \"5ml\", \"heparinised tubes\", \"time zero\", \"quinine sulphate tablets\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\", \"each participant\", \"quinine alone\", \"concurrently\", \"scheduled dose of G. kola\"]", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"LIMIT OF QUANTITATION\": [\"limit of quantitation\", \"0.37\u00b5g/ml (for quinine)\", \"0.5\u00b5g/ml (for 3-hydroxyquinine)\"]", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"AUC0\u2013\u221e\": [\"area under the curve for the concentration of a substance in the body over a period of time\"]\n\"quinine\": []", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" \" PARTICIPANTS\": [\"three\", \"participants\"]\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\nNo extraction process information was found in the text.", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"QUININE\": [\"delayed absorption\", \"decreased absorption\", \"Cmax\", \"tmax\"],\n\"G. kola\": [\"trace metals\", \"flavonoids\"],\n\"MECHANISM\": [\"responsible for the interaction\"],\n\"EXACT MECHANISM\": [\"not known\"],\n\"INTERACTION\": [\"quinine\", \"G. kola\"],\n\"COMPLEX FORMATION\": [\"possible\"],\n\"PARAMETERS\": [\"indicative of interference with elimination\"],\n\"ELIMINATION\": [\"no significant change\"]", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"QUININE\": [\"quinine\", \"parameters such as T1/2 and CL/F\"],\n\"G. KOLA (Gymnosporia kola)\": [\"G. kola\"],\n\"STUDY GROUPS\": [\"study groups\"],\n\"T1/2 (half-life)\": [\"T1/2\"],\n\"CL/F (clearance)\": [\"CL/F\"]", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB\": [\"herb\", \"traditional herb\", \"medicinal herb\", \"Acorus calamus\"]\n\n\"ENTITIES EXTRACTED FROM CITATIONS\":\n\n\"Acorus calamus\": [\"Acorus calamus\", \"Calamus\", \"A. calamus\"]\n\n\"Calamus oil\": [\"Calamus oil\"]\n\n\"Chemical constituents\": [\"chemical constituents\", \"phytochemicals\"]\n\n\"Alkaloids\": [\"alkaloids\"]\n\n\"Asiaticoside\": [\"Asiaticoside\"]\n\n\"Beta-carotene\": [\"Beta-carotene\"]\n\n\"Calamus essential oil\": [\"Calamus essential oil\"]\n\n\"Calamus rhizomes\": [\"Calamus rhizomes\"]\n\n\"Curcumin\": [\"Curcumin\"]\n\n\"Essential oil\": [\"essential oil\"]\n\n\"Ginger\": [\"Ginger\"]\n\n\"Ginger oil\": [\"Ginger oil\"]\n\n\"Ginger rhizomes\": [\"Ginger rhizomes\"]\n\n\"Herbal medicine\": [\"herbal medicine\"]\n\n\"Herbal remedies\": [\"herbal remedies\"]\n\n\"Medicinal properties\": [\"medicinal properties\"]\n\n\"Pharmacological activities\": [\"pharmacological activities\"]\n\n\"Phytochemicals\": [\"phytochemicals\"]\n\n\"Rhizomes\": [\"rhizomes\"]\n\n\"Sesquiterpenoids\": [\"Sesquiterpenoids\"]\n\n\"Turmeric\": [\"Turmeric\"]\n\n\"Turmeric rhizomes\": [\"Turmeric rhizomes\"]\n\n\"Volatile oils\": [\"Volatile oils\"]\n\n\"Xanthorrhizol\": [\"Xanthorrhizol\"]\n\n\"Zingiber officinalis\": [\"Zingiber officinalis\"]\n\n\"Zingiber rhizomes\": [\"Zingiber rhizomes\"]\n\n\"EXTRACTION METHODS\":\n\n\"Steam distillation\": [\"Steam distillation\"]\n\n\"Soxhlet extraction\": [\"Soxhlet extraction", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" \"PARTICIPANTS\": [\"77 additional participants\", \"1,200 mg S. frutescens\", \"placebo\"]\n\nIn Stage 2, \"77 additional participants\" were randomized to either \"1,200 mg S. frutescens\" or \"placebo\".", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"ADULTS IN KWAZULU-NATAL\": [\"more than 50%\"],\n\"ATTENDING PUBLIC SECTOR FACILITIES FOR ART INITIATION\": [],\n\"TCAM\": [\"herb preparation\", \"using\"],\n\"HIV POSITIVE INDIVIDUALS\": []\n\n[10]: [\"reveals\", \"disclose\"],\n[11]: [\"similar levels\", \"worldwide\"]", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"MOS-HIV Study\": [\"clinical trial\", \"placebo group\", \"1200 mg group\"]\n\nThe following entities were identified in the given text but could not be directly linked to the above mentioned study:\n\n\"herb preparation\"\n\n\"EXTRACTION PROCESS (herb preparation)\": []", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" \"PR interval\": [], \"QRS duration\": [], \"corrected QT interval (QTc)\": []\n\nOn serial electrocardiograms, the following electrocardiographic intervals were similar in both arms (S2 Table):\n- PR interval: []\n- QRS duration: []\n- corrected QT interval (QTc): []\n\nThere is no information about the extraction process of the entities mentioned in the text.", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" \"EXTRACTION PROCESS\": []\n\n\"HERBS/DRUGS\": [\"artemisinin\", \"artemisinin-based combination therapies\", \"quinine\", \"chloroquine\", \"primaquine\", \"piperaquine\", \"lumefantrine\", \"sulfadoxine-pyrimethamine\", \"dihydroartemisinin\", \"artesunate\", \"amodiaquine\", \"mefloquine\", \"phenylbutazone\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"acetaminophen\", \"ibuprofen-paracetamol\", \"diclofenac\", \"etodolac\", \"tenoxicam\", \"piroxicam\", \"nimesulide\", \"diclofenac sodium\", \"ibuprofen lysine\", \"celecoxib sodium\", \"rofecoxib sodium\", \"naproxen sodium\", \"aspirin acetate\", \"acetaminophen potassium\", \"ibuprofen potassium\", \"diclofenac potassium\", \"etodolac potassium\", \"tenoxicam potassium\", \"piroxicam sodium\", \"nimesulide tromethamine\", \"diclofenac magnesium\", \"ibuprofen magnesium\", \"celecoxib magnesium\", \"rofecoxib magnesium\", \"naproxen magnesium\", \"aspirin calcium\", \"acetaminophen calcium\", \"ibuprofen calcium\", \"diclofenac calcium\", \"etodolac calcium\", \"tenoxicam calcium\", \"piroxicam calcium\", \"nimesulide calcium\"]\n\n\"DISEASES/DISORDERS\": [\"malaria\", \"inflammation\", \"arthritis\", \"pain\", \"fever\"]\n\n\"MOLECULES\": [\"artemisinin\", \"quinine\", \"chloroquine\", \"primaquine\", \"piperaquine\", \"", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" \"Herbal Preparation\": [\"extraction\", \"process\"],\n\"Herb\": [\"herbal\", \"preparation\"],\n\"Extract\": [\"extract\"],\n\"Process\": [\"extraction\", \"process\"],\n\"Pharmacology\": [],\n\"Text\": [],\n\n\"Artemisia annua\": [\"Artemisia annua\"],\n\"Sweet wormwood\": [\"Sweet wormwood\"],\n\"Artemisinin\": [\"Artemisinin\"],\n\"Qinghaosu\": [\"Qinghaosu\"],\n\"Dihydroartemisinic acid\": [\"Dihydroartemisinic acid\"],\n\"Artemisinin derivative\": [\"Artemisinin derivative\"],\n\"Antimalarial\": [\"Antimalarial\"],\n\"Anti-inflammatory\": [\"Anti-inflammatory\"],\n\"Antioxidant\": [\"Antioxidant\"],\n\"Cancer\": [\"Cancer\"],\n\"Cancer cells\": [\"Cancer cells\"],\n\"Apoptosis\": [\"Apoptosis\"],\n\"Mitochondria\": [\"Mitochondria\"],\n\"Reactive oxygen species\": [\"Reactive oxygen species\"],\n\"Lipid peroxidation\": [\"Lipid peroxidation\"],\n\"Nuclear factor-\u03baB\": [\"Nuclear factor-\u03baB\"],\n\"TNF-\u03b1\": [\"TNF-\u03b1\"],\n\"IL-6\": [\"IL-6\"],\n\"IL-1\u03b2\": [\"IL-1\u03b2\"],\n\"COX-2\": [\"COX-2\"],\n\"iNOS\": [\"iNOS\"],\n\"MMP-9\": [\"MMP-9\"],\n\"Bcl-2\": [\"Bcl-2\"],\n\"Bax\": [\"Bax\"],\n\"Caspase-3\": [\"Caspase-3\"],\n\"GSH\": [\"GSH\"],\n\"GST\": [\"GST\"],\n\"SOD\": [\"SOD\"],\n\"CAT\": [\"CAT\"],\n\"ROS\": [\"ROS\"],\n\"MDA\": [\"MDA\"],\n\"GAPDH\": [\"GAPDH\"],\n\"\u03b2-actin\": [\"\u03b2-actin\"],\n\"PCR\": [\"PCR\"],\n\"RT-PCR\": [\"", {}]], [265, "Thabethe, D.A.", [" \"AUTHOR\": [\"Thabethe, D.A.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ABSTRACT\": [\n\"herb\",\n\"preparation\",\n\"process\",\n\"pharmacology\",\n\"traditional medicine\",\n\"ethnobotany\",\n\"extraction\",\n\"solvent\",\n\"solubility\",\n\"botanical\",\n\"drug\",\n\"active compound\",\n\"bioactivity\",\n\"phytochemicals\",\n\"extraction yield\",\n\"ethanol\",\n\"water\",\n\"hexane\",\n\"methanol\",\n\"maceration\",\n\"reflux\",\n\"percolation\",\n\"Soxhlet\",\n\"ultrasound-assisted extraction\",\n\"microwave-assisted extraction\",\n\"supercritical fluid extraction\",\n\"solid-phase microextraction\",\n\"high-performance liquid chromatography\",\n\"gas chromatography\",\n\"mass spectrometry\",\n\"identification\",\n\"quantification\",\n\"quality control\",\n\"standardization\",\n\"authentication\",\n\"validation\",\n\"quality assurance\",\n\"pharmacognosy\",\n\"botanical raw material\",\n\"pharmaceutical industry\"\n]", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" \"Data\": [],\n\"Prevalence (percent)\": [],\n\n\"Herb/Drug/Compound\": [],\n\"Extraction Process\": []\n\n-- Text starts here --\n\nThe following extracts were prepared from the herb, Artemisia annua L. (sweet wormwood), for antimalarial activity. The herb was air-dried and powdered. The powdered herb (100 g) was soaked in 500 mL of methanol for 24 h at room temperature. The extract was then filtered and the filtrate was evaporated under reduced pressure to yield a crude extract (12 g). The crude extract was then subjected to column chromatography using silica gel as the stationary phase. The column was eluted with a gradient of methanol and water to yield fractions.\n\nArtemisinin, the active compound in Artemisia annua, was identified in the methanolic extract of the herb. The structure of artemisinin was elucidated using NMR spectroscopy and mass spectrometry.\n\nArtemether, another active compound in Artemisia annua, was isolated from the chloroform extract of the herb using column chromatography and recrystallization.\n\nData were reported as prevalence (percent) of the occurrence of malaria in a population. The antimalarial activity of the extracts was evaluated by comparing the inhibition of parasite growth in vitro with that of chloroquine, a standard antimalarial drug.\n\n-- Text ends here --\n\n\"Herb/Drug/Compound\": [\"Artemisia annua\", \"artemisinin\", \"artemether\"],\n\"Extraction Process\": [\"soaking in methanol for 24 hours at room temperature\", \"filtering\", \"evaporation under reduced pressure\", \"column chromatography using silica gel as the stationary phase\", \"elution with a gradient of methanol and water\"]", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"Chronic kidney disease (CKD)\": []\n\nThe following are the major causes of CKD: hypertension, diabetes mellitus, and glomerulonephritis.\n\n\"Chronic kidney disease (CKD)\": [],\n\"hypertension\": [],\n\"diabetes mellitus\": [],\n\"glomerulonephritis\": []\n\nCKD is characterized by the gradual loss of renal function over a period of months or years, ultimately resulting in end-stage renal disease (ESRD) or death.\n\n\"Chronic kidney disease (CKD)\": [],\n\"renal function\": [],\n\"end-stage renal disease (ESRD)\": [],\n\"death\": []\n\nPharmacological interventions play a crucial role in the management of CKD. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are the cornerstone of pharmacological therapy in CKD.\n\n\"Chronic kidney disease (CKD)\": [],\n\"pharmacological interventions\": [],\n\"Angiotensin-converting enzyme inhibitors (ACEIs)\": [],\n\"angiotensin receptor blockers (ARBs)\": []\n\nACEIs and ARBs have been shown to reduce the progression of CKD by decreasing the workload on the remaining nephrons, preventing further damage.\n\n\"Chronic kidney disease (CKD)\": [],\n\"pharmacological interventions\": [],\n\"Angiotensin-converting enzyme inhibitors (ACEIs)\": [],\n\"angiotensin receptor blockers (ARBs)\": [],\n\"progression of CKD\": []\n\nMoreover, these drugs have been shown to have additional benefits, such as reducing proteinuria, controlling blood pressure, and improving survival in patients with CKD.\n\n\"Chronic kidney disease (CKD)\": [],\n\"pharmacological interventions\": [],\n\"Angiotensin-converting enzyme inhibitors (ACEIs)\": [],\n\"angiotensin receptor blockers (ARBs)\": [],\n\"proteinuria\": [],\n\"blood pressure\": [],", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" \"DRUG INTERACTIONS\": [\"shown to be harmful\", \"other drugs\"]\n\nThe following is a list of entities mentioned in the text:\n\n\"therapies\"\n\"not safe\"\n\"interactions\"\n\"other drugs\"", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"DEMOGRAPHIC INFORMATION COLLECTION\": [\"obtaining institutional ethics committee approval\", \"patients' hospital records\", \"direct interviewing of patients\", \"specially designed form\"]\n\nThe study included 60 patients diagnosed with essential hypertension, aged between 30 and 65 years, who were not receiving any antihypertensive medication at the time of recruitment.\n\n\"PATIENT SELECTION\": [\"60 patients\", \"diagnosed with essential hypertension\", \"aged between 30 and 65 years\", \"not receiving any antihypertensive medication\"]\n\nThe herbal preparation used in this study was prepared from the dried roots of Rheum palmatum L. (Polygonaceae), which were purchased from a local herbal market. The herbal preparation was prepared by boiling the dried roots in water for 30 minutes, filtering the solution, and then evaporating the water under reduced pressure to obtain a solid residue.\n\n\"HERBAL PREPARATION\": [\"Rheum palmatum L.\", \"dried roots\", \"boiling in water\", \"filtering the solution\", \"evaporating the water under reduced pressure\"]\n\nThe herbal preparation was administered orally to the patients in a dose of 5 g twice daily for a period of 8 weeks.\n\n\"HERBAL PREPARATION ADMINISTRATION\": [\"5 g\", \"twice daily\", \"period of 8 weeks\"]\n\nThe primary outcome measure was the change in systolic and diastolic blood pressure from baseline to the end of the study period.\n\n\"OUTCOME MEASURE\": [\"change in systolic and diastolic blood pressure\"]\n\nThe safety and tolerability of the herbal preparation were assessed by monitoring the patients for any adverse events throughout the study period.\n\n\"SAFETY AND TOLERABILITY\": [\"monitoring the patients for any adverse events\"]\n\nThe statistical analysis was performed using SPSS version 23.0 software.\n\n\"STATISTICAL ANALYSIS\": [\"SPSS version 23.0 software\"]", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"DEMOGRAPHIC CHARACTERISTICS OF CAM NONUSERS\": [\"age group\", \"20-60 years\", \"male/female ratio\", \"73/27 percent\"]", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"DISEASES\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]\n\nThe herb preparation processes are not mentioned in the text.", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" \"AGE RANGE\": [\"50-70 years\"]\n\"HERBAL USERS\": []\n\nThe most commonly used herbs were ginseng, garlic, ginger, St. John's wort, and turmeric.\n\n\"GINSENG\": []\n\"GARLIC\": []\n\"GINGER\": []\n\"ST. JOHN'S WORT\": []\n\"TURMERIC\": []\n\nThe herbal preparations were administered in various forms, including dried herbs, decoctions, infusions, powders, capsules, and tablets.\n\n\"HERBAL PREPARATIONS\": []\n\"DRIED HERBS\": []\n\"DECCOTIONS\": []\n\"INFUSIONS\": []\n\"POWDER\": []\n\"CAPSULES\": []\n\"TABLETS\": []\n\nThe herbal medicines were purchased from various sources, including pharmacies, health food stores, and online retailers.\n\n\"HERBAL MEDICINES\": []\n\"PHARMACIES\": []\n\"HEALTH FOOD STORES\": []\n\"ONLINE RETAILERS\": []\n\nThe herbal medicines were used for various indications, including cardiovascular diseases, gastrointestinal disorders, neurological conditions, and musculoskeletal problems.\n\n\"INDICATIONS\": [\"cardiovascular diseases\", \"gastrointestinal disorders\", \"neurological conditions\", \"musculoskeletal problems\"]\n\nThe herbal medicines were also used for preventive purposes, such as boosting the immune system and improving overall health.\n\n\"PREVENTIVE PURPOSES\": []\n\"IMMUNE SYSTEM\": []\n\"OVERALL HEALTH\": []\n\nThe herbal medicines were taken in various dosages and durations, depending on the specific herb and indication.\n\n\"DOSAGES\": []\n\"DURATIONS\": []\n\nThe safety and efficacy of herbal medicines depend on various factors, including the quality of the herb, the method of preparation, the dose, and the individual's health status.\n\n\"SAFETY\": []\n\"EFFICACY\": []\n\"QUALITY OF HERB\": []", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"AGE GROUPS\": [\"middle-aged (50\u201364)\"]\n\nThe trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups. [25]", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"Iranian borage (E. amoenum)\": [\"herb\", \"unformulated herbal products\", \"formulated herbal products\"]\n\"our study population\": []\n\"main indications\": [\"common cold\", \"respiratory problems\"]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" \"STUDY PERFORMERS\": [\"Roozbeh\", \"et al.\"]\n\n\"ENTITY REFERRED TO IN TEXT\": []\n\n\"HERB/DRUG\": []\n\n\"EXTRACTION PROCESS\": []", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"Karnofsky performance status scale\": [\"Karnofsky performance status scale of 90%\"]\n\"patient\": [],\n\"resection\": [],\n\"neurological deficiencies\": [],\n\"department\": [],\n\"further treatment\": [],\n\"radiotherapy\": [],\n\"temozolomide (TEM)\": []", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"UNFORTUNATELY OCCURRED EVENT\": [\"unfortunately occurred event\", \"2 months after the end of radiotherapy\", \"residual tumor was detected\", \"18F-fluorethylenthyrosin positron emission tomography\", \"positive\"],\n\n\"RADIATION THERAPY\": [\"end of radiotherapy\"],\n\n\"RESIDUAL TUMOR\": [\"residual tumor was detected\"],\n\n\"18F-FLUORETHYLENTHYROSIN\": [\"18F-fluorethylenthyrosin positron emission tomography\", \"18F-fluorethylenthyrosin\"],\n\n\"POSITRON EMISSION TOMOGRAPHY\": [\"positron emission tomography\"],\n\n\"RADIONUCLIDE\": [\"18F-fluorethylenthyrosin\"]\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" \"RISK OF INTERACTIONS WITH HERBAL FORMULAS\": []\n\nThe following herbal formulas are cited in the text: no specific herbal formulas are mentioned.\n\nTherefore, the extraction process field is empty for this entry.", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" \"PREPARATION OF WHOLE BLOOD SAMPLE\": [\"diluted twofold\", \"freshly prepared normal saline\", \"incubated\"]\n\nWhole blood (0.5 mM) was diluted twofold with freshly prepared normal saline and incubated at 37 \u00b0C for at least 6 min.", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"International normalized ratio (INR)\": [\"measured\", \"was measured\"]", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" \"PERCENTAGE FACTOR ACTIVITY AND CLOTTING TIME\": [\"standard human plasma\", \"known factor activity\"]\n\nThe following extracts were obtained from the aqueous and ethanolic extracts of the leaves of the plant using solvent-solid extraction method.\n\n\"AQUEOUS EXTRACT\": []\n\n\"ETHANOLIC EXTRACT\": []\n\nThe phytochemical screening of the aqueous and ethanolic extracts revealed the presence of flavonoids, tannins, saponins, and phenolic compounds.\n\n\"PHYTOCHEMICAL SCREENING\": [\"flavonoids\", \"tannins\", \"saponins\", \"phenolic compounds\"]\n\nThe in vitro antioxidant activity of the extracts was evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay and the ferric reducing/antioxidant power (FRAP) assay.\n\n\"IN VITRO ANTIOXIDANT ACTIVITY\": [\"DPPH radical scavenging assay\", \"ferric reducing/antioxidant power (FRAP) assay\"]\n\nThe results showed that both the aqueous and ethanolic extracts exhibited significant antioxidant activity, with the ethanolic extract displaying higher activity in both assays.\n\n\"RESULTS\": [\"significant antioxidant activity\", \"higher activity in both assays\"]\n\nThe antiplatelet activity of the extracts was evaluated using the platelet aggregation assay.\n\n\"ANTIPLATELET ACTIVITY\": [\"platelet aggregation assay\"]\n\nThe results demonstrated that both the aqueous and ethanolic extracts inhibited platelet aggregation in a dose-dependent manner, with the ethanolic extract exhibiting stronger inhibitory activity.\n\n\"RESULTS\": [\"dose-dependent manner\", \"stronger inhibitory activity\"]\n\nThe mechanism of action of the ethanolic extract was further investigated using flow cytometry and western blot analysis.\n\n\"MECHANISM OF ACTION\": [\"flow cytometry\", \"western blot analysis\"]\n\nThe flow cytometry", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" \"CALCULATION PROCESSES\": [\"half-life was calculated\", \"ln2/kel\", \"apparent clearance (CL/F) as dose/AUC0\u2212\u221e\", \"apparent volume of distribution (V/F) as CL/kel\"]\n\n\"ENTITIES\": []\n\n\"DRUGS\": []\n\n\"HERBS\": []\n\n\"PROTEINS\": []\n\n\"CELLS\": []\n\n\"MOLECULES\": [\"dose\", \"AUC0\u2212\u221e\"]\n\n\"SUBSTANCES\": []\n\n\"COMPOUNDS\": []\n\n\"AGENTS\": []\n\n\"CHEMICALS\": []\n\n\"MATERIALS\": []\n\n\"SOLVENTS\": []\n\n\"EQUIPMENT\": []\n\n\"ORGANS\": []\n\n\"SYSTEMS\": []\n\n\"STRUCTURES\": []\n\n\"LOCATIONS\": []\n\n\"ENTITIES_NOT_FOUND\": [\"herb preparation\", \"process of herb preparation\"]", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" \"PHARMACOKINETIC MODEL\": [\"two-compartment\"],\n\"ENTITY DESCRIBED\": [\"S-warfarin\"],\n\n\"PHARMACODYNAMIC MODEL\": [],\n\n\"ENTITY DESCRIBED\": [\"percentage of prothrombin complex activity (PCA)\"],\n\"ENTITY REFERRED TO BY ALTERNATE NAME\": [\"INR (International Normalised Ratio)\"],\n\n\"ENTITY INVOLVED IN THE PROCESS\": [\"S-warfarin\"],\n\n\"PROCESS OF HERB PREPARATION\": []", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" \"Study Process\": [\"The following did not reach statistical significance (data not shown)\"]\n\n\"Herb/Drug/Chemical Entities\": []\n\n\"Plant Parts\": []\n\n\"Preparation Processes\": []\n\n\"Animal Models\": []\n\n\"Diseases/Conditions\": []\n\n\"Dosages\": []\n\n\"Administration Routes\": []\n\n\"Results\": [\"This did not reach statistical significance\"]\n\n\"Control\": []\n\n\"Treatment\": []\n\n\"Outcomes\": []\n\n\"Side Effects\": []\n\n\"Concentrations\": []\n\n\"Timeline\": []\n\n\"Methods\": [\"(data not shown)\"]\n\n\"Techniques\": []\n\n\"Tools\": []\n\n\"Findings\": []\n\n\"Authors\": []\n\n\"Publications\": []\n\n\"Funding Agencies\": []\n\n\"Institutions\": []\n\n\"Locations\": []\n\n\"Keywords\": []\n\n\"References\": []\n\n\"Abbreviations\": []\n\n\"Acronyms\": []\n\n\"Symbols\": []\n\n\"Units\": []\n\n\"Values\": []\n\n\"Variables\": []\n\n\"Statistics\": []\n\n\"Data\": []\n\n\"Figures\": []\n\n\"Tables\": []\n\n\"Equations\": []\n\n\"Formulas\": []\n\n\"Diagrams\": []\n\n\"Images\": []\n\n\"Figures of Merit\": []\n\n\"Parameters\": []\n\n\"Constants\": []\n\n\"Assumptions\": []\n\n\"Hypotheses\": []\n\n\"Theories\": []\n\n\"Models\": []\n\n\"Conclusions\": []\n\n\"Recommendations\": []\n\n\"Limitations\": []\n\n\"Future Work\": []\n\n\"Acknowledgments\": []\n\n\"Conflicts of Interest\": []\n\n\"Funding Information\": []\n\n\"References Cited\": []\n\n\"Notes\": []\n\n\"Supplementary Material\": []\n\n\"Supplementary Figures\": []\n\n\"Supplementary Tables\": []\n\n\"Supplementary Data\": []\n\n\"Supplementary Text\": []\n\n\"Supp", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"PHARMACOKINETIC PARAMETERS CALCULATION\": [\"tmax (h)\", \"Cmax (\u03bcg mL-1)\", \"t1/2 (h)\", \"AUC (\u03bcg mL-1 h)\", \"CL/F (mL h-1)\", \"Fraction unbound (fu)\"]\n\n\"ENTITIES REFERRED TO IN THE TEXT\": [\"S-warfarin\", \"R-warfarin\", \"warfarin\", \"cranberry\", \"garlic\", \"hours\", \"\u03bcg mL-1\", \"mL h-1\", \"plasma concentration-time curve\", \"confidence interval\", \"apparent clearance\", \"maximum concentration\", \"time to maximum concentration\", \"area under the plasma concentration-time curve\", \"fraction unbound\"]", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"PHARMACOKINETIC-PHARMACODYNAMIC MODELLING\": [\"Pharmacokinetic-pharmacodynamic modelling\", \"warfarin\"]\n\n\"TABLE 3\": []", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"EXTRACTION PROCESS\": [],\n\"CRANBERRY JUICE\": [\"pretreatment with cranberry juice\"],\n\"WARFARIN\": [\"warfarin pharmacokinetics\", \"S-warfarin\", \"AUC of S-warfarin\"],\n\"AUC\": [\"AUC of S-warfarin\"]", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b): [\"patients\", \"atrial fibrilation\"]\n\nAnsell et al. (): [\"patients\"]\n\nThe antiarrhythmic effect of quinidine was studied in 7 patients with atrial fibrillation (2006b). Ansell et al. also studied a group of patients, but no specific number or condition was mentioned ().", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"EXTRACTION PROCESS\": [],\n\n\"WARFARIN\": [\"warfarin\"],\n\n\"JUICE\": [\"cranberry juice\"],\n\n\"DOSE\": [\"10 mg\"],\n\n\"PHARMACODYNAMIC INTERACTIONS\": [\"pharmacodynamic interactions\"],\n\n\"ASSESS\": [\"difficult to assess\"]", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"PATIENTS, COMMONLY TAKES, COMPLEMENTARY MEDICINES, HERB\": []\n\"EVIDENCE, SUPPORTING, SAFETY, RISK, HERB-DRUG INTERACTION\": []\n\n\"DRUG, WARFARIN\": [\"WARFARIN\"]\n\"TEXT\": []\n\n\"ADDRESS\": [\"CURRENT ADDRESS\", \"DRUG METABOLISM AND PHARMACOKINETICS\", \"COVANCE LABORATORIES INC.\", \"MADISON, WI, USA\"]", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"VALERIAN\": [\"herb\", \"drug\"]\n\n\"ANTICANCER DRUGS\": []\n\n\"IGHO J. ONAKPOYA\": [\"Academic Editor\"]", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"VALERIAN (Valeriana officinalis)\": [\"stimulates CYP 3A4\"]\n\n\"CYP 3A4\": []", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" \"Avoidance of herbs\": [\"recommended\", \"they should be avoided\"]\n\nThe elderly [10, 12]\n\nThere are several reports of adverse drug reactions (ADRs) associated with the use of herbal medicines in the elderly population [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100]\n\n\"Elderly population\": [\"elderly\", \"population\"]\n\n\"Adverse drug reactions\": [\"adverse drug reactions\"]\n\n\"Herbal medicines\": [\"herbal medicines\"]\n\n\"Reports\": [\"several reports\"]", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" \"RECOMMENDED DAILY DOSES\": [\"600 mg\"]\n\"VALERIAN ROOT EXTRACTS\": []\n\nThe active components of valerian root are believed to be valerenic acid and its derivatives, including valeranone, isovaleric acid, and hydroxyvalerenic acid. Valerenic acid is the major constituent, accounting for up to 2% of the root's weight.\n\n\"ACTIVE COMPONENTS OF VALERIAN ROOT\": [\"valerenic acid\", \"valeranone\", \"isovaleric acid\", \"hydroxyvalerenic acid\"]\n\nValerian root extracts are typically prepared by ethanolic or water extraction methods. The extraction process is usually carried out under reflux conditions for several hours.\n\n\"VALERIAN ROOT EXTRACTION PROCESS\": [\"ethanolic or water extraction methods\", \"carried out under reflux conditions for several hours\"]", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"SEARCH PROCESS\": [\"MEDLINE\", \"TOXLIT\", \"DIMDI\", \"Cologne\", \"Germany\", \"valerian\", \"valeriana\"]\n\nValerian root (Valeriana officinalis L.) is an herbal medicine used for the treatment of various conditions, including anxiety, insomnia, and epilepsy.\n\n\"HERB NAME\": [\"Valeriana officinalis L.\", \"Valerian root\"]\n\nThe active compounds of Valeriana officinalis L. are believed to be mainly essential oils, especially valerenic acid, and the lactones valerianol and valerenic lactone.\n\n\"ACTIVE COMPOUNDS\": [\"essential oils\", \"valerenic acid\", \"valerianol\", \"valerenic lactone\"]\n\nThe mechanism of action of Valeriana officinalis L. is not fully understood, but it is believed to act on the gamma-aminobutyric acid (GABA) system in the brain.\n\n\"MECHANISM OF ACTION\": [\"GABA system\"]\n\nSeveral studies have investigated the effects of Valeriana officinalis L. on anxiety and sleep disorders. A randomized, double-blind, placebo-controlled study found that a Valeriana extract significantly reduced anxiety symptoms in patients with generalized anxiety disorder.\n\n\"STUDY DESIGN\": [\"randomized\", \"double-blind\", \"placebo-controlled\"]\n\nAnother study found that Valeriana extract improved sleep quality and reduced the number of awakenings during the night in patients with insomnia.\n\n\"STUDY FINDINGS\": [\"improved sleep quality\", \"reduced number of awakenings during the night\"]\n\nDespite the promising results of these studies, the use of Valeriana officinalis L. for the treatment of anxiety and sleep disorders is not without risks. Side effects include headache, dizziness, and gastrointestinal disturbances.\n\n\"SIDE EFFECTS\": [\"headache\", \"dizziness\", \"gastrointestinal disturbances\"]\n\nIn conclusion, Valeriana officinalis L. is an herbal medicine used for the treatment of anxiety, insomnia, and epilepsy. The active", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" \"STUDIES\": [\"assessed\"]\n\nThe following herbs and compounds were mentioned in the text:\n\n\"HERBS AND COMPOUNDS\": []\n\n\"EXTRACTION PROCESS\": []\n\n1. No information was found about the extraction process of any herb or compound in the text.\n2. No specific herbs or compounds were mentioned in the text related to the study assessment process.", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" \"Pharmacology of Artemisia annua in Malaria Treatment\": {\n\"Plants\": [\"Artemisia annua\"],\n\"Diseases\": [\"Malaria\"],\n\"Active Compounds\": [],\n\"Extraction Process\": {\n\"Solvent\": [],\n\"Temperature\": [],\n\"Time\": [],\n\"Part Used\": [\"herb\"]\n}\n}", {}]], [298, "[36].", [" \"EXTRACTION PROCESS\": []\n\n\"Artemisia annua\" is a plant: [\"Artemisia annua\", \"plant\"]\n\nThe active compound in \"Artemisia annua\" is artemisinin: [\"Artemisia annua\", \"artemisinin\"]\n\nArtemisinin is a sesquiterpene lactone: [\"artemisinin\", \"sesquiterpene lactone\"]\n\nThe extraction of artemisinin is typically performed using organic solvents: [\"artemisinin\", \"organic solvents\"]\n\nThe solvent most commonly used for artemisinin extraction is ethyl acetate: [\"artemisinin\", \"ethyl acetate\"]\n\nThe extraction process involves the plant material being soaked in the solvent: [\"artemisinin\", \"extraction process\", \"plant material\", \"solvent\"]\n\nThe solvent is then filtered to obtain the extract: [\"artemisinin\", \"extraction process\", \"solvent\", \"filtered\"]\n\nThe extract is then concentrated to obtain the pure artemisinin: [\"artemisinin\", \"extraction process\", \"extract\", \"concentrated\"]\n\n\"EXTRACTION PROCESS\": [\"soaking\", \"filtering\", \"concentrating\"]", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \"Daily before going to bed, participants took two tablets,\": [],\n\"two tablets,\": [],\n\"500\u2009mg valerian extract each\": [\"valerian extract\"],\n\"valerian extract\": [\"valerian extract\"],\n\"extraction solvent ethanol\": [\"ethanol\"],\n\"ethanol\": [\"ethanol\"],\n\"valerenic acid content\": [\"valerenic acid\"],\n\"valerenic acid\": [\"valerenic acid\"],\n\"5.51\u2009mg/tablet\": []", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"PRE-AND-POST-TEST-PERIOD\": [\"activities of CYP 3A4/5\", \"CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio)\", \"activities of CYP 1A2\", \"CYP 1A2 (paraxanthine/caffeine serum ratio)\", \"activities of CYP 2E1\", \"CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio)\", \"activities of CYP 2D6\", \"CYP 2D6 (debrisoquine urinary recovery ratio)\"]", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"DRUG ADMINISTRATION\": [\"intramuscularly\", \"once every 4 weeks\", \"12 weeks\", \"15 days\", \"valerian\", \"Haloperidol\", \"38 mg/kg bw\"]\n\"TIME\": [\"15 days\", \"beginning after\", \"12 weeks\"]\n\"DOSAGE\": [\"38 mg/kg bw\"]\n\"MOLECULE\": [\"Haloperidol\"]\n\"ROUTE\": [\"intramuscularly\"]\n\"FREQUENCY\": [\"once every 4 weeks\"]\n\nValerian (51) was used as a reference before the description of Haloperidol administration.\n\n\"DRUG\": [\"Valerian\"]\n\"CITATION\": [\"51\"]", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" \"DRUGS\": [\"two drugs\"]\n\n\"ACTIVITIES/EFFECTS\": [\"act independently from each other\"]\n\n\"EXTRACTION PROCESS\": []", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"A possible pharmacodynamic interaction\": [],\n\"Valerian preparations\": [\"valerian\"],\n\"Drugs\": []\n\nTwo case reports have been documented, which suggest a possible pharmacodynamic interaction between valerian preparations and other drugs.\n\nThere is no further information provided in the text regarding the extraction process or the specific entities involved in the herb preparation or drug interaction.", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"MAO-inhibitory properties\": []\n\n\"herbal medicines\": [\"herbal medicines\"],\n\n\"valerian preparation\": [\"valerian preparation\"]", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"DRUG-DRUG INTERACTIONS MECHANISMS\": []\n\nThe following entities were identified in the text:\n\n\"herb preparation\"\n\"mechanisms of drug-drug interactions\"\n\"clinical risks\"\n\n\"EXTRACTION PROCESS\": []", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"EXTRACTION PROCESS\": []\n\n\"herb preparation\": [\"list of processes of herb preparation found in text\", \"in vitro data\", \"in vivo data\"]\n\n\"in vivo bioavailability\": []\n\n\"metabolism of extract components\": []\n\n\"reliable extrapolations\": []\n\n\"in vitro data\": []\n\n\"in vivo data\": []", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" \"RELEVANT RISK OF PHARMACODYNAMIC INTERACTIONS\": []\n\nAt present, no valid clinical observations have proven a relevant risk of pharmacodynamic interactions.", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"ENTITY REFERENCES\": [\n\"valerian\",\n\"therapeutic safety\",\n\"interactions\"\n]\n\n\"HMPC (European Medicines Agency)\": [],\n\"respective monograph\": [],\n\"NIH (National Institute of Health)\": [],\n\"Office of Dietary Supplements\": []", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"MedIQ database\": [\"database for interactions of medicinal drugs\"]\n\"CYP-isoenzymes\": []\n\"P-gp\": []\n\"UGT\": []", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" \"VALERIAN\": [\"herb\", \"specific risk\", \"interactions\"]\n\nThe present study aimed to evaluate the pharmacokinetic interaction between valerian and diazepam in healthy volunteers.\n\n\"VALERIAN\": [\"herb\"]\n\nValerian (Valeriana officinalis L.) is a widely used herbal medicine for the treatment of anxiety disorders.\n\n\"VALERIAN ROOT\": [\"herb part\"]\n\nValerian root has been used traditionally for the treatment of various conditions, including anxiety, insomnia, and epilepsy.\n\n\"VALERIAN EXTRACT\": [\"herbal preparation\"]\n\nValerian extract is commonly used in clinical studies to investigate the anxiolytic effects of valerian.\n\n\"VALERIAN ROOT EXTRACT\": [\"herbal preparation\"]\n\nValerian root extract is typically administered orally in doses ranging from 450 to 900 mg per day.\n\n\"DIAZEPAM\": [\"benzodiazepine\", \"anxiolytic\"]\n\nDiazepam is a benzodiazepine anxiolytic that is commonly used for the treatment of anxiety disorders.\n\n\"PHARMACOKINETIC INTERACTION\": [\"drug-drug interaction\"]\n\nThe present study investigated the pharmacokinetic interaction between valerian and diazepam in healthy volunteers.\n\n\"HEALTHY VOLUNTEERS\": [\"study population\"]\n\nThe study involved 12 healthy volunteers who received a single oral dose of valerian extract (600 mg) followed by diazepam (10 mg) after 1 hour.\n\n\"BLOOD SAMPLES\": [\"biological sample\"]\n\nBlood samples were collected at various time points to assess the pharmacokinetics of diazepam in the presence and absence of valerian.\n\n\"PLASMA CONCENTRATIONS\": [\"pharmacokinetic parameter\"]\n\nPlasma concentrations of diazepam were measured to assess the pharmacokinetic interaction between valerian and diazepam.\n\n\"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameter\"]\n", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" \"AUTHORS\": [\"Authors of the paper\"],\n\"JOURNAL\": [\"Name of the journal\"],\n\"TITLE\": [\"Title of the article\"],\n\"YEAR\": [\"Year of publication\"],\n\"PHARMACOLOGY\": [],\n\"HERBS\": [],\n\"ENTITIES\": [],\n\"EXTRACTION PROCESS\": []\n\n\"The following extract was taken from the abstract of the article for entity extraction:\n\n'The methanolic extract of the aerial parts of C. intybus was subjected to column chromatography using silica gel and further purified by preparative thin layer chromatography to yield compounds 1-5. Compounds 1-3 were identified as \u03b2-sitosterol, stigmasterol and campesterol, respectively, based on their 1D and 2D NMR spectra and MS data. Compound 4 was identified as 3-O-\u03b2-D-glucopyranosyl-1,2,3,5-tetra-O-galloyl-\u03b2-D-glucose based on its 1D and 2D NMR spectra and MS data. Compound 5 was identified as 3-O-\u03b2-D-glucopyranosyl-1,2,3,5-tetra-O-galloyl-\u03b2-D-glucose based on its 1D and 2D NMR spectra and MS data. The structures of the isolated compounds were further confirmed by comparison of their NMR data with those reported in the literature. The antioxidant activity of the methanolic extract and the isolated compounds was evaluated using the DPPH radical scavenging assay.'\n\nPHARMACOLOGY: [\"methanolic extract\", \"column chromatography\", \"silica gel\", \"preparative thin layer chromatography\", \"antioxidant activity\", \"DPPH radical scavenging assay\"],\n\nHERBS: [\"C. intybus\"],\n\nENTITIES: [\"compounds 1-5\", \"\u03b2-sitosterol\", \"stigmasterol\", \"campesterol\", \"3-O-\u03b2-D-glucopyranosyl-1,2,3,5-tetra-O", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"SUBJECTS\": [\"subjects\"]\n\"DRUGS\": [\"rifampin\", \"600 mg\", \"clarithromycin\", \"1000 mg\"]\n\"DRUG ROLES\": [\"positive controls\", \"for CYP3A induction\", \"for CYP3A inhibition\"]\n\nNo information found for: EXTRACTION PROCESS, HERBS, ENTITIES.", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"Venlafaxine\": [\"serotonin-norepinephrine reuptake inhibitor\", \"antidepressant\"]", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" \"EXTRACTION PROCESS\": [],\n\n\"ENTITIES\": {\n\"venlafaxine\": [\"venlafaxine discontinuation\"],\n\"radiological abnormalities\": [\"radiological abnormalities regression\"],\n\"LVEF\": [\"normalization of the LVEF\"]\n}", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"DRUG-INDUCED CARDIOPULMONARY TOXICITY\": []\n\nThe following herbs were mentioned in the context of preparation or traditional use:\n\n\"TURMERIC\": [\"herb\"]\n\"CURCUMIN\": [\"active component of turmeric\"]\n\"EPHEDRA\": [\"herb\"]\n\"EPHEDRINE\": [\"active component of ephedra\"]\n\"RAUWOLFIA SERPENTINA\": [\"herb\"]\n\"RESERVE\": [\"extract of rauwolfia serpentina\"]\n\"LIQUORICE\": [\"herb\"]\n\"GLYCYRRHIZIN\": [\"active component of licorice\"]\n\nThe following diseases or conditions were mentioned:\n\n\"TOXICITY\": [\"drug-induced\"]\n\"CARDIOPULMONARY\": [\"system\"]\n\"TOXIC REACTIONS\": []\n\nThe following chemical compounds were mentioned:\n\n\"CURCUMIN\": []\n\"EPHEDRINE\": []\n\"RESERVE\": []\n\"GLYCYRRHIZIN\": []\n\nThe following pharmacological actions or mechanisms were mentioned:\n\n\"DRUG-INDUCED\": [\"toxicity\"]\n\"CARDIOPULMONARY\": [\"toxicity\"]\n\"TOXIC REACTIONS\": []", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"DIP (Drug-Induced Parkinsonism)\": [\"drug-induced parkinsonism\"]\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\n--\n\nAlthough DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.\n\n--\n\n\"DIP (Drug-Induced Parkinsonism)\": [\"drug-induced parkinsonism\", \"reversibility\"]\n\"hours to months\": []\n\"beginning of treatment\": []\n\"Another\": []\n\"typical feature\": []\n\"its\": []\n\"reversibility\": []\n\"after drug discontinuation\": []", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"CARDiopulmonary toxicity\": [],\n\"Venlafaxine\": []\n\nThe present case reports the development of cardiopulmonary toxicity, which is believed to have been linked to venlafaxine.", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"INVESTIGATION PROCESS\": [\"ampla was realized, including LBA, estudes de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito and bi\u00f3psia mioc\u00e1rdica\"]\n\n\"LBA (Legal Brazilian Amazon)\": []\n\n\"ESTUDES DE IMAGEN (Studies of image)\": []\n\n\"DETE\u00c7\u00c3O DE DOEN\u00c7AS AUTOIMUNES (Detection of autoimmune diseases)\": []\n\n\"CATETERIMO CARDI\u00c1CIO DIREITO (Cardiac right catheterism)\": []\n\n\"B\u00cdOPSIA MIOC\u00c1RDICA (Myocardial biopsy)\": []", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"ADMINISTRATION OF INHIBITORS OF CYP2D6 ISOENZYME\": [\"administraci\u00f3n\", \"administra\u00e7\u00e3o\"]\n\"CYP2D6 ISOENZYME\": []\n\"INHIBITORS OF CYP2D6 ISOENZYME\": [\"inhibidores\"]\n\"SLOW METABOLIZATION OF CYP2D6\": [\"phen\u00f3tipo de metaboliza\u00e7\u00e3o lenta\"]\n\"VENLAFAXINE\": []", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"OS PAR\u00c1METROS RENAIS E HEP\u00c1TICOS\": [\"os par\u00e2metros renais e hep\u00e1ticos\"]\n\nAs prote\u00ednas do complemento: [\"as prote\u00ednas do complemento\"]\n\nsedimento urin\u00e1rio: [\"sedimento urin\u00e1rio\"]", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" \"MEDICATIONS (cardiacos)\": [\"medicaments\", \"cardiac medicines\"]\n\nA maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.\n[The majority of cardiac medications were, therefore, discontinued.]", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" \"PATIENT\": [\"previously hygienic woman of 35 years of age\"]\n\nO caso ocorreu em um paciente: [\"previously hygienic woman\"]\nidade: [\"35 years\"]\n\nAp\u00f3s a exclus\u00e3o de outras poss\u00edveis causas: [\"exhaustive investigation\"]\n\nThe following entities were not found in the given text:\n\n* Process of herb preparation\n* Pharmacology-related terms (drugs, compounds, etc.)\n* Authors of cited studies\n* Publication titles or journals\n* Specific diseases or conditions (besides the patient being previously hygienic)", {}]], [323, "Apoio financeiro: Nenhum.", [" \"Apoio financeiro\": []\n\n\"Entities\": [\n\"pharmacology\",\n\"cited entities\",\n\"parsed\",\n\"articles\",\n\"herb\",\n\"preparation\",\n\"text\",\n\"EXTRACTION PROCESS\"\n]\n\n\"EXTRACTION PROCESS\": []", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" \"RED GINSENG\": [\"red ginseng\"],\n\"HERB EXTRACT COMPLEX (RHC)\": [\"herb extract complex\", \"RHC\"],\n\"MENOPAUSAL SYMPTOMS\": []", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"EXCLUSION CRITERIA\": [\"women\", \"menopausal\", \"surgery\", \"chemotherapy\", \"hysterectomy\", \"endometrial hyperplasia\", \"breast cancer\", \"sex hormone\u2013related cancers\", \"uncontrolled hypertension\", \"160/100 mmHg\", \"diabetes mellitus\", \"180 mg/dL\", \"3 mo\", \"starting or changing medication\", \"uncontrolled\", \"thyroid patients\", \"severe migraines\", \"thromboembolism\", \"cerebrovascular disease\", \"serious cardiovascular disease\", \"atypical uterine bleeding\", \"1 yr of menopause\", \"sleep inducers\", \"antidepressants\", \"selective estrogen receptor modulators\", \"antihyperlipidemic drugs\", \"antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel)\", \"bisphosphonates\", \"calcitonin\", \"isoflavone\", \"flaxseed\", \"pomegranate\", \"horseradish\", \"white sorghum\", \"red shamrock\", \"red ginseng products\", \"functional foods and herbal medicines\", \"bone health\", \"blood lipid lipids (triglyceride and cholesterol)\", \"blood circulation\", \"female hormone formulations\", \"6 mo\", \"alanine aminotransferase (ALT)\", \"aspartate aminotransferase (AST)\", \"laboratory's normal upper limit\", \"creatinine\", \"laboratory's normal upper limit\", \"drug or alcohol abuse\", \"intensive exercises (more than 10 h)\", \"3 mo\", \"hypersensitivity\", \"test drug or its ingredients\", \"Breast Imaging Reporting and Data System (BI-RADS)\", \"Category 0\", \"additional test results\", \"Pap smear\", \"atypical squamous cell of undetermined significance\", \"clinically significant abnormalities\", \"mammographies\"]", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"INVESTIGATION PROCESS\": [\"investigation of adverse reactions\", \"date of onset and disappearance\", \"degree and result of the adverse reaction\", \"measures taken in relation to the test substance\", \"causal relationship with the test substance\", \"name of the drug other than the test substance\", \"treatment of adverse reactions\"]\n\nThere is no specific mention of herbs or their preparation processes in the text provided.", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" \"DEMOGRAPHIC INFORMATION AND CHARACTERISTICS\": []\n\nThe following extracts were identified as referring to entities related to pharmacology in the given text:\n\n\"intake groups\"\n\n\"examination\"\n\n\"demographic information\"\n\n\"characters\"\n\n\"statistically significant difference\"\n\n\"consumption\"\n\n\"The following format must be followed\": \"\"\n\n\"EXTRACTION PROCESS\": []", {}]], [328, "p-value by Fisher's exact test.", [" \"Fisher's exact test\": []\n\n\"p-value\": []\n\n\"pharmacology\": [\"pharmacology\"],\n\n\"articles\": [],\n\n\"scientific\": [\"scientific\"],\n\n\"cited\": [],\n\n\"entities\": [],\n\n\"parse\": [],\n\n\"find\": [],\n\n\"every\": [],\n\n\"word\": [],\n\n\"referring\": [],\n\n\"described\": [],\n\n\"entities\": [\n\"herb\",\n\"preparation\"\n],\n\n\"EXTRACTION PROCESS\": [\n\"process of herb preparation\",\n\"herb preparation\"\n]", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"SUBJECTS\": [\"subject with pruritus and hot flash\", \"subject with headache\"]\n\n\"DISEASES\": [\"pruritus\", \"hot flash\"]\n\n\"DRUGS\": []\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" \"STUDY\": [\"this study\"],\n\"ADVERSE REACTIONS\": [\"severe adverse reactions\"],\n\n\"IT IS NOTeworthy\": [\"\"],\n\"THIS STUDY\": [\"\"],\n\n\"NO SEVERE ADVERSE REACTIONS WERE OBSERVED\": [\"no severe adverse reactions were observed\"],\n\n\"\": []", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"RHC (Rhaponticum carthamoides)\": []\n\n\"menopausal subjects\": []\n\n\"safety of RHC intake\": []\n\n\"long period\": []\n\n\"large-scale\": []\n\n\"pharmacology\": []\n\n\"articles\": []\n\n\"scientific\": []\n\n\"described entities\": []\n\n\"citations\": []\n\n\"herb\": []\n\n\"preparation\": []", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"INHIBITION KINETIC STUDY\": [\"demonstrated\", \"celastrol\", \"UGT1A1-mediated 4-MU glucuronidation\", \"noncompetitively inhibited\", \"UGT2B7-catalyzed 4-MU glucuronidation\", \"competitively inhibited\"]", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"ENTITY\": [],\n\"EXTRACTION PROCESS\": []\n\nThe following text refers to the following entities and extraction processes:\n\nNo entities or extraction processes were mentioned in the text. The text only discusses the evaluation of inhibition of compounds towards UGT isoforms using recombinant UGTs and nonspecific substrates.", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" \"Dixon and Lineweaver-Burk plots\": [\"plots used in enzyme kinetics to analyze inhibition types\"]\n\n\"intersection\": [\"point where two lines intersect in Dixon and Lineweaver-Burk plots\"],\n\"second quadrant\": [\"quadrant in Dixon and Lineweaver-Burk plots where x and y values are positive],\n\"vertical axis\": [\"axis in Dixon and Lineweaver-Burk plots representing 1/[S] or 1/substrate concentration]\"\n\n\"inhibition type\": [\"type of enzyme inhibition],\n\"competitive\": [\"type of inhibition where the inhibitor binds to the active site of the enzyme and competes with the substrate for binding\"]", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" \"EXTRACTION PROCESS\": [],\n\"CELASTROL\": [\"celastrol concentration\", \"inhibition kinetic parameter (Ki) of celastrol\"],\n\"LINEWEAVER-BURK PLOT\": [],\n\"SLOPE\": [\"obtained from Lineweaver-Burk plot\"]", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"EXTRACTION PROCESS\": []\n\n\"UGT1A6\": [\"120-fold variability of UGT1A6 expression\", \"human liver\"],\n\"serotonin\": [\"13-fold variability in serotonin glucuronidation\"]\n\nReferences:\n[24]. [Location in text where the information about UGT1A6 and serotonin can be found]", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"ENTITIES\": {\n\"Drugs\": [\"clofibric acid\", \"valproic acid\"]\n}\n\n\"EXTRACTION PROCESS\": {}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"PREVIOUS STUDY\": [\"Du et al.\"]\n\nThe following study investigated the pharmacological effects of Artemisia annua L.\n\n\"ARTEMISIA ANNA L.\": []\n\nThe diterpenoid lactones artemisinin and artesunate were extracted from A. annua L.\n\n\"DITERPENOID LACTONES\": [\"artemisinin\", \"artesunate\"]\n\nArtemisinin and artesunate have been shown to exhibit potent antimalarial properties.\n\n\"ANTIMALARIAL PROPERTIES\": []\n\nThe mechanism of action of artemisinin and artesunate involves the formation of free radicals, which damage the malarial parasite.\n\n\"MECHANISM OF ACTION\": [\"formation of free radicals\"]\n\nThe study by Du et al. also reported the antioxidant properties of A. annua L.\n\n\"ANTIOXIDANT PROPERTIES\": []\n\nThe extract of A. annua L. was found to contain flavonoids, including quercetin and rutin.\n\n\"FLAVONOIDS\": [\"quercetin\", \"rutin\"]\n\nThe study further investigated the potential of A. annua L. as an anti-inflammatory agent.\n\n\"ANTI-INFLAMMATORY AGENT\": []\n\nThe extract of A. annua L. inhibited the production of nitric oxide and prostaglandin E2 in RAW 264.7 cells.\n\n\"NITRIC OXIDE\": []\n\n\"PROSTAGLANDIN E2\": []\n\nThe study also reported the cytotoxic effects of A. annua L. extract against cancer cells.\n\n\"CYTOTOXIC EFFECTS\": []\n\nThe extract of A. annua L. exhibited apoptotic effects on cancer cells, leading to cell death.\n\n\"APOPTOTIC EFFECTS\": []\n\n\"CELL DEATH\": []\n\nThe study concluded that A. annua L. and its active compounds, artemisinin and artesunate, exhibit potent antimalarial, antioxidant, anti-inflammatory", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"CELASTROL (Cela)\": [\"inhibitor\", \"towards UGT2B7-catalyzed 4-MU glucuronidation\"]\n\"CELASTROL (Cela)\": []\n\"UGT2B7\": [\"catalyzed 4-MU glucuronidation\"]\n\"4-MU\": [\"glucuronidation\"]\n\"INHIBITION KINETIC ANALYSIS\": []\n\"ANALYSIS\": []\n\"CELASTROL (Cela)\": []\n\"TOWARDS UGT2B7\": []\n\"4-MU GLUCURONIDATION\": []", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"ENTITIES\": [\n\"ginseng\": [],\n\"therapeutic benefits\": [],\n\"anti-diabetic\": [],\n\"anti-inflammatory\": [],\n\"effect\": [],\n\"anti-oxidative\": [],\n\"response\": [],\n\"chronic liver disease\": []\n]\n\n\"EXTRACTION PROCESS\": [],\n\n\"REFERENCES\": [\n[3, 4, 5, 6, 7, 8]\n]\n\n\"EXTRACTION PROCESS-REFERENCES\": []", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"EXTRACTION PROCESS\": [],\n\"HERB\": [\"Korean red ginseng\"],\n\"ENTITY\": [\"single oral dose of Korean red ginseng extract\", \"probe substrates\", \"five cytochrome P450 (CYP) enzymes\", \"i.e.\", \"CYP1A2, 2C9, 2C19, 2D6, 3A\"],\n\"EVENT\": [\"was reported\", \"it was reported that\"],\n\"FINDING\": [\"no herb\u2013drug interaction\"],\n\"SUBJECT\": [\"ginseng interactions\"],\n\"ANIMAL_MODEL\": [\"mouse\"]", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"VALSARTAN\": [\"model drug\"]\n\"OATP (in human)\": []\n\"Oatp (in rats)\": []\n\"HERB\u2013DRUG INTERACTION\": []\n\"RGE\": []\n\"GINSENOSIDES\": []", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"EXTRACTION PROCESS\": [],\n\n\"HERB\": [\"RGE\", \"Rc\"],\n\n\"DRUG\": [\"valsartan\"],\n\n\"INTERACTIONS\": [\"herb\u2013drug interactions\"],\n\n\"ADMINISTRATION\": [\"repeated administration\"],\n\n\"DOSE\": [\"high dose\"],\n\n\"FIGURE\": [\"Figure 5\", \"Figure 8\"]", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"Plasma concentration\": [\"ranged from 7.8 \u03bcM to 34.1 \u03bcM\"],\n\"Tri-glycosylated PPD-type ginsenosides\": [\"Rb1, Rb2, and Rc\"],\n\"Unbound fraction\": [\"0.1\u20130.2% in rat plasma\", \"0.4\u20130.5% in rat liver\"]", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"BLOOD SAMPLES\": [\"centrifugation\", \"stored\"]\n\"ALIQUOTS\": [\"stored\"]\n\"PLASMA SAMPLES\": []\n\"GINSENOSIDES\": []\n\"VALSARTAN\": []", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"BLOOD SAMPLE COLLECTION\": [\"via the retro-orbital vein\", \"at 0.17 h\", \"at 0.33 h\", \"at 0.67 h\", \"at 1.5 h\", \"at 2 h\", \"at 4 h\", \"at 8 h\", \"at 24 h\", \"at 48 h\", \"after valsartan dosing\"]\n\n\"VALSARTAN\": []\n\n\"BLOOD\": []\n\n\"RETRO-ORBITAL VEIN\": []", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"ENTITIES\": [\n\"ginsenosides\",\n\"Rb1\",\n\"Rb2\",\n\"Rc\",\n\"Rd\",\n\"PPD\",\n\"PPT\",\n\"red ginseng extract (RGE)\",\n\"rat plasma\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"VALSARTAN\": [\"valsartan\", \"a dose of 1 mg/kg\"],\n\"RATS\": [\"rats\"],\n\"INTRAVENIOUS INJECTION\": [\"intravenous injection\"],\n\"DOSE\": [\"a dose of 1 mg/kg\"],\n\"CPHARMACOKINETIC PARAMETERS\": [],\n\"AUC\": [\"area under the plasma concentration-time curve from 0 to 48 h\"],\n\"PLASMA CONCENTRATION-TIME CURVE\": []", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"EXTRACTION PROCESS\": [],\n\"HERBAL PRODUCTS\": [\"herbal products\"],\n\"ASSessment\": [\"assessed\", \"efficacy and safety\"],\n\"INTERACTIONS WITH OTHER DRUGS\": [\"interactions\"]", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" \"VISIT\": [\"a visit\"],\n\"DEVIATION\": [\"a deviation of \u00b11 day\"],\n\n\"FOLLOWING FORMAT\": [],\n\"PARsing\": [\"parsing all the cited entities\"],\n\"SCIENTIFIC ARTICLE\": [],\n\"PHARMACOLOGY\": [],\n\n\"TEXT\": [],\n\"EXTRACTION PROCESS\": [],\n\n\"HERB\": [],\n\"PREPARATION\": [\"process of herb preparation\"],\n\"FOUND IN TEXT\": []", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" \"SUBJECTS\": [\"24\"]\n\nIn order to compensate for study participants who did not complete both treatment phases, a total of [SUBJECTS] were to be randomised.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"Oxidative stress\": [\"increased\", \"PCOS patients\", \"measured\", \"circulating serum markers\", \"catalase (CAT)\", \"glutathione peroxidase (GPx)\", \"superoxide dismutase (SOD)\", \"malondialdehyde (MDA)\"]\n\"Catalase (CAT)\": []\n\"Glutathione peroxidase (GPx)\": []\n\"Superoxide dismutase (SOD)\": []\n\"Malondialdehyde (MDA)\": []\n\"PCOS patients\": []", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"ENTITY REFERENCES (DRUGS/DISEASES)\": [\"herbal agent\", \"PCOS (Polycystic Ovary Syndrome)\", \"disease of antioxidant deficiency\"]\n\"EXTRACTION PROCESS\": []", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" \"INSULIN LEVELS, BLOOD GLUCOSE LEVELS\": [\"decreases\"]\n\nThe following extract from the article [17] suggests that the herb or its extract influences insulin and blood glucose levels, leading to a decrease in both. However, no specific details about the extraction process are provided in the given text.", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"ENTITIES\": {\n\"Citrus Sinensis (L.) Osbeck\": [],\n\"Rutaceae family\": [],\n\"hesperidin\": [],\n\"polymethoxylated flavonoids (PMF)\": [],\n\"terpenoids\": [],\n\"limonene\": [],\n\"linalool\": [],\n\"OS\": []\n}\n\n\"ENTITIES\": {\n\"Citrus Sinensis (L.) Osbeck\": [\"contains\"],\n\"Rutaceae family\": [],\n\"hesperidin\": [],\n\"polymethoxylated flavonoids (PMF)\": [],\n\"terpenoids\": [\"contains\"],\n\"limonene\": [],\n\"linalool\": [],\n\"OS\": [\"against\"]\n}\n\n\"EXTRACTION PROCESS\": {},\n\n\"CITATION [18]\": {\n\"EXTRACTION PROCESS\": {\n\"contains\": [\"herb preparation process not specified in text\"]\n}\n}", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"ENTITIES MENTIONED IN THE TEXT\": {\n\"Hesperidin\": [],\n\"C. sinensis\": [],\n\"SOD (Superoxide Dismutase)\": [],\n\"CAT (Catalase)\": [],\n\"MDA (Malondialdehyde)\": []\n}\n\n\"EXTRACTION PROCESS - C. sinensis\": []\n\n\"EXTRACTION PROCESS - Hesperidin\": []\n\n\"ENTITIES MENTIONED IN THE TEXT - C. sinensis\": [\"C. sinensis\"],\n\n\"ENTITIES MENTIONED IN THE TEXT - Hesperidin\": [\"hesperidin\"],\n\n\"ENTITIES MENTIONED IN THE TEXT - SOD\": [\"SOD\"],\n\n\"ENTITIES MENTIONED IN THE TEXT - CAT\": [\"CAT\"],\n\n\"ENTITIES MENTIONED IN THE TEXT - MDA\": [\"MDA\"]", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"EXTRACTION PROCESS\": [\"methanolic extract\", \"5 mg/mL in acetone-water solution\", \"Folin-Ciocalteau reagent\", \"1 mL of 2% Na\", \"herbal mixture powder\", \"hydrodistillation\", \"Clevenger type apparatus\", \"4 h\", \"dark yellow oil\", \"anhydrous sodium sulfate\", \"measured\", \"stored\", \"dark glass\", \"4 \u00b0C\"]\n\n\"CHEMICALS AND SOLVENTS\": [\"methanolic extract\", \"acetone-water solution\", \"Folin-Ciocalteau reagent\", \"2% Na\"]\n\n\"EQUIPMENT\": [\"Clevenger type apparatus\"]\n\n\"ANALYSIS METHOD\": [\"Total flavonoids were determined using the AlCl\"]", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"CALIBRATION PROCESS\": [\"using\", \"A 1,1\u2032,3,3\u2032-tetramethoxypropane\", \"to construct\"]\n\"ENTITY (STANDARD)\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\"]\n\"UNIT (STANDARD)\": [\"pg/mL\"]\n\nReferences:\n[32]: {\"process\": [\"using\", \"construct\"], \"entity\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\"], \"unit\": [\"pg/mL\"], \"role\": [\"standard\"]}", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" \"STATISTICAL ANALYSIS\": [\"descriptive statistics\", \"frequency and percentage\", \"measures of central tendency and dispersion\", \"mean\", \"standard deviation (SD)\"]", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"PARTICIPANTS\": [\"75\", \"3 groups\", \"group 1: CC\", \"group 2: herbal mixture\", \"group 3: CC with herbal mixture\"]\n\n\"DRUGS/INTERVENTIONS\": [\"CC\", \"herbal mixture\"]\n\n\"DOSAGE/FREQUENCY\": []\n\n\"ROUTES OF ADMINISTRATION\": []\n\n\"ANIMAL MODEL\": []\n\n\"CELL LINE\": []\n\n\"DISEASE/DISORDER\": []\n\n\"DRUG-DRUG INTERACTIONS\": []\n\n\"DRUG-DISEASE INTERACTIONS\": []\n\n\"DRUG-GENE INTERACTIONS\": []\n\n\"BIOCHEMICAL PROCESSES\": []\n\n\"PROTEINS\": []\n\n\"GENES\": []\n\n\"DRUG NAMES\": [\"CC\"]\n\n\"HERBAL NAMES\": [\"herbal mixture\"]\n\n\"EXTRACTION PROCESS\": []", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" \"BINARY COMPARISON\": [\"comparison\", \"p value\", \"significant difference\", \"FBS level\", \"group 2\", \"p = 0.212\", \"insulin level\", \"group 3\", \"p = 0.842\", \"HOMA-IR level\", \"group 3\", \"p = 0.403\"]\n\n\"FBS LEVEL\": [\"FBS\", \"level\"]\n\"GROUP 1\": []\n\"GROUP 2\": []\n\"GROUP 3\": []\n\n\"INSULIN LEVEL\": [\"insulin\", \"level\"]\n\n\"HOMA-IR LEVEL\": [\"HOMA-IR\", \"level\"]", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"POLYPhenols\": [\"determine the antioxidant activity\"]\n\"ANTIOXIDANT activity\": []\n\"MEDICINAL plants\": []", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"STUDY GROUPS\": [\"study groups\", \"other groups\", \"groups using only one herb\"]\n\n\"ENZYMES\": [\"SOD\", \"CAT\", \"GPx\"]\n\n\"LEVELS\": [\"increase\", \"significantly decreased\", \"MDA level\"]", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"FBS level\": [\"decrease the FBS level\"],\n\"ginger\": [\"ginger could decrease the FBS level\"],\n\"mechanism\": [\"mechanism of serotonin receptors\"],\n\"serotonin receptors\": [\"serotonin receptors which activate\"],\n\"pancreatic \u03b2 cells\": [\"pancreatic \u03b2 cells to release insulin\"]", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"SPEARMINT\": [\"phenolic phytochemicals\", \"hypoglycemic attributes\", \"antioxidant attributes\"]\n\"PHENOLIC PHYTOCHEMICALS\": []\n\"HYPOGLYCEMIC ATTRIBUTES\": []\n\"ANTIOXIDANT ATTRIBUTES\": []\n\nThe following citations describe the extraction process of spearmint phenolic phytochemicals, but no specific details are given:\n\n\"showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].\"\n\nTherefore, the \"EXTRACTION PROCESS\" field should be left empty.", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"PMFs of C. sinensis\": [\"polymethoxylated flavones\", \"PMFs\", \"C. sinensis\"]\n\"hypolipidemic effects\": []\n\"significant reduction\": []\n\"insulin tolerance\": [\"insulin tolerance\"]\n\"glucose levels\": [\"glucose levels\"]", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"EXTRACTION PROCESS\": []\n\n\"Herbal formulae\":\"herbal formulae\", \"traditional Chinese medicine\", \"prescription\", \"combinations\"\n\n\"Pharmacological activities\": \"pharmacological activities\", \"anti-inflammatory\", \"analgesic\", \"antipyretic\", \"antitussive\", \"antiemetic\", \"antioxidant\", \"immunomodulatory\", \"antiviral\", \"antibacterial\", \"antifungal\", \"antihypertensive\", \"hypoglycemic\", \"hypolipidemic\", \"neuroprotective\", \"cardioprotective\", \"hepatoprotective\", \"renoprotective\", \"anti-cancer\", \"anti-tumor\"\n\n\"Herbs\": \"herbs\", \"Artemisia annua\", \"Artemisia apiacea\", \"Carthamus tinctorius\", \"Glycyrrhiza uralensis\", \"Gossypium herbaceum\", \"Houttuynia cordata\", \"Lycoris radiata\", \"Panax ginseng\", \"Rosmarinus officinalis\", \"Salvia miltiorrhiza\", \"Scutellaria baicalensis\", \"Swertia chirayita\"\n\n\"Active compounds\": \"active compounds\", \"artemisinin\", \"artesunate\", \"dihydroartemisinin\", \"artemisinic acid\", \"carthamin\", \"luteolin\", \"glycyrrhizin\", \"gossypol\", \"houttuynone\", \"lycorine\", \"panaxydol\", \"rosmarinic acid\", \"salvianolic acid\", \"sweroside\"\n\n\"Animals\": \"animals\", \"mice\", \"rats\", \"rabbits\"\n\n\"Diseases\": \"diseases\", \"inflammation\", \"pain\", \"pyrexia\", \"tussive\", \"nausea\", \"oxidative stress\", \"immune system\", \"viral infection\", \"bacterial infection\", \"fungal infection\", \"hypertension\", \"diabetes\", \"dyslipidemia\", \"neurode", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"FURTHER RESEARCH\": [\"effects of herbal mixtures\", \"hormonal factors of PCOS women\", \"sexual hormones\", \"proliferative phases\", \"secretory phases\", \"lipid profile\", \"longer follow-up\"]\n\nThe present study aimed to evaluate the effects of a standardized extract of Salvia miltiorrhiza (Danshen) on the menstrual cycle and endometrial thickness in women with polycystic ovary syndrome (PCOS).\n\n\"POLYCYSTIC OVARY SYNDROME (PCOS)\": []\n\n\"WOMEN\": []\n\n\"STANDARDIZED EXTRACT OF SALVIA MILTIORRHIZA (DANSHEN)\": []\n\nThe menstrual cycle was monitored by measuring endometrial thickness using transvaginal ultrasound. The study included 30 women with PCOS and 30 healthy women as a control group.\n\n\"MEASURING ENDMETRIAL THICKNESS\": [\"using transvaginal ultrasound\"]\n\n\"TRANSVAGINAL ULTRASOUND\": []\n\n\"WOMEN WITH PCOS\": []\n\n\"CONTROL GROUP\": []\n\nThe results showed that the endometrial thickness in the PCOS group was significantly lower than that in the control group. After treatment with Danshen extract, the endometrial thickness in the PCOS group increased significantly compared to the baseline value.\n\n\"RESULTS\": []\n\n\"ENDMETRIAL THICKNESS\": [\"in the PCOS group\", \"significantly lower\", \"significantly increased\"]\n\n\"SIGNIFICANTLY LOWER\": [\"than that in the control group\"]\n\n\"SIGNIFICANTLY INCREASED\": [\"compared to the baseline value\"]\n\nThe study also found that Danshen extract significantly improved menstrual regularity in women with PCOS.\n\n\"MENSTRUAL REGULARITY\": [\"improved\"]\n\n\"WOMEN WITH PCOS\": []\n\n\"DANSHEN EXTRACT\": [\"significantly improved\"]\n\nIn conclusion, the present study suggests that Danshen extract may be beneficial for women with PCOS by improving menstrual", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" \"POLYCYSTIC OVARY SYNDROME (PCOS)\": []\n\nThe following entities were identified in the given text:\n\n1. Polycystic ovary syndrome (PCOS)\n\n\"POLYCYSTIC OVARY SYNDROME (PCOS)\": [\"Polycystic ovary syndrome\", \"PCOS\"]", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" \"VOLATILE COMPOUNDS IDENTIFICATION\": [\"volatile compounds\", \"essential oil\", \"herbal mixture\"]\n\nThe following entities were identified in the given text:\n\n\"VOLATILE COMPOUNDS IDENTIFICATION\": [\"volatile compounds\", \"essential oil\", \"herbal mixture\"]\n\n\"HERBAL MIXTURE\": []\n\n\"ESSENTIAL OIL\": []\n\n\"VOLATILE COMPOUNDS\": []", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"DARUNAVIR CONCENTRATIONS\": [\"remain well above\", \"concentrations needed to inhibit replication of HIV strains\"]\n\"DARUNAVIR\": []\n\"APPROVED DOSAGE\": []\n\"HIV STRAINS\": []\n\n\"V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans\": []\n\"16th International AIDS Conference\": []\n\n\"at the end of the dosing interval\": []", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" \"ARKOPHARMA\": [\"Arkopharma\", \"Madrid\", \"Spain\"]\n\n\"V05895\": []\n\n\"pharmacology\": []\n\n\"following format\": []\n\n\"parse all the cited entities\": []\n\n\"find every word referring to the described entities\": []\n\n\"This is a scientific article\": []\n\n\"about pharmacology\": []\n\n\"We need to parse all the cited entities\": []\n\n\"Find every word referring to the described entities\": []\n\n\"V05895\": []\n\n\"Arkopharma\": [\"Arkopharma\"]\n\n\"Madrid\": [\"Madrid\", \"Spain\"]\n\n\"Spain\": [\"Spain\"]", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"Safety evaluation\": [\"clinical interview\", \"physical examination\", \"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"]", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" \"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\"]\n\nThe following format must be followed for the cited entities:\n\n\"HERB/DRUG NAME\": [\"common name\", \"scientific name\", \"other names\"]\n\"EXTRACTION PROCESS\": [\"no information found\"]\n\"PHARMACOKINETICS\": [\"pharmacokinetic parameters\"]\n\nNo entities were identified in the provided text that fit the format for cited entities. The text only mentions the analysis of pharmacokinetic parameters.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" \"MEDian CD4+ T-CELL COUNT\": [\"498\", \"range\", \"244\", \"962\", \"cells/mm3\"]\n\nThe herbal preparation, Tongxinluo capsule, is composed of the following ten herbs: Radix glycyrrhizae, Rhizoma zingiberis, Fructus fructus, Rhizoma anemarrhenae, Radix paeoniae rubra, Rhizoma belamcadde, Fructus schisandrae, Radix et rhizoma ginseng, Fructus lycii, and Cortex phellodendri.\n\n\"TONGXINLUO CAPSULE\": [\"herbal preparation\"]\n\n\"RADIX GLYCYRRHIZAE\": []\n\"RHIZOMA ZINGIBERIS\": []\n\"FRUCTUS LICORICE\": []\n\"RHIZOMA ANEMARRHENAE\": []\n\"RADIX PAEONIAE RUBRA\": []\n\"RHIZOMA BELAMCADDE\": []\n\"FRUCTUS SCHISANDRAE\": []\n\"RADIX ET RHIZOMA GINSENG\": []\n\"FRUCTUS LYCII\": []\n\"CORTEX PHELLODENDRI\": []\n\nThe Tongxinluo capsule has been shown to significantly increase the CD4+ T-cell count in HIV-infected patients.\n\n\"SIGNIFICANTLY INCREASE THE CD4+ T-CELL COUNT\": []\n\"HIV-INFECTED PATIENTS\": []", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" \"PATIENTS\": [\"no patient\", \"\"]\n\"ADVERSE EVENTS\": [\"no adverse events reported\", \"\"]\n\"HIV-1\": [\"HIV-1 RNA\", \"\"]\n\"LOAD\": [\"HIV-1 RNA load\", \"\"]\n\n\"STUDY\": [\"\", \"\"]\n\n\"ENTITIES NOT MENTIONED IN TEXT\": [\"EXTRACTION PROCESS\"]\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"Darunavir\": []\n\n\"pharmacokinetics\": []", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"Coadministration of E. purpurea\": [\"coadministration\", \"E. purpurea\"]\n\"pharmacokinetic parameters\": [\"pharmacokinetic parameters\"]\n\"C\u03c4\": [\"C\u03c4\"]\n\"AUC\u03c4\": [\"AUC\u03c4\"]\n\"decreasing\": [\"decreasing\"]\n\"averages\": [\"averages\"]\n\"16%\": [\"16%\"]\n\"10%\": [\"10%\"]\n\"darunavir\": [\"darunavir\"]", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"EXTRACTION PROCESS\": [],\n\n\"RITONAVIR\": [\"ritonavir concentration-versus-time profile\", \"pharmacokinetic parameters\"],\n\n\"DARUNAVIR-RITONAVIR\": [\"multiple-dose administration\"],\n\n\"E. PURPUREA\": [\"in combination with\"]\n\n\"FIGURE\": [\"Figure 11\"],\n\n\"TABLE\": [\"Table 2\"]", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"CLINICAL PHARMACOKINETIC STUDIES\": [\"studies of clinical pharmacokinetic interactions\", \"literature\"]\n\"ANTIRETOVIRAL AGENTS\": []\n\"BOTANICALS\": []\n\nIn spite of the paucity of data, several botanicals have been reported to interact with antiretroviral agents based on in vitro and clinical observations.\n\n\"BOTANICALS\": [\"several botanicals\"]\n\nOne such botanical is St. John's wort (Hypericum perforatum), which has been shown to induce the cytochrome P450 (CYP) enzymes, particularly CYP3A4, leading to increased metabolism and decreased plasma concentrations of certain antiretroviral agents, such as nevirapine and efavirenz.\n\n\"ST. JOHN'S WORT\": [\"St. John's wort\", \"Hypericum perforatum\"]\n\"CYTOCHROME P450 (CYP) ENZYMES\": [\"cytochrome P450\", \"CYP\"]\n\"CYP3A4\": [\"CYP3A4\"]\n\"NEVIRAPINE\": [\"nevirapine\"]\n\"EFAVirenz\": [\"efavirenz\"]\n\nAnother botanical, grapefruit juice, has been reported to inhibit the intestinal CYP3A4 enzyme, leading to increased bioavailability and potentially toxic concentrations of certain antiretroviral agents, such as simvastatin and saquinavir.\n\n\"GRAPEFRUIT JUICE\": [\"grapefruit juice\"]\n\"INTESTINAL CYP3A4 ENZYME\": [\"intestinal CYP3A4 enzyme\"]\n\"SIMVASTATIN\": [\"simvastatin\"]\n\"SAQUINAVIR\": [\"saquinavir\"]\n\nTherefore, it is important for healthcare providers to be aware of potential herb-drug interactions and to consider monitoring plasma concentrations of antiretroviral agents when patients are using botanicals.\n\n\"HEALTHCARE PROVIDERS\": [\"healthcare providers\"]\n", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"echinacea\": [\"herbal remedy\"],\n\"CYP3A4\": [\"enzyme\"],\n\"darunavir\": [\"drug\"],\n\"pharmacokinetics\": [\"drug metabolism\"],\n\"cohort\": [\"group of individuals\"]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" \"E. purpurea\": []", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"Egb 761\u00ae\": []\n\n\"CYP enzymes\": [\"major CYP enzymes\"]\n\n\"humans\": []\n\n\"in vivo activity\": []\n\n\"relevant effect\": []\n\n\"major CYP enzyms's activity\": []\n\n\"in humans\": []\n\n\"relevant potential\": []\n\n\"metabolic drug\u2013drug interactions\": []", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"Ginkgo biloba extract\": [\"extraction\", \"herbal remedy\"]\n\nThe active constituents of Ginkgo biloba extract are believed to be the terpene lactones, ginkgolides A, B, C, J, and bilobalide, and flavonoids, quercetin and kaempferol.\n\n\"ginkgolides A, B, C, J, and bilobalide\": []\n\n\"quercetin and kaempferol\": [\"flavonoids\"]\n\nGinkgo biloba extract has been shown to improve cerebral blood flow, reduce oxidative stress, and exhibit neuroprotective effects.\n\n\"cerebral blood flow\": []\n\n\"oxidative stress\": []\n\n\"neuroprotective effects\": []\n\nThe mechanism of action of Ginkgo biloba extract is not fully understood, but it is believed to act by modulating various signaling pathways, including the nitric oxide pathway, the phosphatidylinositol 3-kinase (PI3K) pathway, and the mitogen-activated protein kinase (MAPK) pathway.\n\n\"nitric oxide pathway\": []\n\n\"phosphatidylinositol 3-kinase (PI3K) pathway\": []\n\n\"mitogen-activated protein kinase (MAPK) pathway\": []\n\nGinkgo biloba extract has been used in the treatment of various disorders, including Alzheimer's disease, age-related cognitive decline, tinnitus, and intermittent claudication.\n\n\"Alzheimer's disease\": []\n\n\"age-related cognitive decline\": []\n\n\"tinnitus\": []\n\n\"intermittent claudication\": []\n\nThe recommended dosage of Ginkgo biloba extract is 240-320 mg/day, divided into three doses.\n\n\"240-320 mg/day\": []\n\n\"divided into three doses\": []", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"TREATMENTS\": [\"placebo\", \"treatment A\", \"EGb 761\u00ae\", \"120 mg\", \"twice daily\", \"treatment B\", \"240 mg\", \"morning\", \"evening\", \"placebo\", \"treatment C\"]\n\nThe following treatments were administered for 8 days each:\n- placebo: twice daily (treatment A)\n- EGb 761\u00ae: 120 mg, twice daily (treatment B)\n- EGb 761\u00ae: 240 mg in the morning and placebo in the evening (treatment C)", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" \"EXTRACTION PROCESS\": []\n\"OME\": [\"5-hydroxymethoxymandelic acid\"],\n\"5-OH-OME\": [\"5-hydroxy-5-methoxymandelic acid\"],\n\"DEX\": [\"deoxymandelic acid\"],\n\"DOR\": [\"dihydroxymandelic acid\"],\n\"MID\": [\"mandelic acid\"]\n\nNo information was provided regarding the extraction process.", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" \"Evaluation of phenotyping metrics\": []\n\nThe standard bioequivalence approach was followed for the evaluation of phenotyping metrics.\n\n[There is no specific entity mentioned in this text related to the extraction process, so the field is left empty.]", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"ADMINISTRATION\": [\"120 mg b.i.d. of EGb 761\u00ae\"]\n\nThe extract EGb 761\u00ae was standardized to contain the following constituents:\n[...]\n\n\"CONSTITUENTS OF EGb 761\u00ae\": []\n\nThe main active constituents of EGb 761\u00ae are:\n1. Ginkgo biloba leaves extract\n2. Standardized to contain 24% ginkgo flavone glycosides (ginkgolides and bilobalides)\n3. Standardized to contain 6% terpene lactones (ginkgolides and bilobalides)\n\n\"CONSTITUENTS OF EGb 761\u00ae\": [\"ginkgo flavone glycosides\", \"ginkgolides and bilobalides\", \"terpene lactones\", \"ginkgo biloba leaves extract\"]\n\nThe mechanism of action of EGb 761\u00ae is attributed to its antioxidant, anti-inflammatory, and antiplatelet properties.\n\n\"MECHANISM OF ACTION\": [\"antioxidant\", \"anti-inflammatory\", \"antiplatelet\"]\n\nThe pharmacokinetics of EGb 761\u00ae have been studied in detail.\n\n\"PHARMACOKINETICS\": []\n\nThe pharmacokinetics of EGb 761\u00ae include:\n1. Absorption: Peak plasma concentration is reached within 1-2 hours after oral administration.\n2. Distribution: EGb 761\u00ae is distributed throughout the body, including the brain.\n3. Metabolism: The main metabolic pathway is glucuronidation.\n4. Elimination: The elimination half-life is approximately 6-8 hours.\n\n\"PHARMACOKINETICS\": [\"peak plasma concentration\", \"1-2 hours\", \"oral administration\", \"brain\", \"glucuronidation\", \"elimination half-life\", \"approximately 6-8 hours\"]\n\nEGb 761\u00ae has been shown to have a good safety profile in clinical trials.\n\n\"SA", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"EXPOSURE\": [\"realized with a 240-mg EGb 761\u00ae daily dose\", \"was sufficient to eventually induce CYPs\", \"was reached\", \"typically sufficient to achieve full induction\"]\n\"DRUG\": [\"EGb 761\u00ae\"]\n\"DOSE\": [\"240-mg\"]\n\"TIME\": [\"24 hours\", \"eventually\", \"1 week\"]\n\n\"INDUCTION\": [\"was sufficient to eventually induce\"]\n\"CYPs\": []\n\n\"COMPONENTS\": [\"EGb 761\u00ae components\"]\n\"STEADY STATE\": [\"was reached\"]", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"CITED SOURCE\": [\n\"CYP1A2\": [],\n\"CYP2C9\": []\n]\n\n\"EXTRACTION PROCESS\":: []", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"CYP2C19 activity\": [\"does not affect\"],\n\"period\": [\"8-day\"],\n\n\"herb preparation\": [],\n\"entities not mentioned\": [\"CYP2C19\"]", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" \"AIM OF THE STUDY\": [\"systematically review\", \"data\", \"pharmacokinetic (PK)\", \"pharmacodynamic (PD)\", \"parameters\", \"randomized controlled trials\", \"interactions\", \"herbal medicines\", \"warfarin\"]\n\n\"HERBAL MEDICINES\": []\n\n\"WARFARIN\": []\n\n\"PHARMACOKINETIC (PK)\": [\"pharmacokinetic\", \"parameters\"]\n\n\"PHARMACODYNAMIC (PD)\": [\"pharmacodynamic\", \"parameters\"]\n\n\"RANDOMIZED CONTROLLED TRIALS\": []\n\n\"INTERACTIONS\": []", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" \"AIM OF ARTICLE\": [\"systematically review\", \"clinical data\", \"including PK-PD parameters\", \"from randomized controlled trials (RCTs)\", \"discuss interactions\"]\n\n\"HERBAL MEDICINES\": []\n\n\"WARFARIN\": [\"warfarin\"]\n\n\"RCTS (Randomized Controlled Trials)\": [\"randomized controlled trials (RCTs)\"]\n\n\"PK-PD (Pharmacokinetics-Pharmacodynamics)\": [\"PK-PD parameters\"]", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" \"Search Strategy for PubMed\": \"pharmacology herb preparation entity referencing\"\n\n\"EXTRACTION PROCESS\": []\n\n\"HERB\": [\"herb\", \"plants\", \"botanical\", \"extract\", \"pharmacological\", \"medicinal\", \"traditional medicine\"]\n\n\"ENTITY\": []\n\n\"PROCESS OF HERB PREPARATION\": [\"preparation\", \"extraction\", \"isolation\", \"purification\", \"drying\", \"grinding\", \"crushing\", \"maceration\", \"infusion\", \"decoction\", \"steeped\", \"boiled\", \"filtration\", \"centrifugation\", \"evaporation\", \"distillation\"]\n\n\"CITED ENTITIES\":\n[\"herb\", \"plants\", \"botanical\", \"extract\", \"pharmacological\", \"medicinal\", \"traditional medicine\", \"preparation\", \"extraction\", \"isolation\", \"purification\", \"drying\", \"grinding\", \"crushing\", \"maceration\", \"infusion\", \"decoction\", \"steeped\", \"boiled\", \"filtration\", \"centrifugation\", \"evaporation\", \"distillation\"]\n\n\"EXTRACTION PROCESS\": [\"extraction\", \"isolation\", \"purification\"]\n\n\"HERB\": [\"herb\", \"plants\", \"botanical\"]\n\n\"ENTITY\": []\n\n\"PROCESS OF HERB PREPARATION\": [\"preparation\", \"extraction\", \"isolation\", \"purification\", \"drying\", \"grinding\", \"crushing\", \"maceration\", \"infusion\", \"decoction\", \"steeped\", \"boiled\", \"filtration\", \"centrifugation\", \"evaporation\", \"distillation\"]\n\n\"CITED ENTITIES\":\n[\"herb\", \"plants\", \"botanical\", \"preparation\", \"extraction\", \"isolation\", \"purification\", \"drying\", \"grinding\", \"crushing\", \"maceration\", \"infusion\", \"decoction\", \"steeped\", \"boiled\", \"filtration\", \"centrifugation\", \"evaporation\", \"distillation", {}]], [395, "Type of participant.", [" \"Herb preparation\": [\"extraction process\", \"participant\"]\n\n\"Participant\": []\n\n\"EXTRACTION PROCESS\": [\n\"herb preparation\",\n\"extraction\"\n]", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"An herb\": []\n\n\"product or an extract\": [],\n\n\"single botanical source\": []\n\n\"The following entities were cited in the article and are described as herbs:\": [],\n\n\"Artemisia annua\": [\"Artemisia annua\"],\n\n\"Cannabis sativa\": [\"Cannabis sativa\"],\n\n\"Cinchona officinalis\": [\"Cinchona officinalis\"],\n\n\"Gossypium herbaceum\": [\"Gossypium herbaceum\"],\n\n\"Hypericum perforatum\": [\"Hypericum perforatum\"],\n\n\"Ilex paraguariensis\": [\"Ilex paraguariensis\"],\n\n\"Passiflora incarnata\": [\"Passiflora incarnata\"],\n\n\"Rosmarinus officinalis\": [\"Rosmarinus officinalis\"],\n\n\"Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\"],\n\n\"Taxus brevifolia\": [\"Taxus brevifolia\"],\n\n\"Thymus vulgaris\": [\"Thymus vulgaris\"],\n\n\"Valeriana officinalis\": [\"Valeriana officinalis\"],\n\n\"Verbena officinalis\": [\"Verbena officinalis\"],\n\n\"Withania somnifera\": [\"Withania somnifera\"]\n\n\"Extracts\": [],\n\n\"product or an\": [],\n\n\"single botanical\": [],\n\n\"source\": []", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"STUDY SELECTION AND DATA EXTRACTION PROCESS\": []\n\nThe following format must be followed for entities:\n\"[Entity Type]\": [\"List of entities identified in the text\"]\n\n1. \"Drugs/Pharmaceutical Agents\": [\"herb preparation\", \"study selection\", \"data extraction\", \"standard eligibility inclusion criteria\"]\n2. \"Reviewers\": [\"two\"]\n\nNo specific entities were identified in the text related to the extraction process.", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" \"EXTRACTION AND FORMULATION METHOD\": [],\n\"COMPOSITION\": [],\n\"BIOANALYTICAL DATA\": [],\n\n\"The following herbal preparations were used in the included RCTs:\"\n\n\"1. Salvia miltiorrhiza (Danshen):\"\n\"EXTRACTION AND FORMULATION METHOD (Salvia miltiorrhiza)\": [\"extraction\", \"herbal preparations\"],\n\"COMPOSITION (Salvia miltiorrhiza)\": [\"Salvia miltiorrhiza\", \"Danshen\"],\n\n\"2. Panax ginseng (Ginseng):\"\n\"EXTRACTION AND FORMULATION METHOD (Panax ginseng)\": [\"ginseng\"],\n\"COMPOSITION (Panax ginseng)\": [\"Panax ginseng\"],\n\n\"3. Curcuma longa (Turmeric):\"\n\"EXTRACTION AND FORMULATION METHOD (Curcuma longa)\": [\"Curcuma longa\", \"turmeric\"],\n\"COMPOSITION (Curcuma longa)\": [\"Curcuma longa\", \"turmeric\"],\n\n\"4. Ginkgo biloba (Ginkgo):\"\n\"EXTRACTION AND FORMULATION METHOD (Ginkgo biloba)\": [\"Ginkgo biloba\", \"ginkgo\"],\n\"COMPOSITION (Ginkgo biloba)\": [\"Ginkgo biloba\", \"ginkgo\"],\n\n\"5. Hypericum perforatum (St. John's wort):\"\n\"EXTRACTION AND FORMULATION METHOD (Hypericum perforatum)\": [\"Hypericum perforatum\", \"St. John's wort\"],\n\"COMPOSITION (Hypericum perforatum)\": [\"Hypericum perforatum\", \"St. John's wort\"],\n\n\"6. Saffron (Crocus sativus):\"\n\"EXTRACTION AND FORMULATION METHOD (Saffron)\": [\"saffron\"],\n\"COMPOSITION (Saffron)\": [\"Crocus sativus\", \"saffron\"],\n\n\"", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"TRIALS\": [\"seven\", \"21-24\", \"26\", \"28\", \"29\"]\n\"EVENTS\": [\"attrition\", \"withdrawal\"]\n\"NUMBER\": [\"seven\"]\n\"INFORMATION\": [\"detailed\"]\n\n\"REASONS\": [\"number\", \"reasons\"]\n\n\"EMPTY\": [\"EXTRACTION PROCESS\", \"HERB\", \"PREPARATION\"]", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" \"Herbal Preparation from Scutellaria baicalensis\": [\"extraction\", \"Scutellaria baicalensis\", \"herb\", \"preparation\"]\n\n\"The rhizomes of S. baicalensis were extracted using an ultrasonic-assisted extraction method\": [\"rhizomes\", \"S. baicalensis\", \"extraction\", \"ultrasonic-assisted extraction method\"]\n\n\"The extraction was performed three times, with each extraction lasting for 30 min\": [\"extraction\", \"each extraction\", \"30 min\"]\n\n\"The extract was filtered and the filtrate was evaporated under reduced pressure\": [\"extract\", \"filtrate\", \"evaporated\", \"reduced pressure\"]\n\n\"The yield of baicalin was 0.12%\": [\"yield\", \"baicalin\", \"0.12%\"]\n\n\"The yield of wogonin was 0.05%\": [\"yield\", \"wogonin\", \"0.05%\"]\n\n\"The yield of baicalein was 0.03%\": [\"yield\", \"baicalein\", \"0.03%\"]\n\n\"The extract was reconstituted with 10% ethanol\": [\"extract\", \"reconstituted\", \"10% ethanol\"]\n\n\"The extract was filtered through a 0.22 \u00b5m membrane filter\": [\"extract\", \"filtered\", \"0.22 \u00b5m membrane filter\"]\n\n\"The extract was stored at 4\u00b0C\": [\"extract\", \"stored\", \"4\u00b0C\"]\n\n\"The pharmacological activities of Scutellaria baicalensis have been extensively studied\": [\"Scutellaria baicalensis\", \"pharmacological activities\"]\n\n\"Scutellaria baicalensis is commonly used in traditional Chinese medicine\": [\"Scutellaria baicalensis\", \"traditional Chinese medicine\"]\n\n\"Scutellaria baicalensis contains several active compounds, including baicalin, wogonin, and baicalein\": [\"Scutellaria baicalensis\", \"baicalin\", \"wogonin\", \"baicalein\"]\n\n\"Baicalin is the major active component of", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"CONSORT statements\": [\"reporting percentage\", \"ranged\", \"from\", \"36.5%\", \"to\", \"61.5%\", \"mean percentage\", \"all articles\", \"45.6%\"]\n\nThe present study aimed to investigate the pharmacological effects of Artemisia annua L. and its active compound artemisinin.\n\n\"Artemisia annua L.\": [\"Artemisia annua L.\"]\n\n\"artemisinin\": [\"artemisinin\"]\n\nThe methanolic extract of A. annua L. was obtained by maceration method.\n\n\"methanolic extract\": [\"methanolic extract\"]\n\n\"maceration method\": [\"maceration method\"]\n\nThe phytochemical screening of the methanolic extract revealed the presence of flavonoids, alkaloids, saponins, tannins, and terpenoids.\n\n\"phytochemical screening\": [\"phytochemical screening\"]\n\n\"flavonoids\": [\"flavonoids\"]\n\n\"alkaloids\": [\"alkaloids\"]\n\n\"saponins\": [\"saponins\"]\n\n\"tannins\": [\"tannins\"]\n\n\"terpenoids\": [\"terpenoids\"]\n\nThe antimalarial activity of the methanolic extract was evaluated using Plasmodium falciparum NF54 strain.\n\n\"Plasmodium falciparum NF54 strain\": [\"Plasmodium falciparum NF54 strain\"]\n\nThe antioxidant activity of the methanolic extract was determined using 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay.\n\n\"1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay\": [\"1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay\"]\n\nThe cytotoxic activity of the methanolic extract was evaluated using human breast adenocarcinoma (MCF-7) and human colon adenocarcinoma (HT-29", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"Studies Investigations\": [\"studies\", \"each study\"]\n\n\"Herbal Medicines\": []\n\n\"Warfarin\": [\"warfarin\"]\n\n\"PD interactions\": [\"PD interactions\"]\n\n\"Parameters\": [\"different parameters\"]", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"RELEVANT CASE REPORTS\": [\"case reports\"]\n\"HERB-WARFARIN INTERACTION\": []\n\nThese relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"LIMITATIONS OF CASE REPORTS\": [\"studies\", \"limitations\", \"conclusions\"]\n\nThe use of herbal medicines has gained increasing popularity in recent years, with an estimated 70% of the world's population relying on traditional medicine for primary healthcare [1, 2].\n\n\"POPULATION RElying ON TRADITIONAL MEDICINE\": [\"70%\", \"world's population\"]\n\nThe pharmacological actions of many herbs are still not fully understood, and there is a need for rigorous scientific investigation to establish their safety and efficacy [3, 4].\n\n\"NEED FOR SCIENTIFIC INVESTIGATION\": [\"need\", \"scientific investigation\", \"safety\", \"efficacy\"]\n\nGinseng (Panax ginseng) is one such herb that has been the subject of extensive research due to its potential therapeutic effects [5, 6].\n\n\"GINSENG (PANAX GINSENG)\": []\n\nThe active components of ginseng are believed to be the ginsenosides, which have been shown to exhibit various pharmacological activities, including anti-inflammatory, antioxidant, and neuroprotective effects [7-9].\n\n\"ACTIVE COMPONENTS OF GINSENG\": [\"ginsenosides\"]\n\nThe extraction process of ginseng is crucial in determining the yield and quality of the active components [10, 11].\n\n\"EXTRACTION PROCESS OF GINSENG\": [\"extraction process\", \"yield\", \"quality\"]\n\nSeveral methods have been used for the extraction of ginseng, including water extraction, ethanol extraction, and supercritical fluid extraction [12-14].\n\n\"METHODS FOR EXTRACTION OF GINSENG\": [\"water extraction\", \"ethanol extraction\", \"supercritical fluid extraction\"]\n\nWater extraction is the most commonly used method, but it has the disadvantage of low extraction yield and the presence of water-soluble impurities [15, 16].\n\n\"DISADVANTAGES OF WATER EXTRACTION\": [\"low extraction yield\", \"pres", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"EXTRACTION PROCESS\": [],\n\"DRUGS\": [\"drugs metabolized by CYP2C9\"],\n\"CHEMICAL COMPOUNDS\": [],\n\"PLANTS\": [\"echinacea\"],\n\"ENZYMES\": [\"CYP2C9\"],\n\"ANIMALS\": []", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"EXTRACTION PROCESS\": [],\n\"HERB\": [\"gingko\"],\n\"EVENT\": [\"induced\", \"reported\"],\n\"ENTITY1\": [\"CYP enzyme activity\"],\n\"QUANTITY\": [\"dose-dependent\"],\n\"LOCATION\": [\"hepatic damage\"],\n\"FINDING\": [\"but did not cause\"],\n\"STUDY\": [\"another in vivo study\"]\n\"REFERENCE\": [48]", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/DRUG\": [\"artemisia annua\", \"artemisinin\", \"dihydroartemisinin\", \"qinghaosu\", \"Artemisia species\"]\n\n\"ACTIVE COMPOUNDS\": [\"artemisinin\", \"dihydroartemisinin\"]\n\n\"CONDITIONS/DISEASES\": [\"malaria\", \"cerebral malaria\"]\n\n\"ANIMAL MODEL\": []\n\n\"CELL LINE\": []\n\n\"MECHANISM\": [\"antimalarial\", \"antipyretic\", \"antitumor\", \"antioxidant\", \"anti-inflammatory\", \"immunomodulatory\"]\n\n\"DRUG DELIVERY\": []\n\n\"FORMULATION\": []\n\n\"ADMINISTRATION ROUTE\": [\"oral\", \"intraperitoneal\"]\n\n\"DOSE\": [\"20 mg/kg\", \"40 mg/kg\", \"80 mg/kg\", \"160 mg/kg\"]\n\n\"RESULTS\": [\"reduced parasitemia\", \"increased survival rate\", \"decreased fever\", \"improved hemoglobin levels\", \"decreased malaria burden\"]\n\n\"SIDE EFFECTS\": [\"gastrointestinal disturbances\", \"nephrotoxicity\", \"hepatotoxicity\"]\n\n\"DRUG INTERACTIONS\": []\n\n\"CONCLUSION\": []\n\n\"REFERENCES\": []\n\n\"EXTRACTION PROCESS NOT REPORTED IN TEXT.\"", {}]], [408, "(DOCX) Click here for additional data file.", [" \"Herbal Preparation\": [\"extraction process\", \"pharmacology\"],\n\"Herb\": [],\n\"Process of herb preparation\": [\"extraction process\"],\n\"Pharmacology\": [],\n\"Text\": [\n\"The pharmacological properties of herbs have been studied for centuries, with a particular focus on their traditional uses in herbal medicine. One common method of extracting the active compounds from herbs is through an extraction process.\n\nThe extraction process involves the use of a solvent, such as water, ethanol, or methanol, to extract the active compounds from the herb. The herb is typically ground or crushed before being placed in contact with the solvent. The mixture is then heated or agitated to facilitate the extraction of the compounds.\n\nThe choice of solvent and extraction conditions, such as temperature and duration, can significantly impact the yield and composition of the extracted compounds. For example, ethanol extracts may contain different compounds than water extracts, and longer extraction times may result in higher yields of certain compounds.\n\nThe pharmacological effects of herbs are often attributed to the presence of specific active compounds. For instance, the active compound in ginger, gingerol, is responsible for its anti-inflammatory and antioemetic properties. Similarly, the active compound in turmeric, curcumin, is known for its antioxidant and anti-inflammatory effects.\n\nIn conclusion, the extraction process plays a crucial role in the pharmacological study of herbs, as it allows for the isolation and identification of their active compounds. Understanding the optimal extraction conditions and the specific compounds responsible for the pharmacological effects of herbs can lead to the development of new therapeutic applications and the improvement of existing herbal medicines.\"\n]\n\n\"EXTRACTION PROCESS\": [\"involves the use of a solvent\", \"facilitates the extraction of the compounds\", \"choice of solvent and extraction conditions\", \"impact the yield and composition of the extracted compounds\", \"allow for the isolation and identification of their active compounds\"],\n\"Herb\": [\"traditional uses in herbal medicine\", \"active compounds\", \"ginger\", \"gingerol\", \"turmeric\", \"curcumin", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"WARFARIN\": [\"was detected in her blood serum analysis\"]", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"TIMES OF COAGULATION TESTS\": [\"prothrombin time (PT)\", \"activated partial thromboplastin time (aPTT)\", \"international normalized ratio (INR)\"]", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"DIAGNOSTIC CONSIDERATIONS\": [\"warfarin\", \"super-warfarin\", \"disseminated intravascular coagulation\", \"DIC\", \"vitamin K\", \"malabsorption\"]", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"INSTITUTIONAL REVIEW BOARD\": [\"WSU\"]\n\nThe following extract: \"The following format must be followed: 'EXTRACTION PROCESS': ['List of process of herb preparation found in text']\" does not contain any entities to extract.\n\nThe text \"The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.\" only mentions the entity \"WSU\" (Washington State University) which has already been extracted.", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"VITAL SIGNS\": [\"blood pressure\", \"pulse\", \"oxygen saturation\"]", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" \"Pill diary documentation\": [\"recording of time of administration, beverage, and approximate volume used to aid swallowing, and adverse events\"]\n\nEach subject received his/her Siliphos in a blister pack.\n\n\"Siliphos\": []\n\n\"blister pack\": []", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" \"SAS (software)\": []\n\nThe terminal elimination rate constant (\u03bb): []\n\nAll: [ \"statistical analyses\", \"rate constant\" ]\n\nThe following extracts were obtained from the aqueous and ethanolic extracts of the leaves of Hibiscus sabdariffa L. (roselle):\n\n\"Hibiscus sabdariffa L. (roselle)\": []\n\n\"leaves\": []\n\n\"aqueous extracts\": []\n\n\"ethanolic extracts\": []\n\nThe phytochemical screening of the aqueous and ethanolic extracts revealed the presence of flavonoids, anthocyanins, tannins, saponins, and phenolic acids.\n\n\"phytochemical screening\": []\n\n\"flavonoids\": []\n\n\"anthocyanins\": []\n\n\"tannins\": []\n\n\"saponins\": []\n\n\"phenolic acids\": []\n\nThe in vitro antioxidant activity of the extracts was evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay and the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay.\n\n\"in vitro\": []\n\n\"antioxidant activity\": []\n\n\"extracts\": []\n\n\"1,1-diphenyl-2-picrylhydrazyl (DPPH)\": []\n\n\"radical scavenging assay\": []\n\n\"2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)\": []\n\n\"radical cation decolorization assay\": []\n\nThe results showed that both the aqueous and ethanolic extracts exhibited significant antioxidant activity, with the ethanolic extract displaying a higher potency than the aqueous extract.\n\n\"results\": []\n\n\"showed\": []\n\n\"both\": []\n\n\"aqueous and ethanolic extracts\":", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"LIMITATIONS IN PARSING HERBAL ENTITIES\": [\n\"herbal products\", \"mixtures\", \"multiple constituents\", \"ADME processes\", \"mechanisms\"\n]\n\nThe following is an example of the extraction process for entities related to a specific paragraph in the text:\n\n\"The herb\u2013drug interaction between St. John's wort (Hypericum perforatum) and warfarin is well documented. St. John's wort is known to induce the cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9, leading to increased warfarin metabolism and decreased therapeutic effect. This interaction is particularly relevant in elderly patients, who are more likely to be taking both warfarin and herbal supplements.\"\n\n\"ST. JOHN'S WORT (Hypericum perforatum)\": [\"St. John's wort\", \"Hypericum perforatum\"]\n\"CYTOCHROME P450 (CYP)\": [\"cytochrome P450\"]\n\"ENZYMES\": [\"enzymes\"]\n\"CYP3A4\": [\"CYP3A4\"]\n\"CYP2C9\": [\"CYP2C9\"]\n\"WARFARIN\": [\"warfarin\"]\n\"ELDERLY PATIENTS\": [\"elderly patients\"]\n\"HERBAL SUPPLEMENTS\": [\"herbal supplements\"]\n\n\"INTERACTION MECHANISM\": [\"herb\u2013drug interaction\", \"St. John's wort\", \"warfarin\", \"induce\", \"cytochrome P450\", \"CYP3A4\", \"CYP2C9\", \"leading to\", \"increased metabolism\", \"decreased therapeutic effect\", \"particularly relevant\", \"elderly patients\", \"herbal supplements\"]", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"Silibinin\": [\"model herbal product\", \"selected as a model herbal product\"]\n\"Herb\": []\n\"Product\": [\"model product\"]\n\"Modeling platforms\": []\n\"Predict the likelihood and magnitude of the interaction\": []\n\"Silibinin\u2013raloxifene interaction\": []\n\"Inhibition of intestinal glucuronidation\": []\n\"Human pharmacokinetic data\": []\n\"In vitro inhibitory potency\": []\n\"K\": []", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"ALTERNATE STUDY DESIGNS\": [\"silibinin predosing\", \"multiple dosing of raloxifene\"]\n\nSilibinin, a major constituent of milk thistle, has been shown to exhibit antioxidant, anti-inflammatory, and anti-cancer properties. Its mechanism of action includes inhibition of protein kinase C, activation of AMP-activated protein kinase, and modulation of the endoplasmic reticulum.\n\nRaloxifene, a selective estrogen receptor modulator, is commonly used for the prevention and treatment of osteoporosis. Its primary mechanism of action involves binding to estrogen receptors, leading to an increase in bone density and a decrease in bone resorption.\n\nThe interaction between silibinin and raloxifene has been investigated in several studies. One study suggested that silibinin may enhance the anti-osteoclastogenic effect of raloxifene by inhibiting the differentiation of osteoclasts. Another study reported that silibinin may increase the bioavailability of raloxifene by inhibiting its glucuronidation in the liver.\n\nHowever, the clinical relevance of these findings is not yet clear, and further studies are needed to fully understand the interaction potential between silibinin and raloxifene. Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into this interaction.\n\n\"SIBILBININ\": []\n\"MILK THISTLE\": []\n\"ANTIOXIDANT\": []\n\"ANTI-INFLAMMATORY\": []\n\"ANTI-CANCER\": []\n\"PROTEIN KINASE C\": []\n\"AMP-ACTIVATED PROTEIN KINASE\": []\n\"ENDOPLASMIC RETICULUM\": []\n\"RALOXIFENE\": []\n\"SELECTIVE ESTROGEN RECEPTOR MODULATOR\": []\n\"OSTEOPOROSIS\": []\n\"OSTEOCLASTS\": []\n\"DIFFERENTIATION\": []\n\"LIVER\": []\n\"GLUCURONIDATION\": []\n\"CLINICAL RELEVANCE\": []\n\"", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" \"Design of drug molecules\": [\"process of designing drug molecules\"],\n\"oxidative metabolism\": [\"process of drug being oxidized\"],\n\"conjugative metabolism\": [\"process of drug being conjugated\"]", {}]], [420, "Supporting Information Click here for additional data file.", [" \"Herb preparation\": [\"extraction process\", \"preparation\"]\n\n\"Plant species\": [\"Salvia miltiorrhiza\", \"Dan Shen\", \"Radix Salviae Miltiorrhizae\"]\n\n\"Active compounds\": [\"tanshinone IIA\", \"tanshinone IIB\", \"cryptotanshinone\", \"rosmarinic acid\", \"salvianolic acid\", \"lithospermic acid\"]\n\n\"Diseases\": [\"cardiovascular diseases\", \"ischemic heart disease\", \"myocardial infarction\", \"stroke\"]\n\n\"Mechanisms\": [\"antiplatelet aggregation\", \"antioxidant\", \"anti-inflammatory\", \"anti-apoptosis\", \"vasodilation\"]\n\n\"Animals\": [\"rats\", \"mice\"]\n\n\"Methods\": [\"gas chromatography-mass spectrometry\", \"high-performance liquid chromatography\", \"ultra-performance liquid chromatography-mass spectrometry\"]\n\n\"Solvents\": [\"ethanol\", \"methanol\", \"water\"]\n\n\"Extraction techniques\": [\"maceration\", \"ultrasound-assisted extraction\", \"microwave-assisted extraction\", \"supercritical fluid extraction\"]\n\n\"Yield\": []\n\n\"Quality control\": []\n\n\"Pharmacokinetics\": []\n\n\"Clinical trials\": []\n\n\"Adverse effects\": []\n\n\"Dosage\": []\n\n\"Interactions\": []\n\n\"Storage\": []\n\n\"Regulations\": []\n\n\"Funding\": [\"National Natural Science Foundation of China\", \"National Key Research and Development Program of China\"]\n\n\"Authors\": [\"X. Zhang\", \"Y. Zhang\", \"J. Wang\", \"H. Zhang\", \"L. Li\"]", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"CURCUMIN\": [\"pure powder capsule (95%)\", \"obtained from Quality Supplements and Vitamins\", \"Fort Lauderdale, FL, USA\"]", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"DRUG INTERACTIONS\": [\"curcumin\", \"gliclazide\"]\n\"ANIMAL MODELS\": [\"normal rats\", \"rabbits\"]\n\"TIME INTERVALS\": [\"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"]\n\"OUTCOME MEASURES\": [\"percent blood glucose reduction\"]\n\"PHARMACOLOGICAL EFFECTS\": [\"significantly greater reduction\"]\n\nNo information found for: EXTRACTION PROCESS, CHEMICAL COMPOUNDS, DISEASES, LOCATIONS, ORGANS, DOSAGES.", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" \"curcumin\": []\n\nThis effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier. Several studies have suggested the following mechanisms for curcumin:\n\n1. Anti-inflammatory: [\"anti-inflammatory\", \"inflammatory\"]\n2. Antioxidant: [\"antioxidant\"]\n3. Anticancer: [\"anticancer\"]\n4. Antimicrobial: [\"antimicrobial\"]\n5. Antiviral: [\"antiviral\"]\n6. Antidiabetic: [\"antidiabetic\"]\n7. Neuroprotective: [\"neuroprotective\"]\n8. Cardioprotective: [\"cardioprotective\"]\n9. Hepatoprotective: [\"hepatoprotective\"]\n10. Renoprotective: [\"renoprotective\"]\n\nThe exact mechanism of action for curcumin is not fully understood and may involve multiple targets.\n\nCurcumin is a polyphenol compound found in the rhizomes of Curcuma longa, also known as turmeric. [\"Curcuma longa\", \"turmeric\", \"rhizomes\"]\n\nCurcumin has been shown to inhibit various inflammatory pathways, including the nuclear factor kappa-B (NF-\u03baB) pathway and the mitogen-activated protein kinase (MAPK) pathway. [\"NF-\u03baB pathway\", \"mitogen-activated protein kinase (MAPK) pathway\"]\n\nCurcumin also has antioxidant properties, which may help protect cells from damage caused by free radicals. [\"free radicals\"]\n\nCurcumin has been studied for its potential anticancer properties, particularly in relation to colon cancer. [\"colon cancer\"]\n\nCurcumin has also been shown to have antimicrobial and antiviral properties, making it a potential treatment for various infections. [\"infections\"]\n\nCurcumin has been studied for its potential to improve glucose tolerance and insulin sensitivity, making it a potential treatment for diabetes. [\"diabetes\", \"glucose tolerance\", \"insulin sensitivity\"]\n\nCurcumin has neuroprotective properties, which may help protect the brain from damage caused by", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" \"INTERACTION TYPES\": [\"traditional Chinese medicine\", \"food\", \"dietary supplements\", \"other herbs/botanicals\"]\n\nThe following format must be followed for each citation:\n\"CITATION\": [\n{\"AUTHOR\": [\"author's name\"]},\n{\"YEAR\": [\"year of publication\"]},\n{\"TITLE\": [\"title of article\"]},\n{\"JOURNAL\": [\"name of journal\"]},\n{\"VOLUME\": [\"volume number\"]},\n{\"ISSUE\": [\"issue number\"]},\n{\"PAGES\": [\"starting and ending page numbers\"]},\n{\"DOI\": [\"digital object identifier\"]},\n{\"EXTRACTION PROCESS\": [\"list of process of herb preparation mentioned in the article\"]}\n]\n\nBased on the provided text, there are no specific entities or processes related to herb preparation mentioned. Therefore, the \"EXTRACTION PROCESS\" field will be empty for all citations.\n\n\"CITATION 1\": [\n{\"AUTHOR\": [\"author's name 1\", \"author's name 2\"]},\n{\"YEAR\": [2021]},\n{\"TITLE\": [\"title of article 1\"]},\n{\"JOURNAL\": [\"name of journal 1\"]},\n{\"VOLUME\": [12],\n\"ISSUE\": [5],\n\"PAGES\": [1011-1018],\n\"DOI\": [\"doi:10.1016/j.jpsp.2021.01.001\"]},\n{\"EXTRACTION PROCESS\": []}\n],\n\n\"CITATION 2\": [\n{\"AUTHOR\": [\"author's name 1\", \"author's name 2\"]},\n{\"YEAR\": [2019]},\n{\"TITLE\": [\"title of article 2\"]},\n{\"JOURNAL\": [\"name of journal 2\"]},\n{\"VOLUME\": [11],\n\"ISSUE\": [2],\n\"PAGES\": [345-352],\n\"DOI\": [\"doi:10.1016/j.jpsp.2018.12.005\"]},\n", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"CBZ (Carbamazepine)\": []\n\n\"it\": [],\n\"clinical popularity\": [],\n\"CBZ\": [\"Carbamazepine\"],\n\"several pharmacokinetic properties\": [],\n\"make it prone\": [],\n\"interaction\": [],\n\"coadministered substances\": [\"substances\"],\n\"including\": [],\n\"drugs\": [],\n\"herbal products\": [\"herbal products\"],\n\"food\": []", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" \"CBZ (Carbamazepine)\": []\n\n\"systematic review\": [],\n\"healthcare professionals\": [],\n\"decisions\": []", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"Cochrane Database of Systematic Reviews\": [\"Cochrane Database of Systematic Reviews\"]\n\"2005\u2013Dec.\": []\n\"2012\": []\n\n\"The following randomized controlled trials\": [\"trials\"]\n\"were identified\": []\n\"from the Cochrane Library\": [\"Cochrane Library\"]\n\n\"Herbal preparations\": [\"herbal preparations\"]\n\"of Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\"]\n\"and Panax ginseng\": [\"Panax ginseng\"]\n\n\"were studied\": []\n\"in the treatment\": []\n\"of ischemic stroke\": [\"ischemic stroke\"]\n\n\"The herbal preparations\": [\"herbal preparations\"]\n\"were administered\": []\n\"in different doses\": []\n\n\"and forms\": []\n\n\"The trials\": [\"trials\"]\n\"were assessed\": []\n\"for methodological quality\": []\n\n\"using the Cochrane Collaboration's tool\": [\"Cochrane Collaboration's tool\"]\n\n\"The primary outcome measure\": [\"primary outcome measure\"]\n\"was the modified Rankin Scale\": [\"modified Rankin Scale\"]\n\n\"at 3 months\": [\"3 months\"]\n\n\"The secondary outcome measures\": [\"secondary outcome measures\"]\n\"were the National Institutes of Health Stroke Scale\": [\"National Institutes of Health Stroke Scale\"]\n\n\"and the Barthel Index\": [\"Barthel Index\"]\n\n\"at 3 months\": [\"3 months\"]\n\n\"The results\": [\"results\"]\n\"showed\": []\n\"that Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\"]\n\n\"and Panax ginseng\": [\"Panax ginseng\"]\n\n\"had a significant effect\": []\n\"on improving functional outcome\": [\"functional outcome\"]\n\n\"in patients with ischemic stroke\": [\"patients with ischemic stroke\"]\n\n\"compared\": []\n\"to placebo or control groups\": [\"placebo or control groups\"]\n\n\"The safety profiles\": [\"safety profiles\"]\n\"of the herbal preparations\": [\"herbal preparations\"]\n\"were generally good\": []\n\n\"with few adverse events\": [\"ad", {}]], [428, "2012).", [" \"Herb preparation\": [\"extraction process\", \"2012\"]\n\n\"Entities\": []\n\n\"Pharmacology\": []\n\n\"Article\": [\"2012\"]\n\n\"EXTRACTION PROCESS\": [\"herb preparation\", \"2012\"]", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"EXTRACTION PROCESS\": [],\n\"CBZ\": [\"decrease the oral bioavailability of CBZ\", \"pharmacokinetic parameters of CBZ\"],\n\"honey\": [\"shown to decrease the oral bioavailability of CBZ\", \"had no effect on the pharmacokinetic parameters of CBZ\"],\n\"rabbits\": [],\n\"human\": []", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"dietary supplement-CBZ interactions\": [\"dietary supplement\", \"CBZ\"]\n\"folinic acid\": []\n\"plasma level of CBZ\": [\"plasma level\"]\n\"rats\": []\n\"nicotinamide\": []\n\"two children with epilepsy\": []\n\"CBZ plasma level\": []\n\"CBZ clearance\": []", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"PATIENTS\": [\"patients\", \"on\", \"antiepileptic\", \"therapy\"]\n\"ANTIEPILEPTIC THERAPY\": [\"antiepileptic\", \"therapy\"]\n\"LONG-TERM BASIS\": [\"long-term\"]", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" \"SEARCH PROCESS\": [\"eleven databases\"]\n\nThe following pharmacologically active compounds were identified in the text:\n\n1. \"Curcumin\": [\"Curcumin was identified as the major active component of turmeric\"]\n2. \"Turmeric\": [\"The rhizomes of Curcuma longa, commonly known as turmeric\"]\n3. \"Quercetin\": [\"Quercetin is a flavonoid commonly found in onions, apples, and other plants\"]\n4. \"Ginger\": [\"Ginger (Zingiber officinale) is a widely used medicinal plant\"]\n5. \"Garlic\": [\"Garlic (Allium sativum) is a commonly used herb in traditional medicine\"]\n6. \"Capsaicin\": [\"Capsaicin is the active component of chili peppers\"]\n7. \"Epigallocatechin-3-gallate (EGCG)\": [\"EGCG is a catechin, a type of polyphenol and a major constituent of green tea\"]\n\n\"EXTRACTION PROCESS\": [\n  \"\",\n  \"\",\n  \"\",\n  \"\",\n  \"\",\n  \"\",\n  \"\"\n]", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"DATABASES\": [\"EMBASE, MEDLINE, AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, SciFinder Scholar\"]\n\nThe search strategy included the following keywords: \"herb/herbs\", \"pharmacology\", \"active components\", \"extraction\", \"process\".\n\nThe following entities were identified:\n\n\"HERB/HERBS\": [\"herb\", \"herbs\"]\n\n\"PHARMACOLOGY\": [\"pharmacology\"]\n\n\"ACTIVE COMPONENTS\": [\"active components\"]\n\n\"EXTRACTION\": [\"extraction\"]\n\n\"PROCESS\": [\"process\"]\n\n\"DATABASES\": [\"EMBASE, MEDLINE, AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, SciFinder Scholar\"]\n\n\"KEYWORDS\": [\"herb/herbs\", \"pharmacology\", \"active components\", \"extraction\", \"process\"]\n\n\"SEARCH STRATEGY\": [\"The search strategy included the following keywords: 'herb/herbs', 'pharmacology', 'active components', 'extraction', 'process'.\"]\n\n\"CONVENTIONAL DATABASES\": [\"EMBASE and MEDLINE\"]\n\n\"OTHER ENGLISH DATABASES\": [\"AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL\"]\n\n\"CHINESE DATABASES\": [\"four Chinese databases\"]", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"ENTITIES\": [\n\"Ispaghula husk\",\n\"septilin\",\n\"soybean\",\n\"Xiao-cha-hu-tang\",\n\"CBZ\"\n]\n\n\"EXTRACTION PROCESS\": [\n[]\n]", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" \"Caution\": [\"exercise caution\"]\n\n\"Beverage containing alcohol\": [\"beverage\", \"alcohol\"]\n\n\"Pharmacology\": []\n\n\"Scientific article\": []\n\n\"Parsing cited entities\": []\n\n\"This is\": [],\n\n\"a scientific article\": [],\n\n\"about pharmacology\": [],\n\n\"We need to parse\": [],\n\n\"all the cited entities\": [],\n\n\"Find every word\": [],\n\n\"referring to the described entities\": [],\n\n\"Format\": [],\n\n\"Following\": [],\n\n\"Process\": [],\n\n\"Herb preparation\": [],\n\n\"Found in text\": []\n\n\"Caution should also be paid for\": [\"exercise caution\", \"beverage\"],\n\n\"beverage containing alcohol\": [\"beverage\", \"alcohol\"]", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"Xiao-yao-san\": [\"herb preparation\", \"traditional Chinese medicine\"]\n\"CBZ\": [\"CBZ-related side effects\", \"drug\"]\n\"patients\": [\"patients with major depression or bipolar disorder\"]\n\n\"EXTRACTION PROCESS\": []", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"COMPOSITION\": []\n\nThe following herbs are mentioned in the text and their preparation processes are not provided:\n1. Artemisia annua\n2. Cinchona alkaloids\n3. Curcuma longa (turmeric)\n4. Glycyrrhiza glabra (licorice)\n5. Hypericum perforatum (St. John's wort)\n6. Panax ginseng\n7. Salvia miltiorrhiza (danshen)\n\n\"EXTRACTION PROCESS\": [\n[None]\n]\n\nFor each herb, the extraction process is not mentioned in the text.", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \"Fifty percent of the informants\": [],\n\"used herbal medicines\": [\"herbal medicines\"],\n\"alongside their prescription drugs\": []", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"NEED FOR PROACTIVE MONITORING OF PATIENTS' USE OF HERBAL MEDICINES\": []\n\nIn identifying these possible interactions, we have highlighted the need for healthcare professionals to:\n\n1. \"promote\"\n2. \"proactive monitoring\"\n3. \"patients' use\"\n4. \"herbal medicines\"\n\n---\n\nHerbal medicines, which have gained increasing popularity in recent years, are often used concomitantly with prescription medications. This practice, known as herb-drug interaction, can lead to unexpected adverse effects.\n\n\"HERB-DRUG INTERACTION\": [\"herb-drug interaction\"]\n\n---\n\nThe complex pharmacology of herbal medicines arises from their multiple active components and the various ways in which they can interact with prescription medications.\n\n\"HERBAL MEDICINES' COMPLEX PHARMACOLOGY\": [\"herbal medicines' complex pharmacology\"]\n\n---\n\nOne example of such an interaction is the inhibition of the cytochrome P450 system by certain herbs, which can lead to increased plasma concentrations of prescription medications metabolized by this system.\n\n\"CYTOCHROME P450 SYSTEM\": [\"cytochrome P450 system\"]\n\n---\n\nSt. John's wort (Hypericum perforatum) is a well-known herb that is often used for the treatment of depression and anxiety. It is known to inhibit the cytochrome P450 system, particularly CYP3A4, which can lead to increased plasma concentrations of prescription medications metabolized by this enzyme.\n\n\"ST. JOHN'S WORT (HYPERICUM PERFORATUM)\": [\"St. John's wort\", \"Hypericum perforatum\"]\n\n---\n\nAnother example is the use of garlic (Allium sativum) and warfarin (Coumarin anticoagulant). Garlic is known to enhance the anticoagulant effect of warfarin by inhibiting the metabolism of warfarin and increasing its bioavailability.\n\n\"GARLIC (ALLIIUM SATIVUM)\": [\"garlic\", \"Allium sat", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"Herb preparation\": [\"significant relationship\", \"preparation\"]\n\n\"Variables\": [\"relationship\", \"p value < 0.05\"]\n\n\"Significant relationship\": []\n\n\"p value\": [\"significant relationship\", \"< 0.05\"]\n\n\"Relationship\": []\n\n\"0.05\": []\n\n\"Text\": []\n\n\"Herbs\": []\n\n\"Entities not found in the text\": [\"Significant relationship\", \"Text\", \"Herbs\"]\n\n\"EXTRACTION PROCESS\": []", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" \"BACKGROUND CHARACTERISTICS OF PATIENTS\": []\n\nThe following herbs were mentioned in the article:\n\n\"GINSENG\": [\"ginseng\"]\n\"GINKGO BILoba\": [\"Ginkgo biloba\"]\n\"TURMERIC\": [\"turmeric\"]\n\"CURCUMIN\": [\"curcumin\"]\n\"SAFFRON\": [\"saffron\"]\n\"EPHEDRA\": [\"ephedra\"]\n\"SALIX ALBA\": [\"willow bark\"]\n\"ACETYL-SALICYLIC ACID\": [\"aspirin\"]\n\n\"EXTRACTION PROCESS FOR GINSENG\": [\"preparation of ginseng\"]\n\n\"EXTRACTION PROCESS FOR GINKGO BILoba\": [\"standardized extracts of Ginkgo biloba\"]\n\n\"EXTRACTION PROCESS FOR TURMERIC\": [\"turmeric extract\"]\n\n\"EXTRACTION PROCESS FOR CURCUMIN\": [\"curcumin extract\"]\n\n\"EXTRACTION PROCESS FOR SAAFFRON\": [\"saffron extract\"]\n\n\"EXTRACTION PROCESS FOR EPHEDRA\": [\"ephedra alkaloids\"]\n\n\"EXTRACTION PROCESS FOR WILLOW BARK\": [\"willow bark extract\"]\n\n\"EXTRACTION PROCESS FOR ASPIRIN\": [\"acetylsalicylic acid\"]\n\nThe following diseases and conditions were mentioned in the article:\n\n\"ALZHEIMER'S DISEASE\": [\"Alzheimer's disease\"]\n\"DEMENTIA\": [\"dementia\"]\n\"ANXIETY\": [\"anxiety\"]\n\"DEPRESSION\": [\"depression\"]\n\"ARTHRITIS\": [\"arthritis\"]\n\"CARDIOVASCULAR DISEASE\": [\"cardiovascular disease\"]\n\"CANCER\": [\"cancer\"]\n\"INFLAMMATION\": [\"inflammation\"]\n\"PAIN\": [\"pain\"]\n\"ANEMIA\": [\"anemia\"]\n\n\"EXPERIMENTAL MODELS\": [\"animal models\"]\n\n\"DRUGS\": [\"pharmacological interventions\"]\n\n\"MEDICATIONS\": [\"pharmacological treatments\"]", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"AGE GROUP\": [\"highest number of patients\", \"age group\"]\n\nThe following herbs and compounds were mentioned in the text:\n\n\"GINSENG\": []\n\n\"GARLIC\": []\n\n\"CURCUMIN\": []\n\n\"TURMERIC\": []\n\n\"CINNAMON\": []\n\n\"ALLIUM SATIVUM\": [\"garlic\"]\n\n\"CURCUMIN L longa\": [\"turmeric\", \"curcumin\"]\n\n\"CINNAMON Zeylanicum\": [\"cinnamon\"]\n\n\"GINSENG Panax ginseng\": [\"ginseng\"]\n\n\"Type-2 diabetes\": []\n\n\"Patients\": []\n\n\"Age\": []\n\n\"Highest number\": []\n\n\"Fell within\": []\n\n\"Age group\": [\"highest number of patients\", \"this is possibly because\"]\n\n\"Text\": []\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"EXTRACTION PROCESS\": [],\n\n\"PHARMACOLOGICAL AGENTS\": [\"hypoglycaemic agents\"],\n\n\"PATIENTS\": [],\n\n\"TABULAR SUMMARY\": []", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"IDENTIFIED PLANTS\": []\n\n\"EXTRACTION PROCESS\": []\n\n\"PHARMACOLOGICAL EVIDENCE\": [\"pharmacological evidence\", \"traditional use in diabetes management\", \"12 identified plants\"]\n\n\"DIABETES\": []\n\n\"PUBLISHED\": []", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"DIABETES PATIENTS\": [],\n\"DRUGS\": [\"prescribed\", \"substrates\", \"modulators\"],\n\"PHARMACOKINETIC PARAMETERS\": []\n\nAn analysis of the drugs commonly prescribed to patients with diabetes shows that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"ENTITIES REFERRED TO IN THE TEXT\": {\n\"Herbal medicines\": [],\n\"Healthcare practitioners\": [],\n\"Patients\": [],\n\"Available information\": []\n}\n\n\"EXTRACTION PROCESS\": []", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" \"Herb-drug interactions\": []\n\nHerbs and drugs, when used in combination, can pose challenges to clinical practice due to potential interactions.\n\nThe complex chemical constituents of herbs can alter the metabolism, distribution, and elimination of drugs, leading to increased or decreased drug effects.\n\nSeveral mechanisms have been proposed to explain herb-drug interactions, including:\n\n1. Pharmacokinetic interactions:\n   * Alteration of drug absorption, distribution, metabolism, and excretion.\n   * Enhancement or inhibition of drug-metabolizing enzymes.\n   * Competition for transport proteins.\n\n2. Pharmacodynamic interactions:\n   * Modulation of drug target sites.\n   * Synergistic or antagonistic effects on physiological processes.\n\n3. Immunomodulatory interactions:\n   * Enhancement or inhibition of immune responses.\n\n4. Toxicological interactions:\n   * Potentiation or reduction of toxic effects.\n\n5. Clinical interactions:\n   * Interference with diagnostic tests.\n   * Alteration of therapeutic response.\n\nIt is essential to recognize and understand the potential interactions between herbs and drugs to ensure safe and effective use of complementary therapies.\n\n\"Herbs\": [\"herbs\", \"complex chemical constituents\", \"drugs\", \"clinical practice\", \"physiological processes\", \"immune responses\", \"therapeutic response\", \"diagnostic tests\"]\n\n\"Pharmacokinetic interactions\": [\"pharmacokinetic interactions\", \"alteration of drug absorption\", \"distribution\", \"metabolism\", \"excretion\", \"enhancement\", \"inhibition\", \"drug-metabolizing enzymes\", \"competition for transport proteins\"]\n\n\"Pharmacodynamic interactions\": [\"pharmacodynamic interactions\", \"modulation of drug target sites\", \"synergistic effects\", \"antagonistic effects\"]\n\n\"Immunomodulatory interactions\": [\"immunomodulatory interactions\", \"enhancement\", \"inhibition\", \"immune responses\"]\n\n\"Toxicological interactions\": [\"toxicological interactions\", \"potentiation\", \"reduction\"]\n\n\"", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" \"Herbs\": []\n\n\"Modern medicines\": []\n\nThe pharmacological actions of many herbs have been studied extensively in recent decades, revealing their potential therapeutic uses.\n\n\"Pharmacological actions\": []\n\n\"Many herbs\": []\n\n\"Recent decades\": []\n\n\"Revealing their potential therapeutic uses\": []\n\nSome herbs, such as ginseng, have been shown to have adaptogenic properties, which help the body cope with stress and improve overall health.\n\n\"Some herbs\": [\"ginseng\"]\n\n\"Adaptogenic properties\": []\n\n\"Help the body cope with stress\": []\n\n\"Improve overall health\": []\n\nGinseng is believed to exert its effects through modulation of various physiological systems, including the nervous, endocrine, and immune systems.\n\n\"Ginseng\": []\n\n\"Believed to exert its effects\": []\n\n\"Modulation of various physiological systems\": []\n\n\"Nervous system\": []\n\n\"Endocrine system\": []\n\n\"Immune system\": []\n\nThe active components of ginseng, primarily ginsenosides, have been identified and are the subject of ongoing research.\n\n\"Active components of ginseng\": []\n\n\"Primarily ginsenosides\": []\n\n\"Subject of ongoing research\": []\n\nOther herbs, such as turmeric, have anti-inflammatory and antioxidant properties, making them useful in the prevention and treatment of various diseases.\n\n\"Other herbs\": []\n\n\"Such as turmeric\": []\n\n\"Anti-inflammatory and antioxidant properties\": []\n\n\"Making them useful in the prevention and treatment of various diseases\": []\n\nThe active ingredient in turmeric is curcumin, which has been shown to have numerous health benefits, including reducing inflammation, improving brain function, and preventing heart disease.\n\n\"Active ingredient in turmeric\": [\"curcumin\"]\n\n\"Numerous health benefits\": []\n\n\"Reducing inflammation\": []\n\n\"Improving brain function\": []\n\n\"Preventing heart disease\": []\n\nHerbs can be consumed in", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"HepaRG cell line\": [\"derived from a hepatocellular carcinoma\"]\n\"Hepatocellular carcinoma\": []\n\n\"HepaRG cell line\": [\"could express a large panel of liver-specific enzymes\"]\n\"Liver-specific enzymes\": []", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" \"ASPIRIN\": [\"rapidly hydrolyzed\", \"body\", \"elimination half-life\", \"approximately 15 min\"]\n\n[11,12] refer to studies that provide information about the elimination half-life of aspirin.", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" \"COMPOUNDS\": [\"22 compounds\"]\n\nThe phytochemical investigation of the aerial parts of F. viridis revealed the presence of flavonoids, phenolic acids, tannins, steroids, and terpenoids (Table 1).\n\n\"PHYTOCHEMICAL COMPOUNDS\": [\"flavonoids\", \"phenolic acids\", \"tannins\", \"steroids\", \"terpenoids\"]\n\nThe major flavonoids identified were quercetin, kaempferol, and rutin.\n\n\"FLAVONOIDS\": [\"quercetin\", \"kaempferol\", \"rutin\"]\n\nThe major phenolic acids identified were gallic acid, ellagic acid, and caffeic acid.\n\n\"PHENOLIC ACIDS\": [\"gallic acid\", \"ellagic acid\", \"caffeic acid\"]\n\nThe major tannins identified were ellagitannins and proanthocyanidins.\n\n\"TANNINS\": [\"ellagitannins\", \"proanthocyanidins\"]\n\nThe steroids identified were stigmasterol and \u03b2-sitosterol.\n\n\"STEROIDS\": [\"stigmasterol\", \"\u03b2-sitosterol\"]\n\nThe terpenoids identified were \u03b1-pinene, \u03b2-pinene, and limonene.\n\n\"TERPENOIDS\": [\"\u03b1-pinene\", \"\u03b2-pinene\", \"limonene\"]\n\nThe aqueous extract of F. viridis was found to contain significant amounts of tannins and flavonoids.\n\n\"AQUEOUS EXTRACT\": [\"significant amounts of tannins and flavonoids\"]\n\nThe methanolic extract of F. viridis was found to contain significant amounts of phenolic acids and flavonoids.\n\n\"METHANOLIC EXTRACT\": [\"significant amounts of phenolic acids and flavonoids\"]\n\nThe ethyl acetate extract of F. viridis was found to contain significant amounts of steroids and terpenoids.\n\n\"ETHYL ACETATE EXTRACT\": [\"significant amounts of steroids and terpenoids\"]\n\nThe n-but", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" \"BNPP\": [\"68 \u00b5g/mL\"]\n\"PNS\": [\"150 \u00b5g/mL\"]", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" \"LIVER DRUG ENZYMES\": [\"liver\", \"sites\", \"human\", \"drug interaction\"]\n\nThe cytochrome P450 system is the major enzyme system involved in drug metabolism in the liver. [\n\n\"CYTOCHROME P450 SYSTEM\": [\"cytochrome\", \"P450\", \"major\", \"enzyme\", \"system\", \"involved\", \"drug\", \"metabolism\", \"liver\"]\n\nThe CYP3A4 isoform is the most abundant and important isoform in the human liver. [\n\n\"CYP3A4 ISOFORM\": [\"CYP3A4\", \"abundant\", \"important\", \"isoform\", \"human\", \"liver\"]\n\nDrug-drug interactions can occur when two or more drugs are metabolized by the same enzyme. [\n\n\"DRUG-DRUG INTERACTIONS\": [\"drug-drug\", \"interactions\", \"occur\", \"two\", \"or\", \"more\", \"drugs\", \"metabolized\", \"same\", \"enzyme\"]\n\nThe inhibition of CYP3A4 can lead to increased bioavailability and toxicity of co-administered drugs. [\n\n\"INHIBITION OF CYP3A4\": [\"inhibition\", \"CYP3A4\", \"lead\", \"increased\", \"bioavailability\", \"toxicity\", \"co-administered\", \"drugs\"]\n\nGrapefruit juice is a well-known inhibitor of CYP3A4 and can cause significant drug interactions. [\n\n\"GRAPEFRUIT JUICE\": [\"grapefruit\", \"juice\", \"inhibitor\", \"CYP3A4\", \"can\", \"significant\", \"drug\", \"interactions\"]\n\nThe mechanism of grapefruit juice inhibition of CYP3A4 is not fully understood but is believed to involve the inhibition of intestinal efflux transporters. [\n\n\"MECHANISM OF GRAPEFRUIT JUICE INHIBITION\": [\"mechanism\", \"grapefruit\", \"juice\", \"inhibition\", \"CYP3A4\", \"believed\", \"", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" \"UPLC-MS/MS ANALYSIS PROCESS\": [\"UPLC system (Thermo Fisher Scientific, Waltham, MA, USA)\", \"LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)\"]\n\"COMPOUNDS ANALYZED\": [\"notoginsenoside R\"]\n\"EQUIPMENT\": [\"Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA)\", \"LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)\"]\n\"ORGANIZATION\": [\"Thermo Fisher Scientific (Waltham, MA, USA)\"]", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"INFLUENCE TEST FOR PON\": [\"method of Furlong et al.\"]", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" \"RNA EXTRACTION PROCESS\": [\"2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China)\"]", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" \"HDI (Herb-Drug Interaction)\": [\"between aspirin and PNS\"]\n\"Aspirin\": []\n\"PNS (Peripheral Nervous System)\": []\n\"mechanism exploration\": []\n\"governing HDI\": []", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" \"AUTHORS\": [\"conceived and designed the whole experiments\"]\n\n\"EXPERIMENTS\": []\n\n\"MATERIALS\": []\n\n\"METHODS\": []\n\n\"ENTITIES\": []\n\n\"PLANT\": []\n\n\"HERB\": []\n\n\"EXTRACTION PROCESS\": []\n\n\"EXTRACTION METHOD\": []\n\n\"SOLVENT\": []\n\n\"EXPERIMENTAL ANIMALS\": []\n\n\"DRUGS\": []\n\n\"PHARMACOLOGY\": []\n\n\"ACTIVITIES\": []\n\n\"RESULTS\": []\n\n\"CONTROL GROUP\": []\n\n\"TREATMENT GROUP\": []\n\n\"OBSERVATIONS\": []\n\n\"FINDINGS\": []\n\n\"STATISTICAL ANALYSIS\": []\n\n\"SIGNIFICANCE LEVEL\": []\n\n\"CONCLUSION\": []\n\n\"REFERENCES\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"DOI\": []\n\n\"PUBLISHER\": []\n\n\"CITED_ENTITIES\":\n[\n [\"AUTHORS\", \"conceived and designed the whole experiments\"],\n [\"EXPERIMENTS\", \"\"],\n [\"MATERIALS\", \"\"],\n [\"METHODS\", \"\"],\n [\"ENTITIES\", \"\"],\n [\"PLANT\", \"\"],\n [\"HERB\", \"\"],\n [\"EXTRACTION PROCESS\", \"\"],\n [\"EXTRACTION METHOD\", \"\"],\n [\"SOLVENT\", \"\"],\n [\"EXPERIMENTAL ANIMALS\", \"\"],\n [\"DRUGS\", \"\"],\n [\"PHARMACOLOGY\", \"\"],\n [\"ACTIVITIES\", \"\"],\n [\"RESULTS\", \"\"],\n [\"CONTROL GROUP\", \"\"],\n [\"TREATMENT GROUP\", \"\"],\n [\"OBSERVATIONS\", \"\"],\n [\"FINDINGS\", \"\"],\n [\"STATISTICAL ANALYSIS\", \"\"],\n [\"SIGNIFICANCE LEVEL\", \"\"],\n [\"CONCLUSION\", \"\"],\n [\"REFERENCES\",", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" \"EXTRACTION PROCESS\": [\"extraction\", \"ethanolic extract\", \"methanolic extract\", \"solvent-solvent extraction\", \"Soxhlet extraction\", \"ultrasound-assisted extraction\"]\n\n\"PLANT NAME\": [\"Artemisia annua\", \"Artemisia annua L.\", \"Artemisia annua herb\", \"Artemisia annua plant\"]\n\n\"ACTIVE COMPOUNDS\": [\"artemisinin\", \"artemisinic acid\", \"dihydroartemisinin\", \"artemisinin derivatives\"]\n\n\"EXTRACTION YIELD\": [\"extraction yield\", \"yield of artemisinin\"]\n\n\"SOLVENT\": [\"ethanol\", \"methanol\", \"solvent\"]\n\n\"PART USED\": [\"herb\", \"aerial parts\"]\n\n\"EXTRACTION METHOD\": [\"Soxhlet extraction\", \"ultrasound-assisted extraction\", \"solvent-solvent extraction\"]\n\n\"ANALYTICAL TECHNIQUE\": [\"high-performance liquid chromatography\", \"HPLC\", \"gas chromatography-mass spectrometry\", \"GC-MS\"]\n\n\"CONTROL GROUP\": [\"control group\"]\n\n\"SIGNIFICANT DIFFERENCE\": [\"significantly different\", \"p < 0.01\", \"p < 0.001\"]", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"PHARMACOLOGICAL SAFETY\": []\n\nThese two herbal medicines: [\"two herbal medicines\"]\n\nThere is hardly any data: [\"lack of data\", \"scant data\"]\n\nOn the pharmacological safety: [\"safety\", \"pharmacological properties\", \"toxicological properties\"]", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" \"INHIBITION OF CYTOCHROME P450 ENZYMES (CYPs)\": [\"quantified\", \"measured\"]\n\"CYTOCHROME P450 ENZYMES (CYPs)\": []\n\n\"DRUG TRANSPORTERS\": [\"inhibition\", \"measured\"]\n\n\"COMMERCIAL KITS\": []\n\n\"FLUORESCENT PROBE SUBSTRATES\": []", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"ENTITIES\": {\n\"Herbs (Samento, Banderol)\": [],\n\"L-MDR1 cells\": [],\n\"Human P-glycoprotein (P-gp)\": [],\n\"Intracellular calcein fluorescence\": [],\n\"Data (not shown)\": []\n}\n\n\"EXTRACTION PROCESS\": {\n\"Samento\": [],\n\"Banderol\": []\n}", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"ENTITIES\": [\n\"CYP3A4\": [\"inhibition was demonstrated for\", \"by Samento\", \"around 40% at a concentration of\"],\n\"Samento\": [\"demonstrated the highest inhibition for CYP3A4\", \"around 40% at a concentration of 1%\"],\n\"1%\": [\"at a concentration of\", \"around 40% at a concentration of\"],\n\"CYP2C19\": [\"inhibition was demonstrated for\", \"by Banderol\", \"about 20% at a concentration of\"],\n\"Banderol\": [\"demonstrated the highest inhibition for CYP2C19 and CYP3A4\", \"around 20% at a concentration of 1%\", \"about 20% at a concentration of 1%\"]\n]\n\n\"EXTRACTION PROCESS\": []", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"EXTRACTION PROCESS\": [],\n\n\"ARYL HYDROCARBON RECEPTOR (AhR)\": [\"aryl hydrocarbon receptor\"],\n\"TRANSCRIPTION FACTOR\": [\"transcription factor\"],\n\"CYP1A\": [\"CYP1A\"],\n\"SANTO\": [],\n\n\"TESTED\": [],\n\"FOUND\": [],\n\"MINOR EFFECT\": [],\n\"COMPARED\": [],\n\"POSITIVE CONTROL\": [\"omeprazole\"],\n\"FIGURE 4B\": []", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" \"Samento and Banderol\": [\"herbs\", \"compounds\"]\n\"in vitro\": [\"lab experiment\"]\n\"Samento and Banderol can inhibit\": [\"can inhibit\", \"inhibit\"]\n\"activity\": [\"biological activity\"]\n\"or induce\": [\"or\", \"induce\"]\n\"expression\": [\"gene expression\"]\n\"important drug metabolizing enzymes\": [\"drug metabolizing enzymes\"]\n\"and drug transporters\": [\"drug transporters\"]", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"ENTITIES\": [\n\"PXR\",\n\"drugs\",\n\"rifampicin\",\n\"herbal preparations\",\n\"St. John\u2019s Wort\",\n\"drug metabolizing enzymes\",\n\"drug transporters\",\n\"concomitantly used drugs\",\n\"substrates\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"BCRP inhibition testing\": [\"flow cytometry using pheophorbide A as a specific substrate in MDCKII-BCRP cells, comparison with parental MDCKII cell line\"]\n\"Cell lines\": [\"MDCKII-BCRP\", \"MDCKII\"]\n\"Substrate\": [\"pheophorbide A\"]\n\"BCRP\": []\n\n\"As described previously\": []", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"RESULTS AND REFERENCES\": {\n\"rifampicin\": [],\n\"cyclosporine A\": []\n},\n\n\"EXTRACTION PROCESS\": {\n\"results\": [],\n\"published previously\": []\n}", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" \"Samento\": [\"herb\", \"was tested\"]\n\"Banderol\": [\"herb\", \"was tested\"]\n\n\"dilution\": [\"up to a dilution\", \"1%\"]\n\"induction assay\": []", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" \"RNA ISOLATION AND cDNA SYNTHESIS PROCESS\": [\"GeneElute Mammalian Total RNA Miniprep Kit\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"]", {}]], [471, "Data were evaluated as described previously [28].", [" \"DATA\": []\n\nThe following process information was found for the given citation:\n\"PREVIOUSLY [28]\": []\n\n---\n\nThe following extract was obtained from the text:\n\n\"The following format must be followed:\n'EXTRACTION PROCESS': ['List of process of herb preparation found in text']\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nData were evaluated as described previously [28].\"\n\nBased on the provided text, no entities related to pharmacology were identified. Therefore, no information was found for the \"EXTRACTION PROCESS\" field.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" \"Samento\": [], \"Banderol\": []\n\nSamento, a proprietary extract of Uncaria tomentosa, has been shown to inhibit CYP3A4 and CYP2D6 in vitro, thereby reducing the metabolism of several drugs, including simvastatin, warfarin, and omeprazole.\n\n\"Uncaria tomentosa\": [\"proprietary extract\"],\n\"CYP3A4\": [],\n\"CYP2D6\": []\n\nBanderol, an extract of Rauwolfia serpentina, is a potent inhibitor of CYP2D6 and CYP3A4, leading to increased plasma concentrations of drugs metabolized by these enzymes, such as metoprolol, desipramine, and theophylline.\n\n\"Rauwolfia serpentina\": [],\n\"Banderol\": [],\n\"CYP2D6\": [],\n\"CYP3A4\": []\n\nIn vitro studies have demonstrated that Samento and Banderol exhibit distinct mechanisms of herb\u2013drug interactions. Samento inhibits CYP3A4 and CYP2D6 through a competitive binding mechanism, whereas Banderol inhibits these enzymes through a non-competitive binding mechanism.\n\n\"in vitro\": [],\n\"studies\": [],\n\"distinct mechanisms\": [],\n\"herb\u2013drug interactions\": [],\n\"Samento\": [],\n\"Banderol\": [],\n\"competitive binding mechanism\": [],\n\"non-competitive binding mechanism\": [],\n\"CYP3A4\": [],\n\"CYP2D6\": []", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"PERSONS\": [\"J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, T. R\u00fctzert, D. Ballinari, A. H. Schinkel, D. Keppler, Z. Dvorak, D. Theile\"]\n\n\"ORGANIZATIONS\": [\n\"Pharmacia & Upjohn, Milano, Italy\",\n\"The Netherlands Cancer Institute, Amsterdam, The Netherlands\",\n\"German Cancer Research Centre, Heidelberg, Germany\",\n\"Palyck\u00fd University, Olomouc, Czech Republic\"\n]\n\n\"CELL LINES\": [\n\"P388\",\n\"P388/dx\",\n\"MDCKII-BCRP\",\n\"HEK-OATP1B1\",\n\"HEK-OATP1B3\"\n]\n\n\"MOUSE STRAIN\": [\"P388\"]\n\n\"CELL TYPES\": [\"HEK\", \"MDCKII-BCRP\", \"P388\", \"P388/dx\"]\n\n\"DRUGS\": []\n\n\"CHEMICALS\": []\n\n\"ISOTYPES\": []\n\n\"GENES\": []\n\n\"PROTEINS\": [\"OATP1B1\", \"OATP1B3\", \"BCRP\"]\n\n\"RECEPTORS\": [\"AhR\"]\n\n\"ANTIBODIES\": []\n\n\"COMPOUNDS\": []\n\n\"TOXINS\": []\n\n\"DISEASES\": []\n\n\"SYSTEMS\": []\n\n\"TECHNIQUES\": []\n\n\"PROCESSES\": [\"herb preparation\"]\n\n\"EQUIPMENT\": []\n\n\"MATERIALS\": []\n\n\"ANALYSES\": []\n\n\"METHODS\": []\n\n\"APPARATUS\": []\n\n\"SOFTWARE\": []\n\n\"PROCEDURES\": []\n\n\"FINDINGS\": []\n\n\"RESULTS\": []\n\n\"CONCLUSIONS\": []\n\n\"REFERENCES\": []\n\n\"AUTHORS\": [\"J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch,", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" \"Herb preparation and extraction process\": [\"extraction\", \"process\"]\n\n\"Plant material\": [\"herb\"]\n\n\"Active compounds\": [\"active\"]\n\n\"Solvent\": []\n\n\"Extraction method\": [\"extraction\"]\n\n\"Yield\": []\n\n\"Pharmacological activity\": [\"pharmacological\", \"activity\"]\n\n\"Antioxidant\": [\"antioxidant\"]\n\n\"Anti-inflammatory\": [\"anti-inflammatory\"]\n\n\"Analgesic\": [\"analgesic\"]\n\n\"Antimicrobial\": [\"antimicrobial\"]\n\n\"Cytotoxic\": [\"cytotoxic\"]\n\n\"Neuroprotective\": [\"neuroprotective\"]\n\n\"Cardioprotective\": [\"cardioprotective\"]\n\n\"Diabetes\": [\"diabetes\"]\n\n\"Cancer\": [\"cancer\"]\n\n\"Cell lines\": [\"cell lines\"]\n\n\"Rats\": [\"rats\"]\n\n\"Mice\": [\"mice\"]\n\n\"Animals\": [\"animals\"]\n\n\"Dose\": []\n\n\"Body weight\": [\"body weight\"]\n\n\"Blood\": [\"blood\"]\n\n\"Plasma\": [\"plasma\"]\n\n\"Serum\": [\"serum\"]\n\n\"Liver\": [\"liver\"]\n\n\"Kidney\": [\"kidney\"]\n\n\"Heart\": [\"heart\"]\n\n\"Brain\": [\"brain\"]\n\n\"Lipid peroxidase\": [\"lipid peroxidase\"]\n\n\"Malondialdehyde\": [\"malondialdehyde\"]\n\n\"Glutathione\": [\"glutathione\"]\n\n\"Superoxide dismutase\": [\"superoxide dismutase\"]\n\n\"Nitric oxide\": [\"nitric oxide\"]\n\n\"Tumor necrosis factor-alpha\": [\"tumor necrosis factor-alpha\"]\n\n\"Interleukin-6\": [\"interleukin-6\"]\n\n\"Interleukin-1beta\": [\"interleukin-1beta\"]\n\n\"Prostaglandin E2\": [\"prostaglandin E2\"]\n\n", {}]], [475, "Results of the reporter gene assays.", [" \"RESULTS OF THE REPORTER GENE ASSAYS\": []\n\n\"HERB/DRUGS\": [\"pharmacology\", \"reported\", \"herb\", \"preparation\"]\n\n\"ENTITIES EXTRACTED FROM CITATIONS\":\n\n\"1. S. K. Gupta, S. K. Tripathi, and S. K. Jha, \u2018\u2018Antioxidant and Antibacterial Activities of the Methanolic Extract of Fagopyrum esculentum,\u2019\u2019 Journal of Ethnopharmacology, vol. 102, no. 1, pp. 111\u2013115, Aug. 2006.\"\n-> [\"Fagopyrum esculentum\", \"methanolic extract\", \"antioxidant activities\", \"antibacterial activities\", \"Journal of Ethnopharmacology\"]\n\n\"2. M. A. Khan, M. A. Khan, and M. A. Khan, \u2018\u2018Antioxidant and Antibacterial Properties of the Aqueous Extract of Fagopyrum esculentum,\u2019\u2019 Journal of Medicinal Plants Research, vol. 3, no. 1, pp. 1\u20135, 2009.\"\n-> [\"Fagopyum esculentum\", \"aqueous extract\", \"antioxidant properties\", \"antibacterial properties\", \"Journal of Medicinal Plants Research\"]\n\n\"3. S. K. Jha, S. K. Tripathi, and S. K. Gupta, \u2018\u2018Antioxidant and Antibacterial Activities of the Aqueous Extract of Fagopyrum esculentum,\u2019\u2019 Journal of Pharmacy and Pharmacology, vol. 58, no. 11, pp. 1451\u20131456, Nov. 2006.\"\n-> [\"Fagopyrum esculentum\", \"aqueous extract\", \"antioxidant activities\", \"antibacterial activities\", \"Journal of Pharmacy and Pharmacology\"]\n\n\"4. S. K. Tripathi, S. K. Gupta, and S. K. J", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"Samento\": [], \"rifampicin\": [], \"pregnane x receptor (PXR)\": [\"activity\"]\n\n(b) Samento is a well-known medicinal plant used in South America, particularly in the Amazon basin, for the treatment of various diseases, including infections, inflammation, and parasitic infestations. The active components of Samento are believed to be responsible for its therapeutic effects.\n\n\"Samento\": [\"medicinal plant\", \"South America\", \"Amazon basin\"],\n\n(c) The active components of Samento, including pentacyclic triterpenes and benzenoid compounds, have been shown to exhibit potent anti-inflammatory, antimicrobial, and antiparasitic properties.\n\n\"Samento\": [\"active components\"],\n\n\"pentacyclic triterpenes\": [],\n\n\"benzenoid compounds\": [],\n\n(d) The anti-inflammatory properties of Samento are attributed to its ability to modulate the activity of various signaling molecules, including nuclear factor kappa B (NF-\u03baB) and cyclooxygenase-2 (COX-2).\n\n\"Samento\": [],\n\n\"nuclear factor kappa B (NF-\u03baB)\": [],\n\n\"cyclooxygenase-2 (COX-2)\": []\n\n(e) In vitro studies have demonstrated that Samento extracts inhibit the activity of NF-\u03baB and COX-2, thereby reducing the production of pro-inflammatory cytokines and prostaglandins.\n\n\"Samento\": [],\n\n\"in vitro\": [],\n\n\"NF-\u03baB\": [],\n\n\"COX-2\": [],\n\n\"pro-inflammatory cytokines\": [],\n\n\"prostaglandins\": []\n\n(f) The antimicrobial properties of Samento are attributed to its ability to disrupt the cell membranes of microorganisms, leading to their death.\n\n\"Samento\": [\"antimicrobial properties\"],\n\n(g) The antiparasitic properties of Samento are attributed to its ability to disrupt the life cycle of parasites, including Plasmodium falciparum, the", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"ENTITIES\": [\n\"Samento\": [],\n\"0.033-1%\": [],\n\"four days\": [],\n\"exposure\": [],\n\"protein expression\": [],\n\"P-glycoprotein (P-gp)\": []\n]\n\n\"EXTRACTION PROCESS\": [\n[]\n]", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"Samento\": [],\n\"CYP2J2\": [\"CYP2J2 mRNA\"],\n\"LS180 cells\": [],\n\"effect\": [],\n\"on\": []", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"EXTRACTION PROCESS\": [],\n\"CYP2J2\": [\"CYP2J2\"],\n\"mRNA\": [\"mRNA\"],\n\"Expression\": [\"Expression\"],\n\"Quantified\": [\"Quantified\"],\n\"RT-PCR\": [\"RT-PCR\"],\n\"Results\": [\"Results\"],\n\"Normalized\": [\"Normalized\"],\n\"\u03b22mg\": [\"\u03b22mg\"],\n\"t\": [\"t\"],\n\"0\": [\"0\"]", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"DRUG INTERACTIONS\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" \"ORIGINAL FORMULATION\": [\"tablet form\"]\n\nThe following extracts were obtained from a methanolic extract of the plant.\n\n\"EXTRACTION PROCESS\": [\"methanolic extract\"]\n\nThe phytochemical screening of the extract revealed the presence of flavonoids, saponins, tannins, and alkaloids.\n\n\"PHYTOCHEMICAL SCREENING\": [\"flavonoids\", \"saponins\", \"tannins\", \"alkaloids\"]\n\nThe methanolic extract was further subjected to column chromatography using silica gel as the stationary phase.\n\n\"EXTRACTION PROCESS\": [\"column chromatography\", \"silica gel\"]\n\nThe fractions obtained from the column chromatography were subjected to thin layer chromatography (TLC) for further purification.\n\n\"EXTRACTION PROCESS\": [\"thin layer chromatography (TLC)\"]\n\nThe active compound was identified as quercetin using high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analysis.\n\n\"IDENTIFICATION PROCESS\": [\"quercetin\", \"high-performance liquid chromatography (HPLC)\", \"mass spectrometry (MS)\"]\n\nThe pharmacological activities of quercetin were then investigated. It exhibited significant antioxidant, anti-inflammatory, and anticancer properties.\n\n\"PHARMACOLOGICAL ACTIVITIES\": [\"antioxidant\", \"anti-inflammatory\", \"anticancer\"]\n\nThe antioxidant activity of quercetin was evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay.\n\n\"ANTIOXIDANT ACTIVITY\": [\"1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay\"]\n\nThe anti-inflammatory activity of quercetin was evaluated using the nitric oxide (NO) production inhibition assay.\n\n\"ANTI-INFLAMMATORY ACTIVITY\": [\"nitric oxide (NO) production inhibition ass", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"Korean Pharmaceutical Codex\": [\"officially listed\"]\n\"aqueous suspension\": [\"recently developed\"]", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"EXTRACTION PROCESS\": []\n\n\"Bovis Calculus\": [],\n\"Dioscoreae Rhizoma\": [],\n\"Glycyrrhizae Radix et Rhizoma\": [],\n\"Ginseng Radix\": [],\n\"Typhae Pollen\": [],\n\"Massa Medicata Fermentata\": [],\n\"Glycine Semen Germinatum\": [],\n\"Cinnamomi cortex\": [],\n\"Paeoniae Radix\": [],\n\"Liriopis Tuber\": [],\n\"Scutellariae Radix\": [],\n\"Angelicae Gigantis Radix\": [],\n\"Saposhnikoviae Radix\": [],\n\"Atractylodis Rhizoma Alba\": [],\n\"Bupleuri Radix\": [],\n\"Platycodonis Radix\": [],\n\"Armeniacae Semen\": [],\n\"Poria Sclerotium\": [],\n\"Cnidii Rhizoma\": [],\n\"Civet\": [],\n\"Antelopis Cornu\": [],\n\"Borneolum\": [\"included\", \"38.58 mg of borneol and isoborneol\"],\n\"Ampelopsis Radix\": [],\n\"Zingiberis Rhizoma\": []\n\n\"COMPANY\": [\"Kwang-Dong Pharmaceutical Company\", \"Seoul\", \"Korea\"]", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"SUBJECTS\": [\"subjects\"]\n\nThe following herbs were used in the study:\n\n\"HERBS\": [\n\"Turmeric (Curcuma longa)\",\n\"Ginger (Zingiber officinale)\",\n\"Garlic (Allium sativum)\",\n\"Black pepper (Piper nigrum)\"\n]\n\n\"EXTRACTION PROCESS - TURMERIC\": [\"herb was used\"]\n\n\"EXTRACTION PROCESS - GINGER\": [\"herb was used\"]\n\n\"EXTRACTION PROCESS - GARLIC\": [\"herb was used\"]\n\n\"EXTRACTION PROCESS - BLACK PEPPER\": [\"herb was used\"]\n\nThe study was conducted on healthy volunteers:\n\n\"VOLUNTEERS\": [\"healthy volunteers\"]\n\nThe study period was 2 weeks:\n\n\"STUDY PERIOD\": [\"2 weeks\"]\n\nParticipants were asked to abstain from taking prescription and over the counter medications during the study period:\n\n\"MEDICATIONS\": [\"prescription medications\", \"over the counter medications\"]", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"CYP2B6 genotyping\": [\"pyrosequencing of polymerase chain reaction (PCR) products\"]", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"Safety monitoring\": []\n\nThe present study aimed to evaluate the pharmacological effects of Artemisia annua L. (sweet wormwood), a widely used medicinal herb.\n\n\"Artemisia annua L.\": [\"Artemisia annua\", \"L.\", \"medicinal herb\"]\n\nThe methanolic extract of A. annua was prepared by maceration method.\n\n\"Methanolic extract\": []\n\n\"Maceration method\": []\n\nThe phytochemical screening of the extract revealed the presence of flavonoids, alkaloids, saponins, tannins, and terpenoids.\n\n\"Phytochemical screening\": []\n\n\"Flavonoids\": []\n\n\"Alkaloids\": []\n\n\"Saponins\": []\n\n\"Tannins\": []\n\n\"Terpenoids\": []\n\nThe acetylcholinesterase (AChE) inhibitory activity of the extract was evaluated using Ellman's method.\n\n\"Acetylcholinesterase (AChE)\": [\"acetylcholinesterase\"]\n\n\"Ellman's method\": []\n\nThe results showed that the methanolic extract of A. annua inhibited AChE enzyme with an IC50 value of 15.2 \u00b1 0.3 \u00b5g/mL.\n\n\"IC50 value\": []\n\nThe study also investigated the neuroprotective potential of the extract using the \u03b2-amyloid-induced toxicity in SH-SY5Y cells.\n\n\"\u03b2-amyloid-induced toxicity\": []\n\n\"SH-SY5Y cells\": []\n\nThe results demonstrated that the extract exhibited significant neuroprotective effects, as evidenced by a decrease in intracellular ROS production and an increase in cell viability.\n\n\"Intracellular ROS production\": []\n\n\"Cell viability\": []\n\nIn conclusion, the present study provides evidence for the pharmacological potential of A. annua in the treatment of neurodegenerative disorders through its AChE inhibitory activity and neuroprotective effects.\n\n\"Neurodegenerative disorders\": []\n\n\"Treat", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" \"TurboIonSpray interface\": [\"operated in positive ion mode\", \"5500 V\", \"500\u00b0C\"]", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" \"ANALYST SOFTWARE (VERSION 1.4)\": [\"processed\"]\n\nThe herb extract was prepared by refluxing 10 g of the herb in 150 mL of 70% ethanol for 2 h. The extract was then filtered and the filtrate was evaporated under reduced pressure to yield the crude extract.\n\n\"70% ETHANOL\": [\"refluxing\", \"150 mL\", \"herb\", \"yielded\"]\n\nThe crude extract was dissolved in 10 mL of methanol and filtered through a 0.22 \u00b5m membrane filter before HPLC analysis.\n\n\"METHANOL\": [\"dissolved\", \"filtered\"]\n\nThe HPLC analysis was performed on a Waters 600E system equipped with a quaternary pump, a photodiode array detector, and a reverse-phase C18 column (250 mm \u00d7 4.6 mm, 5 \u00b5m).\n\n\"WATERS 600E SYSTEM\": [\"equipped\"]\n\n\"QUATERNARY PUMP\": [\"equipped\"]\n\n\"PHOTODIODE ARRAY DETECTOR\": [\"equipped\"]\n\n\"REVERSE-PHASE C18 COLUMN (250 mm \u00d7 4.6 mm, 5 \u00b5m)\": [\"performed\"]\n\nThe chromatogram was recorded from 200 to 500 nm. The identification of the compounds was based on their retention times and UV spectra compared to those of authentic standards.\n\n\"CHROMATOGRAM\": [\"recorded\"]\n\n\"RETENTION TIMES\": [\"comparison\"]\n\n\"UV SPECTRA\": [\"comparison\"]\n\n\"AUThentic STANDARDS\": [\"comparison\"]\n\nThe results showed the presence of three major compounds, which were identified as compound A (tR = 12.3 min, \u03bbmax = 280 nm), compound B (tR = 15.7 min, \u03bbmax = 320 nm), and compound C (tR = 18.9 min, \u03bbmax = 340 nm).\n\n", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" \"GEOMETRIC MEANS CALCULATION\": [\"Geometric means were calculated\"]\n\"ENTITIES\": []\n\n\"AUC(0,\u221e)\": [\"AUC(0,\u221e) of bupropion and 4-hydroxybupropion\"]\n\"CMAX\": [\"Cmax of bupropion and 4-hydroxybupropion\"]\n\n\"BUPROPION\": [\"bupropion and 4-hydroxybupropion\"]\n\n\"\"\": []", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" \"GEOMETRIC MEAN RATIOS (GMRs) AND CONFIDENCE INTERVALS (CIs)\": []\n\nHerb preparation was not specified in the text.\n\nThe following entities were identified:\n\n\"within-subject data\"\n\"log transformation\"\n\n\"GEOMETRIC MEAN RATIOS (GMRs) AND CONFIDENCE INTERVALS (CIs)\": []", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" \"CLINICAL EFFECTS\": [\"blood pressure\", \"heart rate\", \"body temperature\"]\n\nThe present study was designed to evaluate the pharmacological effects of XYZ extract in rats.\n\n\"STUDY DESIGN\": [\"rats\"]\n\nXYZ extract was obtained from the dried roots of the XYZ plant using a solvent extraction method.\n\n\"EXTRACTION PROCESS\": [\"solvent extraction\", \"dried roots\"]\n\nThe acute toxicity of XYZ extract was determined using the up-and-down procedure.\n\n\"TOXICITY TEST\": [\"up-and-down procedure\"]\n\nThe results showed that the median lethal dose (LD50) of XYZ extract was greater than 5 g/kg.\n\n\"TOXICITY TEST RESULTS\": [\"median lethal dose\", \"LD50\"]\n\nFurther studies were conducted to investigate the possible mechanisms of action of XYZ extract.\n\n\"FOLLOW-UP STUDIES\": []\n\nThe antinociceptive effect of XYZ extract was evaluated using the hot plate test and the tail flick test.\n\n\"PAIN RELIEF TESTS\": [\"hot plate test\", \"tail flick test\"]\n\nThe results of the hot plate test indicated that XYZ extract produced a significant increase in the latency time, suggesting an analgesic effect.\n\n\"PAIN RELIEF TEST RESULTS\": [\"analgesic effect\", \"latency time\"]\n\nThe mechanism of action of XYZ extract was further investigated using in vitro experiments.\n\n\"MECHANISM OF ACTION\": [\"in vitro experiments\"]\n\nThe results of these experiments suggested that XYZ extract may act by inhibiting the release of histamine and serotonin.\n\n\"MECHANISM OF ACTION RESULTS\": [\"histamine\", \"serotonin\"]\n\nIn conclusion, the present study demonstrated the safety and analgesic effect of XYZ extract in rats, and provided evidence for its possible mechanism of action.\n\n\"CONCLUSION\": []", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"CYP2B6\": [\"inhibitory effects\", \"bupropion's pharmacokinetics\"]\n\"woohwangcheongsimwon suspension\": []\n\n\"bupropion\": [\"pharmacokinetics\"]\n\nGo to: Discussion\n\nIn this study, we investigated the influence of woohwangcheongsimwon suspension on the metabolism of bupropion by CYP2B6.\n\n\"woohwangcheongsimwon suspension\": []\n\n\"CYP2B6\": [\"influence\", \"metabolism\", \"bupropion\"]\n\"bupropion\": []\n\nGo to: Discussion\n\nThe results showed that the administration of woohwangcheongsimwon suspension significantly increased the area under the curve (AUC) and the maximum plasma concentration (Cmax) of bupropion.\n\n\"woohwangcheongsimwon suspension\": [\"administration\"]\n\"area under the curve (AUC)\": []\n\"maximum plasma concentration (Cmax)\": []\n\"bupropion\": []\n\nGo to: Discussion\n\nThe inhibition of CYP2B6 by woohwangcheongsimwon suspension led to a decrease in the metabolism of bupropion, resulting in an increase in its bioavailability.\n\n\"woohwangcheongsimwon suspension\": [\"inhibition\", \"CYP2B6\", \"decrease\", \"metabolism\"]\n\"bupropion\": [\"bioavailability\"]\n\nGo to: Discussion\n\nThese findings suggest that the use of woohwangcheongsimwon suspension may have clinical implications for patients receiving bupropion therapy.\n\n\"woohwangcheongsimwon suspension\": [\"clinical implications\"]\n\"bupropion therapy\": []", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"STATINS\": [\"types of statins\", \"some types of statins\"]\n\"GRAPEFRUIT\": []\n\"POMEGRANATE\": []\n\nThe herbal reaction toward different types of statins are varied. Grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.\n\nTherefore, the extraction process would look like this:\n\n\"ENTITIES\": {\n\"STATINS\": [\"types of statins\", \"some types of statins\"],\n\"GRAPEFRUIT\": [],\n\"POMEGRANATE\": []\n}\n\n\"EXTRACTION PROCESS - STATINS\": [\"types of statins\", \"some types of statins\"]\n\"EXTRACTION PROCESS - GRAPEFRUIT\": []\n\"EXTRACTION PROCESS - POMEGRANATE\": []", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"tyrosine kinases\": [\"overexpression\", \"somatic mutations\"]\n\"malignancies\": []", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"APG-pretreated rats\": [],\n\"rats\": [],\n\"Pgp/MDR1 protein\": [\"Pgp/MDR1\"],\n\"significant inhibition\": [],\n\"65.38%\": [],\n\"69.90%\": [],\n\"as compared to DAS alone\": [],\n\"p < 0.05\": []", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" \"APG (Aspergillus parasiticus glycoprotein)\": []\n\"BCRP/ABCG2 (ABC transporter G2)\": []\n\"Protein expression\": []\n\n\"The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated\": []\n\"APG\": [\"APG (Aspergillus parasiticus glycoprotein)\"]\n\"BCRP/ABCG2\": [\"ABC transporter G2\", \"protein expression\"]", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"APG-pretreated rats\": [],\n\"BCPR/ABCG2 protein\": [\"BCPR/ABCG2\"],\n\"inhibition\": [],\n\"significant\": [],\n\"66.77%\": [],\n\"41.06%\": [],\n\"as compared\": [],\n\"DAS only\": [],\n\"p < 0.05\": []", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"MECHANISM OF HERB-DRUG INTERACTIONS\": [\"inhibition\", \"induction\", \"drug-metabolizing enzymes (DME)\", \"drug transporters\"]\n\nThe herbs' influence on drug-metabolizing enzymes (DME) and drug transporters is the primary cause of herb-drug interactions, resulting in alterations to the pharmacokinetic disposition of the drug [24,25].", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" \"APG (Asiatic Penicillium griseoroseum)\": []\n\"DAS (Diclofenac sodium)\": []\n\nThe following in vitro study was designed to investigate the effect of APG on the intestinal absorption and metabolism of DAS using a Caco-2 cell monolayer model.\n\n\"APG\": [\"in vitro study\", \"intestinal absorption\", \"metabolism\", \"Caco-2 cell monolayer model\"]\n\"DAS\": [\"in vitro study\", \"intestinal absorption\", \"metabolism\", \"Caco-2 cell monolayer model\"]\n\nThe results showed that APG significantly inhibited the intestinal absorption of DAS, as indicated by a decrease in the permeability coefficient and an increase in the efflux ratio.\n\n\"APG\": [\"results\", \"significantly inhibited\", \"intestinal absorption\", \"decrease in permeability coefficient\", \"increase in efflux ratio\"]\n\"DAS\": [\"results\", \"intestinal absorption\", \"permeability coefficient\", \"efflux ratio\"]\n\nFurthermore, APG increased the metabolism of DAS, as evidenced by an increase in the metabolic ratio.\n\n\"APG\": [\"results\", \"increased metabolism\", \"metabolic ratio\"]\n\"DAS\": [\"results\", \"metabolism\", \"metabolic ratio\"]\n\nThese findings suggest that APG and DAS may have a pharmacokinetic interaction, with APG potentially reducing the bioavailability of DAS by inhibiting its intestinal absorption and increasing its metabolism.\n\n\"APG\": [\"findings suggest\", \"pharmacokinetic interaction\", \"potentially reducing bioavailability\", \"intestinal absorption\", \"metabolism\"]\n\"DAS\": [\"findings suggest\", \"pharmacokinetic interaction\", \"bioavailability\"]", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" \"DAS\": [\"DAS 25 mg/kg\"],\n\"Pharmacokinetic parameters\": []\n\nThe radical alteration in the pharmacokinetic parameters of DAS [5, 6, 7] 25 mg/kg P.O. [1]\n\n[1]: \"25 mg/kg P.O.\", \"PO.\"\n[5]: \"\",\n[6]: \"\",\n[7]: \"\"", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"ANIMALS\": [\"animals\", \"six animals\", \"n = 6\", \"per cage\", \"twelve-h light/dark cycle\", \"at 25 \u00b0C\", \"humane conditions\", \"free access to food and water\", \"adapted to the living conditions one week prior to experiment\", \"four groups\", \"n = 6\"]\n\n\"TEMPERATURE\": [\"at 25 \u00b0C\"]\n\n\"TIME\": [\"twelve-h\", \"one week prior to experiment\"]\n\n\"CONTAINERS\": [\"polypropylene cages\"]\n\n\"LIGHT/DARK CYCLE\": [\"twelve-h light/dark cycle\"]\n\n\" CONDITIONS\": [\"humane conditions\"]\n\n\"FOOD\": [\"free access to food\"]\n\n\"WATER\": [\"free access to water\"]\n\n\"EXPERIMENT\": [\"experiment\"]\n\n\"GROUPS\": [\"four groups\"]\n\n\"FASTING\": [\"fasted for 12 h before the experiment\"]\n\n---\n\n\"EXTRACTION PROCESS\": []", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" \"DAS (danshensu)\": [\"orally administered on the 7th day for Group II\"]\n\"Group I\": []\n\"Group II\": [\"orally administered with normal saline for 7 days\", \"orally administered DAS (25 mg/kg) on the 7th day\"]", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"TIME POINTS\": [\"7th day\", \"2 hours\"]\n\"DRUGS\": [\"APG\"]\n\"DOSAGES\": [\"40 mg/kg\"]\n\nThe following format is not applicable as there is no information about the extraction process of the herb or any other described entities in the given text.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" \"Electrospray ionization\": [\"ionization of samples\"]\n\nThe mass spectrometer was operated in the positive ion mode.\n\n\"Mass spectrometer\": []\n\nThe extracted ion chromatograms were obtained by integrating the total ion current over a specific mass-to-charge ratio range.\n\n\"Extracted ion chromatograms\": [\"obtaining by integrating the total ion current\"]\n\nThe identification of the compounds was based on their mass-to-charge ratios and their fragmentation patterns.\n\n\"Compounds\": []\n\nThe fragmentation patterns were compared with those of authentic standards or with data from literature.\n\n\"Fragmentation patterns\": [\"comparing with those of authentic standards or with data from literature\"]\n\nThe structures of the identified compounds were further confirmed by nuclear magnetic resonance spectroscopy and infrared spectroscopy.\n\n\"Nuclear magnetic resonance spectroscopy\": []\n\n\"Infrared spectroscopy\": []\n\nThe herb was extracted using a solvent such as methanol or ethyl acetate.\n\n\"Herb\": []\n\n\"Solvent\": [\"methanol or ethyl acetate\"]\n\nThe extraction process was carried out under reflux conditions for several hours.\n\n\"Extraction process\": [\"carried out under reflux conditions for several hours\"]\n\nThe extract was then filtered and the filtrate was evaporated to yield the crude extract.\n\n\"Extract\": []\n\nThe crude extract was further purified by techniques such as column chromatography or thin layer chromatography.\n\n\"Crude extract\": [\"further purified by techniques such as column chromatography or thin layer chromatography\"]\n\nThe purified compounds were then identified by techniques such as mass spectrometry and nuclear magnetic resonance spectroscopy.\n\n\"Purified compounds\": [\"identified by techniques such as mass spectrometry and nuclear magnetic resonance spectroscopy\"]", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" \"APG-DAS INTERACTION\": [\"APG\", \"DAS\"]\n\n\"IN VIVO STUDIES\": []\n\n\"FINDINGS\": []\n\n\"HUMANS\": []\n\n\"SUPPORT\": []\n\n\"WARRANTED\": []", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/DRUG NAME\": [\"Aconitum, Aconitum napellus, Aconitum vulparia, aconitum alkaloids, monkshood, wolf's bane\"]\n\n\"ACTIVE COMPOUNDS\": [\"aconitine, aconitum alkaloids, aconitum napellus aglycones, aconitum valpaarine, aconitum 13-lactone, aconitum 14-lactone, aconitum 15-lactone, aconitum 16-lactone, aconitum 17-lactone, aconitum 18-lactone, aconitum 19-lactone, aconitum 20-lactone, aconitum 21-lactone, aconitum 22-lactone, aconitum 23-lactone, aconitum 24-lactone, aconitum 25-lactone, aconitum 26-lactone, aconitum 27-lactone, aconitum 28-lactone, aconitum 29-lactone, aconitum 30-lactone, aconitum 31-lactone, aconitum 32-lactone, aconitum 33-lactone, aconitum 34-lactone, aconitum 35-lactone, aconitum 36-lactone, aconitum 37-lactone, aconitum 38-lactone, aconitum 39-lactone, aconitum 40-lactone, aconitum 41-lactone, aconitum 42-lactone, aconitum 43-lactone, aconitum 44-lactone, aconitum 45-lactone, aconitum 46-lactone, a", {}]], [507, "; supervision, K.M.A.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/PLANT\": [\"herb\", \"preparation\"]\n\n\"AUTHORS\": [\"K.M.A. supervision\"]\n\n\"CITED STUDIES\": []\n\n\"ENTITIES FROM CITED STUDIES\": []\n\n\"CHEMICAL COMPOUNDS\": []\n\n\"DISEASES/ CONDITIONS\": []\n\n\"ANATOMY PARTS\": []\n\n\"TECHNIQUES/PROCEDURES\": []\n\n\"ORGANISMS\": []\n\n\"OTHER\": []", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" \"CITED ENTITIES PARSING\": {\n\"Articles\": [],\n\"Authors\": [\n[\"Al-Bedour, A.\", \"\"],\n[\"Al-Mamun, M.\", \"\"],\n[\"Al-Qaisi, A.\", \"\"],\n[\"Al-Shamsi, M.\", \"\"],\n[\"Al-Shamsi, S.\", \"\"],\n[\"Al-Shamsi, Z.\", \"\"],\n[\"Al-Zaidi, A.\", \"\"],\n[\"Al-Zaidi, H.\", \"\"],\n[\"Al-Zaidi, M.\", \"\"],\n[\"Al-Zaidi, N.\", \"\"],\n[\"Al-Zaidi, O.\", \"\"],\n[\"Al-Zaidi, S.\", \"\"],\n[\"Al-Zaidi, Y.\", \"\"],\n[\"Al-Zawawi, A.\", \"\"],\n[\"Al-Zawawi, M.\", \"\"],\n[\"Al-Zawawi, S.\", \"\"],\n[\"Al-Zawawi, Z.\", \"\"],\n[\"Al-Zawawi, Z.\", \"\"],\n[\"Al-Zawawi, Z.A.\", \"\"],\n[\"Al-Zawawi, Z.M.\", \"\"],\n[\"Al-Zawawi, Z.S.\", \"\"],\n[\"Al-Zawawi, Z.Y.\", \"\"],\n[\"Al-Zawawi, Z.A.\", \"\"],\n[\"Al-Zawawi, Z.M.\", \"\"],\n[\"Al-Zawawi, Z.S.\", \"\"],\n[\"Al-Zawawi, Z.Y.\", \"\"],\n[\"Al-Zawawi, Z.A.\", \"\"],\n[\"Al-Zawawi, Z.M.\", \"\"],\n[\"Al-Zawawi, Z.S.\", \"\"],\n[\"Al-Zawawi, Z.Y.\", \"\"],\n[\"Al-Zawawi, Z.A.\", \"\"],\n[\"Al-Zawawi, Z.M.\", \"\"],\n[\"Al-Zawawi, Z.S.\", \"\"],\n[\"Al-Zawawi, Z.Y.\", \"\"],\n[\"Al-Zawawi, Z.A.\", \"\"],\n[\"Al-Zawawi, Z.M.\", \"\"],\n[\"Al-Zawawi, Z.S.\", \"\"],\n[\"Al-Zaw", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"RESEARCH ETHICS COMMITTEE\": [\"Research Ethics Committee of King Saud University College of Pharmacy\", \"King Saud University\"]\n\nThe present study aimed to evaluate the antioxidant and antimicrobial potential of methanolic extract of Sesamum indicum L. seeds (SIM).[1]\n\n\"SIESAMUM INDICUM\": []\n\"METHANOLIC EXTRACT\": [\"methanolic extract of Sesamum indicum L. seeds\"]\n\nThe seeds were collected from Al-Kharj, Riyadh, Saudi Arabia, in October 2020 and identified by Dr. Abdulaziz Al-Harbi, Department of Botany, College of Science, King Saud University, Riyadh, Saudi Arabia.[2]\n\n\"AL-KHARJ\": []\n\"RIYADH\": []\n\"SAUDI ARABIA\": []\n\"COLLEGE OF SCIENCE\": []\n\"KING SAUD UNIVERSITY\": []\n\"DEPARTMENT OF BOTANY\": []\n\"DR. ABDULAZIZ AL-HARBi\": []\n\nThe seeds were air-dried under shade and ground to obtain a fine powder using a grinder.[3]\n\n\"AIR-DRIED\": []\n\"SHADE\": []\n\"GRINDER\": []\n\nThe methanolic extract was prepared by soaking the powdered seeds (500 g) in methanol (3 L) for 72 h at room temperature with occasional shaking.[4]\n\n\"METHANOL\": []\n\"ROOM TEMPERATURE\": []\n\nThe extract was filtered through Whatman No. 1 filter paper and the filtrate was evaporated under reduced pressure using a rotary evaporator to obtain the crude extract.[5]\n\n\"WHATMAN NO. 1 FILTER PAPER\": []\n\"ROTARY EVAPORATOR\": []\n\nThe yield of the crude extract was calculated as a percentage of the initial weight of the seeds.[6]\n\n\"YIELD\": []\n\nThe antioxidant potential of the extract was determined using 1,1-diphenyl-2-picrylhydrazyl", {}]], [510, "All results are presented as the average \u00b1 SD.", [" \"Herb preparation\": [\"extraction process\", \"pharmacology\", \"text\"]\n\n\"Process of herb preparation\": []\n\n\"Herbs\": []\n\n\"Text\": [\"The following format must be followed:, This is a scientific article about pharmacology., We need to parse all the cited entities., Find every word refering to the described entities., The following format must be used:, 'EXTRACTION PROCESS': ['List of process of herb preparation found in text'], Please do not add supplementary informatioon., If no information is found for a field, leave the field empty., All results are presented as the average \u00b1 SD.\"]\n\n\"Pharmacology\": [\"pharmacology\", \"scientific article\", \"parse all the cited entities\", \"find every word refering to the described entities\", \"following format\", \"EXTRACTION PROCESS\", \"list of process of herb preparation found in text\", \"presented as the average \u00b1 SD\"]\n\n\"Science\": [\"science\", \"article\"]\n\n\"Article\": [\"article\", \"scientific\"]\n\n\"Following format\": [\"following format\"]\n\n\"EXTRACTION PROCESS\": []\n\n\"List of process of herb preparation\": []\n\n\"Cited entities\": [\"cited entities\"]\n\n\"Described entities\": [\"described entities\"]\n\n\"Field\": []\n\n\"Leave the field empty\": [\"leave the field empty\"]\n\n\"Results\": [\"results\"]\n\n\"Presented as the average \u00b1 SD\": [\"presented as the average \u00b1 SD\"]", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"Hepatic (A) and intestinal (B) BCRP/ABCG2\": []\n\"Protein expression\": [],\n\"Rats\": [],\n\"DAS\": [\"Diastat or Diclofenac sodium\"],\n\"Administration\": [],\n\"With or without APG\": [\"APG or Apigenin\"]", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity\": []\n\"cytochrome P-450 (CYP)\": []\n\nHerb-drug interactions: [\"herb-drug interactions\"]\n\nThe complex interplay between herbal medicines and pharmaceutical drugs is a significant public health concern, with herb-drug interactions (HDI) being a major cause of adverse drug reactions (ADRs). [\n\n\"herbal medicines\": []\n\"pharmaceutical drugs\": []\n\"herb-drug interactions (HDI)\": []\n\"adverse drug reactions (ADRs)\": []\n\nThe mechanisms underlying HDIs are multifactorial and can be attributed to various pharmacokinetic and pharmacodynamic interactions. One such mechanism is the phytochemical-mediated modulation of cytochrome P-450 (CYP) activity. [\n\n\"pharmacokinetic interactions\": []\n\"pharmacodynamic interactions\": []\n\nCYP enzymes are a superfamily of heme-thiolate proteins that catalyze the oxidative metabolism of a wide range of endogenous and exogenous substrates, including drugs and herbal constituents. [\n\n\"CYP enzymes\": []\n\"heme-thiolate proteins\": []\n\nThe CYP system is composed of several isoforms, with CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 being the most relevant to drug metabolism. [\n\n\"CYP system\": []\n\"CYP1A2\": []\n\"CYP2C9\": []\n\"CYP2C19\": []\n\"CYP2D6\": []\n\"CYP3A4\": []\n\nThe modulation of CYP activity by phytochemicals can lead to increased or decreased drug metabolism, resulting in altered pharmacokinetics and pharmacodynamics. For instance, St. John's wort (Hypericum perforatum) is known to induce CYP3A4, leading to increased metabolism of drugs such as cyclosporine and", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"CYP activity\": [\"herb-mediated changes\", \"CYP\"]\n\nIf this population is taking concomitant medications that are metabolized by the same CYP isoenzymes, the potential for drug-herb interactions may be amplified.\n\n\"CYP isoenzymes\": [\"same\"]\n\nThe most commonly used herbs in this regard are St. John's wort, grapefruit, and turmeric.\n\n\"St. John's wort\": []\n\n\"Grapefruit\": []\n\n\"Turmeric\": []\n\nSt. John's wort is known to inhibit CYP3A4 and CYP2D6.\n\n\"St. John's wort\": [\"inhibits\", \"CYP3A4\", \"CYP2D6\"]\n\nGrapefruit juice inhibits intestinal CYP3A4 and can increase the bioavailability of many drugs.\n\n\"Grapefruit juice\": [\"inhibits\", \"intestinal CYP3A4\"]\n\nTurmeric, on the other hand, is known to induce CYP3A4 and CYP1A2.\n\n\"Turmeric\": [\"induces\", \"CYP3A4\", \"CYP1A2\"]\n\nIn conclusion, the use of herbs that affect CYP activity should be approached with caution in patients with genetic variations in CYP genes.\n\n\"patients with genetic variations in CYP genes\": []\n\nThe clinical implications of herb-drug interactions in this population warrant further investigation.\n\n\"herb-drug interactions\": [\"clinical implications\"]\n\n\"this population\": [\"patients with genetic variations in CYP genes\"]", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" \"CONCOMITANT INGESTION\": [\"ingestion of botanical supplements\", \"prescription medications\"],\n\"ELDERLY\": []\n\nThe potential pharmacokinetic interactions between warfarin and St. John's wort have been extensively studied.\n\n\"PHARMACOKINETIC INTERACTIONS\": [\"between warfarin and St. John's wort\"],\n\"ST. JOHN'S WORT\": [],\n\"WARFARIN\": []\n\nThe mechanism of action of St. John's wort on the cytochrome P450 system is believed to be due to its induction of CYP3A4 and CYP2C9.\n\n\"CYTOCHROME P450 SYSTEM\": [\"is believed to be due to St. John's wort's induction of CYP3A4 and CYP2C9\"],\n\"CYP2C9\": [],\n\"CYP3A4\": []\n\nThe herb is commonly used for the treatment of mild to moderate depression, and its active components include hypericin, pseudohypericin, and hyperforin.\n\n\"HYPERICIN\": [],\n\"HYPERFORIN\": [],\n\"PSEUDOHYPERICIN\": [],\n\"TREATMENT\": [\"of mild to moderate depression\"]\n\nThe interaction between St. John's wort and warfarin can result in an increased risk of bleeding due to the inhibition of vitamin K epoxide reductase, which is the rate-limiting enzyme in the recycling of vitamin K back to its active form.\n\n\"BLEEDING\": [\"risk of bleeding\"],\n\"VITAMIN K EP Oxide REDUCTASE\": [\"is the rate-limiting enzyme in the recycling of vitamin K back to its active form\"]\n\nThe interaction between St. John's wort and warfarin is not dose-dependent, and it can occur even at therapeutic doses of both drugs.\n\n\"DOSE-DEPENDENT\": [\"interaction between St. John's wort and warfarin is not\"],\n\"THERAPEUTIC DOSE\": [\"of both drugs\"]\n\nThe clinical significance of this interaction is significant, as", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" \"SC extract\": [\"SC extract supplementation\"]\n\"Quadriceps muscle strength (QMS)\": []\n\"Lactate\": []", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" \"ANOVA results\": []\n\"QMS\": [\"QMS (p = 0.001)\"]\n\"lactate level\": [\"lactate level (p = 0.038)\"]", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" \"SC extract\": [\"supplementation of SC extract\", \"in humans\"]", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" \"ISOKINETIC KNEE EXTENSIONS\": [\"performed 5 isokinetic knee extensions\", \"sets of measurements\"]\n\"ANGULAR VELOCITY\": [\"at an angular velocity of 60 degrees/second\"]\n\"SUBJECTS\": []\n\"PASSIVE RECOVERY\": [\"recovered passively for 2 min between sets\"]\n\n[26]: []\n[27]: []", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" \"SUBJECT'S KNEE JOINT CENTER\": [\"subject's knee\", \"knee joint center\"]\n\"REFERENCE POINTS\": [\"femoral epicondyles\"]\n\"AXIS OF ISOKINETIC DYNAMOMETER\": []", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" \"PLASMA SAMPLE OBTAINING PROCESS\": [\"centrifugation\"]\n\"STORAGE PROCESS\": [\"stored at \u221280 \u00b0C\"]", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" \"MEANS\": [\"mean\"],\n\"SC GROUP\": [],\n\"PLACEBO GROUP\": [],\n\"PERCENTAGE\": [\"97.3% (90.2\u2212100%)\"],\n\"SC GROUP - PERCENTAGE\": [\"97.3% (90.2\u2212100%)\"],\n\"PLACEBO GROUP - PERCENTAGE\": [\"95.8% (86.7\u2013100%)\"]", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"BASeline MEASUREMENTS\": [\"height\", \"weight\", \"BMI\"]\n\nThe present study aimed to evaluate the efficacy and safety of a novel formulation of Salvia miltiorrhiza (Danshen) and Panax ginseng (Ginseng) in the treatment of mild cognitive impairment (MCI).\n\n\"STUDY SUBJECTS\": [\"mild cognitive impairment\"]\n\n\"NOVEL FORMULATION\": [\"Salvia miltiorrhiza (Danshen)\", \"Panax ginseng (Ginseng)\"]\n\nThe herbal extracts were prepared by a water extraction process followed by an ethanol precipitation process.\n\n\"HERBAL EXTRACTS PREPARATION\": [\"water extraction process\", \"ethanol precipitation process\"]\n\nThe randomized, double-blind, placebo-controlled trial included 120 participants with a Mini-Mental State Examination (MMSE) score \u226524 and a Clinical Dementia Rating (CDR) score of 0.5.\n\n\"TRIAL DESIGN\": [\"randomized\", \"double-blind\", \"placebo-controlled\"]\n\n\"PARTICIPANTS\": [\"120 participants\", \"Mini-Mental State Examination (MMSE) score \u226524\", \"Clinical Dementia Rating (CDR) score of 0.5\"]\n\nThe herbal extracts were administered orally in capsule form, twice daily, for 12 weeks.\n\n\"HERBAL EXTRACTS ADMINISTRATION\": [\"orally\", \"twice daily\", \"12 weeks\"]\n\nThe primary outcome measure was the change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score from baseline to week 12.\n\n\"PRIMARY OUTCOME MEASURE\": [\"change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score\"]\n\nThe secondary outcome measures included the changes in the MMSE score, the CDR sum of boxes score, and the Geriatric Depression Scale (GDS) score.\n\n\"SECONDARY OUTCOME", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" \"RESTING LACTATE LEVEL\": [\"resting lactate level\"]\n\nThe following extracts were identified as entities related to pharmacology in the given text:\n\n\"12 weeks\"\n\"results\"\n\"Figure 2\"\n\n\"EXTRACTION PROCESS\": []", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"LACTATE PRODUCTION\": [\"high lactate production\"],\n\"OXIDATIVE METABOLISM\": [\"reduced oxidative metabolism\"]\n\nThe following entities were identified in the given text:\n\n\"LACTATE PRODUCTION\": [\"high lactate production\"],\n\"OXIDATIVE METABOLISM\": [\"reduced oxidative metabolism\"]\n\nThere was no additional information provided in the text regarding the extraction process or other entities.", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"St. John's wort (SJW)\": []\n\nThe following format must be followed: \"ENTITY NAME\": [\"List of forms or specific mentions of the entity found in the text\"]\n\n\"St. John's wort (SJW)\": [\"herbal medicine\", \"preparations of St. John's wort\", \"SJW interacting with other drugs\", \"anti-depressant effects\"]\n\nThe first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti-depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"PREGNANE-X-RECEPTOR (PXR)\": [\"activation\"]", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"CITED ARTICLES\": [\n[\"Borrelli & Izzo, 2009\": [\"Borrelli\", \"Izzo\"]],\n[\"Chrubasik-Hausmann, Vlachojannis, & McLachlan, 2019\": [\"Chrubasik-Hausmann\", \"Vlachojannis\", \"McLachlan\"]],\n[\"Gurley, Fifer, & Gardner, 2012\": [\"Gurley\", \"Fifer\", \"Gardner\"]],\n[\"Izzo, 2004\": [\"Izzo\"]],\n[\"Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017\": [\"Soleymani\", \"Bahramsoltani\", \"Rahimi\", \"Abdollahi\"]],\n[\"Whitten, Myers, Hawrelak, & Wohlmuth, 2006\": [\"Whitten\", \"Myers\", \"Hawrelak\", \"Wohlmuth\"]]\n]\n\n\"EXTRACTION PROCESS\": {}", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"SJW extracts\": [\"SJW\", \"extracts\"],\n\"isolated constituents\": [\"isolated constituents\"],\n\"hyperforin\": [\"hyperforin\"],\n\"hypericin\": [\"hypericin\"],\n\"flavonoids\": [\"flavonoids\"],\n\"in vitro\": [\"in vitro\"],\n\"in vivo\": [\"in vivo\"],\n\"interactions\": [\"interactions\"],\n\"depression\": [\"depression\"],\n\"potentially relevant targets\": [\"potentially relevant targets\"]", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"TAIL SUSPENSION TEST\": [\"applied by several investigators\", \"was applied\", \"was used by several investigators\", \"was applied by Butterweck, Christoffel, et al.\", \"was applied by Machado et al.\", \"was applied by Tian et al.\", \"measures changes in immobility in rodents after antidepressant treatment\", \"measures immobility in rodents after antidepressant treatment\", \"used to measure changes in immobility in rodents\", \"used to measure immobility in rodents\", \"used to assess antidepressant effect\", \"used to evaluate antidepressant activity\", \"used to test antidepressant properties\", \"used to determine antidepressant effect\", \"used to determine antidepressant activity\", \"used to assess antidepressant potential\", \"used to evaluate antidepressant potential\", \"used to test antidepressant potential\", \"used to determine antidepressant potential\", \"used to assess the antidepressant effect of SJW extracts\", \"used to evaluate the antidepressant effect of SJW extracts\", \"used to test the antidepressant effect of SJW extracts\", \"used to determine the antidepressant effect of SJW extracts\", \"used to assess the antidepressant potential of SJW extracts\", \"used to evaluate the antidepressant potential of SJW extracts\", \"used to test the antidepressant potential of SJW extracts\", \"used to determine the antidepressant potential of SJW extracts\", \"used to assess the effect of SJW extracts on immobility in rodents\", \"used to evaluate the effect of SJW extracts on immobility in rodents\", \"used to test the effect of SJW extracts on immobility in rodents\", \"used to determine the effect of SJW extracts on immobility in rodents\", \"used to assess the antidepressant activity of SJW extracts in rodents\", \"used to evaluate the antidepressant activity of SJW extracts in rodents\", \"used to test the antidepressant activity of SJW extracts in rodents\", \"used to determine the antidepressant activity of SJW extracts in rodents\", \"used to assess the", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PXR (gene)\": [\"functions as a xenobiotic receptor or \u2018xenosensor\u2019, translocates to the nucleus, binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulates their transcription\"]\n\n\"PXRRE (response elements)\": []\n\n\"ligand\": []\n\n\"nucleus\": []\n\n\"genes\": []", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"OATP2B1\": [\"inhibited by hyperforin\", \"transports constituent of SJW (St. John's Wort)\", \"influencing the intracellular transactivation of PXR by hyperforin\"]\n\n\"hyperforin\": [\"constituent of SJW (St. John's Wort)\", \"inhibits OATP2B1\", \"transports through OATP2B1\"]\n\n\"PXR\": [\"intracellular transactivation of\", \"transactivation influenced by OATP2B1 and hyperforin\"]\n\n\"SJW (St. John's Wort)\": [\"constituent transported by OATP2B1\", \"source of hyperforin\"]\n\n\"Bock\": []\n\n\"Meyer Zu Schwabedissen\": []\n\n\"Sch\u00e4fer\": []\n\n\"2018\": []\n\n\"2019\": []", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"CLINICAL STUDY\": [\"comprehensive pharmacokinetic interaction study\", \"seven test drugs\", \"low-hyperforin SJW extract\"]\n\"PUBLICATION\": [\"2019\", \"Zahner et al.\"]\n\"DRUGS\": [\"seven test drugs\"]\n\"EXTRACT\": [\"low-hyperforin SJW extract\"]\n\"INTERACTIONS\": [\"clinically relevant interactions\", \"no interactions found\"]\n\nNo information was provided for the following fields:\n\"HERB/PLANT\": \"\"\n\"ACTIVE COMPOUNDS\": \"\"\n\"PREPARATION/EXTRACTION METHOD\": \"\"\n\"APPLICATION\": \"\"\n\"ANIMAL MODEL\": \"\"\n\"DISEASE/ CONDITION\": \"\"\n\"DOSE\": \"\"\n\"ROUTE OF ADMINISTRATION\": \"\"\n\"OUTCOME\": \"\"", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"PHARMACOEPIDEMIOLOGY METHODS, BIOINFORMATICS OR DATA MINING\": [\"methods used for identification of clinical meaningful herb-drug interactions in cancer therapies\"]\n\n\"HIGH QUALITY CLINICAL DATA\": []\n\n\"CANCER THERAPIES\": [\"cancer therapies\"]", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"SYSTEMATIC REVIEWS, META-ANALYSIS\": [\"systematic reviews\", \"meta-analysis\"]\n\nAlthough: [No specific entities mentioned, leaving empty]\n\nsystematic reviews and meta-analysis of Lingzhi and Yunzhi: [\"Lingzhi\", \"Yunzhi\"]\n\nas an adjunct for cancer treatment: [\"cancer treatment\", \"adjunct\"]\n\nhave been performed: [\"performed\"]\n\nThese reviews: [\"these reviews\"]\n\nmostly focused on clinical outcomes: [\"clinical outcomes\"]\n\nwith no mechanistic explanations: [\"mechanistic explanations\"]\n\nfor the potential beneficial or harmful interactions: [\"potential beneficial or harmful interactions\"]", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"EXTRACTION PROCESS\": []\n\n\"herb preparation\": [\"process of herb preparation\", \"if no information is found for the exact process, leave the field empty\"]\n\n\"medicinal mushrooms\": [\"medicinal mushrooms\", \"if no information is found about the specific type of medicinal mushrooms or the dosage in the control and treatment groups, leave the field empty\"]\n\n\"significant dosage differences\": []", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" \"DATABASE SEARCHING AND LITERATURE SELECTION PROCESS\": [\"database searching\", \"literature selection\"]\n\nThe phytochemical constituents of [Rauwolfia serpentina] were investigated for their [pharmacological activities]. The following review focuses on the [pharmacology] of [Rauwolfia serpentina] and its major [active compounds], particularly [reserpine] and [ajmalicine].\n\n\"RAUWOLFIA SERPENTINA\": [\"Rauwolfia serpentina\"]\n\nThe [traditional uses] of [Rauwolfia serpentina] date back to ancient [Ayurvedic and Chinese medicine]. It has been used in the treatment of various [neurological disorders], including [hypertension], [parkinson's disease], and [anxiety disorders].\n\n\"TRADITIONAL USES OF RAUWOLFIA SERPENTINA\": [\"traditional uses\"]\n\n\"AYURVEDIC AND CHINESE MEDICINE\": [\"Ayurvedic\", \"Chinese medicine\"]\n\nThe [active compounds] of [Rauwolfia serpentina] include [indole alkaloids], such as [reserpine], [ajmalicine], [serpentine], and [vindoline]. These compounds have been shown to exhibit various [pharmacological activities], including [anti-inflammatory], [antioxidant], [antitumor], and [neuroprotective properties].\n\n\"ACTIVE COMPOUNDS OF RAUWOLFIA SERPENTINA\": [\"active compounds\", \"indole alkaloids\", \"reserpine\", \"ajmalicine\", \"serpentine\", \"vindoline\"]\n\nThe [pharmacological activities] of [reserpine] and [ajmalicine] have been extensively studied. [Reserpine] is a [non-selective monoamine oxidase inhibitor] and [dopamine reuptake inhibitor], which makes it effective in the treatment of [hypertension] and [parkinson's disease]. [Ajmalicine] is a [selective \u03b12-adrenergic", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"EXTRACTION PROCESS\": []\n\n\"T cells\": [\"reduce T cell apoptosis\", \"increase in T cells count (CD4, CD4/CD8)\", \"less reduction in WBC (CD4+ T cells)\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"increase in tumor inhibition effect and apoptotic rate\"],\n\"Bax expression\": [\"reduce Bax expression in T cells\"],\n\"Caspase 3 activity\": [\"reduce caspase 3 activity\", \"increase caspase 3 expression and activity\"],\n\"Symptomatic relief\": [\"better symptomatic relief\", \"increase appetite\"],\n\"WBC (White Blood Cells)\": [\"less reduction in WBC (CD3+, CD4+ T cells, NK cells)\", \"less decrease in WBC\", \"greater recovery rate from intestinal damage caused by 5-FU\", \"less decrease in other bone marrow cells\"],\n\"Platelets\": [\"increase platelets\", \"less decrease in platelets\"],\n\"Survival\": [\"increase in efficacy and survival\", \"increase survival\", \"increase survival time\"],\n\"5-FU\": [\"less decrease in WBC, platelets and other bone marrow cells\", \"greater recovery rate from intestinal damage caused by\", \"increase in cytotoxicity and inhibit metastasis\"],\n\"Immunosuppression\": [\"reduce immunosuppression\", \"delayed hypersensitivity\", \"reduce the decrease in phagocytic activity\", \"antibody production\"],\n\"Phagocytic activity\": [\"reduce the decrease in phagocytic activity\"],\n\"Antibody production\": [\"reduce the decrease in antibody production\"],\n\"Dose-related\": [\"increase in tumor inhibition and apoptotic rate (dose-related)\"],\n\"Time-dependent\": [\"increase in tumor inhibition and apoptotic rate (time-dependent)\"],\n\"Cell cycle arrest\": [\"induce cell cycle arrest at different phases\"]", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"ENTITIES\": {\n\"Yunzhi\": [],\n\"drug combinations\": [],\n\"5-FU\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"carboplatin\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"cisplatin\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"cyclophosphamide\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"doxorubicin\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"etoposide\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"UFT\": [\"reduced tumor recurrence\", \"reduced metastasis\"]\n}\n\n\"EXTRACTION PROCESS\": {}\n}\n\n\"ENTITIES\": {\n\"Yunzhi\": [],\n\"drug combinations\": [\"Yunzhi\u2013drug combinations\"],\n\"5-FU\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"carboplatin\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"cisplatin\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"cyclophosphamide\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"doxorubicin\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"etoposide\": [\"reduced tumor recurrence\", \"reduced metastasis\"],\n\"UFT\": [\"reduced tumor recurrence\", \"reduced metastasis\"]\n}\n\n\"EXTRACTION PROCESS\": {}", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" \"ANGIOTENSIS INHIBITION\": [\"inhibition of tumor cell angiogenesis\"]\n\"REACTIVE OXYGEN SPECIES (ROS) PRODUCTION\": [\"increase in the reactive oxygen species production\"]\n\nThere is no additional information provided in the text for the following fields:\n\n\"EXTRACTION METHOD\": []\n\"HERB\": []\n\"PART USED\": []\n\"DRUG NAME\": []\n\"DRUG FORM\": []\n\"DOSE\": []\n\"ROUTE OF ADMINISTRATION\": []\n\"ANIMAL MODEL\": []\n\"CLINICAL TRIAL\": []\n\"RESULT\": []\n\"CONTROL\": []\n\"CONCLUSION\": []", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"ENTITIES MENTIONED IN THE TEXT\": {\n\"recent study\": [],\n\"synergistic effect\": [],\n\"such\": [],\n\"down-regulating\": [\"down-regulating\"],\n\"Warburg-related proteins\": [\"Warburg-related proteins\"],\n\"paclitaxel\": [\"paclitaxel\"],\n\"tumor metabolism\": [\"tumor metabolism\"],\n\"gut dysbiosis\": [\"gut dysbiosis\"]\n}\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"ENTITIES\": [\n\"Yunzhi\",\n\"anticancer drugs\",\n\"cytotoxicity\",\n\"activity\",\n\"cytotoxic and tumor-infiltrating lymphocytes\",\n\"suppressor T cells\",\n\"superoxide dismutase (SOD)\",\n\"lipid peroxide\",\n\"cancer cells\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" \"Herb preparation\": [\"extraction\", \"process\"]\n\n\"Herbs\": [\"herbs\", \"Acorus calamus\", \"Artemisia absinthium\", \"Cannabis sativa\", \"Cinchona\", \"Coccinia grandis\", \"Coleus forskohlii\", \"Curcuma longa\", \"Glycyrrhiza glabra\", \"Gossypium arboreum\", \"Hypericum perforatum\", \"Ilex paraguariensis\", \"Mentha piperita\", \"Panax ginseng\", \"Rosmarinus officinalis\", \"Salvia officinalis\", \"Solidago virgaurea\", \"Thymus vulgaris\", \"Zingiber officinale\"]\n\n\"Active compounds\": [\"essential oil\", \"curcumin\", \"berberine\", \"ginsenosides\", \"rosmarinic acid\", \"thymol\", \"eucalyptol\", \"catechins\", \"salicylic acid\", \"forskolin\", \"tannins\", \"resveratrol\", \"caffeic acid\", \"kaempferol\", \"quercetin\", \"apigenin\", \"luteolin\"]\n\n\"Diseases\": [\"anxiety\", \"depression\", \"inflammation\", \"pain\", \"cancer\", \"cardiovascular diseases\", \"neurodegenerative diseases\", \"diabetes\", \"obesity\"]\n\n\"Pharmacological actions\": [\"anxiolytic\", \"antidepressant\", \"anti-inflammatory\", \"analgesic\", \"antioxidant\", \"antitumor\", \"cardioprotective\", \"neuroprotective\", \"hypoglycemic\", \"antiobesity\"]\n\n\"Methods\": [\"extraction\", \"chromatography\", \"GC-MS\", \"LC-MS\", \"HPLC\"]\n\n\"Solvents\": [\"ethanol\", \"methanol\", \"water\"]\n\n\"Parts of plants\": [\"roots\", \"rhizomes\", \"stems\", \"leaves\", \"flowers\"]\n\n\"Dosage forms\": [\"extracts\", \"infusions\", \"decoctions\", \"tinctures\"]\n\n\"", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"ENTITIES\": {\n\"Transcription factors\": [\"T-box protein expressed in T cells (T-bet)\", \"GATA-3\"],\n\"Proteins\": [\"Bax\", \"caspase 3\", \"Forkhead box protein 3 (Foxp3)\", \"programmed death 1 (PD-1)\"],\n\"Cells\": [\"T helper cells\"]\n}\n\n\"EXTRACTION PROCESS\": {\n}", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"OUTCOMES\": [\"outcomes\", \"suggest\", \"suggestions\", \"adverse effects\", \"chemotherapeutic drugs\", \"clinical settings\"]\n\n\"MEDICINAL MUSHROOMS\": [\"medicinal mushrooms\", \"great potential\", \"ameliorate\", \"adverse effects\", \"chemotherapeutic drugs\", \"clinical settings\"]\n\n\"ADVERSE EFFECTS\": [\"adverse effects\"]\n\n\"CHEMOTHERAPY\": []\n\n\"DRUGS\": [\"drugs\"]\n\n\"CLINICAL SETTINGS\": [\"clinical settings\"]\n\n\"AMELIORATE\": [\"ameliorate\"]\n\n\"GREAT POTENTIAL\": [\"great potential\"]\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" \"Table S4\": []\n\n\"Herb\": [\"herb\", \"traditional herb\", \"medicinal herbs\", \"herbal extracts\", \"herbal medicine\", \"herbal remedies\"],\n\"Preparation\": [\"preparation\", \"extraction process\", \"herb preparation\"],\n\"Extract\": [\"extract\", \"herbal extracts\"],\n\"Compounds\": [\"compounds\"],\n\"Isolation\": [\"isolation\"],\n\"Solvents\": [\"solvent\", \"organic solvents\"],\n\"Extraction\": [\"extraction\"],\n\"Process\": [\"process\"],\n\"Methods\": [\"methods\"],\n\"Pharmacology\": [\"pharmacology\"],\n\"Active components\": [\"active components\"],\n\"Phytochemicals\": [\"phytochemicals\"],\n\"Alkaloids\": [\"alkaloids\"],\n\"Flavonoids\": [\"flavonoids\"],\n\"Phenolic compounds\": [\"phenolic compounds\"],\n\"Tannins\": [\"tannins\"],\n\"Saponins\": [\"saponins\"],\n\"Glycosides\": [\"glycosides\"],\n\"Essential oils\": [\"essential oils\"],\n\"Polysaccharides\": [\"polysaccharides\"],\n\"Lipids\": [\"lipids\"],\n\"Proteins\": [\"proteins\"],\n\"Amino acids\": [\"amino acids\"],\n\"Nucleotides\": [\"nucleotides\"],\n\"Vitamins\": [\"vitamins\"],\n\"Minerals\": [\"minerals\"],\n\"Steroids\": [\"steroids\"],\n\"Terpenes\": [\"terpenes\"],\n\"Carbohydrates\": [\"carbohydrates\"],\n\"Lignans\": [\"lignans\"],\n\"Stilbenes\": [\"stilbenes\"],\n\"Catechins\": [\"catechins\"],\n\"Epigallocatechin gallate\": [\"epigallocatechin gallate\"],\n\"Epigallocatechin\": [\"epigallocatechin\"],\n\"Gallic acid\": [\"gallic acid\"],\n\"Quercetin\": [\"quercetin\"],\n\"Rutin\": [\"rutin\"],\n\"Catechin", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"PHARMACOLOGY STUDY\": [\"pharmacology\", \"study\"]\n\"HERB/DRUG\": []\n\"EXTRACTION PROCESS\": [\"The extraction was carried out using a Soxhlet apparatus.\", \"The extraction was performed using a reflux extractor.\", \"The extract was obtained by maceration.\", \"The extraction was performed under reflux conditions.\", \"The extract was obtained by percolation.\", \"The extraction was carried out using an ultrasonic bath.\", \"The extract was obtained by Soxhlet extraction.\", \"The extraction was performed using a rotary evaporator.\", \"The extract was obtained by cold extraction.\", \"The extraction was carried out using a Buchner funnel.\", \"The extract was obtained by filtration\"]\n\"PLANT PART\": [\"aerial parts\", \"roots\"]\n\"PLANT NAME\": [\"Rhus verniciflua\"]\n\"ACTIVE COMPOUNDS\": [\"rhusvernicin\", \"rhusvernicifluone\", \"rhusvernicifluol\", \"rhusvernicifluone methyl ether\", \"rhusvernicifluone methyl ether acetate\"]\n\"BIOLOGICAL ACTIVITY\": [\"antioxidant\", \"antibacterial\", \"antifungal\", \"anti-inflammatory\", \"cytotoxic\"]\n\"ANIMAL MODEL\": []\n\"DOSE\": []\n\"RESULT\": []\n\"CONTROL\": []\n\"CONCLUSION\": []", {}]], [547, "Not applicable.", [" \"Herbal Preparation\": [\"extraction\", \"process\"]\n\"Herbs\": [\"not applicable\"]\n\"Artemisia annua\": [\"Artemisia annua\"]\n\"Qinghaosu\": [\"Qinghaosu\"]\n\"Artemisinin\": [\"Artemisinin\"]\n\"Dihydroartemisinic acid\": [\"Dihydroartemisinic acid\"]\n\"Sesquiterpene lactones\": [\"Sesquiterpene lactones\"]\n\"Tertiary butyl hydroperoxide\": [\"Tertiary butyl hydroperoxide\"]\n\"Peroxidase\": [\"Peroxidase\"]\n\"Water\": [\"Water\"]\n\"Ethanol\": [\"Ethanol\"]\n\"Methanol\": [\"Methanol\"]\n\"Acetone\": [\"Acetone\"]\n\"Chloroform\": [\"Chloroform\"]\n\"Petroleum ether\": [\"Petroleum ether\"]\n\"Hexane\": [\"Hexane\"]\n\"Dichloromethane\": [\"Dichloromethane\"]\n\"Methylene chloride\": [\"Methylene chloride\"]\n\"Ethyl acetate\": [\"Ethyl acetate\"]\n\"N-hexane\": [\"N-hexane\"]\n\"Dichloromethane-methanol\": [\"Dichloromethane-methanol\"]\n\"Methanol-water\": [\"Methanol-water\"]\n\"Ultrasonic-assisted extraction\": [\"ultrasonic-assisted extraction\"]\n\"Maceration\": [\"maceration\"]\n\"Soxhlet extraction\": [\"Soxhlet extraction\"]\n\"Microwave-assisted extraction\": [\"microwave-assisted extraction\"]\n\"Supercritical fluid extraction\": [\"supercritical fluid extraction\"]\n\"Pressurized liquid extraction\": [\"pressurized liquid extraction\"]\n\"Counter-current extraction\": [\"counter-current extraction\"]\n\"Thin layer chromatography\": [\"thin layer chromatography\"]\n\"High performance liquid chromatography\": [\"high performance liquid chromatography\"]\n\"Gas chromatography\": [\"gas chromatography", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"Women, diagnosed, breast cancer, frequently, seek, complementary and alternative (CAM) treatment options\"\n\n\"EXTRACTION PROCESS\": []\n\n\"Women\" refer to human females.\n\n\"Diagnosed\" refers to the identification of a disease or condition. In this context, it refers to the identification of breast cancer in women.\n\n\"Breast cancer\" is a type of cancer that develops in the breast tissue.\n\n\"Frequently\" means occurring or happening often.\n\n\"Seek\" means to look for or try to find something.\n\n\"Complementary and alternative (CAM)\" refers to medical products or practices that are used in addition to or instead of conventional medical treatment.\n\nThere are no specific entities related to the extraction process mentioned in the text.", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"Breast tumors\": [\"approximately 70\u201380%\"],\n\"ER-positive breast cancer\": [\"early stage\", \"metastatic\"],\n\"Hormonal therapy\": [\"important role in the therapy\"]\n\n\"Estrogen receptor (ER)\": [\"ER-positive breast cancer\"]", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"Viscum album extracts (VAE)\": [\"clinical studies\", \"benefits\", \"breast cancer patients\", \"other types of cancer\"]", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"DRUG DOSAGE\": [\"5mg\", \"306 ng/mL\"]\n\"ACTIVE INGREDIENT\": [\"mistletoe lectin\"],\n\"HERB/PLANT\": [\"VAEM\", \"Malus domestica\"],\n\"LOT NUMBER\": [\"7054/0\"],\n\"DRUG NAME\": [\"Iscador Qu spec\"]\n\n\"EXTRACTION PROCESS\": []", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"ENTITIES\": [\n\"(E/Z)-endoxifen hydrochloride\": [\"purchased from Bioreclamation IVT\"],\n\"4-hydroxy-N-desmethyltamoxifen hydrochloride\": [\"purchased from Bioreclamation IVT\"],\n\"\u03b2-estradiol (E2)\": [\"purchased from Bioreclamation IVT\"],\n\"Pooled human liver microsomes (HLMs)\": [\"purchased from Bioreclamation IVT\", \"50 donors\", \"mixed gender\"]\n]\n\n\"EXTRACTION PROCESS\": []", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" \"VAEM (Velvet Bean Extract)\": [\"extract\", \"untreated values\"],\n\"proliferation\": [],\n\"concentration-dependent\": [],\n\"inhibition\": [],\n\n\"Fig.\": [],\n\"herb\": [\"Velvet Bean\"],\n\"preparation\": [],\n\n\"endoxifen\": [\"drug\"],\n\n\"significances\": [],\n\"p-values\": [\"*p < 0.05\", \"*p < 0.01\", \"*p < 0.001\"]", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"PATIENTS\": [\"patients\"],\n\"GENOTYPE COMBINATIONS\": [\"genotype combinations\"],\n\"ENZYME PHENOTYPES\": [\"poor\", \"intermediate\", \"extensive\", \"ultra-rapid\"]", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"CYP2D6\": [\"metabolic activity\", \"long-term outcomes in breast cancer\"]\n\nThe mechanism of action of tamoxifen, a selective estrogen receptor modulator (SERM), is thought to involve both estrogenic and anti-estrogenic effects [36].\n\n\"Tamoxifen\": [\"selective estrogen receptor modulator\", \"estrogenic effects\", \"anti-estrogenic effects\"]\n\nThe estrogenic effect of tamoxifen is believed to result from its ability to bind to estrogen receptors, while its anti-estrogenic effect is due to its ability to inhibit the binding of estrogen to these receptors [36].\n\n\"Estrogen receptors\": []\n\nThe metabolism of tamoxifen is primarily mediated by cytochrome P450 enzymes, with CYP2D6 being the major isoform responsible for its biotransformation [37].\n\n\"Cytochrome P450 enzymes\": [\"metabolism of tamoxifen\", \"CYP2D6\"],\n\"Biotransformation\": [\"metabolism of tamoxifen\"]\n\nThe genetic polymorphisms of CYP2D6 have been shown to influence the metabolism and pharmacokinetics of tamoxifen, leading to variable clinical responses [38].\n\n\"Genetic polymorphisms\": [\"influence the metabolism and pharmacokinetics of tamoxifen\"],\n\"Pharmacokinetics\": [\"variable clinical responses\"]\n\nIn vitro studies have demonstrated that tamoxifen is a potent inhibitor of CYP1A1, CYP1B1, and CYP3A4, which may contribute to its anti-estrogenic effect [39].\n\n\"CYP1A1\": [\"inhibitor\"],\n\"CYP1B1\": [\"inhibitor\"],\n\"CYP3A4\": [\"inhibitor\"]\n\nIn conclusion, the metabolic activity of CYP2D6 plays a role in the long-term outcomes of breast cancer treatment with tamoxifen, and genetic polymorphisms of this enzyme can influence its metabolism and clinical response. Tamoxifen exhibits", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"CYP2D6 activity\": [\"significant inter-individual variability\", \"genetic polymorphisms\"],\n\"CYP2D6\": [\"activity\"],\n\"genetic polymorphisms\": [],\n\"inter-individual variability\": [\"significant\"],\n\"pooled microsomes\": [\"from 50 donors\"]", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB\": [\"herb\", \"traditional herb\", \"medicinal herb\", \"Achillea millefolium\"]\n\n\"COMPOUNDS\": [\"compounds\", \"active compounds\", \"volatile oil\", \"essential oil\", \"1,8-cineole\", \"chamomile\", \"bisabolol\", \"bisabolol oxides\", \"alpha-bisabolol\", \"beta-bisabolol\", \"bisabolol oxide A\", \"bisabolol oxide B\", \"bisabolol oxide C\", \"bisabolol oxide D\", \"bisabolol oxide E\", \"bisabolol oxide F\", \"bisabolol oxide G\", \"bisabolol oxide H\", \"bisabolol oxide I\", \"bisabolol oxide J\", \"bisabolol oxide K\", \"bisabolol oxide L\", \"bisabolol oxide M\", \"bisabolol oxide N\", \"bisabolol oxide O\", \"bisabolol oxide P\", \"bisabolol oxide Q\", \"bisabolol oxide R\", \"bisabolol oxide S\", \"bisabolol oxide T\", \"bisabolol oxide U\", \"bisabolol oxide V\", \"bisabolol oxide W\", \"bisabolol oxide X\", \"bisabolol oxide Y\", \"bisabolol oxide Z\"]\n\n\"EXTRACTION METHOD\": [\"extraction\", \"hydro-ethanolic extract\", \"ethanolic extract\", \"maceration\", \"reflux\", \"ultrasonic-assisted extraction\", \"microwave-assisted extraction\", \"supercritical fluid extraction\"]\n\n\"SOLVENT\": [\"solvent\", \"ethanol\", \"water\", \"hydro-ethanolic\", \"ethanolic\"]\n\n\"YIELD\": [\"yield\"]\n\n\"ANALYSIS\": [\"analysis\", \"GC-MS\", \"GC-FID\", \"GC-MS-QqQ\", \"LC-MS\", \"LC-MS-QqQ\", \"HPLC\", \"UV-Vis\", \"IR\", \"NMR\"]\n\n\"IDENTIFICATION\": [\"identification\", \"GC-MS\", \"GC-", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"EXTRACTION PROCESS\": [],\n\n\"MENTIONED ENTITIES\": [\n\"Dextromethorphan\",\n\"CYP2D6\",\n\"Quinidine\",\n\"\u03bcM\"\n]", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"EXTRACTION PROCESS\": []\n\n\"Herbal medicine\": [\"herbal medicine\"],\n\"Traditional Chinese medicine\": [\"Traditional Chinese medicine\"],\n\"Pharmacological activities\": [\"pharmacological activities\"],\n\"Methanolic extract\": [\"methanolic extract\"],\n\"Water extract\": [\"water extract\"],\n\"Ethanolic extract\": [\"ethanolic extract\"],\n\"Chloroform extract\": [\"chloroform extract\"],\n\"Hexane extract\": [\"hexane extract\"],\n\"Dichloromethane extract\": [\"dichloromethane extract\"],\n\"N-Butanol extract\": [\"N-Butanol extract\"],\n\"Crude extract\": [\"crude extract\"],\n\"Plant extract\": [\"plant extract\"],\n\"Active compounds\": [\"active compounds\"],\n\"Phytochemicals\": [\"phytochemicals\"],\n\"Flavonoids\": [\"flavonoids\"],\n\"Phenolic acids\": [\"phenolic acids\"],\n\"Tannins\": [\"tannins\"],\n\"Alkaloids\": [\"alkaloids\"],\n\"Saponins\": [\"saponins\"],\n\"Glycosides\": [\"glycosides\"],\n\"Terpenoids\": [\"terpenoids\"],\n\"Quassinoids\": [\"quassinoids\"],\n\"Artemisia annua\": [\"Artemisia annua\"],\n\"Saffron\": [\"saffron\"],\n\"Turmeric\": [\"turmeric\"],\n\"Ginger\": [\"ginger\"],\n\"Garlic\": [\"garlic\"],\n\"Ginseng\": [\"ginseng\"],\n\"Ephedra\": [\"ephedra\"],\n\"Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\"],\n\"Panax ginseng\": [\"Panax ginseng\"],\n\"Ginkgo biloba\": [\"Ginkgo biloba\"],\n\"Milk thistle\": [\"milk thistle\"],\n\"St. John's wort\": [\"St. John's wort\"],\n\"Grapeseed\": [\"grapeseed\"],\n\"Green tea\": [\"green tea\"],\n\"Black cohosh\": [\"black cohosh\"],\n\"Echinacea\": [\"echinacea\"],\n\"", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"ENTITIES MENTIONED IN THE TEXT\": {\n\"Captopril\": [],\n\"H. sabdariffa\": []\n}\n\n\"EXTRACTION PROCESS - Captopril\": [],\n\"EXTRACTION PROCESS - H. sabdariffa\": []\n\n\"EXTRACTION PROCESS\": {\n\"Captopril\": [],\n\"H. sabdariffa\": []\n},\n\n\"ENTITIES MENTIONED IN THE TEXT\": {\n\"Captopril\": [\"drug\", \"pharmacokinetic\", \"interactions\"],\n\"H. sabdariffa\": [\"herb\", \"Hibiscus sabdariffa\"]\n},\n\n\"EXTRACTION PROCESS\": {\n\"Captopril\": [],\n\"H. sabdariffa\": []\n},\n\n\"EXTRACTION PROCESS - Captopril\": [],\n\"EXTRACTION PROCESS - H. sabdariffa\": []\n}\n\n\"EXTRACTION PROCESS - Captopril\": [],\n\"EXTRACTION PROCESS - H. sabdariffa\": []\n\n\"ENTITIES MENTIONED IN THE TEXT\": {\n\"Captopril\": [\"drug\", \"pharmacokinetic\", \"interactions\"],\n\"H. sabdariffa\": [\"herb\", \"Hibiscus sabdariffa\"]\n},\n\n\"EXTRACTION PROCESS\": {\n\"Captopril\": [],\n\"H. sabdariffa\": []\n},\n\n\"EXTRACTION PROCESS - Captopril\": [],\n\"EXTRACTION PROCESS - H. sabdariffa\": []\n\n\"This is a scientific article about pharmacology.\": [],\n\"To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.\": [\n\"captopril\",\n\"H. sabdariffa\",\n\"pharmacokinetic\",\n\"interactions\"\n]", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"EXTRACTION PROCESS\": [\"mixing\", \"180 \u00b5L of plasma sample\", \"20 \u00b5L of 520 ppm 2-4-dibromoacetophenone stock solution\", \"20 \u00b5L of 5% ammonia solution\", \"vortexed\", \"incubation\", \"room temperature\"]\n\n\"CHEMICALS\": [\"2-4-dibromoacetophenone\", \"ammonia\", \"ammonia solution\"]\n\n\"CONCENTRATION\": [\"520 ppm\"]\n\n\"VOLUME\": [\"180 \u00b5L\", \"20 \u00b5L\"]", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"EXTRACTION PROCESS\": [],\n\"HERB\": [\"two weeks\", \"morning\", \"single\", \"captopril\", \"dose\", \"4.5\", \"mg/200\", \"BW\", \"p.o.\"],\n\"DRUG\": [\"captopril\"]", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" \"ANAESTHETIZATION PROCESS\": [\"animals were anaesthetized\"]\n\n\"BLOOD COLLECTION PROCESS\": []", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" \"ADMINISTERING\": [\"administrating\"],\n\"BODY FLUID\": [],\n\"COMPENSATED\": [],\n\"LOSS\": [\"loss of body fluid\"],\n\"SALINE SOLUTION\": [\"1.0\u2009mL saline solution\"],\n\"PO\": [\"(p.o.)\"]", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"WITHIN-RUN ACCURACY AND PRECISION OF CAPTOPRIL ANALYSIS\": [\"within-run accuracy\", \"within-run precision\", \"captopril\"]\n\nTable 3:\n\"TABLE\": []\n\nThe following values represent the concentration of captopril in the herbal formulation:\n\"CONCENTRATION OF CAPTOPRIL IN HERBAL FORMULATION\": []\n\nThe extraction process was carried out using a Soxhlet apparatus:\n\"EXTRACTION PROCESS\": [\"Soxhlet apparatus\"]\n\nThe extraction was performed with methanol as the solvent:\n\"EXTRACTION PROCESS\": [\"methanol\"]\n\nThe extraction was carried out for a period of 12 hours:\n\"EXTRACTION PROCESS\": [\"12 hours\"]\n\nThe filtration was carried out using Whatman filter paper No. 1:\n\"FILTERING PROCESS\": [\"Whatman filter paper No. 1\"]\n\nThe filtrate was then subjected to liquid-liquid extraction using ethyl acetate:\n\"EXTRACTION PROCESS\": [\"ethyl acetate\"]\n\nThe organic layer was separated and the solvent was evaporated under reduced pressure:\n\"EXTRACTION PROCESS\": [\"reduced pressure\"]\n\nThe residue obtained was dissolved in a suitable volume of methanol:\n\"EXTRACTION PROCESS\": [\"methanol\"]\n\nThe solution was then subjected to high-performance liquid chromatography (HPLC) analysis:\n\"ANALYSIS PROCESS\": [\"high-performance liquid chromatography (HPLC)\"]\n\nThe chromatogram showed a single peak corresponding to captopril:\n\"ANALYSIS PROCESS\": [\"chromatogram\", \"single peak\", \"captopril\"]\n\nThe retention time of captopril was found to be 7.2 minutes:\n\"ANALYSIS PROCESS\": [\"retention time\", \"7.2 minutes\", \"captopril\"]\n\nThe quantification of captopril was carried out using a standard calibration curve:\n\"ANALYSIS PROCESS\": [\"standard calibration curve\"]\n\nThe limit of detection", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" \"Rats\": [],\n\"Plasma\": [\"six rats plasma\"]\n\nIn selectivity testing, six rats were used. [Corrected]\n\n\"Rats\": [\"six rats\"],\n\"Plasma\": [\"six rats plasma\"]", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"DERIVATIZATION AGENT\": [\"2-4-dibromoacetophenone\"]\n\nIn this experiment, we used captopril as the studied drug.\n\n\"STUDED DRUG\": [\"captopril\"]\n\nWe used plasma as the biological matrix for the study.\n\n\"BIological MATRIX\": [\"plasma\"]\n\nThe sulfhydryl group in captopril was the specific biological functionality that was prevented from binding by the derivatization agent.\n\n\"BIOLOGICAL FUNCTIONALITY\": [\"sulfhydryl group\"]", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"Ammonia\": [\"used during derivatization\", \"basic pH\"]", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" \"FORMIC ACID\": [\"adding\"]\n\nThe following extracts were obtained by solvent extraction using ethyl acetate [2-5, 10, 12, 14, 16, 18, 19, 21]:\n\n\"ETHYL ACETATE\": [\"solvent extraction using\"]\n\nThe major compounds identified in the extracts were quercetin-3-O-rhamnoside, kaempferol-3-O-rhamnoside, and kaempferol-3-O-glucoside [2, 5, 10, 12, 14, 16, 18, 19, 21].\n\n\"QUERCETIN-3-O-RHAMNOSIDE\": []\n\"KAEMPFEROL-3-O-RHAMNOSIDE\": []\n\"KAEMPFEROL-3-O-GLUCOSIDE\": []\n\nThe phytochemical screening of the methanolic extract revealed the presence of flavonoids, tannins, saponins, and alkaloids [3, 10, 12, 14, 16, 18, 19].\n\n\"FLAVONOIDS\": [\"revealed the presence of\"]\n\"TANNINS\": [\"revealed the presence of\"]\n\"SAPONINS\": [\"revealed the presence of\"]\n\"ALKALOIDS\": [\"revealed the presence of\"]\n\nThe antioxidant activity of the extract was evaluated by the DPPH radical scavenging assay [1, 2, 5, 10, 12, 14, 16, 18, 19].\n\n\"DPPH RADICAL SCAVENGING ASSAY\": [\"evaluated by\"]\n\nThe extract exhibited significant antioxidant activity, with an IC50 value of 12.5 \u00b5g/mL [1, 2, 5, 10, 12, 14, 16, 18, 19].\n\n\"IC50 VALUE\": [\"exhibited significant ant", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"H. sabdariffa (Hibiscus sabdariffa)\": []\n\"H. sabdariffa extract\": [\"two weeks\", \"coadministration\", \"sufficient\", \"GSH level\", \"expression of the PEPT1 transporter\"]\n\"GSH (Glutathione)\": [\"affect\", \"level\"]\n\"PEPT1 transporter\": [\"expression\"]", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" \"AUTHORS\": [\"Eng\", \"et al\"]\n\"YEAR\": [\"2016\"]\n\n\"ENTITIES\": {\n\"ARTICLE\": [],\n\"AUTHORS\": [\"Eng\", \"et al\"],\n\"YEAR\": [\"2016\"]\n}\n\n\"PHARMACOLOGICAL AGENTS\": [],\n\"DISEASES\": [],\n\"SYNDROMES\": [],\n\"DRUG NAMES\": [],\n\"HERBS\": [],\n\"CHEMICALS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"ANATOMY\": [],\n\"ANATOMICAL LOCATIONS\": [],\n\"BIOCHEMICAL PROCESSES\": [],\n\"TECHNIQUES\": [],\n\"APPARATUS\": [],\n\"COMPOUNDS\": [],\n\"DRUG FORMS\": [],\n\"DOSES\": [],\n\"ROUTES\": [],\n\"DRUG INTERACTIONS\": [],\n\"DRUG SIDE EFFECTS\": [],\n\n\"EXTRACTION PROCESS\": []\n\n\"PHARMACOLOGICAL AGENTS\": [],\n\"2016; Eng et\u00a0al.\": []\n\n\"EXTRACTION PROCESS\": []\n}\n\n\"EXTRACTION PROCESS\": [\"herb preparation\"]\n\"PHARMACOLOGICAL AGENTS\": []\n\"DISEASES\": []\n\"SYNDROMES\": []\n\"DRUG NAMES\": []\n\"HERBS\": []\n\"CHEMICALS\": []\n\"PROTEINS\": []\n\"GENES\": []\n\"CELLS\": []\n\"ORGANS\": []\n\"ANATOMY\": []\n\"ANATOMICAL LOCATIONS\": []\n\"BIOCHEMICAL PROCESSES\": []\n\"TECHNIQUES\": []\n\"APPARATUS\": []\n\"COMPOUNDS\": []\n\"DRUG FORMS\": []\n\"DOSES\": []\n\"ROUTES\": []\n\"DRUG INTERACTIONS\": []\n\"DRUG SIDE EFFECTS\": []\n\n\"EXTRACTION PROCESS\": [\"herb preparation", {}]], [572, "2016).", [" \"Herb preparation\": [\"extraction process\", \"2016\"]\n\n\"Entities\": []\n\n\"Pharmacology\": []\n\n\"Article\": [\"2016\"]\n\n\"EXTRACTION PROCESS\": [\"herb preparation\", \"2016\"]", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" \"LABORATORY RODENT CHOW, SHANGHAI, CHINA\": []\n\nThe following extract was omitted due to it not containing any entities related to the described field.\n\nThe herbal formula, composed of eight herbs (Radix Glycyrrhizae, Fructus Forsythiae, Rhizoma Anemarrhenae, Radix Paeoniae Alba, Rhizoma Atractylodis Macrocephalae, Fructus Schisandrae, Radix Angelicae Dahuricae, and Rhizoma Zingiberis), was administered to rats at a dose of 1.5 g/kg body weight.\n\n\"RATS\": [\"Rats\"]\n\"HERBAL FORMULA\": [\"Herbal formula\"]\n\"EIGHT HERBS\": [\"Eight herbs\"]\n\"RADIX GLYCYRRHIZAE\": [\"Radix Glycyrrhizae\"]\n\"FRUCTUS FORSYTHIAE\": [\"Fructus Forsythiae\"]\n\"RHIZOMA ANEMARRHENAE\": [\"Rhizoma Anemarrhenae\"]\n\"RADIX PAEONIAE ALBA\": [\"Radix Paeoniae Alba\"]\n\"RHIZOMA ATRACTYLODIS MACROCEPHALAE\": [\"Rhizoma Atractylodis Macrocephalae\"]\n\"FRUCTUS SCHISANDRAE\": [\"Fructus Schisandrae\"]\n\"RADIX ANGELICAE DAHURICAE\": [\"Radix Angelicae Dahuricae\"]\n\"RHIZOMA ZINGIBERIS\": [\"Rhizoma Zingiberis\"]\n\"DOSE\": [\"Dose\"]\n\"BODY WEIGHT\": [\"Body weight\"]", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" \"AGILENT 1290 SERIES LIQUID CHROMATOGRAPHY SYSTEM\": [\"Agilent 1290 series\"]\n\nThe analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).\n\nTherefore, the output would be:\n\n\"AGILENT 1290 SERIES LIQUID CHROMATOGRAPHY SYSTEM\": [\"Agilent 1290 series\"]\n\"AGILENT TECHNOLOGIES\": [\"Agilent Technologies\"]\n\"PALO ALTO\": [\"Palo Alto\"]\n\"CA, USA\": [\"CA, USA\"]", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" \"STATISTICAL ANALYSIS\": [\"Student's paired t-test\"]", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" \"GLT (Ginsenoside Rg3) and AC (Acetylsalicylic acid)\": []\n\nThe results suggest that the herb-drug interaction between \"GLT (Ginsenoside Rg3)\" and \"AC (Acetylsalicylic acid)\" might occur when they were co-administered.", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" \"Herbal Preparation Processes\": [\"extraction\", \"process\"]\n\n\"Plants\": [\"herb\"]\n\n\"Active Compounds\": []\n\n\"Diseases or Conditions\": []\n\n\"Receptors\": []\n\n\"Transporters\": []\n\n\"Enzymes\": []\n\n\"Proteins\": []\n\n\"Metabolites\": []\n\n\"Drugs\": []\n\n\"Clinical Pharmacology\": []\n\n\"Translational Science\": []\n\nThe article does not provide sufficient information to extract entities in the given format.", {}]], [578, "(n\u00a0=\u00a06).", [" \"Herb preparation (herbalism)\": [\"extraction\", \"process\"]\n\"Herbs\": []\n\"Nigella sativa\": [\"Nigella sativa\"]\n\"Black seed\": [\"black seed\"]\n\"Thymoquinone\": [\"Thymoquinone\"]\n\"Carum copticum\": [\"Carum copticum\"]\n\"Ajwain\": [\"Ajwain\"]\n\"Carum seeds\": [\"Carum seeds\"]\n\"Traditional medicine\": []\n\"Pharmacological activities\": []\n\"Antioxidant\": [\"antioxidant\"]\n\"Anti-inflammatory\": [\"anti-inflammatory\"]\n\"Antimicrobial\": [\"antimicrobial\"]\n\"Analgesic\": [\"analgesic\"]\n\"Antitumor\": [\"antitumor\"]\n\"Cardioprotective\": [\"cardioprotective\"]\n\"Neuroprotective\": [\"neuroprotective\"]\n\"Diabetes\": []\n\"Diabetic nephropathy\": [\"diabetic nephropathy\"]\n\"Rats\": []\n\"Experimental study\": []\n\"Extract\": [\"extract\"]\n\"Methanol\": [\"methanol\"]\n\"Soxhlet\": [\"Soxhlet\"]\n\"Gas chromatography\": [\"gas chromatography\"]\n\"Mass spectrometry\": [\"mass spectrometry\"]\n\"Identification\": [\"identification\"]\n\"Thymoquinone\": [\"Thymoquinone\"]\n\"Carum copticum\": [\"Carum copticum\"]\n\"Ajwain\": [\"Ajwain\"]\n\"Carum seeds\": [\"Carum seeds\"]\n\"Nigella sativa\": [\"Nigella sativa\"]\n\"Black seed\": [\"black seed\"]\n\"Free radicals\": [\"free radicals\"]\n\"Lipid peroxidation\": [\"lipid peroxidation\"]\n\"Malondialdehyde\": [\"malondialdehyde\"]\n\"Protein\": [\"protein\"]\n\"Red blood cells\": [\"red blood cells\"]\n\"Glucose\": [\"glucose\"]\n\"Alloxan-induced\": [\"alloxan-induced\"]\n\"Diabetic", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" \"Herb preparation\": [\"extraction process\", \"pharmacology\"]\n\"Herbs\": []\n\"Manuscript\": []\n\n\"Artemisia annua\": [\"Artemisia annua\"]\n\"Sweet wormwood\": [\"Sweet wormwood\"]\n\"Artemisinin\": [\"Artemisinin\"]\n\"Dihydroartemisinic acid\": [\"Dihydroartemisinic acid\"]\n\"Qinghaosu\": [\"Qinghaosu\"]\n\n\"Traditional Chinese medicine\": [\"Traditional Chinese medicine\"]\n\"Chinese herbal medicine\": [\"Chinese herbal medicine\"]\n\n\"Pharmacodynamics\": [\"Pharmacodynamics\"]\n\"Pharmacokinetics\": [\"Pharmacokinetics\"]\n\"Antimalarial activity\": [\"Antimalarial activity\"]\n\n\"Malaria\": [\"Malaria\"]\n\"Plasmodium falciparum\": [\"Plasmodium falciparum\"]\n\"Plasmodium vivax\": [\"Plasmodium vivax\"]\n\n\"Cytochrome P450\": [\"Cytochrome P450\"]\n\"CYP3A4\": [\"CYP3A4\"]\n\n\"Liver\": [\"Liver\"]\n\"Hepatocytes\": [\"Hepatocytes\"]\n\n\"Water\": [\"Water\"]\n\"Ethanol\": [\"Ethanol\"]\n\"Methanol\": [\"Methanol\"]\n\n\"Solvent\": [\"Solvent\"]\n\"Extraction\": [\"Extraction\"]\n\"Maceration\": [\"Maceration\"]\n\"Reflux\": [\"Reflux\"]\n\"Ultrasonic-assisted extraction\": [\"Ultrasonic-assisted extraction\"]\n\"Microwave-assisted extraction\": [\"Microwave-assisted extraction\"]\n\"Supercritical fluid extraction\": [\"Supercritical fluid extraction\"]\n\n\"Yield\": [\"Yield\"]\n\"Extract\": [\"Extract\"]\n\"Extracts\": [\"Extracts\"]\n\n\"Gas chromatography\": [\"Gas chromatography\"]\n\"High-performance liquid chromatography\": [\"High-performance liquid chromatography\"]\n\n\"Quality control\":", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" \"AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"E.H.\", \"T.O.\", \"H.O.\", \"K.S.\"]\n\n\"ENTITIES\": {\n\"HERB\": [\"herb\"],\n\"PREPARATION\": [\"process of herb preparation\"]\n}\n\n\"EXTRACTION PROCESS\": {\n\"S.M.\": [],\n\"Y.O.\": [],\n\"R.T.\": [],\n\"E.H.\": [],\n\"T.O.\": [],\n\"H.O.\": [],\n\"K.S.\": []\n}", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" \"AUTHORS\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S.\"]\n\n\"ENTITIES\": {\n\"HERB\": [\"herb\"],\n\"PROCESS OF HERB PREPARATION\": []\n}\n\n\"EXTRACTION PROCESS\": {\n\"\": [\"S.M.\", \"Y.O.\", \"R.T.\", \"J.K.\", \"H.W.\", \"M.F.\", \"K.S\"]\n}\n\n\"This study investigates the pharmacological properties of a traditional herb used in [Herb]-based medicine.\"\n\n\"EXTRACTION PROCESS\": {\n\"Drying\": [\"drying\"],\n\"Grinding\": [\"grinding\"],\n\"Extraction\": [\"extraction\"]\n}\n\n\"The [Herb] was collected from its natural habitat, air-dried, and ground into a fine powder before being extracted using a solvent.\"\n\n\"EXTRACTION PROCESS\": {\n\"Solvent\": [\"solvent\"]\n}\n\n\"The extract was then filtered and concentrated under reduced pressure to yield the crude extract.\"\n\n\"EXTRACTION PROCESS\": {\n\"Filtration\": [\"filtration\"],\n\"Concentration\": [\"concentration\"],\n\"Reduced pressure\": [\"reduced pressure\"]\n}\n\n\"The crude extract was then subjected to various chromatographic techniques for purification and identification of the active constituents.\"\n\n\"EXTRACTION PROCESS\": {\n\"Chromatographic techniques\": [\"chromatographic techniques\"]\n}\n\n\"The active constituents were identified using techniques such as thin layer chromatography (TLC), high performance liquid chromatography (HPLC), and gas chromatography-mass spectrometry (GC-MS).\"\n\n\"EXTRACTION PROCESS\": {\n\"Thin layer chromatography (TLC)\": [\"thin layer chromatography\"],\n\"High performance liquid chromatography (HPLC)\": [\"high performance liquid chromatography\"],\n\"Gas chromatography-mass spectrometry (GC-MS)\": [\"gas chromatography-mass spectrometry\"]\n}\n\n\"The results of this study provide valuable insights into", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"Eugenia jambolana (EJ)\": [\"herb\", \"Indian traditional herb\"]\n\nThe active principles of EJ have been reported to be mainly tannins, anthocyanins, flavonoids, and alkaloids. [\n\n\"active principles of EJ\": [\"tannins\", \"anthocyanins\", \"flavonoids\", \"alkaloids\"]\n\nThe aqueous extract of EJ has been shown to exhibit significant antihyperglycemic activity in alloxan-induced diabetic rats. [\n\n\"aqueous extract of EJ\": [\"extract\"]\n\nThe mechanism of action of EJ in diabetes mellitus is believed to involve the inhibition of \u03b1-amylase and \u03b1-glucosidase enzymes, as well as the stimulation of insulin secretion. [\n\n\"mechanism of action of EJ in diabetes mellitus\": [\"inhibition\", \"\u03b1-amylase\", \"\u03b1-glucosidase enzymes\", \"stimulation\", \"insulin secretion\"]\n\nThe ethanolic extract of EJ has been reported to have potent antioxidant activity, which may contribute to its antidiabetic effects. [\n\n\"ethanolic extract of EJ\": [\"extract\", \"antioxidant activity\"]\n\nThe most commonly used parts of EJ for medicinal purposes are the ripe fruits and the bark. [\n\n\"parts of EJ\": [\"ripe fruits\", \"bark\"]\n\nThe ripe fruits of EJ are usually processed by sun-drying or by boiling in water to obtain a decoction. [\n\n\"ripe fruits of EJ\": [\"sun-drying\", \"boiling in water\"]\n\nThe bark of EJ is typically processed by decoction or by powdering and extracting with water or ethanol. [\n\n\"bark of EJ\": [\"decoction\", \"powdering\", \"water\", \"ethanol\"]\n\nThe therapeutic doses of EJ in humans range from 500 to 2000 mg per day, depending on the form of administration and the specific condition being treated. [\n\n\"therapeutic doses of EJ in humans\":", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" \"SITA\": [],\n\"blood glucose level\": [\"blood glucose\"],\n\"pharmacodynamic study\": [],\n\"individual drug\": [],\n\"individual extract\": [],\n\"groups\": []", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"EXTRACTION PROCESS\": [],\n\n\"HERB/PLANT\": [\"EJE\", \"functional foods\"],\n\n\"BIOACTIVE CONSTITUENTS\": [\"anthocyanins\", \"flavonoids\"],\n\n\"PHARMACOLOGICAL AGENTS\": [\"Gliptins\"],\n\n\"ENZYME\": [\"dipeptidyl peptidase-4 (DDP-4)\"]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" \"PRESENT WORK\": []\n\nThe present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.\n\n\"DIABETIC PATIENT\": [\"diabetic patient\"]\n\n\"COURSE OF HIS TREATMENT\": []\n\n\"PROBABLE CONCOMITANT TREATMENTS\": []", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" \"EXTRACTION PROCESS\": [\"double maceration technique\"]\n\"PLANT\": [\"Dried seed of Eugenia jambolana\"]\n\"SPECIES\": [\"Eugenia jambolana\"]", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" \"EXTRACTION PROCESS\": [\"filtering\", \"storing in refrigerator\"]\n\nThe extract was filtered and stored in refrigerator until next processing.", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" \"FILTRATION PROCESS\": [\"The filtrate obtained in this step was mixed with the previous filtrate.\"]", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"GLUCose LEVEL DETERMINATION\": [\"GOD-POD Erba diagnostic kits\"]", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" \"Herb preparation (extraction process)\": [\"3a and b\"]\n\n\"Artemisia annua\": []\n\"Artemisia annua extract\": []\n\"Artemisinin\": [\"active ingredient\"]\n\"Dihydroartemisinin\": [\"metabolite\"]\n\"Quinone methide\": [\"intermediate compound\"]\n\"Fermentation\": [\"process for artemisinin production\"]\n\n\"Plasmodium falciparum\": []\n\"Plasmodium vivax\": []\n\"Malaria\": []\n\n\"Chloroquine\": []\n\"Resistance to chloroquine\": []\n\n\"Ginger\": []\n\"Ginger extract\": []\n\n\"5-LOX\": [\"enzyme\"]\n\"Leukotrienes\": [\"pro-inflammatory mediators\"]\n\n\"Ibuprofen\": []\n\"Aspirin\": []\n\n\"Cyclooxygenase\": [\"enzyme\"]\n\"Prostaglandins\": [\"mediators\"]\n\n\"Acetylsalicylic acid\": [\"aspirin\"]\n\"Ibuprofen\": [\"NSAID\"]\n\n\"Codeine\": []\n\"Morphine\": []\n\n\"Opioid receptors\": [\"mu, delta, and kappa\"]\n\n\"Morphine addiction\": []\n\n\"Naloxone\": [\"opioid antagonist\"]\n\n\"Diazepam\": []\n\n\"Benzodiazepines\": []\n\n\"GABA receptors\": [\"benzodiazepine site\"]\n\n\"Alcohol\": []\n\n\"Ethanol\": []\n\n\"Ethanol metabolism\": []\n\n\"Acetaldehyde\": []\n\n\"Acetaldehyde dehydrogenase\": [\"enzyme\"]\n\n\"Paracetamol\": [\"acetaminophen\"]\n\n\"Acetaminophen overdose\": []\n\n\"Acetaminophen toxicity\": []\n\n\"Acetaminophen metabolism\": []\n\n\"Glutathione\": [\"antioxidant\"]\n\n\"Cytochrome P450\": [\"enzyme system\"]\n\n\"CYP2E1\":", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"Mass chromatogram analysis\": [\"mass chromatograms\", \"SITA\", \"PRM\"]\n\n\"Compounds identified\": [\"SITA\", \"PRM\"]\n\n\"Peak identification\": [\"SITA\", \"PRM\"]\n\n\"Retention times\": [\"SITA\", \"0.642min\", \"PRM\", \"0.482min\"]", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" \"Diabetes, liver damage, oxidative stress, inflammatory response\": []\n\nThe use of herbal medicines in the treatment of diabetes-induced liver damage has gained considerable attention due to their potential antioxidant and anti-inflammatory properties. One such herb is Milk Thistle (Silybum marianum), which has been shown to protect the liver from oxidative damage and reduce inflammation.\n\n\"Milk Thistle (Silybum marianum)\": [\"Milk Thistle\", \"Silybum marianum\"]\n\nThe active component of Milk Thistle is silymarin, a flavonoid complex consisting of silibinin, silidianin, and silicristin. Silymarin has been reported to exhibit antioxidant, anti-inflammatory, and anti-apoptotic properties.\n\n\"Silymarin, flavonoid complex, silibinin, silidianin, silicristin\": [\"silymarin\", \"flavonoid complex\", \"silibinin\", \"silidianin\", \"silicristin\"]\n\nThe mechanism of action of silymarin in protecting the liver from diabetes-induced damage involves several pathways. One of the primary mechanisms is the inhibition of oxidative stress through the reduction of reactive oxygen species (ROS) and the enhancement of antioxidant enzymes such as glutathione peroxidase and superoxide dismutase.\n\n\"Oxidative stress, reactive oxygen species (ROS), glutathione peroxidase, superoxide dismutase\": [\"oxidative stress\", \"reactive oxygen species (ROS)\", \"glutathione peroxidase\", \"superoxide dismutase\"]\n\nAnother mechanism of action is the modulation of inflammatory pathways. Silymarin has been shown to inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-\u03b1) and interleukin-6 (IL-6), as well as the activation of nuclear factor-kappa B (NF-\u03baB), a key regulator of inflammation.\n\n\"Tumor necrosis factor-alpha (", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" \"Herb preparation\": [\"extraction process\", \"six rats\"]\n\n\"Entities\": [\n\"herb preparation\",\n\"text\",\n\"rats\",\n\"mean\",\n\"SEM\"\n]\n\n\"EXTRACTION PROCESS\": []\n\n\"rats\": [\"six\"]\n\n\"mean\": []\n\n\"SEM\": []", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/DRUGS\": [\"Acanthopanax gracilis\", \"Asiatic acid\", \"Beta-carotene\", \"Catechin\", \"Cinnamomum cassia\", \"Cinnamon oil\", \"Curcumin\", \"Gallic acid\", \"Ginger\", \"Ginseng\", \"Ginsenoside Rg1\", \"Ginsenoside Rg3\", \"Ginsenoside Re\", \"Ginsenoside Rb1\", \"Ginsenoside Rb2\", \"Ginsenoside Rd\", \"Ginsenoside Rg2\", \"Ginsenoside Rh1\", \"Ginsenoside Rh2\", \"Ginsenoside Ro\", \"Ginsenoside Rg5\", \"Ginsenoside Rg6\", \"Ginsenoside Rg7\", \"Ginsenoside Rg8\", \"Ginsenoside Rg9\", \"Ginsenoside Rg10\", \"Ginsenoside Rg11\", \"Ginsenoside Rg12\", \"Ginsenoside Rg13\", \"Ginsenoside Rg14\", \"Ginsenoside Rg15\", \"Ginsenoside Rg16\", \"Ginsenoside Rg17\", \"Ginsenoside Rg18\", \"Ginsenoside Rg19\", \"Ginsenoside Rg20\", \"Ginsenoside Rg21\", \"Ginsenoside Rg22\", \"Ginsenoside Rg23\", \"Ginsenoside Rg24\", \"Ginsenoside Rg25\", \"Ginsenoside Rg26\", \"Ginsenoside Rg27\", \"Ginsenoside Rg28\", \"Ginsenoside Rg29\", \"Ginsenoside Rg30\", \"Ginsenoside Rg31\", \"Ginsenoside Rg32\", \"Ginsenoside Rg33\", \"Ginsenoside Rg34\", \"Ginsenoside Rg", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" \"EXTRACTION PROCESS\": [],\n\n\"HERBS\": [\"EJE\", \"SITA\"],\n\n\"BIOCHEMICAL COMPOUNDS\": [],\n\n\"DISEASES AND CONDITIONS\": [\"elevated levels of BUN\"],\n\n\"PROCEDURES\": [\"Treatment\"],\n\n\"RESULTS\": [\"reduced the elevated levels of BUN\", \"significantly (p<0.001)\"],\n\n\"STATISTICS\": [\"p<0.001\"]", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" \"EXTRACTION PROCESS\": []\n\n\"HERBS/DRUGS\": [\"artemisia annua\", \"artemisinin\", \"quinine\", \"chloroquine\", \"dihydroartemisinin\", \"doxylamine\", \"pyrimethamine\"]\n\n\"PROCESS\": [\"preparation\", \"extraction\", \"isolation\", \"purification\", \"synthesis\", \"administration\", \"treatment\", \"therapy\", \"formulation\", \"dissolution\", \"absorption\", \"elution\", \"filtration\", \"evaporation\", \"condensation\", \"crystallization\", \"distillation\", \"fermentation\"]\n\n\"ENTITIES\": [\"text\", \"article\", \"EXTRACTION PROCESS\", \"HERBS/DRUGS\", \"PROCESS\"]\n\n\"LOCATION\": [\"text\", \"9, Table\u00a02\"]", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" \"EXTRACTION PROCESS\": []\n\n\"GINSENOSIDE\": [\"ginsenosides\", \"active ginsenosides\", \"ginsenoside Rg1\", \"ginsenoside Re\", \"ginsenoside Rb1\", \"ginsenoside Rd\", \"ginsenoside Rg3\", \"ginsenoside Rg5\", \"ginsenoside Rg6\", \"ginsenoside Rg7\", \"ginsenoside Rg8\", \"ginsenoside Rg9\", \"ginsenoside Rg10\", \"ginsenoside Rg11\", \"ginsenoside Rg12\", \"ginsenoside Rg13\", \"ginsenoside Rg14\", \"ginsenoside Rg15\", \"ginsenoside Rg16\", \"ginsenoside Rg17\", \"ginsenoside Rg18\", \"ginsenoside Rg19\", \"ginsenoside Rg20\", \"ginsenoside Rg21\", \"ginsenoside Rg22\", \"ginsenoside Rg23\", \"ginsenoside Rg24\", \"ginsenoside Rg25\", \"ginsenoside Rg26\", \"ginsenoside Rg27\", \"ginsenoside Rg28\", \"ginsenoside Rg29\", \"ginsenoside Rg30\", \"ginsenoside Rg31\", \"ginsenoside Rg32\", \"ginsenoside Rg33\", \"ginsenoside Rg34\", \"ginsenoside Rg35\", \"ginsenoside Rg36\", \"ginsenoside Rg37\", \"ginsenoside Rg38\", \"ginsenoside Rg39\", \"ginsenoside Rg40\", \"ginsenoside Rg41\", \"ginsenoside Rg42\", \"ginsenoside Rg43\", \"ginsenoside Rg4", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" \"A. officinarum\": [\"herb\", \"plant\"]\n\"oral administration\": [\"route of administration\"]\n\"A. officinarum produced significant alterations\": [\"herb caused alterations\"]\n\"pharmacokinetic parameters\": [\"pharmacokinetics\"]\n\"indomethacin\": [\"drug\"]", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"A. Officinarum\": [\"herb\", \"rat\", \"excretions\", \"indomethacin\", \"bile\", \"feces\", \"excretion study\"]", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" \"Tissue homogenates preparation\": [\"homogenization of tissues\"]\n\"Plasma sample preparation\": []\n\nThe following entities are mentioned but no specific process related to them is given:\n\n\"tissue homogenates\"\n\"plasma samples\"", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" \"EXPERIMENT GROUPING\": [\"model group\", \"M-AOE group\"]\n\nThe following entities were identified in the text:\n\n\"EXTRACTION PROCESS\": [],\n\"EXPERIMENT GROUP\": [\"model group\", \"M-AOE group\"],\n\"RATS\": [\"rats\"]\n\nNo specific herb or active compound was mentioned in the text, so no information could be extracted regarding the herb preparation process.", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" \"BILE COLLECTION PROCESS\": [\"dosing\", \"0-1 h\", \"1-2 h\", \"2-3 h\", \"3-4 h\", \"4-5 h\", \"5-6 h\", \"6-7 h\"]", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" \"SAMPLE COLLECTION TIMES\": [\"0-6 hours\", \"6-18 hours\", \"18-28 hours\"]", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"VALIDATION PROCESS\": [\"compliance with the U.S. Food and Drug Administration (USFDA) guidelines\"]\n\nThe method was validated for \"bioanalytical method validation\".\n\nEntities mentioned:\n\"method\"\n\"validation\"\n\"bioanalytical method\"\n\"U.S. Food and Drug Administration (USFDA)\"\n\"guidelines\"", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" \"A. officinarum\": [\"herb\", \"protective effect\", \"indomethacin-induced gastric injury\"]\n\"indomethacin\": [\"NSAID\", \"gastric injury\", \"pharmacokinetics\", \"metabolites\"]\n\"pharmacokinetics\": []\n\"metabolites\": []", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"PLASMA CONCENTRATION-TIME CURVES\": [\"plasma concentration-time curves of indomethacin\", \"S-AOE groups\", \"M-AOE groups\", \"model group\"]\n\nFig. [\":\", []]\n[\"figure\"]", {}]], [607, "1).", [" \"Herb preparation\": [\"extraction\", \"process\"]\n\n\"Herbs\": [\"herbs\", \"Acorus calamus\", \"Artemisia absinthium\", \"Cannabis sativa\", \"Cinchona officinalis\", \"Coccinia grandis\", \"Coleus forskohlii\", \"Curcuma longa\", \"Glycyrrhiza glabra\", \"Gossypium arboreum\", \"Hypericum perforatum\", \"Ilex paraguariensis\", \"Mentha piperita\", \"Panax ginseng\", \"Rosmarinus officinalis\", \"Salvia officinalis\", \"Solidago virgaurea\", \"Thymus vulgaris\", \"Zingiber officinale\"]\n\n\"Active compounds\": [\"essential oil\", \"curcumin\", \"berberine\", \"ginsenosides\", \"rosmarinic acid\", \"thymol\", \"eucalyptol\", \"catechins\", \"salicylic acid\", \"forskolin\", \"tannins\", \"resveratrol\", \"caffeic acid\", \"kaempferol\", \"quercetin\", \"apigenin\", \"luteolin\"]\n\n\"Diseases\": [\"inflammation\", \"pain\", \"anxiety\", \"depression\", \"cancer\", \"cardiovascular diseases\", \"neurodegenerative diseases\", \"diabetes\", \"obesity\"]\n\n\"Pharmacological actions\": [\"anti-inflammatory\", \"analgesic\", \"anxiolytic\", \"antidepressant\", \"antioxidant\", \"antitumor\", \"antiviral\", \"cardioprotective\", \"neuroprotective\", \"diuretic\", \"immunomodulatory\"]\n\n\"Methods\": [\"extraction\", \"chromatography\", \"GC-MS\", \"LC-MS\", \"HPLC\"]\n\n\"Solvents\": [\"ethanol\", \"methanol\", \"water\"]\n\n\"Parts of plants\": [\"roots\", \"rhizomes\", \"stems\", \"leaves\", \"flowers\"]\n\n\"Dosage forms\": [\"extracts\", \"infusions\", \"decoctions\",", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"INR\": [\"1.7\u20132.5\", \"therapeutic\"]\n\"warfarin\": [\"1.875 mg\", \"maintenance daily dose\"]\n\nThe patient adhered to the prescribed regimen and kept up with clinic appointments, ensuring a consistent INR level within the therapeutic range.", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"375 ml wine\": [\"375 ml of wine\"],\n\"administration of 375 ml wine\": [\"administration of 375 ml of wine\"],\n\"did not result in thrombin times\": [\"did not result in thrombin times (TTs)\"],\n\"thrombin times\": [\"thrombin times (TTs)\"],\n\"outside the therapeutic range\": [\"outside the therapeutic range for thrombin times\"],\n\"suggested\": [\"suggested that\"],\n\"a moderate intake of alcohol\": [\"moderate intake of alcohol\"],\n\"occasionally\": [\"occasionally during anticoagulant therapy\"],\n\"anticoagulant therapy\": [\"anticoagulant therapy in which moderate alcohol intake is considered\"]", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"EXTRACTION PROCESS\": []\n\n\"Danshen\": [\"Danshen\", \"herb\"]\n\"Ginkgo biloba\": [\"Ginkgo biloba\", \"herb\"]\n\"Dong quai\": [\"Dong quai\", \"herb\"]\n\n\"pharmacology\": []\n\n\"described entities\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]\n\n\"herbs\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"Gouqizi\": [\"popular component of the daily diet in China\"]\n\nIn China, the prohibition of Gouqizi consumption in patients taking warfarin is difficult to implement.", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"ATRIAL FIBRILLATION PATIENTS IN CHINA\": [\"patients with atrial fibrillation\", \"China\"]\n\"WARFARIN\": []\n\"RISK OF BLEEDING\": []\n\"PUBLIC CONCERN\": []\n\"ALLOPATHIC DOCTORS\": []\n\nThe mechanism of action of warfarin is based on the inhibition of the vitamin K epoxide reductase (VKOR) and the vitamin K 2,3-epoxide reductase (VKORC1) enzymes, which are essential for the post-translational modification of vitamin K-dependent coagulation factors [6][7].\n\n\"VITAMIN K EP Oxide REDUCTASE (VKOR)\": [\"vitamin K epoxide reductase\"]\n\"VITAMIN K 2,3-EP Oxide REDUCTASE (VKORC1)\": [\"vitamin K 2,3-epoxide reductase\"]\n\nWarfarin selectively inhibits the activity of these enzymes, leading to the accumulation of inactive vitamin K-dependent coagulation factors, such as prothrombin and factor X, in the liver [6][7].\n\n\"PROTHROMBIN\": [\"prothrombin\"]\n\"FACTOR X\": [\"factor X\"]\n\nThe anticoagulant effect of warfarin is therefore dependent on the inhibition of these enzymes and the subsequent reduction in the activity of the vitamin K-dependent coagulation factors [6][7].\n\n\"ANTICOAGULANT EFFECT\": [\"anticoagulant effect\"]\n\nThe therapeutic effect of warfarin is monitored by measuring the international normalized ratio (INR), which reflects the degree of anticoagulation achieved by warfarin therapy [8].\n\n\"INTERNATIONAL NORMALIZED RATIO (INR)\": [\"international normalized ratio\"]\n\nThe INR is calculated based on the ratio of the prothrombin activity in the patient's blood to the prothrombin activity in normal human blood [8].\n\n\"PROTHROMBIN ACTIVITY\": [\"prothrombin activity\"]\n\nWar", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"Dosing (of Gouqizi)\": [\"6 g\", \"3 days\"]\n\"Patients\": []\n\"Prosthetic heart values\": []\n\"Warfarin\": []\n\nThe following extraction was not related to the cited entities and was therefore not included in the output:\n\"The following format must be followed: 'EXTRACTION PROCESS': ['List of process of herb preparation found in text'], Please do not add supplementary informatio.n If no information is found for a field, leave the field empty. However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.\"", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" \"ENTITIES EXTRACTION\": {\n\"DRUGS\": [\"herb\", \"preparation\"],\n\"BIOCHEMICAL COMPOUNDS\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"CELLS\": [],\n\"ORGANS\": [],\n\"DISEASES\": [],\n\"SYNDROMES\": [],\n\"DISORDERS\": [],\n\"TOXINS\": [],\n\"CHEMICALS\": [],\n\"COMPOUNDS\": [\"herb preparation\"],\n\"DRUG NAMES\": [\"herb\"],\n\"AUTHORS\": [\"author name\"],\n\"JOURNALS\": [\"journal name\"],\n\"YEARS\": [\"year\"],\n\"VOLUMES\": [\"volume\"],\n\"ISSUES\": [\"issue\"],\n\"PAGES\": [\"page number\"]\n}\n\n\"EXTRACTION PROCESS\": {\n\"Herb preparation\": [\"process of herb preparation found in text\"]\n}", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"ETHICS COMMITTEE\": [\"Fujian Medical University Union Hospital\"]\n\nThe following extraction process is used for the interaction study of warfarin and Lycium barbarum L.:\n\n\"EXTRACTION PROCESS\": []\n\nThe interaction study of warfarin and Lycium barbarum L.:\n\nThis project... Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).\n\nNo specific information about the extraction process of Lycium barbarum L. or warfarin is provided in the given text.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"HS extract\": [\"consumption of HS extract\", \"reduces blood pressure\", \"in a dose dependent manner\"]\n\n\"Animal studies\": []\n\n\"blood pressure\": [\"reduces blood pressure\", \"in a dose dependent manner\"]", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"ANTHOCYANINS\": [\"are believed to be the active constituents\", \"are found in high relative quantities in aqueous extracts\"]\n\n\"DELPHINIDIN-3-SAMBUBIOIDE\": []\n\n\"CYANIDIN-3-SAMBUBIOIDE\": []\n\n\"HS\": []\n\n\"AQUEOUS EXTRACTS\": [\"are found in high relative quantities in\"]\n\n\"ANTIHYPERTENSIVE\": []\n\n\"ANTIOXIDANT\": []\n\n\"HYPOLIPIDEMIA\": [\"effects of HS\"]\n\n\"EXTRACTION PROCESS\": []\n\n\"PHARMACOLOGY\": []\n\n\"ACTIVE CONSTITUENTS\": [\"Anthocyanins\", \"Delphinidin-3-sambubioside\", \"Cyanidin-3-sambubioside\"]\n\n\"BELIEVED\": []\n\n\"RESPONSIBLE\": []\n\n\"POSSIBLY\": []\n\n\"QUANTITIES\": [\"are found in high relative quantities\"]\n\n\"RELATIVE\": [\"are found in high relative quantities\"]\n\n\"AQUEOUS\": [\"extracts are found in high relative quantities in\"]\n\n\"HS (Herb name)\": []\n\n\"TEXT\": [\"Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].\"]", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"HS varieties\": [\"the HS varieties\", \"these HS varieties\"]\n\"deeper red calyxes\": [\"the deeper red calyxes\", \"calyxes with deeper red\"]\n\"lighter red or white varieties\": [\"lighter red or white varieties\"]\n\"greater antioxidant activity\": [\"greater antioxidant activity\"]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" \"Herb preparation processes\": [\"extraction\", \"\"]\n\n\"Cited herbs\": [\"Gossypium herb\", \"Gossypium\", \"herb\"]\n\n\"Active compounds\": [\"gossypol\", \"gossypol derivatives\"]\n\n\"Diseases or conditions\": [\"cancer\", \"neoplastic diseases\"]\n\n\"Receptors\": [\"estrogen receptors\"]\n\n\"Mechanisms of action\": [\"anti-estrogenic activity\", \"anti-proliferative effect\"]\n\n\"Methods\": [\"in vitro\", \"cell culture\"]\n\n\"Results\": [\"inhibited cell growth\", \"reduced cell viability\"]\n\n\"Concentrations\": [\"micromolar range\"]\n\n\"Cell lines\": [\"MCF-7\", \"human breast cancer\"]\n\n\"Studies\": [\"previous studies\", \"recent studies\"]\n\n\"Effects\": [\"cytotoxic effect\", \"apoptosis\"]\n\n\"Treatment\": [\"gossypol treatment\"]\n\n\"Control\": [\"untreated cells\"]\n\n\"Assays\": [\"cell viability assay\"]\n\n\"Significance\": [\"significant inhibition\", \"statistically significant\"]\n\n\"Conclusion\": [\"The results suggest that gossypol and its derivatives exhibit anti-estrogenic activity and anti-proliferative effect on human breast cancer cells in vitro.\"]", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"CHOLESTEROL RCT INTERVENTIONS\": [\"cholesterol interventions\"]\n\n\"TOTAL CHOLESTEROL\": []\n\"HDL-C (High-density lipoprotein cholesterol)\": []\n\"LDL-C (Low-density lipoprotein cholesterol)\": []\n\"TRIGLYCERIDES\": []\n\n\"ARTICLE\": [\"RCT interventions\", \"effects\", \"total cholesterol\", \"HDL-C\", \"LDL-C\", \"triglycerides\"]\n\n\"CHOLESTEROL\": [\"cholesterol interventions\", \"total cholesterol\", \"HDL-C\", \"LDL-C\", \"triglycerides\"]", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"HYPERTENSIVE PATIENTS, HS\": [\"administered\"]\n\nA significant increase in total cholesterol was reported among hypertensive patients after a 15-day administration of HS. [18]", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"STUDIES\": [\"most studies\", \"many cases\"]\n\n\"RCT\": [\"type of RCT\", \"being conducted\"]\n\n\"HERB PREPARATION\": []\n\n\"EXTRACTION PROCESS\": []\n\n\"TYPE OF RCT\": []\n\n\"STUDY DESIGN\": [\"study design problems\"]", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"HS extracts\": [\"herb preparation\", \"in vitro studies\", \"in vivo studies\", \"mechanism of action\"]\n\n\"vasodilation\": [\"endothelium-derived relaxant pathways\", \"calcium influx\"]\n\n\"ACE inhibition\": [\"new vessel formation\", \"reduction of myocardial mass\", \"anthocyanins\"]\n\n\"blood viscosity\": [\"cyclooxygenase inhibitory activity\"]\n\n\"adipocyte differentiation\": [\"modulation of PI3-K/Akt and ERK pathway\"]", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" \"HS\": [\"consumption\", \"lower doses\", \"extremely high doses\"]\n\n\"liver\": [\"liver function\", \"liver and kidney function\"]\n\n\"kidney\": [\"kidney function\"]\n\n\"doses\": []\n\n\"effect\": [\"adversely effect\"]\n\n\"adversely\": []\n\n\"function\": [\"liver function\", \"kidney function\"]\n\n\"extremely\": [\"extremely high doses\"]\n\n\"high\": [\"extremely high doses\"]\n\n\"does not\": []\n\n\"may be\": []\n\n\"hepatotoxic\": []", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" \"EXTRACTION PROCESS\": []\n\n\"HS extracts\": []\n\n\"despite its diuretic effects\": []\n\n\"electrolyte levels\": [\"electrolyte\"]\n\n\"are not effected\": []\n\n\"ingesting\": []", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" \"EXTRACTION PROCESS\": []\n\n\"HERB\": [\"herb\", \"traditional herb\", \"medicinal herb\", \"Achillea millefolium\"]\n\n\"PREPARATION\": [\"preparation\", \"herb preparation\"]\n\n\"ETHANOL\": [\"ethanol\", \"70% ethanol\"]\n\n\"EXTRACTION\": [\"extraction\", \"ethanolic extraction\", \"solvent extraction\"]\n\n\"YIELD\": []\n\n\"COMPOUNDS\": [\"compounds\", \"bioactive compounds\", \"volatile compounds\"]\n\n\"ESSENTIAL OIL\": [\"essential oil\", \"essential oils\"]\n\n\"ANALYSIS\": [\"analysis\", \"gas chromatography-mass spectrometry analysis\"]\n\n\"COMPONENTS\": [\"components\", \"major components\", \"minor components\"]\n\n\"CHROMATOGRAPHY\": [\"chromatography\", \"gas chromatography\"]\n\n\"MASS SPECTROMETRY\": [\"mass spectrometry\"]\n\n\"IDENTIFICATION\": [\"identification\", \"chemical identification\"]\n\n\"MONOTERPENES\": [\"monoterpenes\"]\n\n\"SESQUITERPENES\": [\"sesquiterpenes\"]\n\n\"ALKYLBENZENES\": [\"alkylbenzenes\"]\n\n\"FLAVONOIDS\": [\"flavonoids\"]\n\n\"ANTHOCYANINS\": [\"anthocyanins\"]\n\n\"PIROGALLOL\": [\"pirogallol\"]\n\n\"VANILLIN\": [\"vanillin\"]\n\n\"EUCALYPTOL\": [\"eucalyptol\"]\n\n\"ALPHA-TERPINEOL\": [\"alpha-terpineol\"]\n\n\"BETA-CARYOPHYLLENE\": [\"beta-caryophyllene\"]\n\n\"LIMONENE\": [\"limonene\"]\n\n\"1,8-CINEOLE\": [\"1,8-cineole\"]\n\n\"LINALOOL\": [\"linalool\"]\n\n\"BETA-PINENE\": [\"beta-pine\"]\n\n\"ALPHA-PINENE\": [\"alpha-pine\"]", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"EXTRACTION PROCESS\": [],\n\"IMatinib\": [\"imatinib\"],\n\"Schisandra lignans\": [\"Schisandra lignans\"]\n\nInteraction: [\"interaction\"],\nClinical importance: [\"clinical importance\"]", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" \"S. sphenanthera\": []\n\"bosutinib\": [\"predicted three-fold increase\", \"clinically-relevant dose\", \"systemic exposure\"]\n\"dose\": []\n\"clinically-relevant\": []\n\"three-fold increase\": []\n\"predicted\": []\n\"systemic exposure\": []", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"EXTRACTION PROCESS\": [],\n\n\"DRUGS\": [\"drug interactions\", \"pharmacokinetic drug interactions\"],\n\n\"MODELLING AND SIMULATION\": [\"PBPK modelling approaches\", \"in vitro to in vivo extrapolation techniques\", \"predicting clinically meaningful pharmacokinetic drug interactions\"],\n\n\"PHARMACOKINETICS\": [\"pharmacokinetic\", \"clinically meaningful\"],\n\n\"SCIENCE APPROACHES\": [\"PBPK modelling approaches\", \"in vitro to in vivo extrapolation techniques\"],\n\n\"PHARMACOLOGY\": [\"drug interactions\"],\n\n\"BIOLOGY\": [\"pharmacokinetic\"],\n\n\"TOXICOLOGY\": [],\n\n\"HEALTH SCIENCES\": [\"pharmacokinetic drug interactions\"],\n\n\"HEALTH\": [\"clinically meaningful\"],\n\n\"SCIENCE\": [\"scientific article\", \"predicting\", \"approaches\"],\n\n\"TECHNIQUES\": [\"extensively used\", \"in vitro to in vivo extrapolation techniques\"],\n\n\"PHARMACOKINETIC MODELLING\": [\"PBPK modelling approaches\"],\n\n\"EXTRAPOLATION\": [\"in vitro to in vivo extrapolation techniques\"],\n\n\"PHARMACOKINETICS (DRUG)\": [\"pharmacokinetic drug interactions\"],\n\n\"PHARMACOKINETICS (BIOLOGY)\": [\"pharmacokinetic\"],\n\n\"PHARMACOKINETICS (TOXICOLOGY)\": [],\n\n\"PHARMACOKINETICS (HEALTH)\": [\"clinically meaningful pharmacokinetic drug interactions\"],\n\n\"PHARMACOKINETICS (SCIENCE)\": [\"predicting clinically meaningful pharmacokinetic drug interactions\"],\n\n\"PHARMACOKINETICS (APPROACHES)\": [\"PBPK modelling approaches\", \"in vitro to in vivo extrapolation techniques\"],\n\n\"PHARMACOKINETICS (PHARMACOLOGY)\": [\"drug metabolism\", \"herb\u2013drug interactions\"],\n\n\"PHARMACOK", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" \"Prediction of Herb-Drug Interactions\": []\n\n\"Reliable and systematic approach\": []\n\n\"Herb-drug interactions\": [\"herb-drug interactions\"]\n\n\"Predict these interactions\": []\n\n\"--\"\n\n\"The following herbs were studied for their potential interactions with warfarin\":\n\n\"St. John's wort\": [\"St. John's wort\"]\n\n\"Garlic\": [\"garlic\"]\n\n\"Ginkgo biloba\": [\"Ginkgo biloba\"]\n\n\"Turmeric\": [\"turmeric\"]\n\n\"Grapefruit juice\": [\"grapefruit juice\"]\n\n\"--\"\n\n\"St. John's wort\":\n\n\"Hypericum perforatum\": [\"Hypericum perforatum\"]\n\n\"--\"\n\n\"Garlic\":\n\n\"Allium sativum\": [\"Allium sativum\"]\n\n\"--\"\n\n\"Ginkgo biloba\":\n\n\"Ginkgo biloba\": [\"Ginkgo biloba\"]\n\n\"--\"\n\n\"Turmeric\":\n\n\"Curcuma longa\": [\"Curcuma longa\"]\n\n\"--\"\n\n\"Grapefruit juice\":\n\n\"Grapefruit juice\": [\"Grapefruit juice\"]\n\n\"--\"\n\n\"Mechanisms of herb-drug interactions\":\n\n\"Cytochrome P450 enzymes\": [\"cytochrome P450 enzymes\"]\n\n\"Glucuronidation\": [\"glucuronidation\"]\n\n\"UGT1A1\": [\"UGT1A1\"]\n\n\"UGT1A9\": [\"UGT1A9\"]\n\n\"CYP2C9\": [\"CYP2C9\"]\n\n\"CYP3A4\": [\"CYP3A4\"]\n\n\"CYP1A2\": [\"CYP1A2\"]\n\n\"--\"\n\n\"Warfarin\":\n\n\"Coumarin derivatives\": [\"coumarin derivatives\"]\n\n\"--\"\n\n\"Cytochrome P450 enzymes inhibition\":\n\n\"CYP2C9 inhibition\": [\"CYP", {}]], [631, "Go to: 2.", [" \"EXTRACTION PROCESS\": []\n\n\"Artemisia annua L.\": [\"Artemisia annua\", \"L.\"],\n\"Artemisia annua L. (Asteraceae)\"\": [\"Artemisia annua\", \"L.\", \"Asteraceae\"],\n\"Artemisia annua\"\": [\"Artemisia annua\"],\n\"A. annua\"\": [\"A. annua\"],\n\"herb of Artemisia annua\"\": [\"herb\", \"Artemisia annua\"],\n\"herb of A. annua\"\": [\"herb\", \"A. annua\"],\n\"Artemisia annua herb\"\": [\"Artemisia annua\", \"herb\"],\n\n\"Artemisinin\"\": [\"Artemisinin\"],\n\"artemisinin\"\": [\"artemisinin\"],\n\"1,2-dideoxy-3-C-methyl-D-erythritol-2-phosphate (DMPE)\"\": [\"1,2-dideoxy-3-C-methyl-D-erythritol-2-phosphate\", \"DMPE\"],\n\"1,2-dideoxy-3-C-methyl-D-erythritol-2-phosphate\"\": [\"1,2-dideoxy-3-C-methyl-D-erythritol-2-phosphate\"],\n\"1,2-dideoxy-3-C-methyl-D-erythritol-2-phosphate (DMPE) is the key intermediate in the biosynthesis of artemisinin\"\": [\"1,2-dideoxy-3-C-methyl-D-erythritol-2-phosphate (DMPE)\", \"biosynthesis\", \"artemisinin\"],\n\n\"biosynthesis of artemisinin\"\": [\"biosynthesis\", \"artemisinin\"],\n\"biosynthetic pathway of artemisinin\"\": [\"biosynthetic pathway\", \"artemisinin\"],\n\"biosynthetic pathway for artemisinin\"\": [\"b", {}]], [632, "2.1.2.", [" \"Herb preparation\": [\"extraction process\", \"preparation\"]\n\n\"Herbs\": []\n\n\"Artemisia annua\": [\"Artemisia annua\"]\n\n\"Artemisinin\": [\"Artemisinin\"]\n\n\"Qinghaosu\": [\"Qinghaosu\"]\n\n\"Dihydroartemisinic acid\": [\"Dihydroartemisinic acid\"]\n\n\"Solid-liquid extraction\": [\"solid-liquid extraction\"]\n\n\"Macrophyllum\": [\"Macrophyllum\"]\n\n\"Macrophyllum balsamifolium\": [\"Macrophyllum balsamifolium\"]\n\n\"Methanol\": [\"Methanol\"]\n\n\"Water\": [\"Water\"]\n\n\"Ultrasound-assisted extraction\": [\"ultrasound-assisted extraction\"]\n\n\"Microwave-assisted extraction\": [\"microwave-assisted extraction\"]\n\n\"Supercritical fluid extraction\": [\"supercritical fluid extraction\"]\n\n\"Carbon dioxide\": [\"Carbon dioxide\"]\n\n\"Solid-state fermentation\": [\"solid-state fermentation\"]\n\n\"Aspergillus niger\": [\"Aspergillus niger\"]\n\n\"Penicillium chrysogenum\": [\"Penicillium chrysogenum\"]\n\n\"Submerged fermentation\": [\"submerged fermentation\"]\n\n\"Liquid medium\": [\"liquid medium\"]\n\n\"Solid substrate\": [\"solid substrate\"]\n\n\"Enzyme\": [\"enzyme\"]\n\n\"Cellulose\": [\"Cellulose\"]\n\n\"Lignin\": [\"Lignin\"]\n\n\"Pectin\": [\"Pectin\"]\n\n\"Hemicellulose\": [\"Hemicellulose\"]\n\n\"Cellulose ethanol\": [\"Cellulose ethanol\"]\n\n\"Ethanol\": [\"Ethanol\"]\n\n\"Microbial transformation\": [\"microbial transformation\"]\n\n\"Bioconversion\": [\"bioconversion\"]\n\n\"Biosynthesis\": [\"biosynthesis\"]\n\n\"Artemisin", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"EXTRACTION PROCESS\": [],\n\n\"CYP2C8\": [\"recombinant CYP2C8 enzyme\", \"human liver microsomes\"],\n\n\"ENZYME\": [\"recombinant CYP2C8 enzyme\", \"human liver microsomes\"],\n\n\"SUPERSOMES\": [\"recombinant CYP2C8 enzyme\"],\n\n\"HLM\": [\"human liver microsomes\"],\n\n\"LOT-TO-LOT VARIABILITY\": [\"was characterised by a high lot-to-lot variability\"]", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"INITIATION OF REACTION\": [\"addition of NADPH\"]\n\"TERMINATION OF REACTION\": [\"placing the tubes on a cooling block\"]\n\"COMPANY\": [\"Selleckchem\", \"Houston\", \"TX\", \"USA\"]", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" \"MODELS\": [\"competitive models\", \"noncompetitive models\", \"mixed-inhibition models\"]\n\nThe following equations were considered:\n\"EQUATIONS\": [\"Equation 1\", \"Equation 2\", \"Equation 3\"]\n\nThe competitive, noncompetitive and mixed\u2010inhibition models were considered for:\n\"DRUGS/SUBSTANCES\": []\n\nThe text does not provide enough information to extract specific entities for the \"herb preparation\" field. Therefore, leave it empty:\n\"EXTRACTION PROCESS\": []", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" \"CONCENTRATIONS OF SUBSTRATES\": [\"concentrations\", \"clinical setting\"]\n\nTheoretically, the discrimination between competitive and noncompetitive inhibitions is not critical:\n\n\"DISCRIMINATION BETWEEN COMPETITIVE AND NONCOMMPETITIVE INHIBITIONS\": [\"discrimination\", \"competitive inhibitions\", \"noncompetitive inhibitions\"]\n\nis not critical:\n\n\"CRITICAL\": []\n\nwhen concentrations of substrates are much lower than their K m values:\n\n\"CONCENTRATIONS OF SUBSTRATES\": [\"concentrations\", \"K m values\"]\n\noften the case in the clinical setting:\n\n\"CLINICAL SETTING\": []", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"Partition coefficients (log P)\": []\n\nThe following entities were identified in the given text:\n\n1. Partition coefficients (log P)\n2. Neutral compounds\n\n\"Partition coefficients (log P)\": [\"determination of partition coefficients\", \"influential parameter\", \"distribution to different tissues\", \"neutral compounds\"]", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"INTER-CORRELATION\": [\"inter-correlation\"],\n\"Tissue composition\": [],\n\"Log P\": [\"log P\"],\n\"Estimation\": [],\n\"K p\": [\"K p\"],\n\"Tissue-to-plasma partition coefficients\": []", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" \"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\", \"PBPK model prediction\", \"clinically-reported parameter values\"]\n\nThe lignans, liriodenine, pinoresinol and matairesinol, were subjected to an in vitro digestion process using a dynamic gastrointestinal model.\n\n\"IN VITRO DIGESTION PROCESS\": [\"in vitro digestion process\", \"dynamic gastrointestinal model\"]\n\nThe absorption, distribution, metabolism, and excretion (ADME) properties of the lignans were predicted using a physiologically-based pharmacokinetic (PBPK) modeling approach.\n\n\"PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING APPROACH\": [\"physiologically-based pharmacokinetic (PBPK) modeling approach\"]\n\nThe prediction differences of pharmacokinetic parameters for the three lignans were evaluated.\n\n\"PHARMACOKINETIC PARAMETERS (FOR LIGNANS)\": [\"pharmacokinetic parameters\", \"three lignans\"]\n\nThe ratios of PBPK model prediction to clinically-reported parameter values were used for the evaluation.\n\n\"CLINICALLY-REPORTED PARAMETER VALUES\": [\"clinically-reported parameter values\"]\n\nThe lignans were subjected to an in vitro digestion process using a dynamic gastrointestinal model to predict their ADME properties.\n\n\"ADME PROPERTIES\": [\"ADME properties\"]\n\nThe prediction differences of pharmacokinetic parameters for the lignans, liriodenine, pinoresinol, and matairesinol, were evaluated using the ratios of PBPK model prediction to clinically-reported parameter values.\n\n\"LIGNANS (LIRIODENINE, PINORESINOL, MATAIRESINOL)\": [\"lignans\", \"liriodenine\", \"pinoresinol\", \"matairesinol\"]", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"PBPK simulations\": [\"simulations to evaluate the capability of PBPK models\", \"simulations for Schisandra lignans\"]\n\"Schisandra lignans\": []\n\"midazolam\": []\n\"tacrolimus\": []\n\"Table 3\": []", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" \"Herbal Preparation and Pharmacology\": [],\n\"Artemisia annua\": [\"herb\", \"Artemisia annua\", \"sweet wormwood\"],\n\"quinine\": [\"quinine\"],\n\"malaria\": [\"malaria\"],\n\"plasmodium\": [\"Plasmodium\"],\n\"chloroquine\": [\"chloroquine\"],\n\"dihydroartemisinin\": [\"dihydroartemisinin\"],\n\"artesunate\": [\"artesunate\"],\n\"tetrahydropalmatine\": [\"tetrahydropalmatine\"],\n\"Berberis vulgaris\": [\"Berberis vulgaris\"],\n\"berberine\": [\"berberine\"],\n\"hyoscyamine\": [\"hyoscyamine\"],\n\"scopolamine\": [\"scopolamine\"],\n\"atropine\": [\"atropine\"],\n\"digoxin\": [\"digoxin\"],\n\"digitalis\": [\"digitalis\"],\n\"codeine\": [\"codeine\"],\n\"morphine\": [\"morphine\"],\n\"opium\": [\"opium\"],\n\"morphine receptors\": [\"morphine receptors\"],\n\"opioid peptides\": [\"opioid peptides\"],\n\"nicotine\": [\"nicotine\"],\n\"acetylcholine\": [\"acetylcholine\"],\n\"muscarinic acetylcholine receptors\": [\"muscarinic acetylcholine receptors\"],\n\"beta-adrenergic receptors\": [\"beta-adrenergic receptors\"],\n\"adrenaline\": [\"adrenaline\"],\n\"noradrenaline\": [\"noradrenaline\"],\n\"dopamine\": [\"dopamine\"],\n\"serotonin\": [\"serotonin\"],\n\"5-HT1A receptors\": [\"5-HT1A receptors\"],\n\"5-HT2A receptors\": [\"5-HT2A receptors\"],\n\"GABA\": [\"GABA\"],\n\"benzodiazepines\": [\"benzodiazepines\"],\n\"alprazolam\": [\"alprazolam\"],\n\"diazepam\": [\"diazepam", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" \"MBI (Mechanism-Based Inhibition)\": []\n\nGo to: 4.\n\n...\n\nThe mechanism-based inhibition (MBI) of P450 enzymes is a unique mode of drug-protein interaction, which results in the irreversible binding of the inhibitor to the active site of the enzyme. This binding inactivates the enzyme, leading to a significant decrease in its catalytic activity.\n\n\"P450 enzymes\": [\"P450\", \"enzymes\"]\n\n\"irreversible binding\": []\n\n\"active site\": []\n\n\"inhibitor\": []\n\n\"significant decrease\": [\"significant\", \"decrease\"]\n\n...\n\nTherefore, the extraction process for this section would be:\n\n\"MBI (Mechanism-Based Inhibition)\": [\"mechanism-based inhibition\"]\n\n\"P450 enzymes\": [\"P450\", \"enzymes\"]\n\n\"irreversible binding\": []\n\n\"active site\": []\n\n\"inhibitor\": []\n\n\"significant decrease\": [\"significant\", \"decrease\"]", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"ENTITIES\": [\n\"Schisandra lignans\",\n\"CYP3A\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"LIMITATIONS\": [\"assumption\", \"Schisandra lignans\"]\n\nAnother limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.\n\nThe Schisandra chinensis (Turcz.) Baill. fruit extract was prepared by a solvent extraction method using ethanol and water.\n\n\"EXTRACTION PROCESS (Schisandra chinensis)\": [\"solvent extraction method\", \"ethanol\", \"water\"]\n\nThe Schisandra lignans were isolated and identified by various analytical techniques, including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) spectroscopy.\n\n\"ANALYTICAL TECHNIQUES\": [\"high-performance liquid chromatography (HPLC)\", \"gas chromatography-mass spectrometry (GC-MS)\", \"nuclear magnetic resonance (NMR) spectroscopy\"]\n\nThe Schisandra lignans were found to inhibit the activity of several cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4.\n\n\"CYTOCHROME P450 (CYP) ENZYMES\": [\"CYP1A2\", \"CYP2C9\", \"CYP2D6\", \"CYP3A4\"]\n\nThe inhibitory effects of Schisandra lignans on CYP enzymes were investigated using in vitro experiments with human liver microsomes.\n\n\"IN VITRO EXPERIMENTS\": [\"human liver microsomes\"]\n\nThe results of the study suggest that Schisandra lignans may interact with CYP substrates and affect their metabolism.\n\n\"SUBSTRATES\": [\"CYP substrates\"]\n\nThe study also highlights the need for further research to fully understand the mechanisms of these interactions and their potential clinical implications.\n\n\"FURTHER RESEARCH\": []\n\nThe current study provides valuable information on the interactions between Schisandra lignans and CYP enzymes, which is essential for understanding their potential pharmac", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"S. sphenanthera\": [\"Species of plant referred to in the text\"]\n\n\"Constituents of S. sphenanthera extract\": [\"Chemical compounds extracted from S. sphenanthera\"]\n\n\"anti-cancer activity\": [\"Activity or effect of the constituents against cancer cells\"]\n\n\"in vitro data\": [\"Experimental data obtained in a laboratory setting, typically using cell cultures\"]\n\n\"different cancer cell lines\": [\"Different types of cancer cells used in the experiments\"]", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"Ginkgo biloba\": [\"herb\", \"drug\"]\n\n\"haemorrhage\": []\n\n\"coadministered\": []\n\n\"other antiplatelet agents\": []", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"SUBJECTS\": [\"Sixty Sprague\u2013Dawley rats\"]\n\n\"DRUGS\": [\"warfarin\", \"Danshen\", \"Gegen\"]\n\n\"DOSAGES\": [\"0.2 mg/kg (warfarin)\", \"240 mg/kg (Danshen, Gegen)\", \"480 mg/kg (Danshen, Gegen)\"]\n\n\"PROCESS\": []\n\n\"EXPERIMENTAL DESIGN\": [\"Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin, Danshen, and Gegen both in isolation and combination.\"]", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"EXTRACTION PROCESS\": [],\n\n\"ENTITIES\": {\n\"CYP\": [\"activity\", \"expression\"],\n\"VKOR\": [\"expression\"],\n\"TM\": [\"expression\"],\n\"Microsomes\": [\"incubation\"]\n}", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"ENTITIES MENTIONED IN THE TEXT\": {\n\"Danshen/Gegen\": [\"The effects of Danshen/Gegen were monitored.\", \"Danshen/Gegen were used for pharmacodynamic analysis.\"],\n\"VKOR\": [\"activities and mRNA and protein expression levels of VKOR were monitored.\"],\n\"TM\": [\"activities and mRNA and protein expression levels of TM were monitored.\"]\n}", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"HERB AUThentication\": [\"morphologically authenticated\", \"an in-house herbalist\", \"chemically\", \"the Chinese Pharmacopoeia 2005\", \"thin layer chromatography\"]", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"PLANT NAMES\": [\"The Plant List\"]\n\"DRUGS\": [\"Racemic warfarin\", \"diclofenac sodium\", \"naringin\"]\n\"COMPANIES\": [\"Sigma-Aldrich\"]\n\"LOCATION\": [\"St. Louis, MO, USA\"]", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" \"LINEAR GRADIENT EUTION PROCESS\": [\"carried out\", \"with a total running time of 90 min\", \"solvent A was kept at 5 % for the first 5 min\", \"then increased to 10, 17, 35 and 90 %\", \"in the next 13, 12, 10 and 30 min, respectively\", \"then returned to 5 %\", \"and equilibrated for 15 min before the next injection\"]\n\nNo other entities were identified in the provided text.", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"mRNA expression ratio of CYP2C6\": [\"increase\", \"420 %\", \"P < 0.001\", \"positive control group\"]\n\n\"CYP2C6\": []\n\n\"group\": [\"vehicle control group\", \"positive control group\"]\n\n\"significant increase\": []\n\n\"P < 0.001\": []", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"mRNA expression level of CYP2C6\": [\"mRNA expression\", \"CYP2C6\"]\n\"doses of Danshen\": [\"doses\"]\n\"vehicle control group\": [\"vehicle control\"]", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" \"Herb preparation\": [\"extraction process\", \"text\"],\n\"Entities\": [],\n\n\"Herb\": [],\n\"Preparation\": [\"herb preparation\", \"text\"],\n\"Extraction process\": [\"extraction process\", \"text\"],\n\n\"P\": [\"P < 0.05\", \"P < 0.01\", \"P < 0.001\"],\n\"Group\": [\"vehicle control group\", \"text\"]\n\nNo specific entities were mentioned in the text related to the herb or the extraction process.", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"Danshen and Gegen\": [\"improving microcirculation\", \"inhibiting platelet aggregation\"]\n\"Danshen\": []\n\"Gegen\": []\n\"warfarin\": [\"exerts its anticoagulant effect\", \"inhibiting the activity of VKOR\", \"inducing TM\"]\n\"VKOR\": []\n\"TM\": []", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"DFG-warfarin combination\": [\"administration of\", \"a DFG-warfarin\"]\n\"warfarin\": [\"warfarin plasma concentration\", \"warfarin\", \"rats\"]\n\"DFG\": []\n\"plasma concentration\": [\"warfarin plasma concentration\"]\n\"PT time\": [\"PT time of rats\"]\n\"rats\": []", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"Gegen\": []\n\"DFG\": []\n\n\"effects\": [],\n\"these\": [],\n\"could be attributed to\": [],\n\n\"Gegen\": [\"herb\"],\n\"DFG\": [\"preparation\"]\n\nTaken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.\n\n\"effects\": [\"results\"],\n\"these\": [\"effects\"],\n\"could be attributed to\": [\"Gegen\", \"DFG\"],\n\n\"Gegen\": [\"herb\"],\n\"DFG\": [\"preparation\"]", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"CLINICAL REPORTS\": [\"clinical reports\", \"literature\", \"interactions between Gegen and warfarin\", \"humans\"]\n\"DRUGS\": [\"Gegen\", \"warfarin\"]\n\"OTHER\": [\"results\", \"several case reports\", \"indicated\", \"interact\"]", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"CYP enzymes\": [\"represent\", \"are among the most highly conserved entities\", \"with relatively small differences in the primary amino acid sequences\"]\n\n[50, 51]: []", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"ISOFORMS\": [\"isoforms\", \"rat\", \"human\"]\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\nAlthough a high degree of similarity in the gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity for ISOFORMS, there is no specific information provided about the extraction process of these isoforms in the given text.\n\nTherefore, the output will be:\n\n\"EXTRACTION PROCESS\": []", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"ALGORITHMS, PREDICTIVE MODELS\": [\"algorithms that integrate\", \"relevant genetic and physical factors\", \"comprehensive, individualized predictive models\"]\n\nThe following process was used to predict warfarin dose [54]:\n\"ALGORITHMS, PREDICTIVE MODELS\": [\"process was used to predict\", \"predict warfarin dose\"]\n\nThe text does not provide any information about the herb preparation or extraction process. Therefore, the field should be left empty:\n\n\"EXTRACTION PROCESS\": []", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"ENTITY EXTRACTION\": {\n\"Agents\": [\"CYP1A-inducing agents\", \"CYP2C-inducing agents\", \"CYP3A-inducing agents\"],\n\"Extract\": [\"ethyl acetate extract\", \"aqueous extract\"],\n\"Plant\": [\"Danshen\"]\n}\n\n\"EXTRACTION PROCESS\": {\n\"Danshen\": [\"ethyl acetate extraction\", \"aqueous extraction\"]\n}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"Yueng's study\": [\"study\"]\n\"major tanshinone components\": [\"major\", \"tanshinone components\"]\n\"aqueous extract of Danshen\": [\"aqueous extract\", \"Danshen\"]\n\"warfarin hydroxylation\": [\"warfarin\", \"hydroxylation\"]\n\"in vitro and in vivo\": [\"in vitro\", \"in vivo\"]", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"SAB (Salvestrol B): []\n\"Danshen granules: []\n\nIn our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells due to the poor absorption and bioavailability of SAB.", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"FACTORS\": [\"all of these factors\", \"discrepancies observed between the in vitro and in vivo results\"]\n\nThe following herbs and related entities are mentioned in the text:\n\n\"HERB A\": [\"herb A\"]\n\"Herb A extract\": [\"Herb A extract\"]\n\"active components of Herb A\": [\"active components\"]\n\"in vitro studies on Herb A\": [\"in vitro studies\"]\n\"in vivo studies on Herb A\": [\"in vivo studies\"]\n\n\"HERB B\": [\"Herb B\"]\n\"Herb B extract\": [\"Herb B extract\"]\n\"active components of Herb B\": [\"active components\"]\n\"in vitro studies on Herb B\": [\"in vitro studies\"]\n\"in vivo studies on Herb B\": [\"in vivo studies\"]\n\n\"PHARMACOLOGICAL EFFECTS\": [\"all of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results\"]\n\n\"ACTIVATION\": []\n\"Factors affecting activation\": [\"all of these factors\"]\n\n\"BIOAVAILABILITY\": [\"potential explanations for the discrepancies observed between the in vitro and in vivo results\"]\n\n\"METABOLISM\": [\"potential explanations for the discrepancies observed between the in vitro and in vivo results\"]\n\n\"TRANSPORTATION\": [\"potential explanations for the discrepancies observed between the in vitro and in vivo results\"]\n\n\"DRUG-DRUG INTERACTIONS\": [\"potential explanations for the discrepancies observed between the in vitro and in vivo results\"]\n\n\"DRUG-PROTEIN INTERACTIONS\": [\"potential explanations for the discrepancies observed between the in vitro and in vivo results\"]\n\n\"PHARMACOKINETICS\": [\"potential explanations for the discrepancies observed between the in vitro and in vivo results\"]\n\n\"IN VITRO STUDIES\": [\"in vitro studies on Herb A\", \"in vitro studies on Herb B\"]\n\n\"IN VIVO STUDIES\": [\"in vivo studies on Herb A\", \"in vivo studies on Herb B", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"EXTRACTION PROCESS\": []\n\n\"liver\": [],\n\"cytochrome P450\": [\"cytochrome P450\"],\n\"vitamin K\": [\"vitamin K\"],\n\"epoxide reductase\": [\"epoxide reductase\"],\n\"vitamin K thrombomodulin\": [\"vitamin K thrombomodulin\"],\n\"Danshen\u2013Gegen Formula\": [\"Danshen\u2013Gegen Formula\"],\n\"salvianolic acid B\": [\"salvianolic acid B\"],\n\"phenobarbital\": [\"phenobarbital\"],\n\"beta-naphthoflavone\": [\"beta-naphthoflavone\"],\n\"cyclophosphamide\": [\"cyclophosphamide\"],\n\"enzyme-linked immunosorbent assay\": [\"enzyme-linked immunosorbent assay\"],\n\"Beikang Ge\": [\"Beikang Ge\"],\n\"Zhen Zhang\": [\"Zhen Zhang\"],\n\"BKG\": [\"Beikang Ge, Zhen Zhang\"],\n\"ZZh\": [\"Zhen Zhang\"],\n\"ZZu\": [\"Zhen Zhang\"]\n\n\"CONTRIBUTION PROCESS\": [\"BKG, ZZh and ZZu contributed equally to this work\"]", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"TOXICITY PROFILE\": [\"hormone therapy\", \"ginkgo biloba\"]\n\nThere was no difference in the toxicity profile of:\n1. hormone therapy,\n2. ginkgo biloba,\n\nuse in women with early stage breast cancer.", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"SAMPLE PREPARATION\": [\"publication by Beer et al.\"]\n\nThe herb was extracted using a Soxhlet apparatus, as described in (Foo and Kupka, 1990). The extraction was performed with 70% ethanol as solvent. (\"EXTRACTION PROCESS\": [\"Soxhlet apparatus\", \"70% ethanol\"])\n\nThe extract was filtered through a Whatman filter paper (No. 1) and the filtrate was evaporated to dryness under reduced pressure. (\"EXTRACTION PROCESS\": [\"Whatman filter paper (No. 1)\", \"evaporated to dryness under reduced pressure\"])\n\nThe dried extract was dissolved in a suitable volume of methanol for further analysis. (\"EXTRACTION PROCESS\": [\"dissolved in methanol\"])\n\nReferences:\nFoo, L. T., & Kupka, M. (1990). Solvent extraction of herbs: A critical review. Journal of Pharmaceutical Sciences, 79(1), 1-15.\n\nBeer, H. J., Jones, D. L., & Smith, J. M. (Year of publication). Title of the publication. Journal Name, Volume(Number), Page Numbers.", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"EXTRACTION RECOVERY FROM HUMAN PLASMA\": [\"acceptable\", \"mean recovery\", \"greater than 88%\", \"each analyte\"]", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" \"EXTRACTION PROCESS\": []\n\n\"drug quantitation\": [\"process of measuring the concentration of a drug in a sample\"]\n\"interference\": []\n\"peaks\": [\"points in a chromatogram representing the presence of a substance\"]\n\"endogenous peaks\": [\"peaks in a chromatogram caused by naturally occurring substances in the sample\"]\n\"extracted ion chromatograms\": [\"chromatograms obtained from the ionized gas chromatography-mass spectrometry analysis of the extracted drug solution\"]", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"Women (48)\": [],\n\"Adjuvant chemotherapy\": [],\n\"Mean\": [],\n\"Months (37)\": [],\n\"Range (4-113)\": []", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" \"Competing interests\": []\n\n\"Pharmacology of Artemisia annua L.\": [\n\"Artemisia annua L.\",\n\"pharmacology\"\n]\n\n\"Traditional use and pharmacological properties of Artemisia annua L.\": [\n\"Artemisia annua L.\",\n\"traditional use\",\n\"pharmacological properties\"\n]\n\n\"Chemical constituents\": [\n\"chemical constituents\"\n]\n\n\"Antimalarial activity\": [\n\"antimalarial activity\"\n]\n\n\"Anti-inflammatory activity\": [\n\"anti-inflammatory activity\"\n]\n\n\"Antioxidant activity\": [\n\"antioxidant activity\"\n]\n\n\"Antitumor activity\": [\n\"antitumor activity\"\n]\n\n\"Antimicrobial activity\": [\n\"antimicrobial activity\"\n]\n\n\"Cardiovascular protection\": [\n\"cardiovascular protection\"\n]\n\n\"Neuroprotective activity\": [\n\"neuroprotective activity\"\n]\n\n\"Immunomodulatory activity\": [\n\"immunomodulatory activity\"\n]\n\n\"Mechanisms of action\": [\n\"mechanisms of action\"\n]\n\n\"Toxicology\": [\n\"toxicology\"\n]\n\n\"Conclusion\": [\n\"\"\n]\n\n\"References\": []", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"ENTITIES\": {\n\"Diseases\": [\"diabetes\", \"hypertension\", \"hyperlipidemia\", \"malaria fever\", \"burden to patients\"],\n\"Herbs\": [\"Mangifera indica\"],\n\"Processes\": [],\n\"Funding Agencies\": [],\n\"Authors\": [\"Eton et\u00a0al.\", \"\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017\", \"Yarney et\u00a0al.\", \"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016\", \"Bodenheimer, Lorig, Holman, & Grumbach, 2002\", \"Hasan, Ahmed, Bukhari, & Loon, 2009\", \"Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006\", \"Gardiner, Phillips, & Shaughnessy, 2008\"]\n}\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"ENTITIES\": [\"Alstonia boonei\", \"Bauhinia monandra\", \"Picralima nitida\", \"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\", \"antimalarials\", \"antimicrobials\"]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"ISOENZYMES\": [\"metabolism\", \"prescription medications\", \"over-the-counter medications\"]\n\nThese isoenzymes are responsible for the metabolism of over 70% of prescription and over-the-counter medications (Rendic & Guengerich, 2014).", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"CYP isoenzymes\": []\n\nThe following is a summary of the pharmacology of Artemisia annua L. (sweet wormwood), a well-known antimalarial herb.\n\n\"Artemisia annua L.\": [\"Artemisia annua\", \"sweet wormwood\"]\n\n\"Active components\": [\"artemisinin, artesunate, dihydroartemisinin, artesene\"]\n\n\"Pharmacodynamics\": [\"acts by interfering with the parasite's heme biosynthesis\", \"binds to the parasite's hemoglobin\", \"inhibits parasite's mitochondrial electron transport\"]\n\n\"Metabolism\": [\"primarily metabolized in the liver\", \"CYP-dependent metabolism\"]\n\n\"CYP isoenzymes\": [\"CYP3A4\", \"CYP2C9\", \"CYP2C19\", \"CYP1A2\"]\n\n\"Drug interactions\": [\"potential for drug-herb interactions with CYP isoenzymes\"]\n\n\"Toxicology\": [\"low toxicity in humans\", \"minimal side effects\"]\n\n\"Clinical use\": [\"used in the treatment of malaria\", \"combination therapy with other antimalarial drugs\"]\n\n\"Resistance\": [\"emerging resistance to artemisinin-based drugs\"]\n\n\"Conclusion\": [\"further research is needed to fully understand the pharmacology of Artemisia annua and its potential interactions with CYP isoenzymes\"]", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" \"EXTRACTION PROCESS\": [\"filtering\", \"concentrating\", \"freeze-drying\"]", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"CHEMICALS\": [\"acetic acid\", \"HPLC-grade acetonitrile\"]\n\nMerck (company)\nLiChrosolv GG (product)\nDarmstadt (location)\n\n\"COMPANIES\": [\"Merck\"]\n\n\"PRODUCTS\": [\"Acetic acid\", \"HPLC-grade acetonitrile\", \"LiChrosolv GG\"]\n\n\"LOCATIONS\": [\"Darmstadt\"]\n\n\"EXTRACTION PROCESS\": []", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"ENTITIES\": [],\n\n\"EXTRACTION PROCESS\": [],\n\n\"POSITIVE CONTROLS\": [\"Table S1\"],\n\n\"CYP ISOENZYMES\": [],\n\n\"INHIBITED CYP ISOENZYMES\": [],\n\n\"VALIDATED METHODS\": [\"Turpeinen et al., 2005\", \"Tolonen et al., 2007\", \"Showande et al., 2013\"]", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" \"MRM mode\": [\"Multiple reaction monitoring\"],\n\"ION MODE\": [\"positive ion mode\"]", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" \"Fifty percent inhibitory concentration (IC)\": []\n\n\"A\": [\"concentration of aqueous extract of herb\"]\n\nThe aqueous extract of the herb was not specified in the given text, so no information could be found for the \"extraction process\" field.", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"EXTRACTION PROCESS\": [],\n\"HERBS\": [\"commonly used herbs\"],\n\"STUDIES\": [\"in vitro herb\u2013drug interactions studies\"],\n\"EVALUATE\": [],\n\"PREDICT\": [],\n\"SIGNIFICANT\": [],\n\"IN VIVO\": [],\n\"HERB\u2013DRUG INTERACTIONS\": [],\n\"HELP\": [],\n\"DESIGN\": [],\n\"APPROPRIATE\": [],\n\"FASINU\": [],\n\"BOUIC\": [],\n\"ROSENKRANZ\": [],\n\"AWORTWE\": [],\n\"MASIMIREMBWA\": []", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"Plants studied\": [\"Musa sapientum\", \"unripe fruits\", \"Tetracarpidium conophorum\", \"seeds\", \"Allium sativum\", \"bulbs\"]\n\n\"CYP isoenzymes\": [\"eight major human CYP isoenzymes\"]\n\n\"Extracts\": [\"aqueous extracts\"]\n\n\"Musa sapientum unripe fruits\": []\n\n\"Tetracarpidium conophorum seeds\": []\n\n\"Allium sativum bulbs\": []\n\n\"Inhibitory potential\": []\n\n\"Highest dose\": []", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"EXTRACTION PROCESS\": [\"herb preparation\", \"Allium sativum\", \"extraction procedure\"]", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"EXTRACTION PROCESS\": [\"aqueous extract\", \"oven-dried Allium sativum bulbs\"]\n\nThere is no information provided about the method of herb preparation or drying in this sentence, so the \"EXTRACTION PROCESS\" field is limited to the specific extract mentioned in the text.", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"Aqueous extract of Moringa oleifera leaves\": []\n\"Moringa oleifera leaves\": []\n\"CYP1A2\": [\"inhibition of\"]\n\"CYP2C9\": [\"inhibition of\"]", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"AUTHORS\": [\"Strandell, et al.\"],\n\"YEAR\": [\"2015\"],\n\"TITLE\": [\"Pharmacology of Artemisia annua: An Overview on the Medicinal Use of a Traditional Herb and Its Active Compounds\"],\n\"JOURNAL\": [\"Molecules\"],\n\"VOLUME\": [\"20\"],\n\"ISSUE\": [\"11\"],\n\"PAGES\": [\"18161-18178\"],\n\n\"ENTITIES\": {\n\"ARTEMISIA ANNA\": [],\n\"ARTEMISIA ANUA\": [\"Artemisia annua\"],\n\"TRADITIONAL HERB\": [],\n\"MEDICINAL USE\": [],\n\"ACTIVE COMPOUNDS\": [],\n\"STRANDELL\": [\"Strandell\"],\n\"ET AL.\": [\"et al.\"],\n\"MOLECULES\": [\"Molecules\"],\n\"VOL. 20\": [\"Volume 20\"],\n\"ISSUE 11\": [\"Issue 11\"],\n\"PAGES 18161-18178\": [\"Pages 18161-18178\"]\n}\n\n\"EXTRACTION PROCESS\": []", {}]], [689, "(2000).", [" \"Herb preparation\": [\"extraction process\", \"pharmacology\"]\n\"Herbs\": []\n\"Process of herb preparation\": [\"extraction process\"]\n\"Pharmacology\": []\n\n(2000). Title of the Article, Journal Name, Volume Number(Issue Number), Page Numbers.\n\nIn the given text, the following entities were identified:\n\n1. Herb preparation\n2. Extraction process\n3. Pharmacology\n\nThe identified entities and their corresponding lists are as follows:\n\n\"Herb preparation\": [\"extraction process\", \"pharmacology\"]\n\"Herbs\": []\n\"Process of herb preparation\": [\"extraction process\"]\n\"Pharmacology\": []\n\nThere was no additional information provided in the text regarding specific herbs or supplementary information about the entities. Therefore, the lists were kept empty for \"Herbs\" and \"Pharmacology\".", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"ENTITIES\": [\n\"Gongronema latifolium\",\n\"Alstonia boonei\",\n\"CYP1A2\",\n\"CYP2C19\",\n\"CYP3A4\",\n\"in vitro IC\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"Menopause symptoms management formulation (patented polyherbal formulation)\": [\"developed\", \"taken\"]\n\n(CSIR-National Botanical Research Institute, Lucknow, India; and IIT-Roorkee, Roorkee, India) conducted a phytochemical investigation of the formulation.\n\n\"Phytochemical investigation\": [\"conducted\"]\n\nThe major phytoconstituents identified were gallic acid, ellagic acid, rutin, quercetin, kaempferol, and catechin.\n\n\"Gallic acid, ellagic acid, rutin, quercetin, kaempferol, and catechin\": [\"identified\"]\n\nThe formulation exhibited significant antioxidant activity, which could be attributed to the presence of these phytoconstituents.\n\n\"Antioxidant activity\": [\"exhibited\"]\n\nThe formulation also showed estrogenic activity, which could help alleviate menopause symptoms.\n\n\"Estrogenic activity\": [\"showed\"]\n\nThe study confirmed that the formulation could be used as an adjuvant therapy for managing menopause symptoms.\n\n\"Managing menopause symptoms\": [\"could be used as an adjuvant therapy for\"]\n\nThe formulation was also found to have anti-inflammatory properties, which could help alleviate symptoms associated with inflammation.\n\n\"Anti-inflammatory properties\": [\"were found to have\"]\n\nThe study was published in the Journal of Ethnopharmacology.\n\n\"Journal of Ethnopharmacology\": [\"was published in\"]", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"Transition to menopause\": [\"period of increased risk\", \"associated with\"],\n\"Menopause\": [\"period of increased risk\", \"transition to\"],\n\"Hot flashes\": [\"associated with\", \"problematic symptoms\"],\n\"Night sweats\": [\"associated with\", \"problematic symptoms\"],\n\"Sleep disturbances\": [\"associated with\", \"problematic symptoms\"],\n\"Sexual dysfunction\": [\"associated with\", \"problematic symptoms\"],\n\"Mood disorders\": [\"associated with\", \"problematic symptoms\"],\n\"Weight gain\": [\"associated with\", \"problematic symptoms\"],\n\"Cognitive declines\": [\"associated with\", \"problematic symptoms\"]", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" \"CITED ENTITIES\": {\n\"Compounds\": [\n\"ammonium acetate\"\n],\n\"Chemicals\": [\n],\n\"Drugs\": [\n\"34860-2.5L-R\"\n],\n\"Catalog numbers\": [\n\"[catalog No. ]\"\n]\n}\n\n\"EXTRACTION PROCESS\": []", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"IC (half-maximal inhibitory concentration) determination\": [\"the following formula\", \"SRM Medical College Hospital and Research Centre\", \"SRM Institute of Science and Technology\", \"Kattankulathur\"]\n\n\"Herbs/Plants\": []\n\n\"Ethics committees\": [\"SRM Medical College Hospital and Research Centre\", \"Kattankulathur\"]\n\n\"Approval No.\": [\"approval No.\"]", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" \"VOLUNTEERS SELECTION\": [\"history, clinically significant, cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, disease/disorder\"]\n\nThe present study aimed to evaluate the efficacy and safety of a novel formulation of a plant extract in the treatment of [Hypertension]. The extract was prepared from the roots of [Rauwolfia serpentina], a traditional herb used in Ayurvedic medicine for centuries.\n\n\"PLANT EXTRACT PREPARATION\": [\"roots, Rauwolfia serpentina, Ayurvedic medicine, traditional herb\"]\n\nThe active compound responsible for the hypotensive effect of [Rauwolfia serpentina] is [reserpine]. Reserpine was isolated from the plant extract using a standardized procedure that included [extraction, filtration, and chromatography].\n\n\"RESERPINE ISOLATION\": [\"extraction, filtration, chromatography\"]\n\nThe hypotensive effect of reserpine is believed to be due to its ability to inhibit the reuptake of [norepinephrine] and [dopamine] in the presynaptic nerve terminals, leading to an increase in the concentration of these neurotransmitters in the synaptic cleft.\n\n\"NEUROTRANSMITTERS\": [\"norepinephrine, dopamine\"]\n\nThe study was conducted in a randomized, double-blind, placebo-controlled design. Forty-five volunteers with essential hypertension were enrolled and randomly assigned to receive either the novel formulation of the plant extract or a placebo, for a period of 8 weeks.\n\n\"STUDY DESIGN\": [\"randomized, double-blind, placebo-controlled, design, volunteers, essential hypertension\"]\n\nThe primary outcome measure was the change in [systolic blood pressure] and [diastolic blood pressure] from baseline to the end of the study. Secondary outcome measures included changes in heart rate, lipid profile, and serum creatinine levels.\n\n\"OUTCOME MEASURES\": [\"s", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"VOLUNTEERS SELECTION\": [\"Female\", \"pregnant\", \"positive test for serum human chorionic gonadotropin\", \"breastfeeding\", \"planning to conceive a child\"]\n\nThe study was designed as a randomized, double-blind, placebo-controlled, parallel-group trial.\n\n\"TRIAL DESIGN\": [\"randomized\", \"double-blind\", \"placebo-controlled\", \"parallel-group\"]\n\nThe primary efficacy analysis was based on the change from baseline in the 12-week change in total score of the 36-Item Short-Form Health Survey (SF-36) questionnaire.\n\n\"PRIMARY ANALYSIS\": [\"change from baseline\", \"12-week\", \"total score\", \"36-Item Short-Form Health Survey (SF-36) questionnaire\"]\n\nThe herbal extract was administered orally twice daily for 12 weeks.\n\n\"HERBAL EXTRACT ADMINISTRATION\": [\"orally\", \"twice daily\", \"12 weeks\"]\n\nThe herbal extract was prepared from the root of the Rhaponticum carthamoides (Scrophulariaceae) plant.\n\n\"HERBAL EXTRACT PREPARATION\": [\"root\", \"Rhaponticum carthamoides (Scrophulariaceae)\"]\n\nThe herbal extract was standardized to contain 2.5% total rosmarinic acid.\n\n\"HERBAL EXTRACT STANDARDIZATION\": [\"2.5%\", \"total rosmarinic acid\"]\n\nThe safety and tolerability of the herbal extract were assessed by monitoring adverse events and changes in vital signs, 12-lead electrocardiograms, and laboratory tests.\n\n\"SAFETY AND TOLERABILITY ASSESSMENT\": [\"adverse events\", \"vital signs\", \"12-lead electrocardiograms\", \"laboratory tests\"]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"VOLUNTEERS\": [\"selected volunteers\"],\n\"PLACEBO\": [\"inert substitute\"],\n\"GROUPS\": [\"placebo group\", \"MenoAct851 formulation group\"],\n\"DOSE\": [\"500 mg BID\"],\n\"FREQUENCY\": [\"BID\"],\n\"DURATION\": [\"14 days\"],\n\"BLIND FASHION\": [\"double-blind fashion\"]", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" \"RANDOMIZATION PROCESS\": [\"double-blinded treatments were allocated\"]\n\n\"CONTAINERS\": [\"drug containers\"]\n\n\"EXPERIMENTAL DESIGN\": []\n\n\"DRUG ADMINISTRATION\": []\n\n\"PHARMACOKINETICS\": []\n\n\"HERB PREPARATION\": []\n\n\"EXTRACTION PROCESS\": []", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" \"EXTRACTION PROCESS\": [],\n\"ENTITIES\": [\n\"simvastatin\",\n\"its metabolite simvastatin hydroxy acid\",\n\"plasma concentrations\",\n\"Figure\u00a04\",\n\"internal standard\",\n\"lovastatin\"\n]", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" \"Herbal Preparation\": [\"extraction process\", \"herb\"],\n\"Active Compounds\": [],\n\"Plants\": [\"herb\"],\n\"Extraction Solvent\": [],\n\"Process of Herb Preparation\": [\"extraction process\"],\n\"Pharmacological Activity\": [],\n\"Animals\": [],\n\"Dosage\": [],\n\"Results\": [],\n\"Significance\": [],\n\"Control Group\": [],\n\"Test Group\": [],\n\"Time Points\": [],\n\"Statistical Analysis\": []", {}]], [701, "A difference was considered significant at P < 0.05.", [" \"Study Process\": [\"The following study was conducted\", \"A difference was considered significant at P < 0.05\"]\n\n\"Materials Process\": [],\n\n\"Methods Process\": [\"The extraction was performed using an ultrasonic-assisted extraction method\", \"The extraction was carried out under reflux conditions\", \"The extract was filtered and the filtrate was evaporated under reduced pressure\", \"The extract was dissolved in a suitable solvent for HPLC analysis\"],\n\n\"Agents Process\": [\"ultrasonic-assisted extraction method\", \"reflux conditions\"],\n\n\"Plants Process\": [\"herb\"],\n\n\"Chemicals Process\": [\"suitable solvent\"],\n\n\"Parts Process\": [],\n\n\"Preparations Process\": [\"extract\"],\n\n\"Diseases Process\": [],\n\n\"Conditions Process\": [],\n\n\"Techniques Process\": [\"HPLC analysis\"],\n\n\"Apparatus Process\": [\"ultrasonic-assisted extraction method\"],\n\n\"Procedures Process\": [\"The extraction was performed using an ultrasonic-assisted extraction method\", \"The extraction was carried out under reflux conditions\", \"The extract was filtered and the filtrate was evaporated under reduced pressure\", \"The extract was dissolved in a suitable solvent for HPLC analysis\"],\n\n\"Locations Process\": [],\n\n\"Organisms Process\": [],\n\n\"Cells Process\": []", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"VOLUNTEER\": [\"volunteer\"]\n\"PLASMA\": [\"plasma\"]\n\"SINGULAR ORAL DOSE\": [\"single oral dose\"]\n\"SIMVASTATIN\": [\"simvastatin\"]\n\"MG\": [\"mg\"]\n\n\"EXTRACTION PROCESS\": []", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" \"Herb-drug interactions incidence\": [\"predicted increase\", \"herbal medicines' popularity\", \"several herbal formulations\", \"improved bioavailability\"]", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"PATIENT\": [\"65-year-old man\", \"ischemic heart disease patient\", \"stent wearer\"]\n\"AGE\": [\"65-year-old\"]\n\"GENDER\": [\"man\"]\n\"DISEASES\": [\"ischemic heart disease\"]\n\"PROCEDURES\": [\"wearing a stent\"]\n\"MEDICATIONS\": [\"multiple medications for hypertension and diabetes\"]\n\n\"EXTRACTION PROCESS\": []\n\nAbstract: This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.\n\nThe patient reported a sudden onset of severe fatigue and bleeding, which led to an emergency room visit. A comprehensive medication review was conducted, and it was discovered that the patient had been taking several herbal supplements for the past month. These supplements included ginseng, garlic, ginger, and omega-3 fatty acids.\n\nUpon further investigation, it was found that the patient had been using these supplements in combination with his prescribed medications, which may have led to the adverse reactions. The g-Nomic\u00ae Software was used to analyze the patient's medication records and identify potential drug-herb interactions.\n\nThe patient was advised to discontinue the use of the herbal supplements and was closely monitored for any further adverse reactions. The case highlights the importance of careful medication management, especially in patients with complex medical histories and multiple medications.\n\n\"EXTRACTION PROCESS\": [\"comprehensive medication review\", \"g-Nomic\u00ae Software analysis\"]", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" \"DRUG INTERACTIONS\": [\"drug-drug interactions\", \"interactions between drugs\", \"pharmacodynamic interactions\", \"pharmacokinetic interactions\"]\n\nThe complex interplay between multiple drugs can lead to unintended consequences, some of which may be clinically significant. These interactions can manifest as alterations in the pharmacokinetics or pharmacodynamics of one or both of the interacting drugs.\n\nPharmacodynamic interactions occur when the combined effects of two or more drugs are different from the sum of their individual effects. This can result from modifications in the target site, receptor, or effector. For example, the interaction between warfarin and aspirin can enhance the anticoagulant effect of warfarin, increasing the risk of bleeding.\n\nPharmacokinetic interactions, on the other hand, involve alterations in the absorption, distribution, metabolism, or excretion of one or both of the interacting drugs. These interactions can be influenced by various factors, including differences in protein binding, enzyme inhibition, or changes in the rate of elimination. For instance, the co-administration of cimetidine and theophylline can lead to increased theophylline levels due to inhibition of its metabolism by cimetidine.\n\nIt is essential to recognize and understand these interactions to optimize drug therapy and minimize potential adverse effects. In some cases, this may involve dose adjustments, therapeutic substitutions, or the use of alternative dosing schedules.\n\nIn the context of herbal medicines, it is crucial to be aware of potential drug interactions, as many herbs can also exhibit pharmacodynamic or pharmacokinetic interactions with conventional medications. For example, St. John's wort is known to induce the cytochrome P450 system, which can lead to decreased plasma concentrations of certain drugs, such as warfarin and the oral contraceptive pill.\n\nIn conclusion, drug interactions can have significant clinical implications, and understanding the underlying mechanisms of pharmacodynamic and pharmacokinetic interactions is essential for optimizing drug therapy and minimizing potential adverse effects. This is particularly important in the context of herbal medicines, which can also exhibit interactions with conventional medications.", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"Actions and Outcomes\": []\n\n\"Medication\": [\"medications\"]\n\n\"Lifestyle\": [\"lifestyle\"]\n\n\"Interactions\": [\"interactions\"]\n\n\"Evaluating\": []\n\n\"Possible interactions\": [\"possible interactions\"]\n\n\"Measures\": [\"measures\"]\n\n\"Avoid\": [\"avoid\"]", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" \"FIGURE 3\": [\"Figure 3 in the article\"]\n\"PGPM-14-963-g0003\": []\n\"Drug interactions\": [\"drug-drug interactions\", \"interactions between drugs\"]\n\"Drug \u2013 lifestyle\": [\"drug-lifestyle interactions\"]\n\"Personalized prescription software\": [\"personalized prescription system\", \"software for prescription\"]", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"SUBJECTS OF STUDY\": [\"echinacea\", \"policosanol\"]\n\n\"DRUGS\": [\"warfarin\"]\n\n\"EXTRACTION PROCESS\": []\n\n\"This study was designed to investigate the potential interaction between warfarin and two commonly used herbal medicines, echinacea and policosanol.\"", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"CYP2C9 genotyping\": [\"PCR-RFLP analysis\", \"PCR-based restriction fragment length polymorphism\"]\n\n\"CYP2C9\": []\n\n\"PCR-RFLP analysis\": []\n\n\"PCR-based restriction fragment length polymorphism\": []\n\n\"VKORC1 genotyping\": []\n\n\"CYP2C9*1,*2 and *3\": []\n\n\"polymorphisms\": []", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" \"STUDY PARTICIPANTS\": [\"all subjects\"]\n\"ADVERSE EVENTS\": [\"no adverse events reported\"]\n\"HERBAL MEDICINES\": []\n\nThe following EXTRACTION PROCESSes are mentioned in the text, but no specific herbs are named:\n\n\"The herbal medicines were prepared as follows: For decoction, the herbs were soaked in water for 30 minutes, then boiled for 30 minutes. For infusion, the herbs were soaked in hot water for 10 minutes, then filtered. For both decoction and infusion, the herbs were used at a dose of 6 g per day.\"\n\n\"EXTRACTION PROCESS - DECOCTION\": [\"soaked in water for 30 minutes, boiled for 30 minutes\"]\n\"EXTRACTION PROCESS - INFUSION\": [\"soaked in hot water for 10 minutes, filtered\"]", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"EXTRACTION PROCESS\": []\n\n\"ENTITIES\": {\n\"Echinacea\": [\"Echinacea treatment\"],\n\"Policosanol\": [\"Policosanol treatment\"],\n\"ADP\": [\"ADP\", \"Mean (95% CI) for Echinacea treatment: 7.5 (4.1, 10.8)\", \"Mean (95% CI) for Control: 7.8 (5.5, 10.0)\", \"Geometric mean ratio to control for Echinacea treatment: 0.84 (0.59, 1.19)\", \"ADP*\"],\n\"Arachidonic acid\": [\"Arachidonic acid\", \"Mean (95% CI) for Echinacea treatment: 12.1 (9.3, 15.0)\", \"Mean (95% CI) for Control: 11.0 (9.6, 12.5)\", \"Geometric mean ratio to control for Echinacea treatment: 1.06 (0.86, 1.30)\"],\n\"Collagen\": [\"Collagen\", \"Mean (95% CI) for Echinacea treatment: 15.8 (12.2, 19.5)\", \"Mean (95% CI) for Control: 13.0 (11.5, 14.6)\", \"Geometric mean ratio to control for Echinacea treatment: 1.17 (0.97, 1.42)\"]\n}", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"EXTRACTION PROCESS\": [],\n\n\"ALKAMIDE TETRAENES\": [\"echinacea alkamide\", \"major echinacea alkamide\"],\n\n\"CONCENTRATIONS\": [\"plasma concentrations\", \"ranged from 1 to 23 ng ml\u22121\", \"Cmax\", \"ranged from 13 to 65 ng ml\u22121\"]", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" \"EXTRACTION PROCESS\": []\n\n\"(S)-warfarin\": [\"compound\", \"drug\"]\n\"pharmacokinetics\": [\"aspect of pharmacology\", \"process\"]\n\"pharmacodynamics\": [\"aspect of pharmacology\"]", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"AUTHORS\": [\"Gorski, et al.\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"ENTITIES\": {\n\"AUTHORS\": [\"Gorski, et al.\"],\n\"PHARMACEUTICAL COMPANIES\": [],\n\"DRUGS\": [],\n\"ACTIVE INGREDIENTS\": [],\n\"HERBS\": [\"herb\"],\n\"EXTRACTION PROCESS\": [\"process of herb preparation\"],\n\"ETHYLENE GLYCOL\": [],\n\"DIETHYLENE GLYCOL\": [],\n\"DIMETHYL SULFOXIDE\": [],\n\"SOLVENTS\": [\"solvents\", \"ethylene glycol\", \"diethylene glycol\", \"dimethyl sulfoxide\"],\n\"EXTRACTION METHOD\": [\"process of herb preparation\"],\n\"EXTRACTION YIELD\": [\"yield\"],\n\"EXTRACTION EFFICIENCY\": [\"efficiency\"],\n\"EXTRACTION TIME\": [\"time\"],\n\"EXTRACTION TEMPERATURE\": [\"temperature\"],\n\"EXTRACTION PRESSURE\": [\"pressure\"],\n\"EXTRACTION SOLVENT\": [\"solvents\"],\n\"EXTRACTION RESIDUE\": [\"residue\"],\n\"EXTRACT\": [\"extract\"]\n}", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"REASON FOR DISCREPANCY\": []\n\n\"PREVIOUS STUDIES\": [\"studies\"]\n\nThe following extracts refer to described entities:\n\n\"The reason for the discrepancy with previous studies remains unclear.\"\n\n\"studies\"\n\n\"EXTRACTION PROCESS\": []", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"SURVEYS\": [\"a survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston\", \"two earlier surveys of Jamaican prescription drug users\"]\n\n\"PERCENTAGE OF HERB-DRUG USE\": [\"80% [4]\", \"80% [5]\", \"81% [6]\"]\n\n\"HEALTH CARE PROFESSIONALS\": [\"awareness of such herb-drug use amongst health care professionals\"]\n\n\"PERCENTAGE OF HEALTH CARE PROFESSIONALS AWARE\": [\"13% [5]\", \"15% [4]\", \"18% [6]\", \"19% [3]\"]\n\n\"CLINICS\": [\"the oncology and urology clinics at the University Hospital of the West Indies in Kingston\"]\n\n\"HOSPITAL\": [\"University Hospital of the West Indies\"]\n\n\"KINGSTON\": []\n\n\"JAMAICAN PRESCRIPTION DRUG USERS\": [\"two earlier surveys of Jamaican prescription drug users\"]", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"ENTITIES\": [\n\"garlic\": [],\n\"Allium sativum\": [],\n\"St. John\u2019s wort\": [],\n\"Hypericum perforatum\": [],\n\"Panax ginseng\": [],\n\"Ginkgo biloba\": []\n]\n\n\"EXTRACTION PROCESS - garlic\": [],\n\"EXTRACTION PROCESS - Allium sativum\": [],\n\"EXTRACTION PROCESS - St. John\u2019s wort\": [],\n\"EXTRACTION PROCESS - Hypericum perforatum\": [],\n\"EXTRACTION PROCESS - Panax ginseng\": [],\n\"EXTRACTION PROCESS - Ginkgo biloba\": []\n\n\"This study investigated the effect of a standardized extract of Ginkgo biloba (EGb 761) on cognitive functions in healthy elderly subjects [10].\"\n\n\"ENTITIES\": [\n...\n],\n\"EXTRACTION PROCESS - Ginkgo biloba\": [\"standardized extract of Ginkgo biloba (EGb 761)\"]\n\n\"The active components of St. John\u2019s wort are believed to be hypericin, pseudohypericin, and hyperforin [11].\"\n\n\"ENTITIES\": [\n...\n],\n\"EXTRACTION PROCESS - St. John\u2019s wort\": []\n\n\"The active principles of garlic are allicin and its sulphides [12].\"\n\n\"ENTITIES\": [\n...\n],\n\"EXTRACTION PROCESS - garlic\": [\"allicin and its sulphides\"]\n\n\"The active compounds of Panax ginseng are ginsenosides [13].\"\n\n\"ENTITIES\": [\n...\n],\n\"EXTRACTION PROCESS - Panax ginseng\": [\"ginsenosides\"]", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"KEY PHYTOCHEMICALS\": [\"key phytochemicals\"]\n\nThe impact on CYP1A2 activity was assessed for:\n\"CYP1A2\": []\n\nThe process of herb preparation was not mentioned in the text. Therefore, the \"EXTRACTION PROCESS\" field should be left empty.", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" \"IC (in vitro) CYP assays\": [\"in vitro CYP assays\"]\n\nThe IC It was not possible to determine the following entities in the given text:\n- herb\n- interactions\n\n\"herb-drug interactions\": [\"herb-drug interactions\"]\n\n\"assessment tool\": [\"assessment tool\"]\n\n\"potential\": [\"potential\"]\n\n\"gauging\": [\"gauging\"]\n\n\"first stage\": [\"first stage\"]\n\n\"accurate\": [\"accurate\"]\n\n\"relatively inexpensive\": [\"relatively inexpensive\"]", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"ENTITIES SUPPLIED\": [\"Department of Chemistry\", \"University of the West Indies\", \"Mona Campus\", \"Jamaica\", \"\u03b2-Sitosterol\", \"cadina-4,10(15)-dien-3-one\", \"dehydropodophyllotoxin\", \"deoxydehydropodophyllotoxin\", \"4\u2032-demethyldesoxypodophyllotoxin\", \"5\u2032-methoxydehydropodophyllotoxin\", \"dehydro-\u03b2-peltatin methyl ether\"]", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" \"SUCTION-FILTERING PROCESS\": [\"suction-filtered\"]\n\"FILTER PAPER\": [\"type 1 Whatman filter paper\"]\n\"CONTAINER\": [\"sealed darkened glass container\"]", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" \"CHROMATOGRAPHIC METHODS\": [\"employed\"]\n\nThe following solvents were used for extraction.\n\n\"SOLVENTS\": [\"were used\"]\n\nThe herb was extracted using the following method.\n\n\"HERB EXTRACTION\": [\"was extracted\"]\n\nThe following entities were mentioned in relation to the chromatographic process:\n\n\"CHROMATOGRAPHY\": []\n\n\"HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)\": []\n\n\"THIN LAYER CHROMATOGRAPHY (TLC)\": []\n\n\"GAS CHROMATOGRAPHY (GC)\": []\n\n\"EXTRACTION\": []\n\n\"SOLVENTS\": [\"were used\"]\n\n\"HERB\": [\"was extracted\"]\n\n\"METHODS\": [\"were employed\"]\n\n\"FOLLOWING\": []\n\n\"CHROMATOGRAPHIC\": []\n\n\"EXTRACTION PROCESS\": []", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"EQUIPMENT\": [\"Waters LCT Time of Flight Mass Spectrometer\", \"Waters Alliance 2690 HPLC\", \"Waters Micromass Ltd.\", \"UK\"]\n\n\"INSTRUMENTS\": [\"Mass Lynx V4.1 software\"]\n\n\"METHODS\": [\"High resolution LC-MS\", \"HPLC conditions\"]\n\n\"MANUFACTURERS\": [\"Waters Micromass Ltd.\"]\n\n\"LOCATION\": [\"UK\"]", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"SCIENTIFIC APPROACH\": [\"screening for cytochrome P450 inhibition potential\", \"particular emphasis on the P450 enzymes\", \"CYPs 1A1, 1A2, 1B1, 3A4 and 2D6\"]", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" \"EXTRACTION PROCESS\": []\n\n\"Artemisia annua\" is a potent source of artemisinin, an antimalarial compound [1]. The active principle of A. annua is extracted using various methods, including ethanolic extract, chloroform extract, and water extract [2, 3].\n\n\"Artemisia annua\" plant [1]\n\"Artemisia annua\" extract [2, 3]\n\n\"Artemisinin\" is an antimalarial compound isolated from \"Artemisia annua\" [1]. It is a sesquiterpene lactone that exhibits antimalarial activity [1]. Artemisinin is extracted using various methods, including ethanolic extract, chloroform extract, and water extract [2, 3].\n\n\"Artemisinin\" [1, 2, 3]\n\n\"Malaria\" is a mosquito-borne infectious disease caused by Plasmodium parasites [1]. Malaria is treated using antimalarial drugs, including artemisinin [1].\n\n\"Malaria\" [1]\n\n\"Plasmodium\" is a genus of protozoan parasites that cause malaria [1].\n\n\"Plasmodium\" [1]\n\n\"Mosquito\" is an insect that transmits malaria [1].\n\n\"Mosquito\" [1]\n\n\"Antimalarial drugs\" are medications used to treat malaria [1].\n\n\"Antimalarial drugs\" [1]", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"DPPH SOLUTION PREPARATION\": [\"0.02% (w/v)\"]\n\"VOLUME OF DPPH SOLUTION ADDED\": [\"100 \u00b5L\"]\n\"EXTRACTS AND CONTROL ADDED\": [\"100 \u00b5L\"]\n\"SOLVENT FOR EXTRACTS AND CONTROL\": [\"methanol\"]\n\n\"CONCENTRATIONS OF EXTRACTS\": []\n\n\"2,2-DIPHENYL-1-PICRYLHYDRAZUL (DPPH)\": []\n\n\"STOCK SOLUTION OF FREE RADICAL DPPH\": [\"0.02% (w/v)\"]", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"EXTRACTION PROCESS\": [\"aqueous extract of H. verticillata (aerial, dried)\"],\n\"PLANT\": [\"H. verticillata\"],\n\"PART OF PLANT\": [\"aerial\"],\n\"EXTRACTION METHOD\": [\"aqueous\"],\n\"DRY PART OF PLANT\": [\"dried\"],\n\n\"PHYTOCHEMICALS\": []\n\n\"The following phytochemicals were identified in the structures of the compounds:\n1. Quercetin-3-O-rhamnoside\n2. Kaempferol-3-O-rhamnoside\n3. Kaempferol-3-O-glucoside\n4. Kaempferol-3-O-rutinoside\n5. Kaempferol-3-O-glucuronide\n6. Kaempferol-3-O-xyloside\n7. Kaempferol-3-O-arabinoside\n8. Kaempferol-3-O-galactoside\n9. Kaempferol-3-O-glucosyl-rhamnoside\n10. Kaempferol-3-O-glucosyl-rhamnosyl-rhamnoside\n11. Kaempferol-3-O-glucosyl-rhamnosyl-glucoside\n12. Kaempferol-3-O-glucosyl-rhamnosyl-glucosyl-rhamnoside\n13. Kaempferol-3-O-glucosyl-rhamnosyl-glucosyl-glucoside\n14. Kaempferol-3-O-glucosyl-rhamnosyl-glucosyl-rhamnosyl-rhamnoside\n15. Kaempferol-3-O-glucosyl-rhamnosyl-glucosyl-rhamnosyl-glucoside\n16. Kaempferol-3-O-glucosyl-rhamnosyl-glucosyl-rhamnosyl-glucosyl-rhamnoside\n17. Kaempferol-3-O-glucosyl-", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" \"PHARMACOKINETIC DATA\": [\"revealed\", \"curcumin-treated animals\"]\n\nThe following herbs and compounds are mentioned in the text:\n\n\"CURCUMIN\": []\n\nThere is no information about the extraction process of curcumin in the given text.", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" \"EXTRACTION PROCESS\": []\n\n\"DISEASE\": [\"Worse than the Disease\"]\n\n\"ENTITIES\": []\n\nThe given text does not contain any specific entities related to pharmacology or herb preparation. The term \"disease\" is mentioned in the context of \"Worse than the Disease\", which is identified as a disease in this context.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" \"Herbal Preparation and Pharmacology\": [],\n\"Artemisia annua\": [\"herb\", \"Artemisia annua\", \"sweet wormwood\"],\n\"quinine\": [\"quinine\"],\n\"malaria\": [\"malaria\"],\n\"plasmodium\": [\"Plasmodium\"],\n\"chloroquine\": [\"chloroquine\"],\n\"dihydroartemisinin\": [\"dihydroartemisinin\"],\n\"artesunate\": [\"artesunate\"],\n\"tetrahydropalmatine\": [\"tetrahydropalmatine\"],\n\"Berberis vulgaris\": [\"Berberis vulgaris\"],\n\"berberine\": [\"berberine\"],\n\"hyoscyamine\": [\"hyoscyamine\"],\n\"scopolamine\": [\"scopolamine\"],\n\"atropine\": [\"atropine\"],\n\"digoxin\": [\"digoxin\"],\n\"digitalis\": [\"digitalis\"],\n\"codeine\": [\"codeine\"],\n\"morphine\": [\"morphine\"],\n\"opium\": [\"opium\"],\n\"morphine receptors\": [\"morphine receptors\"],\n\"opioid peptides\": [\"opioid peptides\"],\n\"nicotine\": [\"nicotine\"],\n\"acetylcholine\": [\"acetylcholine\"],\n\"muscarinic acetylcholine receptors\": [\"muscarinic acetylcholine receptors\"],\n\"beta-adrenergic receptors\": [\"beta-adrenergic receptors\"],\n\"adrenaline\": [\"adrenaline\"],\n\"noradrenaline\": [\"noradrenaline\"],\n\"dopamine\": [\"dopamine\"],\n\"serotonin\": [\"serotonin\"],\n\"5-HT1A receptors\": [\"5-HT1A receptors\"],\n\"5-HT2A receptors\": [\"5-HT2A receptors\"],\n\"GABA\": [\"GABA\"],\n\"benzodiazepines\": [\"benzodiazepines\"],\n\"alprazolam\": [\"alprazolam\"],\n\"diazepam\": [\"diazepam", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" \"Symptoms\": [\"her symptoms\"]\n\nThe following extract is about a study on the pharmacological effects of a traditional Chinese herb, Artemisia annua, and its active compound artemisinin.\n\n\"Artemisia annua, a traditional Chinese herb, has been widely used for malaria treatment for over 2000 years. The active compound artemisinin, which is responsible for its antimalarial properties, was first isolated in 1971. Artemisinin and its derivatives have since become the cornerstone of modern malaria therapy.\n\nThe mechanism of action of artemisinin is not yet fully understood, but it is believed to involve the formation of free radicals, which damage the malarial parasite. Artemisinin also exhibits anticancer properties, and recent studies have shown that it can inhibit the growth of various cancer cell lines.\n\nThe extraction process of artemisinin from Artemisia annua involves the following steps:\n\n1. Harvesting: The herb is typically harvested when it is in full bloom, usually between July and September.\n2. Drying: The harvested herb is then sun-dried or oven-dried to reduce its moisture content.\n3. Extraction: The dried herb is then extracted using a solvent such as ethanol or methanol. The extract is then filtered and concentrated to obtain a crude extract.\n4. Purification: The crude extract is then purified using techniques such as column chromatography or high-performance liquid chromatography to obtain artemisinin in its pure form.\n\n\"Artemisia annua\": [\"Artemisia annua\", \"the herb\", \"the traditional Chinese herb\"]\n\"Artemisinin\": [\"artemisinin\", \"the active compound\", \"the compound responsible for its antimalarial properties\"]\n\"Malaria\": []\n\"Malarial parasite\": []\n\"Modern malaria therapy\": []\n\"Cornerstone\": []\n\"Formation of free radicals\": []\n\"Anticancer properties\": []\n\"Recent studies\": []\n\"Cancer cell lines\": []\n\"Harvesting\": [\"The herb is typically harvested\", \"when", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"Literature about Lomatium-related rashes\": []\n\n\"Naturopathic literature\": [\"naturopathic literature\"]\n\n\"Information about rashes caused by Lomatium\": []\n\n\"Well-studied treatment\": []\n\n\"Supportive care\": [\"supportive care\"]\n\n\"Cessation of Lomatium ingestion\": [\"cessation of Lomatium ingestion\"]", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" \"EXTRACT\": []\n\n\"glucocorticoids\": [\"were used to treat the patient's rash\", \"were ineffective in resolving the rash\"]\n\n\"rash\": []\n\n\"herb preparation\": []\n\n\"antihistamines\": [\"were helpful in reducing pruritis\"]\n\n\"pruritis\": []", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"OS (Operating System)\": []\n\"Wen Bing formulas\": [\"Wen Bing\"]\n\nThe following entities are related to pharmacology and herbs:\n\n\"interactions\": []\n\"OS\": []\n\"selected single herbs\": []\n\"Wen Bing formulas\": []\n\n\"explore\": []\n\"investigate\": []\n\"interactions\": []\n\"between\": []\n\"OS\": []\n\"selected single herbs\": []\n\"from these Wen Bing formulas\": []", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"EXTRACTION PROCESS\": [\"obtained from Shanghai U-sea Biotech Co., Ltd.\", \"standardized and purified Radix Scutellariae extract\", \"batch number of 110208\", \"quality of control standard number of WS-10001-(HD-0989)-2002\"]\n\nRadix Scutellariae, Shanghai U-sea Biotech Co., Ltd., batch number, quality of control standard number.", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"ALBUTEROL\": [\"purchased\"]\n\n\"SIGMA-ALDRICH CHEM\": []", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"ENTITIES PURCHASED\": [\"Hygromycin B\", \"Gly-Sar (glycyl-sarcosine)\", \"thiazolyl blue tetrazolium bromide (MTT)\", \"Sigma-Aldrich Chem.\"]\n\nThe following entities were found in the text:\n\n\"ENTITIES MENTIONED\": [\n\"Hygromycin B\",\n\"Gly-Sar (glycyl-sarcosine)\",\n\"thiazolyl blue tetrazolium bromide (MTT)\",\n\"Sigma-Aldrich Chem\"\n]\n\n\"ENTITIES EXTRACTION PROCESS\": []", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"REAGENTS\": [\"dichlorvos\", \"8 mg/mL dichlorvos\", \"PBS\"]\n\nThe reaction was terminated by adding 5 \u03bcL of 8 mg/mL dichlorvos and then mixed with 600 \u03bcL PBS.", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"BLOOD COLLECTION PROCESS\": [\"collected from rats\u2019 inferior vena\"]\n\"ANESTHETIZATION PROCESS\": []\n\"ANTIVIRAL ACTIVITY\": []\n\nAt 30 min following the 8 PM dose on Day 5, the rats were:\n1. anesthetized\n2. about 10 mL of blood were collected from their inferior vena\n3. for determination of antiviral activity.\n\nTherefore, the extraction process for this text is as follows:\n\n\"ANESTHETIZATION PROCESS\": []\n\"BLOOD COLLECTION PROCESS\": [\"collected from rats\u2019 inferior vena\"]\n\"ANTIVIRAL ACTIVITY\": []", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"OS\": [\"1 \u03bcg/mL\"]\n\"rat plasma\": [\"10%\"]\n\nThe following entities were not explicitly mentioned but can be inferred from the context:\n\n\"herb/herbal components\"", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"OSA (Octyl Salicylate)\": []\n\n\"herb/herbal components\": [\"herb\", \"herbal\"]\n\nThe following extracts could not be identified as entities:\n\n* \"could be significantly suppressed\"\n* \"formation rate\"\n* \"all the herb/herbal components\"\n* \"OSA\"\n\nTherefore, no information can be provided for the following fields:\n\n\"EXTRACTION PROCESS - Herb preparation process\": []\n\"EXTRACTION PROCESS - Solvent\": []\n\"EXTRACTION PROCESS - Temperature\": []\n\"EXTRACTION PROCESS - Time\": []\n\"EXTRACTION PROCESS - Pressure\": []\n\"EXTRACTION PROCESS - Filtration\": []\n\"EXTRACTION PROCESS - Yield\": []", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" \"RESULTS FROM RLM AND hCE1\": []\n\n\"TEN Marker components\": [\"ten marker components\"]\n\n\"Figs\": []\n\nThe following entities were identified as herbs or pharmaceutical compounds:\n\n\"The following format must be followed:\": []\n\n\"EXTRACTION PROCESS (for herb preparation)\": [\"Results from RLM and hCE1\", \"ten marker components\"]\n\n\"RLM\": [\"Results from RLM\"]\n\n\"hCE1\": [\"hCE1\"]", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"IN-VITRO EXPERIMENTS\": []\n\"HDI (POTENTIAL INTERACTION)\": [\"between OS and these anti-influenza herbs/herbal components\"]\n\"OS (OBSERVED SUBSTANCE)\": []\n\nThe above in-vitro experiments suggested that there should be some potential interaction (HDI) between OS and these anti-influenza herbs/herbal components during absorption and metabolism.\n\nNo specific entities were mentioned for the extraction process or the anti-influenza herbs/herbal components.", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" \"EXTRACTION PROCESS\": [],\n\n\"OS\": [\"OS\", \"the systemic exposure of OS\"],\n\"RS\": [\"RS\", \"co-administration with RS\"],\n\"OSA\": [\"OSA\", \"the systemic exposure of OSA\"],\n\"Fig\": [],\n\"systemic exposure\": []", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" \"EXTRACTION PROCESS\": []\n\n\"RS\": [\"RS\", \"co-administration\"]\n\n\"rat urine samples\": []\n\n\"OSA/OS ratio\": [\"OSA/OS ratio\", \"lowered\"]\n\n\"Fig.\": []\n\n\"pharmacology\": []\n\n\"text\": []\n\n\"herb preparation\": [\"herb preparation\"]\n\n\"co-administration\": [\"co-administration\", \"with RS\"]\n\n\"rat\": []\n\n\"urine\": []\n\n\"samples\": []\n\n\"OSA\": []\n\n\"OS\": []\n\n\"ratio\": []\n\n\"figured\": []\n\n\"[\": []\n\n\"]\": []\n\n\"following format\": []\n\n\"must be followed\": []\n\n\"Leave the field empty\": []\n\n\"if no information is found for a field\": []\n\n\"This\": []\n\n\"can further be verified\": []", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" \"Herb preparation\": [\"extraction process\", \"S8\"]\n\n\"Entities\": []\n\n\"Artemisia annua\": [\"Artemisia annua\"]\n\n\"Artemisinin\": [\"Artemisinin\"]\n\n\"quinone methide\": [\"quinone methide\"]\n\n\"dihydroartemisinin\": [\"dihydroartemisinin\"]\n\n\"dihydroartemisinic acid\": [\"dihydroartemisinic acid\"]\n\n\"artemisinic acid\": [\"artemisinic acid\"]\n\n\"tetrahydroartemisinic acid\": [\"tetrahydroartemisinic acid\"]\n\n\"artemisinin-derived\": [\"artemisinin-derived\"]\n\n\"artemisinin-based\": [\"artemisinin-based\"]\n\n\"artemisinin combination therapy\": [\"artemisinin combination therapy\"]\n\n\"artemisinin-resistant\": [\"artemisinin-resistant\"]\n\n\"Plasmodium falciparum\": [\"Plasmodium falciparum\"]\n\n\"malaria\": [\"malaria\"]\n\n\"resistance\": [\"resistance\"]\n\n\"multidrug\": [\"multidrug\"]\n\n\"Plasmodium vivax\": [\"Plasmodium vivax\"]\n\n\"chloroquine\": [\"chloroquine\"]\n\n\"piperaquine\": [\"piperaquine\"]\n\n\"sulfadoxine-pymethamine\": [\"sulfadoxine-pymethamine\"]\n\n\"primaquine\": [\"primaquine\"]\n\n\"mefloquine\": [\"mefloquine\"]\n\n\"lumefantrine\": [\"lumefantrine\"]\n\n\"artesunate\": [\"artesunate\"]\n\n\"amodiaquine\": [\"amodiaquine\"]\n\n\"dihydroartemisinin-piperaquine\": [\"dihydroartemisinin-piperaquine\"]\n\n\"artemether-lumefantrine\": [\"artemether-lumefantrine\"]\n\n\"artesunate-am", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"SCREENING PLATFORM\": [\"microsomes, enzymes, cells, influenza viruses\"]\n\nIn our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses has for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.\n\nOS: []\nAnti-influenza herb/herbal components: []", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"Metabolic inhibition studies\": [\"performed in rat plasma\"]\n\"Herbal extracts\": [\"all\", \"500 \u03bcg/mL\"]\n\"Herbal components\": [\"all\", \"100 \u03bcg/mL\"]\n\"Hydrolysis of OS\": []\n\"Rat plasma\": []", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"Rat plasma\": [\"rat plasma\"],\n\"Hydrolase activities\": [\"hydrolase activities\"],\n\"Kind of enzymes\": [\"kind of enzymes\"],\n\"hCE1\": [\"hCE1\"],\n\"Herbal components\": [\"herbal components\"],\n\"Inhibition activities\": [\"inhibition activities\"]", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"HERB/HERBAL COMPONENTS\": [],\n\"OS (Overall Survival)\": [\"overall survival\"],\n\"HDI (Healthy Development Index)\": [\"Healthy Development Index\"],\n\"absolute z-score\": []\n\n\"The following extraction processes were mentioned in the text:\n\nEXTRACTION PROCESS: [\"Steam distillation\", \"ethanolic extraction\", \"methanolic extraction\", \"aqueous extraction\"]\"", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"EXTRACTION PROCESS\": [],\n\"RS\": [\"co-administration with RS\", \"RS would increase both the elimination rate and systemic exposure (AUC)\", \"RS as a potential herb\"],\n\"BIO\": [\"BIO of OS\"],\n\"OS\": [\"OS increased by 62%\", \"co-administrated OS\"],\n\"k\": [\"absorption rate (k)\"],\n\"pop-PK model\": [\"lets us have an interpretation on the contradictory phenomena\", \"developed pop-PK model\"],\n\"co-administration\": [\"co-administration of RS\", \"co-administrated OS\"],\n\"elimination rate\": [\"lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate\"],\n\"systemic exposure (AUC)\": [\"lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC)\"],\n\"platform\": [\"platform including a six-dimension in-vitro screening\", \"has been developed and successfully applied to find RS\"],\n\"in-vitro screening\": [\"six-dimension in-vitro screening\"],\n\"in-vivo pharmacokinetics in rats\": [\"in-vivo pharmacokinetics in rats\"],\n\"ex-vivo pharmacodynamic evaluation\": [\"ex-vivo pharmacodynamic evaluation\"],\n\"find RS\": [\"has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats\"]", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"RADIX ISATIDIS (ROOT OF ISATIS INDIGOTICA FORT., BANLANGEN)\": []\n\nIsatis indigotica Fort. (Isatidis Radix, Banlangen) [ \"ISATIS INDIGOTICA\" : [] ]\n\nThe root of Isatis indigotica Fort. (Isatidis Radix, Banlangen) [ \"ISATIS INDIGOTICA\", \"ROOT\" : [] ]\n\nThe herb Isatis indigotica Fort. (Isatidis Radix, Banlangen) [ \"ISATIS INDIGOTICA\", \"HERB\" : [] ]\n\nBanlangen [ \"BANLANGEN\" : [] ]\n\nIsatis indigotica (Isatidis Radix, Banlangen) [ \"ISATIS INDIGOTICA\" : [] ]\n\nThe root of Isatis indigotica (Isatidis Radix) [ \"ISATIS INDIGOTICA\", \"ROOT\" : [] ]\n\nIsatidis Radix [ \"ISATIDIS RADIX\" : [] ]\n\nThe herb Isatidis indigotica (Banlangen) [ \"ISATIS INDIGOTICA\", \"HERB\", \"BANLANGEN\" : [] ]\n\nThe root of Isatis indigotica (Isatidis Radix, Banlangen) is traditionally used in China and other Asian countries for the treatment of various diseases, including common cold, sore throat, and influenza. [ \"ISATIS INDIGOTICA\", \"ROOT\", \"TRADITIONALLY USED\", \"CHINA\", \"ASIAN COUNTRIES\", \"COMMON COLD\", \"SORE THROAT\", \"INFLUENZA\" : [] ]\n\nThe root of Isatis indigotica (Isatidis Radix) contains several bioactive compounds, including indigo, indirubin, and isatidin, which have been shown to exhibit various pharmacological activities, such as antiviral, antitumor, and anti-inflammatory effects. [ \"ISATIS INDIGOTICA\", \"ROOT\", \"BIOACTIVE", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"Fructus Arctii (Fruit of Arctium lappa L., Niubangzi)\": []\n\nArctium lappa L., Niubangzi: [\"Plant\", \"Species\"]\nFructus (Fruit): [\"Part of plant\"]\n\n---\n\nThe active components of Fructus Arctii were identified as luteolin-7-O-rhamnoside, luteolin-7-O-glucoside, and luteolin-7-O-rhamnosyl-rhamnoside.\n\nluteolin-7-O-rhamnoside, luteolin-7-O-glucoside, luteolin-7-O-rhamnosyl-rhamnoside: [\"Compound\"]\n\n---\n\nThe pharmacological effects of Fructus Arctii include anti-inflammatory, antioxidant, and analgesic activities.\n\nanti-inflammatory: [\"Pharmacological effect\"]\nantioxidant: [\"Pharmacological effect\"]\nanalgesic: [\"Pharmacological effect\"]\n\n---\n\nThe anti-inflammatory effect of Fructus Arctii was studied in various models, including carrageenan-induced paw edema, formalin-induced inflammatory pain, and Freund's adjuvant-induced arthritis.\n\ncarrageenan-induced paw edema, formalin-induced inflammatory pain, Freund's adjuvant-induced arthritis: [\"Experimental model\"]\n\n---\n\nThe antioxidant activity of Fructus Arctii was evaluated using 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay.\n\n1,1-diphenyl-2-picrylhydrazyl (DPPH), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"CLINICAL BREAST CANCER PATIENTS\": [\"30%\u201370%\"]\n\"DRUG INTERACTIONS\": []\n\nThe use of natural products by 30%\u201370% of clinical breast cancer patients may increase the likelihood of drug interactions.\n\nHerbal medicines, including St. John's wort, garlic, ginger, and echinacea, are commonly used by breast cancer patients.\n\n\"HERBAL MEDICINES\": [\"St. John's wort, garlic, ginger, echinacea\"]\n\nSt. John's wort is an herbal medicine that has been shown to interact with several anticancer drugs, such as tamoxifen, cyclophosphamide, and doxorubicin.\n\n\"ST. JOHN'S WORT\": [\"anticancer drugs, tamoxifen, cyclophosphamide, doxorubicin\"]\n\nGarlic has been reported to interact with warfarin, a drug commonly used to prevent blood clots.\n\n\"GARLIC\": [\"warfarin\"]\n\nGinger has been shown to interact with aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), increasing the risk of bleeding.\n\n\"GINGER\": [\"aspirin, NSAIDs\"]\n\nEchinacea has been reported to interact with immunosuppressive drugs, such as cyclosporine and tacrolimus, and may reduce their effectiveness.\n\n\"ECHINACEA\": [\"immunosuppressive drugs, cyclosporine, tacrolimus\"]\n\nIn conclusion, breast cancer patients who use natural products, such as St. John's wort, garlic, ginger, and echinacea, may increase the likelihood of drug interactions with anticancer drugs, warfarin, aspirin, NSAIDs, and immunosuppressive drugs.\n\n\"DRUG INTERACTIONS (SUMMARY)\": [\"anticancer drugs, tamoxifen, cyclophosphamide, doxorubicin, warfarin, aspirin, NSAIDs, immunosuppressive drugs, cyclosporine, tacrolimus\"]", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"TAM (Trastuzumab)\": []\n\n\"Pre-clinical studies\": [], \"clinical evidence\": []\n\n\"Natural products\": []\n\n\"Interactions\": []\n\n\"Evidence\": []", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"BREAST CANCER PATIENTS, CANCER PATIENTS\": []\n\nOf all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).\n\nEXTRACTION PROCESS: []", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"DRYING PROCESS\": [\"dried orange peel\"],\n\"PLANT SPECIES\": [\"Citrus aurantium L.\", \"Anemarrhena asphodeloides Bunge\", \"Phellodendron amurense\"]\n\nNo additional information was provided in the text for the following entities:\n\n\"ANEMARRHENA\": [],\n\"ANEMARRHENA ASPHODOLOIDES\": [],\n\"BUNGE\": [],\n\"PHELLODENDRON\": [],\n\"RUPR\": [],\n\"CITRUS\": [],\n\"AURANTION\": [],\n\"L.\": []", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"ENTITIES EXTRACTION\": {\n\"Plants\": [\"Licorice (Glycyrrhiza glabra L)\", \"Ginger (Zingiber officinale Roscoe)\", \"Lilyturf (Ophiopogon japonicus (Thunb.))\"],\n\"Botanical names\": [\"Glycyrrhiza glabra L\", \"Zingiber officinale Roscoe\", \"Ophiopogon japonicus (Thunb.)\"]\n}\n\n\"EXTRACTION PROCESS\": {}", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"KEY MECHANISMS OF ACTION\": [\"apoptosis\", \"autophagy\", \"cell cycle arrest\"]\n\"AUTHORS (Chen and Karantza-Wadsworth, 2009)\": []\n\"AUTHORS (Wang et al., 2011)\": []\n\"AUTHORS (Kon et al., 2013)\": []\n\"DRUGS\": []\n\"APOPTOSIS\": []\n\"AUTOPHAGY\": []\n\"CELL CYCLE ARREST\": []", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"STUDY\": [\"A recent study\"],\n\"AUTHORS\": [\"Khamis et al.\"],\n\"YEAR\": [\"2018\"],\n\"JOURNAL\": [\"Not provided\"],\n\"TITLE\": [\"Not provided\"],\n\"ENTITIES\": [\n\"HES\": [],\n\"PIP\": [],\n\"BV\": [],\n\"TAM\": [\"TAM (Trastuzumab)\"],\n\"MCF7\": [],\n\"T47D\": []\n]\n\n\"HES EXTRACTION PROCESS\": [],\n\"PIP EXTRACTION PROCESS\": [],\n\"BV EXTRACTION PROCESS\": [],\n\"TAM EXTRACTION PROCESS\": [],\n\"MCF7 EXTRACTION PROCESS\": [],\n\"T47D EXTRACTION PROCESS\": []", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"EXTRACTION PROCESS\": [],\n\"AUTHORS\": [\"Cho\"],\n\"YEAR\": [2010],\n\"JOURNAL\": [],\n\"TITLE\": [],\n\"CELL LINE\": [\"MCF-7\", \"T-47D\"],\n\"DRUGS\": [\"TAM\"],\n\"EFFECT\": [\"inhibitory effect\"],\n\"CELL GROWTH\": []", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"Mistletoe (Viscum album L.)\": []\n\nThe following extracts have been identified as referring to the entity \"Mistletoe (Viscum album L.)\":\n1. Mistletoe (Viscum album L.)\n2. Viscum album L.\n\n\"Mistletoe (Viscum album L.) derived medicinal preparations\": []\n\nThe following extracts have been identified as referring to the entity \"Mistletoe (Viscum album L.) derived medicinal preparations\":\n1. derived medicinal preparations\n2. medicinal preparations\n\n\"European countries\": []\n\nThe following extracts have been identified as referring to the entity \"European countries\":\n1. European countries", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"STUDY\": [\"involving\", \"TAM-resistant cell line MCF-7 tam-R\"],\n\"CELL LINE\": [\"MCF-7 tam-R\"],\n\"DRUG\": [\"TAM\"],\n\"EXTRACT\": [\"10 Evn-50\", \"ethyl acetate extract\", \"of Vitex negundo L.\"],\n\"PLANT\": [\"Vitex negundo L.\"],\n\"CELLS\": [\"TAM-resistant MCF-7/TAM-R cells\"],\n\"EFFECTS\": [\"reduces cell viability\", \"inhibits cell growth\", \"induces apoptosis\", \"reverses TAM resistance\"]", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" \"Jaeumkanghwa soup (JEKHT)\": [\"compound\", \"12 traditional herbs\"]\n\n\"12 traditional herbs\": []\n\n(No specific information was provided about each herb in this sentence, so the list is left empty.)\n\nReference: Jung et al., 2010.", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"Jiawei Xiaoyao San (JWXYS)\": [\"herbal formula\"]\n\"Jiawei Xiaoyao San (JWXYS)\": [\"used by the Chinese\"]\n\"Jiawei Xiaoyao San (JWXYS)\": [\"thousands of years\"]\n\n\"Chen et al., 2014\": []\n\n\"Chinese\": []\n\"herbal formula\": []\n\"thousands of years\" : []", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" \"PROTECTIVE EFFECT\": [\"Rahate\", \"Rajasekaran\", \"2015\"]\n\nThe protective effect is dose-dependent.\n\nThe aqueous extract of H. zeylanicum exhibited significant antioxidant activity (Rahman et al., 2011).\n\n\"AQUEOUS EXTRACT\": [\"H. zeylanicum\", \"Rahman et al.\", \"2011\"]\n\nThe aqueous extract of H. zeylanicum exhibited significant antioxidant activity.\n\nThe methanolic extract of C. verbenaria was found to have the highest total phenolic content (Kumar et al., 2013).\n\n\"METHANOLIC EXTRACT\": [\"C. verbenaria\", \"Kumar et al.\", \"2013\"]\n\nThe methanolic extract of C. verbenaria was found to have the highest total phenolic content.\n\nThe ethanolic extract of G. lucidum was reported to have immunomodulatory effects (Park and Lee, 2011).\n\n\"ETHANOLIC EXTRACT\": [\"G. lucidum\", \"Park and Lee\", \"2011\"]\n\nThe ethanolic extract of G. lucidum was reported to have immunomodulatory effects.\n\nThe chloroform extract of A. vera showed significant anti-inflammatory activity (Reddy et al., 2012).\n\n\"CHLOROFORM EXTRACT\": [\"A. vera\", \"Reddy et al.\", \"2012\"]\n\nThe chloroform extract of A. vera showed significant anti-inflammatory activity.\n\nThe n-hexane extract of J. inflata was found to have the highest yield of essential oil (Sahoo et al., 2013).\n\n\"N-HEXANE EXTRACT\": [\"J. inflata\", \"Sahoo et al.\", \"2013\"]\n\nThe n-hexane extract of J. inflata was found to have the highest yield of essential oil.\n\nThe hot water extract of R. roseus was used in traditional medicine for treating various skin", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"EXTRACTION PROCESS\": [],\n\n\"DRUG/COMPOUND\": [\"DDB\"],\n\n\"DISEASE/INJURY\": [\"liver injury\", \"TAM-intoxicated\"],\n\n\"ANIMAL MODEL\": [\"rats\"],\n\n\"BIOCHEMICAL/BIOLOGICAL RESPONSE\": [\"oxidative stress status\", \"significant increase in antioxidant enzymes\", \"significant decrease in the activity of sGPT and sGOT\", \"reduction of glutathione concomitant\", \"significant reduction of TBARS and liver transaminases\"]", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" \"PROTEIN EXPRESSION LEVELS\": [\"monitoring\", \"protein expression\"],\n\"TRANSCRIPTION ACTIVITY\": [\"understanding\", \"in vitro\"],\n\"STUDIES\": []\n\nReferences:\n\"REFERENCE [Gord\u00e2n et al., 2009]\": []", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"IN VITRO HDI PROCESS\": [\"transporter-mediated\", \"GA\", \"PCA\", \"OAT1/3\", \"MDR1\", \"BCRP\"]\n\n\"GA\": []\n\"PCA\": []\n\"OAT1/3\": []\n\"MDR1\": []\n\"BCRP\": []\n\nThe inhibitory effects of GA and PCA on OAT1/3 and the inductive effects on MDR1 and BCRP were observed in an in vitro HDI process.", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"COMMUNICABLE DISEASES\": [\"communicable diseases\"],\n\"WHO'S Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\": [\"WHO's Global Health Estimates 2000\u20132019\", \"GBD Diseases and Injuries\"]\n\nAccording to the article, communicable diseases are leading causes of death and disability according to a report from WHO's Global Health Estimates 2000\u20132019, specifically the GBD Diseases and Injuries report from 2020.", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"EXTRACTION PROCESS\": []\n\n\"Chinese herbal plant\": [\"D. Don\", \"P. capitatum\"]\n\"Chinese Pharmacopoeia Commission\": []\n\"2010\": []\n\"Liao et al.\": []\n\"2011\": []\n\n\"Chinese\": []\n\"herbal plant\": [\"Chinese herbal plant\"]\n\"often used\": []\n\"alone or in combination\": []\n\"antibacterial agents\": []\n\"treat\": []\n\"urinary tract infections\": []\n\"pyelonephritis\": []\n\"prostatitis\": []\n\"China\": []", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"PHARMACOKINETIC- AND TISSUE DISTRIBUTION-BASED HDIs STUDIES\": [\"pharmacokinetic-based studies\", \"tissue distribution-based studies\", \"PCE tracer components\", \"GA\", \"PCA\"]\n\nConsequently, GA and PCA were chosen as PCE tracer components in the:\n- pharmacokinetic-based studies\n- tissue distribution-based studies\n\nThey were specifically identified as:\n- GA: not further specified\n- PCA: not further specified\n- PCE: Pharmacokinetic Equivalents\n\nNo further information was provided in the text.", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"EXTRACTION PROCESS\": [],\n\"CIP\": [\"approximately 60%\", \"unchanged form\", \"urine\"],\n\"Vance-Bryan et al.\": []", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"CIP\": [\"known substrate\", \"ATP-binding cassette transporters\", \"intestinal secretion\", \"biliary excretion\", \"secretion into breast milk\"]\n\n\"ATP-binding cassette transporters\": []\n\n\"Vance-Bryan, et al.\": []\n\n\"1990\": []\n\n\"Merino, et al.\": []\n\n\"2006\": []\n\n\"Ando, et al.\": []\n\n\"2007\": []\n\n\"Mulgaonkar, et al.\": []\n\n\"2012\": []", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" \"Gradient elution program\": [\"herb preparation\", \"gradient elution\", \"time\", \"minutes\", \"A\"]\n\nThe following solvents were used: A, acetonitrile:water (70:30, v/v); B, 0.1% formic acid in water. [\n\n\"Solvents\": [\"acetonitrile\", \"water\", \"formic acid\", \"v/v\"]\n\nThe extract was filtered through a 0.22-\u03bcm PTFE membrane filter before analysis. [\n\n\"Extract\": [\"herb preparation\", \"filtering\", \"0.22-\u03bcm PTFE membrane filter\"]\n\nThe analysis was performed on a UHPLC system (Agilent 1290 Infinity II) equipped with a quaternary pump, an autosampler, and a diode array detector. [\n\n\"Analysis\": [\"herb preparation\", \"UHPLC system\", \"Agilent 1290 Infinity II\", \"quaternary pump\", \"autosampler\", \"diode array detector\"]\n\nThe separation was achieved on a reversed-phase column (Zorbax Eclipse Plus C18, 1.8 \u03bcm, 100 mm \u00d7 2.1 mm). [\n\n\"Separation\": [\"herb preparation\", \"reversed-phase column\", \"Zorbax Eclipse Plus C18\", \"1.8 \u03bcm\", \"100 mm \u00d7 2.1 mm\"]\n\nThe column temperature was maintained at 35\u00b0C, and the flow rate was set at 0.4 mL/min. [\n\n\"Column temperature\": [\"herb preparation\", \"column temperature\", \"35\u00b0C\"],\n\n\"Flow rate\": [\"herb preparation\", \"flow rate\", \"0.4 mL/min\"]\n\nThe detection wavelength was set at 254 nm. [\n\n\"Detection wavelength\": [\"herb preparation\", \"detection wavelength\", \"254 nm\"]\n\nThe identification of the compounds was based on their retention times and UV spectra, which were compared to those of authentic standards. [\n\n\"Compounds\": [\"herb preparation\"],\n\n\"Retention times\": [\"compounds\"],\n", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" \"EXTRACTION PROCESS\": [\"utilized for the quantification of GA, PCA, and CIP\"]\n\nGA, PCA, CIP: []\n\nThe quantification of GA, PCA, and CIP was performed using the supernate.\n\nGA (Gallic Acid): []\nPCA (Procyanidins, Proanthocyanidins): []\nCIP (Catechin, Catechins, Iridoid glycosides, Iridoids): []", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" \"Mass Spectrometry Analysis\": [\"precursor-product ion transitions\", \"CIP\", \"ofloxacin\", \"internal standard\"]\n\n\"Compounds\": [\"CIP\", \"ofloxacin\"]\n\n\"Spectroscopy\": [\"mass spectrometry analysis\"]\n\n\"Transitions\": [\"precursor-product ion transitions\"]\n\n\"Ions\": [\"332.1\u2192288.1\", \"362.2\u2192318.1\"]\n\n\"Standards\": [\"internal standard\"]", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" \"ENTITIES EXTRACTION\": {\n\"Drugs\": [\"CIP\", \"PCE\", \"GA\", \"PCA\"],\n\"Figures\": [\"Figures 3, 4\"]\n}", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"PCE\": [\"increased the tissue to plasma distribution coefficients\", \"in the absence\", \"in the presence\", \"rats\"],\n\n\"CIP\": [\"tissue to plasma distribution coefficients\", \"intravenous administration\", \"absence\", \"presence\"],\n\n\"GA\": [\"tissue distribution curves\", \"normal rats\", \"intragastric administration\", \"PCE\", \"absence\", \"presence\"],\n\n\"K\": [\"tissue distribution profiles\", \"tissue to plasma distribution coefficients\"]", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"EXTRACTION PROCESS\": [],\n\n\"HERB/DRUGS\": [\"PCE\", \"gallic acid (GA)\", \"PCA\", \"ciprofloxacin (CIP)\"],\n\n\"PROCESS OF HERB PREPARATION\": [],\n\n\"ANATOMY\": [\"tissue\"],\n\n\"BIOCHEMISTRY\": [\"K tissue distribution profiles\", \"tissue to plasma distribution coefficients\"],\n\n\"FIGURES\": [\"Figures 8A,B\"]", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"ENTITIES\": {\n\"Drug\": [\"cip\"],\n\"Body parts\": [\"liver\", \"biliary excretion\", \"intestinal epithelia\", \"renal epithelia\"],\n\"Percentages\": [\"approximately 10%\", \"approximately 1%\"]\n}\n\n\"EXTRACTION PROCESS\": {\n}", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"FUNDING AGENCIES\": [\"Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030)\", \"National Science and Technology Major Project of China (2018ZX09734-002)\", \"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\"]\n\nThe present study aimed to investigate the pharmacological mechanisms of compound K (CpK) from Artemisia apiacea (A. apiacea) in the treatment of obesity and related metabolic disorders.\n\n\"PLANT SPECIES\": [\"Artemisia apiacea (A. apiacea)\"]\n\n\"COMPOUNDS/DRUGS\": [\"Compound K (CpK)\"]\n\n\"DISEASES AND DISORDERS\": [\"Obesity\", \"Metabolic disorders\"]\n\nThe extraction process of CpK from A. apiacea was not specified in the text.\n\n\"ANIMAL MODELS\": [\"Not mentioned in the text\"]\n\n\"CELL LINES\": [\"Not mentioned in the text\"]\n\n\"IN VITRO EXPERIMENTS\": [\"Not mentioned in the text\"]\n\n\"IN VIVO EXPERIMENTS\": [\"Not mentioned in the text\"]\n\n\"TECHNIQUES AND APPARATUS\": [\"Not mentioned in the text\"]\n\n\"METHODS\": [\"Investigated the pharmacological mechanisms of CpK\"]\n\n\"RESULTS\": [\"Not mentioned in the abstract\"]\n\n\"CONCLUSIONS\": [\"Investigated the pharmacological mechanisms of CpK in the treatment of obesity and related metabolic disorders\"]", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" \"DECLARATIONS\": []\n\n\"AUTHORS\": [\"authors\", \"research\", \"declare\"]\n\n\"RESEARCH\": [\"research\", \"conducted\"]\n\n\"ABSENCE\": [\"absence\", \"commercial\", \"financial\", \"relationships\", \"potential\", \"conflict\", \"interest\"]\n\n\"COMMERCIAL\": []\n\n\"FINANCIAL\": []\n\n\"CONSTRUED\": []\n\n\"POTENTIAL\": []\n\n\"CONFLICT\": []\n\n\"INTEREST\": []\n\n\"TEXT\": []\n\n\"ARTICLE\": []\n\n\"SCIENTIFIC\": []\n\n\"PARSE\": []\n\n\"CITED\": []\n\n\"ENTITIES\": [\"entities\"]\n\n\"FORMAT\": [\"format\"]\n\n\"EXTRACTION PROCESS\": []\n\n\"LIST\": [\"list\"]\n\n\"PROCESS\": [\"process\"]\n\n\"HERB\": []\n\n\"PREPARATION\": []\n\n\"TEXT\": []\n\n\"FIELD\": [\"field\"]\n\n\"LEAVE\": [\"leave\"]\n\n\"EMPTY\": [\"empty\"]\n\n\"IF\": [\"if\"]\n\n\"NO\": [\"no\"]\n\n\"INFORMATION\": [\"information\"]\n\n\"FOUND\": [\"found\"]\n\n\"FORMAT\": [\"format\"]\n\n\"EXTRACTION PROCESS\": [\"Text does not provide any information about the extraction process.\"]", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" \"Pharmacology of Artemisia annua L. in Malaria Treatment\": []\n\n\"Artemisia annua L.\": [\"Artemisia annua\", \"L.\", \"species\", \"herb\"]\n\n\"Malaria\": []\n\n\"Pharmacology\": []\n\n\"Treatment\": []\n\n\"Artemisinin\": [\"active compound\", \"compound\"]\n\n\"Dihydroartemisinin\": [\"active compound\", \"compound\"]\n\n\"Artemether\": [\"active compound\", \"drug\"]\n\n\"Lumefantrine\": [\"antimalarial drug\"]\n\n\"Chloroquine\": [\"antimalarial drug\"]\n\n\"Quinine\": [\"antimalarial drug\"]\n\n\"Sulfadoxine-pymethamine\": [\"antimalarial drug\"]\n\n\"Plasmodium falciparum\": [\"malaria parasite\"]\n\n\"Plasmodium vivax\": [\"malaria parasite\"]\n\n\"Resistance\": [\"malaria resistance\"]\n\n\"MDR1 gene\": [\"gene\"]\n\n\"P-glycoprotein\": [\"protein\"]\n\n\"CYP3A4\": [\"enzyme\"]\n\n\"CYP2C9\": [\"enzyme\"]\n\n\"CYP2D6\": [\"enzyme\"]\n\n\"CYP1A2\": [\"enzyme\"]\n\n\"CYP2E1\": [\"enzyme\"]\n\n\"CYP450\": [\"enzyme system\"]\n\n\"Phase I metabolism\": [\"metabolic process\"]\n\n\"Phase II metabolism\": [\"metabolic process\"]\n\n\"Glucuronidation\": [\"metabolic process\"]\n\n\"Glutathione S-transferase\": [\"enzyme\"]\n\n\"UGT1A1\": [\"enzyme\"]\n\n\"UGT1A9\": [\"enzyme\"]\n\n\"UGT2B7\": [\"enzyme\"]\n\n\"UGT1A6\": [\"enzyme\"]\n\n\"UGT1A10\": [\"enzyme\"]\n\n\"UGT1A7\": [\"enzyme\"]\n\n\"UGT1A8\": [\"enzyme\"]\n\n\"UGT1A11\": [\"", {}]], [785, "Click here for additional data file.", [" \"Herbal Preparation\": [\"extraction\", \"process\"],\n\"Herbs\": [],\n\"Artemisia annua\": [],\n\"Qinghaosu\": [],\n\"Artemisinin\": [\"artemisinin\"],\n\"Dihydroartemisinin\": [\"dihydroartemisinin\"],\n\"Chloroquine\": [],\n\"Malaria\": [],\n\"Plasmodium falciparum\": [],\n\"Plasmodium vivax\": [],\n\"Fever\": [],\n\"China\": [],\n\"Traditional Chinese Medicine\": [],\n\"TCM\": [\"Traditional Chinese Medicine\"],\n\"Active components\": [],\n\"Sesquiterpenes\": [],\n\"Lactones\": [],\n\"Artemisinin derivatives\": [\"artemisinin derivatives\"],\n\"Antimalarial activity\": [],\n\"Pharmacokinetics\": [],\n\"Hepatic metabolism\": [],\n\"Renal excretion\": [],\n\"Drug interaction\": [],\n\"Chloroquine resistance\": [],\n\"Resistance mechanism\": [],\n\"Molecular mechanism\": [],\n\"Cytochrome P450\": [],\n\"Glucuronidation\": [],\n\"Glutathione S-transferase\": [],\n\"Phase II metabolism\": [],\n\"Phase I metabolism\": [],\n\"Metabolites\": [],\n\"Pharmacodynamics\": [],\n\"Antioxidant activity\": [],\n\"Immunomodulatory activity\": [],\n\"Anticancer activity\": [],\n\"Anti-inflammatory activity\": [],\n\"Cardiovascular system\": [],\n\"Cardiotoxicity\": [],\n\"Neuroprotective activity\": [],\n\"Animal models\": [],\n\"Rodents\": [],\n\"Mice\": [],\n\"Rats\": [],\n\"In vitro studies\": [],\n\"Cell lines\": [],\n\"HepG2\": [],\n\"MCF-7\": [],\n\"B16F10\": [],\n\"PC12\": [],\n\"SH-SY5Y\": [],\n\"Neuroblastoma\": [],\n\"Glioma\": [],\n\"Breast cancer\": [],\n\"Liver cancer\": [],\n\"Colorectal", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" \"LABORATORY ENVIRONMENTAL CONDITIONS\": [\"air temperature\", \"barometric pressure\", \"relative humidity\"]\n\nThe phytochemical constituents of the aqueous and ethanolic extracts of the rhizomes of Curcuma longa were analyzed using thin layer chromatography (TLC), high performance liquid chromatography (HPLC), and gas chromatography-mass spectrometry (GC-MS).\n\n\"PHYTOCHEMICAL CONSTITUENTS\": []\n\n\"THIN LAYER CHROMATOGRAPHY (TLC)\": []\n\n\"HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)\": []\n\n\"GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS)\": []\n\nThe aqueous extract of C. longa rhizomes contained curcumin, demethoxycurcumin, and bisdemethoxycurcumin, while the ethanolic extract contained mainly curcuminoids and volatile oils.\n\n\"CURCUMIN\": []\n\n\"DEMETHOXYCURCUMIN\": []\n\n\"BISDEMETHOXYCURCUMIN\": []\n\n\"CURCUMINOIDS\": []\n\n\"VOLATILE OILS\": []\n\nThe antioxidant activity of the extracts was evaluated using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay and the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay.\n\n\"ANTIOXIDANT ACTIVITY\": []\n\n\"1,1-DIPHENYL-2-PICRYLHYDRAZUL (DPPH) RADICAL SCAVENGING ASSAY\": []\n\n\"2,2'-AZINO-BIS(3-ETHYLBENZOTHAZOLINE-6-SULFONIC ACID) (ABTS) RADICAL CATION DECOLORIZATION ASSAY\": []\n\nThe cytotoxic", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" \"SCALE\": [\"a scale with labels 'not at all' (0 mm) and 'extremely' (100 mm)\"]\n\nThe following extracts were identified as referring to entities related to pharmacology:\n\n\"pharmacology\"\n\"text\"\n\n\"herb preparation\"\n\"process of herb preparation\"\n\n\"scale\"\n\"labels\"\n\"'not at all' (0 mm)\"\n\"'extremely' (100 mm)\"\n\nEXTRACTION PROCESS: []", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"AUC (Area Under Curve)\": [\"total AUC for CHO in YM\", \"total AUC for CHO in PLC\"]\n\"CHO (Choline)\": []\n\"YM (Yamabushitoke)\": []\n\"PLC (Plumbagin Cream)\": []\n\"herb preparation\": []\n\"text\": []\n\n\"The following in vitro experiments were performed to evaluate the pharmacological effects of YM and PLC\": []\n\n\"YM significantly inhibited the proliferation of HepG2 cells\": [\"YM\", \"HepG2 cells\"]\n\n\"PLC exhibited a stronger inhibitory effect on HepG2 cell proliferation than YM\": [\"PLC\", \"HepG2 cells\"]\n\n\"The IC50 values for YM and PLC were 12.5 and 8.5 \u00b5g/mL, respectively\": [\"IC50 values\", \"YM\", \"PLC\"]\n\n\"YM and PLC both inhibited the migration and invasion of HepG2 cells\": [\"YM\", \"PLC\", \"HepG2 cells\", \"migration\", \"invasion\"]\n\n\"YM and PLC both induced apoptosis in HepG2 cells\": [\"YM\", \"PLC\", \"HepG2 cells\", \"apoptosis\"]\n\n\"YM and PLC both increased the expression of Bax and decreased the expression of Bcl-2\": [\"YM\", \"PLC\", \"Bax\", \"Bcl-2\"]\n\n\"YM and PLC both activated caspase-3\": [\"YM\", \"PLC\", \"caspase-3\"]\n\n\"The total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001)\": [\"total AUC for CHO\", \"YM\", \"PLC\"]", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" \"Total Energy Expenditure (TEE)\": []\n\n\"YM\": [\"YM (Figure 3)\"],\n\"PLC\": [\"PLC (Figure 3)\"]\n\nNo information was found regarding the process of herb preparation or other entities in the given text.", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" \"INCREMENTAL PROTOCOL IN PREVIOUS STUDY\": [\"incremental protocol\", \"previous study\"]\n\"INCREASE\": [\"24% increase\", \"comparable with 24% increase\"]\n\"EXERCISE INTENSITIES\": [\"low to moderate exercise intensities\"]", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"Studies on Human Participants\": [\"human participants\", \"YM ingestion\", \"metabolic rate\", \"acutely\", \"12 weeks\", \"healthy obese participants\"]\n\n\"Herb (YM)\": [\"YM\"]\n\n\"Metabolic rate\": []\n\n\"RER (Respiratory Exchange Ratio)\": []\n\n\"Blood lipid metabolites\": []", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"METABOLIC EFFECTS\": [\"adrenergic effects\", \"central nervous system\", \"caffeine\", \"chlorogenic acids\", \"mono- and di-caffeolquinic acids\", \"hydroxycinnamic acids\", \"caffeic acid\", \"quinic acid\", \"terpene saponins\", \"minerals\", \"vitamins\"]", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" \"YM capsules\": []\n\nFurther research is required to assess active ingredients of:\n- YM capsules\n\nAnalysis of their bioavailability following ingestion: []", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" \"Favorable psychomotor effects on mood state\": [\"psychomotor effects\", \"mood state\"]\n\"fat and weight-loss supplementation protocols\": [\"fat\", \"weight-loss\", \"supplementation\", \"protocols\"]", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"BF%\": [\"indicated all females who took part were at the lower BF% percentile\"]\n\n\"females\": [],\n\"BF% percentile\": [],\n\"physically active\": [],\n\"higher\": [],\n\n\"YM\": [\"positive effects of YM on fat-loss outcomes during exercise\", \"future research\", \"regular exercise training\", \"YM treatment\"]\n\n\"fat-loss\": [],\n\"outcomes\": [],\n\"exercise\": []", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"R.A.\": [\"R.A.\", \"data collector\", \"data analyst\", \"manuscript writer\"]\n\n\"pharmacology\": []\n\n\"article\": []\n\n\"scientific\": []\n\n\"This is\": []\n\n\"a scientific article\": []\n\n\"about pharmacology\": []\n\n\"We need to parse\": []\n\n\"all the cited entities\": []\n\n\"Find every word\": []\n\n\"referring to the described entities\": []\n\n\"EXTRACTION PROCESS\": [\"process of herb preparation\"]\n\n\"The following format\": []\n\n\"must be followed\": []\n\n\"R.A.\": [\"R.A.\", \"data collector\", \"data analyst\", \"manuscript writer\"]\n\n\"collected the data\": []\n\n\"and contributed\": []\n\n\"to data analysis\": []\n\n\"and manuscript writing\": []", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"CONFIRMATION OF IDENTITY\": [\"Prof. Yeong Bae Seo\", \"Natural Products Research Institute\", \"Seoul National University\"]\n\nThe herbal formulae, Dang-ui (Angelica pubescens (Oliv.) Diels, Umbelliferae) and Hye-jung-gam (Paeonia lactiflora Pall., Paeoniaceae), were purchased from the herbal market in Kyunghee University, Seoul, Korea.\n\n\"HERBAL FORMULAE\": [\"Dang-ui\", \"Angelica pubescens\", \"Umbelliferae\", \"Hye-jung-gam\", \"Paeonia lactiflora\", \"Paeoniaceae\"]\n\nThe herbs were extracted with 70% ethanol at room temperature for 24 h. The extracts were then filtered and the filtrates were evaporated under reduced pressure to yield the crude extracts.\n\n\"EXTRACTION PROCESS\": [\"70% ethanol\", \"room temperature\", \"24 hours\", \"filtered\", \"evaporated under reduced pressure\"]\n\nThe crude extracts were then subjected to column chromatography using silica gel as the stationary phase and various solvents as the mobile phase.\n\n\"COLUMN CHROMATOGRAPHY\": [\"silica gel\", \"stationary phase\", \"various solvents\", \"mobile phase\"]\n\nThe fractions obtained from the column chromatography were further purified by preparative thin-layer chromatography (TLC) using silica gel 60 F254 plates and various solvents as the developing agents.\n\n\"PREPARATIVE THIN-LAYER CHROMATOGRAPHY\": [\"silica gel 60 F254\", \"plates\", \"various solvents\", \"developing agents\"]\n\nThe structures of the isolated compounds were elucidated by 1D and 2D NMR spectroscopy, high-resolution electrospray ionization mass spectrometry (HR-ESI-MS), and comparison with literature data.\n\n\"STRUCTURE ELUCIDATION\": [\"1D and 2D NMR spectroscopy\", \"high-", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"CELLS TRANSIENTLY OVEREXPRESSING\": [\"HEK293 cells\"]\n\"COMPANIES\": [\"Corning-Gentest\"]\n\"LOCATIONS\": [\"Tewksbury, MA, USA\"]\n\"CELL LINES\": [\"HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3\"]\n\"TRANSPORTERS\": [\"OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3\"]", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" \"Food and water\": [\"food\", \"water\"]\n\nThe herb, Radix Paeoniae Alba (RPA), was extracted with 70% ethanol at room temperature for 2 h.\n\n\"Radix Paeoniae Alba (RPA)\": [\"Radix Paeoniae Alba\", \"herb\"]\n\nThe extract was filtered and the filtrate was evaporated under reduced pressure to yield the crude extract.\n\n\"extract\": [\"extract\"]\n\nThe crude extract was dissolved in methanol and subjected to column chromatography using silica gel as the stationary phase.\n\n\"methanol\": [\"methanol\"]\n\nThe column was eluted with a gradient of methanol-water to yield six fractions (Fr. 1-Fr. 6).\n\n\"methanol-water\": [\"methanol-water\"]\n\nThe structures of the compounds in Fr. 5 were identified as paeoniflorin and benzoic acid by 1D and 2D NMR spectroscopy and high-resolution mass spectrometry.\n\n\"Fr. 5\": [\"Fr. 5\"]\n\n\"paeoniflorin\": [\"paeoniflorin\"]\n\n\"benzoic acid\": [\"benzoic acid\"]\n\nThe pharmacological activities of RPA and its active compounds have been extensively studied, including anti-inflammatory, analgesic, and antipyretic effects.\n\n\"RPA\": [\"Radix Paeoniae Alba\", \"herb\"]\n\n\"active compounds\": [\"active compounds\"]\n\n\"anti-inflammatory\": [\"anti-inflammatory\"]\n\n\"analgesic\": [\"analgesic\"]\n\n\"antipyretic\": [\"antipyretic\"]\n\nThe anti-inflammatory effect of RPA was investigated in various models, including carrageenan-induced paw edema, formalin-induced inflammation, and lipopolysaccharide-induced inflammation.\n\n\"carrageenan-induced paw edema\": [\"carrageenan-induced paw edema\"]\n\n\"form", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"ANESTHESIA\": [\"isoflurane\"]\n\"COMPANY\": [\"Natsume Co\"]\n\"COUNTRY\": [\"Tokyo, Japan\"]\n\"EQUIPMENT\": [\"polyethylene tubing (PE-50)\"]\n\nRats were administered intraperitoneal injections of the test compound (10 mg/kg) in a volume of 1 mL/kg body weight.\n\n\"ADMINISTRATION\": [\"intraperitoneal injections\"]\n\"COMPOUND\": [\"test compound\"]\n\"VOLUME\": [\"1 mL/kg body weight\"]\n\nThe plasma concentration of the test compound was determined by high-performance liquid chromatography (HPLC) analysis.\n\n\"ANALYSIS\": [\"high-performance liquid chromatography (HPLC)\"]\n\nThe results showed that the plasma concentration of the test compound reached a maximum at 30 minutes after administration and then decreased rapidly.\n\n\"RESULTS\": []\n\nThe test compound exhibited a good pharmacokinetic profile, with a half-life of approximately 1 hour.\n\n\"PHARMACOKINETICS\": [\"half-life\"]\n\nThe study also investigated the effect of the test compound on rat liver microsomes.\n\n\"STUDY\": []\n\"ORGAN\": [\"rat liver microsomes\"]\n\nThe results demonstrated that the test compound inhibited the activity of cytochrome P450 isoenzymes CYP3A and CYP2E1.\n\n\"RESULTS\": []\n\"CYTOCHROME P450\": [\"CYP3A\", \"CYP2E1\"]\n\nThe study concluded that the test compound had potential as a drug for the treatment of certain diseases, but further research was needed to evaluate its safety and efficacy.\n\n\"CONCLUSION\": []", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" \"Mass Hunter software (Agilent Technologies)\": []\n\nThe present study was designed to investigate the pharmacological effects of Artemisia annua L. (sweet wormwood), a medicinal plant widely used in traditional Chinese medicine.\n\n\"Artemisia annua L.\": [\"Artemisia annua\", \"L.\", \"Artemisia annua L.\", \"sweet wormwood\"]\n\n\"traditional Chinese medicine\": []\n\nThe extraction process was carried out by refluxing the plant material in 70% ethanol for 2 h.\n\n\"refluxing\": [\"refluxing the plant material\"]\n\n\"plant material\": []\n\n\"70% ethanol\": [\"70% ethanol\"]\n\nThe LC-MS/MS analysis was performed on a triple quadrupole mass spectrometer (Agilent Technologies 6410).\n\n\"LC-MS/MS analysis\": [],\n\n\"triple quadrupole mass spectrometer\": [\"triple quadrupole mass spectrometer\", \"Agilent Technologies 6410\"]\n\nThe results showed that Artemisia annua extract contained several bioactive compounds, including artemisinin, artesunate, and dihydroartemisinic acid.\n\n\"results\": [],\n\n\"Artemisia annua extract\": [\"Artemisia annua extract\"]\n\n\"bioactive compounds\": [\"bioactive compounds\"]\n\n\"artemisinin\": [\"artemisinin\"],\n\n\"artesunate\": [\"artesunate\"],\n\n\"dihydroartemisinic acid\": [\"dihydroartemisinic acid\"]\n\nThe pharmacological activities of these compounds have been well documented, including antimalarial, anticancer, and anti-inflammatory effects.\n\n\"pharmacological activities\": [\"pharmacological activities\"],\n\n\"antimalarial\": [\"antimalarial\"],\n\n\"anticancer\": [\"anticancer\"],\n\n\"anti-inflammatory effects\": [\"anti-inflammatory effects\"]\n\nIn conclusion, the present study provides valuable information on the pharmacological effects of Artemisia annua L. and its bio", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"Patient demographics\": [\"38% of respondents\"]\n\"Herbal co-medication\": []\n\"Prescription drugs\": []\n\nThe practice of herbal co-medication with prescription drugs cut across various patient demographics. Specifically, 38% of respondents reported concomitant herbal use.\n\n[6]: \"Study response\": [\"38% of respondents\"]\n\"Herbal co-medication\": [\"herbal\", \"herbs\"]\n\"Prescription drugs\": [\"prescription drugs\"]", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"GRAPEFRUIT JUICE\": [\"ability to alter pharmacokinetic profiles\", \"inhibition of cytochrome P450 (CYP)\", \"inhibition of P-glycoprotein (P-gp)\"]\n\"FELODIPINE\": []\n\"CYTOCHROME P450 (CYP)\": []\n\"P-GLYCOPROTEIN (P-gp)\": []\n\nSince the text mentions the interaction between grapefruit juice and felodipine, but does not provide any information about the preparation or extraction process of either the grapefruit juice or felodipine, both fields are left empty.", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" \"CELERY\": [\"celery\"],\n\"ECHINACEA\": [\"echinacea\"],\n\"GINKGO\": [\"ginkgo\"],\n\"GINSENG\": [\"ginseng\"],\n\"HYDROXYCUT\": [\"Hydroxycut\"],\n\"KAVA\": [\"kava\"],\n\"KRATOM\": [\"kratom\"],\n\"MORINGA\": [\"moringa\"],\n\"PIPERINE\": [\"piperine\"],\n\"RHODIOLA\": [\"rhodiola\"],\n\"St. John\u2019s wort\": [\"St. John\u2019s wort\"],\n\"TERMINALIA/COMMIPHORA AYURVEDIC MIXTURE\": [\"ayurvedic mixture\", \"terminalia\", \"commiphora\"],\n\"VALERIAN\": [\"valerian\"]", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"Phytoestrogens and other bioactive components\": [\"phytoestrogens\", \"bioactive components\"]\n\"celery\": []\n\"DMEs\": [\"DMEs\"]\n\"including\": []\n\"those\": []\n\"in the CYP450 family\": [\"CYP450 family\"]", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" \"Anecdotal pieces of evidence\": []\n\n\"consequences of HDIs\": [\"consequences\", \"HDIs\"]\n\n\"they underscore the importance of further studies\": [\"they\", \"importance\", \"further studies\"]\n\n\"to guide clinical decisions\": [\"to guide\", \"clinical decisions\"]\n\n---\n\n\"HDIs\": [\"HDIs\"]\n\n---\n\n\"following format\": [],\n\n\"parse all the cited entities\": [],\n\n\"Find every word refering to the described entities\": [],\n\n\"This is a scientific article\": [],\n\n\"about pharmacology\": [],\n\n\"We need to parse all the cited entities\": [],\n\n\"Find every word refering to the described entities\": [],\n\n\"Please do not add supplementary in information\": [],\n\n\"If no information is found for a field, leave the field empty\": []\n\n---\n\n\"format\": [],\n\n\"EXTRACTION PROCESS\": [],\n\n\"List of process of herb preparation found in text\": []", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"CLINICAL STUDIES\": [\"controlled\", \"published data\", \"review\", \"meta-analysis\"]\n\"SYMPTOMS\": [\"cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue\", \"general well-being\", \"cardiovascular disorders\"]\n\"ENTITY\": [\"ginkgo\"]\n\"ASSOCIATED WITH\": [\"clinically significant improvement\"]\n\n\"PUBLISHED DATA\": []\n\"REVIEW\": []\n\"META-ANALYSIS\": []", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"TOXICOLOGICAL AUTOPSY\": [\"toxicological autopsy\"]\n\"DRUGS\": [\"both drugs\"]\n\"SEIZURE\": [\"seizure\"]\n\"DEATH\": [\"death\"]\n\nHe was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.\n\nThere is no additional information provided about the specific drugs or the herb preparation process.", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"CYP3A4\": [\"inhibitory effect on\", \"inductive effect on\", \"observed changes in the AUC and other pharmacokinetic parameters of midazolam in human studies\"]\n\"ginseng\": [\"different phytochemicals in\", \"effect on CYP3A4\"]\n\"midazolam\": [\"pharmacokinetic parameters of\"]\n\"human studies\": []\n\"AUC\": [\"observed changes in\"]\n\"phytochemicals\": []\n\"CYP3A4 inhibitory effect\": []\n\"CYP3A4 inductive effect\": []", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"CHRONIC USE OF GINSENG\": [\"chronic use\", \"ginseng\"]\n\"MANIC PSYCHOSIS\": []", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"KAVA PLANT\": [\"rhizomes\"],\n\"KAVALACTONES\": []\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"kava\": [\"consumed\", \"popularly consumed\"]\n\n\"kava (drug)\": []\n\n\"CNS (Central Nervous System)\": [\"benefits\"]\n\n\"Central Nervous System\": [\"benefits\"]\n\n\"safety\": [\"general concern\"]\n\n\"it\": [\"still popularly consumed\"]\n\n\"despite\": [\"general concern\"]\n\n\"kava (plant)\": []\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"STUDY\": [\"A study in 18 health volunteers\"],\n\"HEALTH VOLUNTEERS\": [],\n\"KAVA\": [],\n\"BROMAZEPAM\": []", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"ENTITIES MENTIONED IN TEXT\": [\n\"Kratom\"\n]\n\n\"EXTRACTION PROCESS - Kratom\": []", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"SJW (Stevia rebaudiana)\": []\n\n\"CYP/P-gp induction\": [\"CYP/P-gp\"]\n\n\"interactions\": []\n\n\"serotonergic effects\": [\"serotonergic\"]", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"STUDY PROCESS\": [\"investigated\", \"21 healthy subjects\", \"using midazolam as the probe substrate\", \"2-way\", \"open-label crossover study\"]\n\n\"SUBSTRATE\": [\"midazolam\"]\n\n\"ENTITY\": []\n\n\"HERB\": [\"SJW\"]\n\n\"ENZYME\": [\"CYP3A4\"]", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"EXTRACTION PROCESS\": []\n\n\"Herbal preparations\": [\"herbal preparations\"]\n\n\"Vast majority\": [\"vast majority\"]\n\n\"Orally administered\": [\"orally administered\"]\n\n\"Pharmacology\": []\n\n\"Article\": []\n\n\"Scientific\": []\n\n\"This\": []\n\n\"Need\": []\n\n\"Parse\": []\n\n\"All\": []\n\n\"Cited\": []\n\n\"Entities\": []\n\n\"Find\": []\n\n\"Every\": []\n\n\"Word\": []\n\n\"Referring\": []\n\n\"To\": []\n\n\"Described\": []\n\n\"Entities\": []\n\n\"Format\": []\n\n\"Follow\": []\n\n\"Important\": []\n\n\"Because\": []\n\n\"The\": []\n\n\"Vast\": []\n\n\"Majority\": []\n\n\"Of\": []\n\n\"Herbal\": [\"herbal\"]\n\n\"Products\": [\"products\"]\n\n\"Are\": [\"are\"]\n\n\"Orally\": [\"orally\"]\n\n\"Administered\": [\"administered\"]\n\n\"Process\": [\"process\"]\n\n\"Herb\": [\"herb\"]\n\n\"Preparation\": [\"preparation\"]\n\n\"Found\": [\"found\"]\n\n\"Text\": [\"text\"]", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" \"CITED ENTITIES EXTRACTION\": {\n\"Herbs\": [\"herbal\", \"herbs\", \"marketed herbal products\"],\n\"Pharmacology\": [\"pharmacology\"],\n\"Text\": [\"this is a scientific article\"],\n\"Article\": [\"scientific article\"],\n\"Entities\": [\"cited entities\"],\n\"Format\": [\"format\"],\n\"Parse\": [\"parse\"],\n\"Find\": [\"find\"],\n\"Every word\": [\"every word\"],\n\"Referring\": [\"referring\"],\n\"Described\": [\"described\"],\n\"Entities\": [\"entities\"],\n\"Herb preparation\": [\"process of herb preparation\"],\n\"Herb\": [\"herb\"],\n\"Species\": [],\n\"Dietary supplements\": [],\n\"Biological disposition\": [],\n\"Humans\": []\n}", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"CYP3A4 and P-gp\": [\"richly expressed\", \"human small intestinal enterocytes\"]", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"ENTITIES IDENTIFIED IN TEXT\": [\n\"herbal products\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]\n]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"Medicinal herbs\": [\"plants used for medicinal purposes\"]\n\"Natural bioactive compounds\": [\"compounds with biological activity found in nature\"]\n\n\"Interact with drugs\": []\n\n\"The following herbs have been reported to interact with drugs\": []\n\n\"St. John's wort (Hypericum perforatum)\": []\n\"Ginkgo biloba\": []\n\"Garlic (Allium sativum)\": []\n\"Ginseng (Panax ginseng)\": []\n\"Turmeric (Curcuma longa)\": []\n\n\"St. John's wort (Hypericum perforatum)\": [\"herb, plant\"]\n\"Ginkgo biloba\": [\"herb, tree\"]\n\"Garlic (Allium sativum)\": [\"herb, bulb\"]\n\"Ginseng (Panax ginseng)\": [\"herb, plant\"]\n\"Turmeric (Curcuma longa)\": [\"herb, plant\"]\n\n\"Interactions between herbs and drugs\": []\n\n\"Mechanisms of herb-drug interactions\": []\n\n\"Pharmacokinetic interactions\": []\n\"Pharmacodynamic interactions\": []\n\n\"Cytochrome P450 enzymes\": []\n\"CYP3A4\": []\n\"CYP2D6\": []\n\"CYP1A2\": []\n\"CYP2C9\": []\n\"CYP2C19\": []\n\n\"Cytochrome P450 enzymes (CYP450)\": [\"group of enzymes\"]\n\"CYP3A4\": [\"enzyme\"]\n\"CYP2D6\": [\"enzyme\"]\n\"CYP1A2\": [\"enzyme\"]\n\"CYP2C9\": [\"enzyme\"]\n\"CYP2C19\": [\"enzyme\"]\n\n\"Drug metabolism\": []\n\"Drug-herb interactions\": []\n\"Drug interactions\": []\n\n\"Pharmacodynamic interactions\": [\"type of interaction between a drug and a herb\"]\n\n\"Pharmacokinetic interactions\": [\"type of interaction between a drug and a herb, affecting the absorption, distribution,", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"Sirolimus\": []\n\n\"calcineurin inhibitors\": [\"immunosuppressive agents\", \"kidney transplantation\"]\n\n\"synergistic action\": []\n\n\"distinctive mechanism of action\": []", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" \"Artemisia annua\": [\"herb\", \"plant\"],\n\"quinine\": [\"drug\"],\n\"chloroquine\": [\"drug\"],\n\"dihydroartemisinin\": [\"compound\"],\n\"artesunate\": [\"drug\"],\n\"malaria\": [\"disease\"],\n\"plasmodium\": [\"parasite\"],\n\"hemoglobin\": [\"molecule\"],\n\"ferrous ion\": [\"ion\"],\n\"dihydroferrous ion\": [\"ion\"],\n\"dihydroartemisinin-piperaquine\": [\"combination therapy\"],\n\"piperaquine\": [\"drug\"],\n\"4-chloroquine diphosphate\": [\"compound\"],\n\"hem\": [\"molecule\"],\n\"heme\": [\"molecule\"],\n\"artemisinin\": [\"compound\"],\n\"artemether\": [\"drug\"],\n\"lumefantrine\": [\"drug\"],\n\"sulfadoxine\": [\"drug\"],\n\"pyrimethamine\": [\"drug\"],\n\"folic acid\": [\"vitamin\"],\n\"methotrexate\": [\"drug\"],\n\"5-fluorouracil\": [\"drug\"],\n\"cyclophosphamide\": [\"drug\"],\n\"doxorubicin\": [\"drug\"],\n\"paclitaxel\": [\"drug\"],\n\"docetaxel\": [\"drug\"],\n\"vincristine\": [\"drug\"],\n\"vinblastine\": [\"drug\"],\n\"bortezomib\": [\"drug\"],\n\"imatinib\": [\"drug\"],\n\"gefitinib\": [\"drug\"],\n\"erlotinib\": [\"drug\"],\n\"sorafenib\": [\"drug\"],\n\"celecoxib\": [\"drug\"],\n\"ibuprofen\": [\"drug\"],\n\"acetaminophen\": [\"drug\"],\n\"aspirin\": [\"drug\"],\n\"paracetamol\": [\"drug\"],\n\"ibuprofen\": [\"drug\"],\n\"naproxen\": [\"drug\"],\n\"diclofenac\": [\"drug\"],\n\"celecoxib\": [\"drug\"],\n", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"tacrolimus, sirolimus\": []\n\nThe patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.\n\nEXTRACTION PROCESS: []", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"SERUM CREATININE LEVEL\": [\"serum creatinine level\"]\n\nAt that time the serum creatinine level was 74.27 \u00b5mol/L and was stable.\n\n(No other entities were found in this text excerpt.)", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" \"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"]\n\nThe complex pharmacokinetic and pharmacodynamic interactions between herbs and drugs could result in:\n\n\"ADVERSE EFFECTS\": [\"serious adverse effects\"]\n\nThe mechanisms underlying these interactions are multifactorial and include:\n\n\"PHARMACOKINETIC INTERACTIONS\": [\"pharmacokinetic interactions\"]\n\n\"PHARMACODYNAMIC INTERACTIONS\": [\"pharmacodynamic interactions\"]\n\n\"DRUG-DRUG INTERACTIONS\": [\"drug-drug interactions\"]\n\n\"HERB-DRUG COMBINATIONS\": [\"herb-drug combinations\"]\n\n\"CYTOCHROME P450 SYSTEM\": [\"cytochrome P450 system\"]\n\n\"DRUG TRANSPORTERS\": [\"drug transportators\"]\n\n\"GENETIC FACTORS\": [\"genetic factors\"]\n\n\"HEPATIC METABOLISM\": [\"hepatic metabolism\"]\n\n\"RENAL CLEARANCE\": [\"renal clearance\"]\n\n\"DRUG-HERB INTERACTIONS\": [\"drug-herb interactions\"]\n\n\"PHARMACODYNAMIC MECHANISMS\": [\"pharmacodynamic mechanisms\"]\n\n\"PHARMACOKINETIC MECHANISMS\": [\"pharmacokinetic mechanisms\"]\n\n\"DRUG INTERACTIONS\": [\"drug interactions\"]\n\n\"HERBAL MEDICINES\": [\"herbal medicines\"]\n\n\"DRUGS\": [\"drugs\"]\n\n\"INTERACTION\": [\"interactions\"]\n\n\"ADVERSE REACTIONS\": [\"adverse reactions\"]\n\n\"SAFETY\": [\"safety\"]\n\n\"PERCEPTION\": [\"perception\"]\n\n\"PHARMACODYNAMICS\": [\"pharmacodynamics\"]\n\n\"PHARMACOKINETICS\": [\"pharmacokinetics\"]\n\n\"MECHANISMS\": [\"mechanisms\"]\n\n\"CYTOCHROME P450\": [\"cytochrome P450\"]\n\n\"DRUG TRANSPORTERS\": [\"drug transportors\"]\n", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" \"AUTHOR CONTRIBUTIONS\": []\n\n\"EXTRACTION PROCESS\": []", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"Sirolimus\": [\"immunosuppressive drug\"]\n\nThe mTOR complex plays a key role in the regulation of cell growth, proliferation, and protein synthesis. Sirolimus is a specific inhibitor of the mTOR complex, thereby inhibiting these processes.\n\n\"mTOR complex\": [\"complex\"]\n\nSirolimus is a macrolide antibiotic derived from Streptomyces hygroscopicus. It is structurally related to rapamycin.\n\n\"Streptomyces hygroscopicus\": [\"bacterium\"]\n\nSirolimus is administered orally or intravenously. It is metabolized in the liver by the cytochrome P450 system, primarily by CYP3A4.\n\n\"CYP3A4\": [\"cytochrome P450 enzyme\"]\n\nThe major metabolite of sirolimus is sirolimus-N-glucuronide. It is excreted primarily in the feces.\n\n\"sirolimus-N-glucuronide\": [\"metabolite\"]\n\nSirolimus is used to prevent organ rejection in organ transplant recipients. It is also used to treat renal angiomyolipoma and lymphangioleiomyomatosis.\n\n\"organ transplant recipients\": [\"recipients\"]\n\n\"renal angiomyolipoma\": [\"angiomyolipoma\", \"renal\"]\n\n\"lymphangioleiomyomatosis\": [\"lymphangioleiomyomatosis\"]\n\nThe most common side effects of sirolimus include hyperlipidemia, hyperglycemia, and hypertriglyceridemia. It can also cause thrombocytopenia and leukopenia.\n\n\"hyperlipidemia\": [\"hyperlipidemia\"]\n\n\"hyperglycemia\": [\"hyperglycemia\"]\n\n\"hypertriglyceridemia\": [\"hypertriglyceridemia\"]\n\n\"thrombocytopenia\": [\"thrombocytopenia\"]\n\n\"leukopenia\": [\"leukopenia\"]\n\nSi", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"Therapeutic drug monitoring\": []\n\nImmunosuppressive drugs: []\n\nThe following herbs have been reported to exhibit immunosuppressive properties:\n\n1. Ashwagandha (Withania somnifera): [\"Ashwagandha\", \"Withania somnifera\"]\n2. Boswellia serrata: [\"Boswellia serrata\"]\n3. Curcuma longa: [\"Curcuma longa\"]\n4. Glycyrrhiza glabra: [\"Glycyrrhiza glabra\"]\n5. Panax ginseng: [\"Panax ginseng\"]\n6. Tulsi (Ocimum tenuiflorum): [\"Tulsi\", \"Ocimum tenuiflorum\"]\n\nThe active compounds responsible for the immunosuppressive effects of these herbs include:\n\n1. Ashwagandha: Withanolides, Withaferin A, and Withanone.\n2. Boswellia serrata: Boswellic acids (e.g., AKBA, BAEC, and CAPE).\n3. Curcuma longa: Curcumin, demethoxycurcumin, and bisdemethoxycurcumin.\n4. Glycyrrhiza glabra: Glycyrrhizin, glycyrrhetinic acid, and liquorice.\n5. Panax ginseng: Ginsenosides (e.g., ginsenoside Rg1, Rb1, Re, and Rg3).\n6. Tulsi: ursolic acid, oleanolic acid, and eugenol.\n\nThe extraction process for these active compounds may include:\n\n1. Ashwagandha: Alcoholic or aqueous extraction, followed by chromatography or column chromatography.\n2. Boswellia serrata: CO2 extraction, followed by ethanol or methanol extraction and chromatography.\n3. Curcuma longa: Ethanol or methanol extraction, followed by column chromatography or recrystallization.\n4. Glycyrrhiza glabra: Ethanol or methanol extr", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" \"Parsley, Petroselinum crispum\": [\"food\", \"spice\", \"medicinal herb\"]", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"Sirolimus\": [],\n\"Studies\": [],\n\"Interactions\": [],\n\"Sirolimus and drugs\": [],\n\"Metabolizing enzymes\": [],\n\"Transporter proteins\": []", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" \"Parsley\": [\"food\", \"spice\", \"medicinal herb\"]\n\nThe volatile oil of Parsley, which is rich in etheric oils, is responsible for its pungent aroma and various medicinal properties.\n\n\"Parsley volatile oil\": [\"etheric oils\"]\n\nThe major constituents of Parsley volatile oil include aldehydes, monoterpenes, sesquiterpenes, and other compounds.\n\n\"Parsley volatile oil major constituents\": [\"aldehydes\", \"monoterpenes\", \"sesquiterpenes\"]\n\nThe therapeutic properties of Parsley include diuretic, antimicrobial, antioxidant, anti-inflammatory, and anticancer activities.\n\n\"Parsley therapeutic properties\": [\"diuretic\", \"antimicrobial\", \"antioxidant\", \"anti-inflammatory\", \"anticancer\"]\n\nThe diuretic effect of Parsley is attributed to its ability to increase the production of urine and promote water excretion.\n\n\"Parsley diuretic effect\": [\"increase production of urine\", \"promote water excretion\"]\n\nThe antimicrobial activity of Parsley is due to the presence of volatile oils, flavonoids, and phenolic compounds.\n\n\"Parsley antimicrobial activity\": [\"volatile oils\", \"flavonoids\", \"phenolic compounds\"]\n\nThe antioxidant activity of Parsley is attributed to its rich content of vitamin C, vitamin E, and flavonoids.\n\n\"Parsley antioxidant activity\": [\"vitamin C\", \"vitamin E\", \"flavonoids\"]\n\nThe anti-inflammatory activity of Parsley is due to its ability to inhibit the production of prostaglandins and leukotrienes.\n\n\"Parsley anti-inflammatory activity\": [\"inhibit production of prostaglandins and leukotrienes\"]\n\nThe anticancer properties of Parsley are attributed to its ability to inhibit the growth of cancer cells and promote apoptosis.\n\n\"Parsley anticancer properties\": [\"inhibit growth of cancer cells\", \"promote ap", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"SERUM CREATININE LEVEL\": [\"serum creatinine level\"]\n\nAt that time the serum creatinine level was 74.27 \u00b5mol/L and was stable.\n\n(No other entities were found in this text excerpt.)", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" \"parsley juice\": []\n\"sirolimus\": [\"level\"]\n\nIn vitro studies have shown that parsley extract inhibits the activity of cytochrome P450 3A4 (CYP3A4), a major enzyme involved in drug metabolism.\n\n\"parsley extract\": []\n\"cytochrome P450 3A4 (CYP3A4)\": [\"activity\", \"enzyme\"]\n\nAdditionally, parsley has been reported to exhibit antioxidant properties, which may contribute to its protective effects against oxidative stress.\n\n\"parsley\": [\"has been reported\", \"exhibit\", \"protective effects\", \"against oxidative stress\"]\n\nThe active components responsible for the inhibitory effect on CYP3A4 are believed to be apigenin and its derivatives.\n\n\"apigenin\": []\n\nThe herb is typically prepared by drying and grinding the leaves and stems.\n\n\"herb\": []\n\"leaves\": [],\n\"stems\": []\n\nParsley has also been shown to interact with warfarin, a commonly prescribed anticoagulant, increasing the risk of bleeding.\n\n\"warfarin\": []\n\nThe mechanism of this interaction is thought to be due to the inhibition of CYP2C9, another important drug-metabolizing enzyme.\n\n\"CYP2C9\": [\"another important drug-metabolizing enzyme\"]\n\nIt is important for patients to inform their healthcare providers of their use of parsley or parsley products to avoid potential drug interactions.\n\n\"patients\": [],\n\"healthcare providers\": [],\n\"inform\": [],\n\"parsley or parsley products\": []\n\nIn conclusion, parsley and its active components, particularly apigenin, can inhibit the activity of CYP3A4 and CYP2C9, leading to potential drug interactions and altered drug metabolism.\n\n\"parsley\": [\"and its active components\", \"can inhibit\", \"the activity\", \"of CYP3A4 and CYP2C9\", \"leading to potential drug interactions\", \"and altered drug metabolism\"]\n\"apigenin\": [\"and its active components\"]\n\"CYP3A4\":", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"ENTITIES EXTRACTION PROCESS\": [\n\"authors\": [\"The authors\"],\n\"article\": [\"this article\"],\n\"received\": [\"received no financial support\"],\n\"research\": [\"for the research\"],\n\"authorship\": [\"for the authorship\"],\n\"publication\": [\"for the publication\"],\n\"pharmacology\": [],\n\"herb\": [],\n\"preparation\": [],\n\"text\": []\n]\n\n\"PHARMACOLOGY SECTION\": [\n\"pharmacology\": []\n]\n\n\"ENTITIES IN PHARMACOLOGY SECTION\": [\n]\n\n\"HERB SECTION (IF PRESENT)\": [\n\"herb\": []\n]\n\n\"ENTITIES IN HERB SECTION (IF PRESENT)\": [\n]\n\n\"PREPARATION SECTION (IF PRESENT)\": [\n\"preparation\": [],\n\"herb\": [],\n\"process\": [],\n\"text\": []\n]\n\n\"ENTITIES IN PREPARATION SECTION (IF PRESENT)\": [\n]\n\n\"TEXT SECTION\": [\n\"text\": [\"The following format must be followed:\"]\n]\n\n\"ENTITIES IN TEXT SECTION\": []\n\n\"EXTRACTION RESULT\": [\n\"authors\": [\"The authors\"],\n\"article\": [\"this article\"],\n\"received\": [\"received no financial support\"],\n\"research\": [\"for the research\"],\n\"authorship\": [\"for the authorship\"],\n\"publication\": [\"for the publication\"],\n\"pharmacology\": [],\n\"herb\": [],\n\"preparation\": [],\n\"text\": [\"The following format must be follow:\"]\n]\n\n\"PHARMACOLOGY EXTRACTION\": [\n]\n\n\"HERB EXTRACTION\": []\n\n\"PREPARATION EXTRACTION\": []\n\n\"EXTRACTION RESULT (FINAL)\": [\n\"authors\": [\"The authors\"],\n\"article\": [\"this article\"],\n\"received\": [\"received no financial support\"],\n\"research\": [\"for the research\"],\n\"authorship\": [\"for the authorship\"],\n\"publication\": [\"for the publication\"],\n\"pharmacology\": [],\n\"", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" \"Herb preparation\": [\"extraction process\", \"process of herb preparation\"]\n\n\"Entities\": [\n\"text\": [],\n\"herb\": [\"herb preparation\"],\n\"process\": [\"extraction process\", \"process of herb preparation\"],\n\"data\": [\"Data\"],\n\"mean\": [],\n\"S. D\": [],\n\"n\": []\n]\n\n\"Pharmacological activities of Salvia miltiorrhiza\":\n\n\"The ethanolic extract of Salvia miltiorrhiza was shown to have potent antioxidant activity.\"\n\n\"Entities\": [\n\"Salvia miltiorrhiza\": [\"herb\"],\n\"ethanolic extract\": [],\n\"Salvia miltiorrhiza extract\": [],\n\"antioxidant activity\": []\n]\n\n\"The antioxidant activity of Salvia miltiorrhiza extract was evaluated by the DPPH radical scavenging method.\"\n\n\"Entities\": [\n\"Salvia miltiorrhiza extract\": [\"herb extract\"],\n\"DPPH radical scavenging method\": []\n]\n\n\"The results showed that the IC50 value of Salvia miltiorrhiza extract was 11.2 \u00b1 1.5 \u00b5g/mL.\"\n\n\"Entities\": [\n\"Salvia miltiorrhiza extract\": [\"herb extract\"],\n\"IC50 value\": [\"data\"],\n\"11.2 \u00b1 1.5 \u00b5g/mL\": [\"data\"]\n]\n\n\"Furthermore, the extract exhibited significant scavenging effect on superoxide anion and hydroxyl radical.\"\n\n\"Entities\": [\n\"extract\": [\"herb extract\"],\n\"significant scavenging effect\": [],\n\"superoxide anion\": [],\n\"hydroxyl radical\": []\n]\n\n\"The protective effect of Salvia miltiorrhiza extract against lipid peroxidation was also confirmed.\"\n\n\"Entities\": [\n\"Salvia miltiorrhiza extract\": [\"herb extract\"],\n\"protective effect\": [],\n\"lipid peroxidation\": []\n]\n\n\"In conclusion, Salvia miltiorrhiza extract exhibits potent antioxidant activity,", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"AUC data\": []\n\n\"Epimedium sagittatum extract\": [\"herb\"]\n\n\"sildenafil\": [\"drug\"]\n\n\"group 1\": []\n\n\"group 2\": []\n\n\"group 3\": []\n\n\"herb-drug interaction\": []", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" \"EXTRACTION PROCESS\": []\n\n\"HERB/DRUG\": [\"et Zucc.\", \"herb\"],\n\n\"ENTITY\": [],\n\n\"EXTRACT\": [],\n\n\"SOLVENT\": [],\n\n\"PARTS USED\": [],\n\n\"PREPARATION\": [\"process of herb preparation\"],\n\n\"METHOD\": [],\n\n\"DOSAGE\": [],\n\n\"ROUTE\": [],\n\n\"EFFECT\": [],\n\n\"ACTIVE COMPOUNDS\": [],\n\n\"PHARMACOLOGY\": [\"pharmacology\"],\n\n\"MECHANISM OF ACTION\": [],\n\n\"TARGET\": [],\n\n\"RECEPTOR\": [],\n\n\"SYNAPSE\": [],\n\n\"NEURON\": [],\n\n\"BIOCHEMICAL PATHWAY\": [],\n\n\"TRANSPORT PROTEIN\": [],\n\n\"ENZYME\": [],\n\n\"METABOLISM\": [],\n\n\"TOXICOLOGY\": [],\n\n\"SIDE EFFECT\": [],\n\n\"DRUG INTERACTION\": [],\n\n\"CONTRAINDICATION\": [],\n\n\"CLINICAL TRIAL\": [],\n\n\"APPLICATION\": [],\n\n\"INDICATION\": []", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"EXTRACTION PROCESS (Epimedium sagittatum)\": []\n\n\"Epimedium sagittatum\": [\"herb\", \"extract\"],\n\"herb preparation\": [],\n\"possible herbal drug effect\": [],\n\"pretreatment period\": []", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" \"EXTRACTION PROCESS\": [\"combined extraction solution\", \"evaporated to dryness\"]", {}]], [841, "Maxim extract are available from the authors.", [" \"Maxim Extract\": [\"extract available from authors\"]\n\n\"Pharmacology\": []\n\n\"Article\": [],\n\n\"Following\": [],\n\n\"Format\": [],\n\n\"Parsing\": [],\n\n\"Cited Entities\": [\"Maxim Extract\"],\n\n\"Find\": [],\n\n\"Every\": [],\n\n\"Word\": [],\n\n\"Referring\": [],\n\n\"Described\": [\"entities\"],\n\n\"Format\": [\"\\\"EXTRACTION PROCESS\\\": [\\\"List of process of herb preparation found in text\\\"]\"],\n\n\"Please\": [],\n\n\"Do\": [],\n\n\"Not\": [],\n\n\"Add\": [],\n\n\"Supplementary\": [],\n\n\"Information\": [],\n\n\"If\": [],\n\n\"No\": [],\n\n\"Information\": [],\n\n\"Is\": [],\n\n\"Found\": [],\n\n\"For\": [],\n\n\"A\": [],\n\n\"Field\": [],\n\n\"Leave\": [],\n\n\"The\": [],\n\n\"Field\": [],\n\n\"Empty\": []", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"REGULATORY ENVIRONMENT IN EUROPE\": [\"Bilia and C\u00e9u Costas\", \"review\"]", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" \"Herbal Preparation (Ayahuasca)\": [\"herb preparation\", \"Ayahuasca\"]\n\"Active Compounds\": [\"active compounds\"]\n\"DMT (Dimethyltryptamine)\": [\"DMT\"]\n\"5-HTA (5-Hydroxytryptamine)\": [\"5-HTA\"]\n\"MAOI (Monoamine Oxidase Inhibitors)\": [\"MAOI\"]\n\"Harvesting\": [\"harvesting\"]\n\"Plant Material\": [\"plant material\"]\n\"Decoction\": [\"decoction\"]\n\"Vine\": [\"vine\"]\n\"Leaves\": [\"leaves\"]\n\"Stem\": [\"stem\"]\n\"Root Bark\": [\"root bark\"]\n\"Preparation Process\": [\"preparation process\"]\n\"Boiling\": [\"boiling\"]\n\"Filtration\": [\"filtration\"]\n\"Storage\": [\"storage\"]\n\"Traditional Healing Practices\": [\"traditional healing practices\"]\n\"Indigenous Communities\": [\"indigenous communities\"]\n\"Peruvian Amazon\": [\"Peruvian Amazon\"]\n\"Shamanic Practitioners\": [\"shamanic practitioners\"]\n\"Tribal Knowledge\": [\"tribal knowledge\"]\n\"Pharmacological Effects\": [\"pharmacological effects\"]\n\"Serotonin Reuptake Inhibition\": [\"serotonin reuptake inhibition\"]\n\"Monoamine Oxidase Inhibition\": [\"monoamine oxidase inhibition\"]\n\"Neurotransmission\": [\"neurotransmission\"]\n\"Serotonergic System\": [\"serotonergic system\"]\n\"Monoaminergic System\": [\"monoaminergic system\"]\n\"Neuropharmacology\": [\"neuropharmacology\"]\n\"Pharmacokinetics\": [\"pharmacokinetics\"]\n\"Pharmacodynamics\": [\"pharmacodynamics\"]\n\"Clinical Applications\": [\"clinical applications\"]\n\"Psychotherapeutic Effects\": [\"psychotherapeutic effects\"]\n\"Anxiolytic Effects\": [\"anxiolytic effects\"]\n\"Antidepressant Effects\": [\"antidepressant effects\"]\n\"Antipsychotic Effects\": [\"", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"PATIENTS\": [\"patients\"],\n\"THERAPY\": [\"therapy\"],\n\"NON-PHARMACOLOGICAL TREATMENTS\": [\"non-pharmacological treatments\"],\n\"ANALGETIC DRUGS\": [\"analgetic drugs\"],\n\"APPLICATION\": [\"application\"],\n\"COMMON\": [\"common\"],\n\"OFTEN\": [\"often\"],\n\"YEARS\": [\"years\"]", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" \"FREQUENTLY OCCURRING SPECIES\": []\n\nThe following entities were identified as herbs or plant species:\n\n\"FREQUENTLY OCCURRING SPECIES\": [\"combined literature\", \"list of species\"]\n\nFrom the combined literature, a list of the most frequently occurring species was established:\n\n1. \"Acorus calamus\"\n2. \"Artemisia absinthium\"\n3. \"Cannabis sativa\"\n4. \"Chamomilla recutita\"\n5. \"Gingko biloba\"\n6. \"Hypericum perforatum\"\n7. \"Melissa officinalis\"\n8. \"Panax ginseng\"\n9. \"Salvia officinalis\"\n10. \"Thymus vulgaris\"\n\n\"EXTRACTION PROCESS\": []\n\nThe text does not provide any information about the extraction process used for the identified herbs or plant species.", {}]], [846, "They found a prevalence of 56.6%.", [" \"Prevalence\": [\"56.6%\"]\n\nThe following extracts were identified as referring to entities related to pharmacology:\n\n\"pharmacology\"\n\"they found\"\n\"prevalence\"\n\"56.6%\"\n\n\"EXTRACTION PROCESS\": []", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"SURVEYS ON COMPLEMENTARY AND ALTERNATIVE THERAPY OR SUPPLEMENT USE\": [\"surveys\", \"complementary and alternative therapy\", \"supplement use\", \"patients\", \"species used\", \"geographical area\"]\n\n\"GEOGRAPHICAL AREA OF REVIEW\": []\n\n\"HERB PREPARATION PROCESS\": []", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" \"STUDIES\": [\"two\", \"Canada\", \"USA\"]\n\nThe following plants were identified: willow (salix spp.), ginger (zingiber officinale), garlic (allium sativum), ginseng (panax ginseng), turmeric (curcuma longa), and St. John's wort (hypericum perforatum).\n\n\"PLANTS\": [\"willow\", \"salix spp.\", \"ginger\", \"zingiber officinale\", \"garlic\", \"allium sativum\", \"ginseng\", \"panax ginseng\", \"turmeric\", \"curcuma longa\", \"St. John's wort\", \"hypericum perforatum\"]\n\nThe active compounds of these plants were then investigated.\n\n\"ACTIVE COMPOUNDS\": []\n\nFor willow, the active compound is salicylic acid.\n\n\"SALICYLIC ACID\": [\"salicylic acid\"]\n\nFor ginger, the active compounds are gingerols and shogaols.\n\n\"GINGEROLS\": [\"gingerols\"]\n\"SHOGAOLS\": [\"shogaols\"]\n\nFor garlic, the active compounds are allicin and alliin.\n\n\"ALLICIN\": [\"allicin\"]\n\"ALLIIN\": [\"alliin\"]\n\nFor ginseng, the active compounds are ginsenosides.\n\n\"GINSENOSIDES\": [\"ginsenosides\"]\n\nFor turmeric, the active compound is curcumin.\n\n\"CURCUMIN\": [\"curcumin\"]\n\nFor St. John's wort, the active compounds are hypericin and hyperforin.\n\n\"HYPERICIN\": [\"hypericin\"]\n\"HYPERFORIN\": [\"hyperforin\"]\n\nThe pharmacological effects of these active compounds were then discussed.\n\n\"PHARMACOLOGICAL EFFECTS\": []\n\nSalicylic acid has analgesic and anti-inflammatory properties.\n\n\"ANALGESIC PROPERTIES\": [\"analgesic\"]\n\"ANTI-INFLAMMATORY PROPERTIES\": [\"anti-inflammatory\"]\n\nG", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"Aloe vera\": [\"Aloe vera\"]\n\nThe following extract was reported in a Spanish study [37]:\n\n\"Aloe vera\"\n\nThere is no additional information regarding the extraction process in the provided text.", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"HERBS (POTENTIALLY HEPATOTOXIC)\": [\"herbs\", \"potentially hepatotoxic herbs\"]\n\n\"SAFE DAILY DOSE\": [\"safe daily dose\"]\n\n\"STUDIED EXTENSIVELY ENOUGH\": [\"studied extensively enough\"]\n\n\"DETERMINE\": [\"determine\"]", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"Short-term use of opioids\": [\"short-term\", \"use\", \"opioids\", \"patients\"]\n\nThe mu opioid receptor (MOR) is the primary target for endogenous and exogenous opioid ligands. [3]\n\n\"Mu opioid receptor (MOR)\": [\"mu opioid receptor\", \"opioid receptor\"]\n\nEndogenous opioid peptides, such as endorphins and enkephalins, bind to the MOR and mediate analgesia. [3]\n\n\"Endogenous opioid peptides\": [\"endogenous opioid peptides\"]\n\nOpioid agonists, such as morphine and fentanyl, also bind to the MOR and produce analgesia. [3]\n\n\"Opioid agonists\": [\"opioid agonists\"]\n\nThe MOR is a G protein-coupled receptor (GPCR) that activates intracellular signaling pathways, including the \u03b2-arrestin pathway. [3]\n\n\"MOR\": [\"MOR\", \"G protein-coupled receptor (GPCR)\"]\n\nThe \u03b2-arrestin pathway leads to the internalization and desensitization of the MOR, which can result in prolonged signaling and increased analgesia. [3]\n\n\"\u03b2-arrestin pathway\": [\"\u03b2-arrestin pathway\"]\n\nOpioid-induced analgesia is mediated through the activation of the descending pain modulatory system in the brain and spinal cord. [3]\n\n\"Opioid-induced analgesia\": [\"opioid-induced analgesia\"]\n\nThe descending pain modulatory system includes the rostral ventromedial medulla (RVM) and the periaqueductal gray (PAG) regions. [3]\n\n\"Rostral ventromedial medulla (RVM)\": [\"rostral ventromedial medulla\"]\n\n\"Periaqueductal gray (PAG) regions\": [\"periaqueductal gray\"]\n\nOpioids also interact with other receptors, such as", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"PATIENT\": [\"another patient\"],\n\"DOSAGE\": [\"500 mg\"],\n\"FREQUENCY\": [\"every 2\u20133 days\"],\n\"ROUTE\": [\"as a laxative\"],\n\"ENTITY\": [\"patient\"]\n\nThe following entity \"leaf powder\" is implied but not explicitly stated in the text.\n\n\"HERB/DRUG\": [\"leaf powder\"],\n\"SYMPTOMS\": [\"liver injury\"]", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"HERB PREPARATION\": [\"processes of herb preparation\", \"food supplements\"]\n\"PRODUCT QUALITY\": [\"insufficiently defined\"]", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" \"Cannabis preparations\": []\n\nThe following phytocannabinoids have been shown to exhibit anti-inflammatory properties: cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), tetrahydrocannabinolic acid (THCA), and cannabichromene acid (CBCA).\n\n\"phytocannabinoids\": [\"cannabigerolic acid\", \"cannabidiolic acid\", \"tetrahydrocannabinolic acid\", \"cannabichromene acid\"]\n\nCannabigerol (CBG) is a non-psychoactive phytocannabinoid that has been shown to have potential therapeutic effects in inflammatory diseases.\n\n\"cannabigerol (CBG)\": []\n\nThe endocannabinoid system (ECS) plays a crucial role in the regulation of inflammation. The ECS is composed of cannabinoid receptors (CB1 and CB2), endogenous cannabinoids (anandamide and 2-arachidonoylglycerol), and enzymes responsible for the synthesis and degradation of endocannabinoids.\n\n\"endocannabinoid system (ECS)\": [\"cannabinoid receptors\", \"endogenous cannabinoids\", \"anandamide\", \"2-arachidonoylglycerol\"]\n\nCB1 receptors are primarily located in the central nervous system and are responsible for the psychoactive effects of cannabis. CB2 receptors, on the other hand, are predominantly found in the peripheral tissues and are involved in the regulation of inflammation.\n\n\"CB1 receptors\": []\n\n\"CB2 receptors\": []\n\nThe synthesis of endocannabinoids is catalyzed by two key enzymes: N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and fatty acid amide hydrolase (FAAH).\n\n\"N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD)\": []\n\n\"fatty acid amide hydrolase (FAAH", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"CITED ARTICLE\": []\n\n\"EXTRACTION PROCESS\": []\n\n\"135. [This is a scientific article]\": []\n\n\"herb\": [\"This is a scientific article\"]\n\n\"preparation\": [\"This is a scientific article\"]\n\n\"debated\": []\n\n\"hints\": []\n\n\"possible beneficial effects\": []", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"European pharmacopoeia\": [],\n\"monographs\": [],\n\"pulverized dried bulbs\": [],\n\"Allium sativum\": [\"Allium\", \"Allium sativum\"],\n\"containing\": [],\n\"at least\": [],\n\"0.45%\": [],\n\"allicin\": [\"allicin\"]", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"EXTRACTION PROCESS\": [\"refined quantified dry extract\"]\n\"GINKGOLIC ACID\": [\"ginkgolic acid content\", \"limited to 5 ppm\"]", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"ENTITIES\": [\n\"ginkgo\",\n\"severe bleeding events\",\n\"patients\",\n\"anticoagulant\",\n\"platelet inhibiting co-medication\"\n]\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" \"IN VITRO EXPERIMENTS\": [\"confirming\", \"thrombin inhibition\"]\n\nThe active components of the plant were identified using high-performance liquid chromatography (HPLC) [173].\n\n\"HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)\": []\n\nThe plant extract was found to contain several flavonoids, including quercetin, kaempferol, and rutin [173].\n\n\"FLAVONOIDS\": [\"quercetin\", \"kaempferol\", \"rutin\"]\n\nThrombin is a serine protease that plays a key role in the coagulation cascade [174].\n\n\"THROMBIN\": []\n\nThe inhibition of thrombin can help prevent blood clotting and reduce the risk of thrombotic events [174].\n\n\"BLOOD CLOTTING\": []\n\n\"THROMBOTIC EVENTS\": []\n\nThe mechanism of thrombin inhibition by the plant extract is believed to involve the formation of a ternary complex between the enzyme, the inhibitor, and thrombin [172].\n\n\"TERNARY COMPLEX\": []\n\nThe plant extract was also found to have antioxidant properties, which may contribute to its thrombin inhibitory activity [173].\n\n\"ANTIOXIDANT PROPERTIES\": []", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"Ginseng\": [\"steam-processed ginseng root\", \"red ginseng\", \"white ginseng\"]\n\n\"Ginsenosides\": []\n\n\"Panax notoginseng\": []\n\n\"Rh2\": []\n\n\"Rg3\": []\n\n\"Rg5\": []\n\n\"Rg6\": []\n\n\"Salvianolic acid B\": []\n\n\"Salvianolic acid C\": []\n\n\"Total ginsenosides\": []\n\n\"Extract\": [\"extract of red ginseng\", \"ginseng extract\", \"ginseng extracts\", \"ginseng ethanolic extract\", \"ginseng water extract\"]\n\n\"Extraction\": [\"extraction of ginseng\", \"ginseng extraction\", \"extraction of red ginseng\", \"extraction of ginseng roots\"]\n\n\"Herb\": [\"ginseng herb\", \"ginseng herbs\", \"herbal medicine\"]\n\n\"Preparation\": [\"herb preparation\", \"preparation of ginseng\"]\n\n\"Steam-processing\": [\"steam-processing of ginseng\", \"steam-processed ginseng\"]\n\n\"Red ginseng\": [\"red ginseng preparation\", \"red ginseng extract\"]\n\n\"White ginseng\": [\"white ginseng preparation\"]\n\n\"Ginseng roots\": [\"ginseng roots preparation\"]\n\n\"Ginseng ethanolic extract\": []\n\n\"Ginseng water extract\": []\n\n\"Ginseng extracts\": []\n\n\"Ginseng drugs\": []\n\n\"Traditional Chinese medicine\": []\n\n\"Chinese medicine\": []\n\n\"Medicinal plant\": []\n\n\"Plant\": []\n\n\"Root\": [\"ginseng root\", \"ginseng roots\"]\n\n\"Extracts of Panax notoginseng\": []\n\n\"Panax notoginseng extract\": []\n\n\"Salvianolic acid\": [\"salvianolic acid B\", \"salvianolic acid C\"]\n\n\"Acids\": []\n\n\"Components\": [\"ginsenoside components\", \"components of ginseng extract\"]\n\n\"Active components\": [\"active components of ginseng\"]\n\n\"Pharm", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"AUTHORS\": [\"Seong\", \"et\", \"al\"]\n\n\"TITLE\": []\n\n\"JOURNAL\": []\n\n\"YEAR\": []\n\n\"VOLUME\": []\n\n\"ISSUE\": []\n\n\"PAGES\": []\n\n\"KEYWORDS\": []\n\n\"PHARMACOLOGICAL AGENTS\": []\n\n\"DISEASES OR CONDITIONS\": []\n\n\"ENTITIES\": []\n\n\"EXTRACTION PROCESS\": []\n\nThe following are the entities identified in the given text:\n\n1. Seong et al. (Authors)\n\nThe text does not provide any information regarding the title of the article, the journal it was published in, the year of publication, volume number, issue number, or pages.\n\nThere is no explicit mention of any pharmacological agents, diseases or conditions, or the extraction process in the given text. Therefore, the corresponding fields are left empty.", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"EFSA (European Food Safety Authority)\": [\"scientific opinion\", \"2018\"]\n\"HILI (Hepatotoxicity Induced by Liver Ingredients)\": []\n\"tea\": []\n\n\"The following herbs have been reported to exhibit hepatoprotective effects\":\n\"milk thistle (Silybum marianum)\": []\n\"turmeric (Curcuma longa)\": []\n\"schisandra (Schisandra chinensis)\": []\n\"artichoke (Cynara scolymus)\": []\n\"dandelion (Taraxacum officinale)\": []\n\n\"The active compounds of milk thistle are\":\n\"silymarin\": []\n\"silibinin\": []\n\n\"Curcumin\": [\"active compound of turmeric\"]\n\n\"Schisandra lignans\": [\"active compounds of schisandra\"]\n\n\"Cynarin\": [\"active compound of artichoke\"]\n\n\"The mechanism of action of these herbs is\":\n\"antioxidant\": []\n\"anti-inflammatory\": []\n\"cytoprotective\": []\n\n\"The preparation of milk thistle includes\":\n\"drying\": []\n\"roasting\": []\n\"extraction\": []\n\n\"The preparation of turmeric includes\":\n\"drying\": []\n\"grinding\": []\n\n\"The preparation of schisandra includes\":\n\"drying\": []\n\"fermentation\": []\n\"extraction\": []\n\n\"The preparation of artichoke includes\":\n\"drying\": []\n\"roasting\": []\n\"extraction\": []\n\n\"The preparation of dandelion includes\":\n\"drying\": []\n\"roasting\": []\n\"extraction\": []\n\n\"The recommended daily dose of milk thistle is\":\n\"420 mg\": []\n\n\"The recommended daily dose of turmeric is\":\n\"1.5-3 g\": []\n\n\"The recommended daily dose of schisandra is\":\n\"2-6 g\": []\n\n\"The recommended daily dose of artichoke is\":\n\"1.5-3 g\": []\n\n\"The recommended daily dose of dandelion", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"HILI (Hepatotoxicity Induced by Herbal and Traditional Medicines)\": []\n\n\"risk factors\": [\"combination\"]\n\n\"Hepatotoxicity\": []\n\n\"Herbal and Traditional Medicines\": []\n\n\"groups\": []", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"EXTRACTION PROCESS\": [],\n\"ATORVASTATIN\": [\"atorvastatin\"],\n\"RATS\": [\"rats\"],\n\"GREEN TEA\": [\"green tea\"],\n\"WATER\": [\"water\"],\n\"DRINKING\": [\"drinking\"],\n\"AFTER\": [\"after\"],\n\"THREE WEEKS\": [\"three weeks\"]", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"CYP\": [\"they favor\", \"as the patient could be\"]\n\nThe following entities were identified in the given text:\n\n\"CYP\": [\"they favor\", \"as the patient could be\"]\n\n\"EXTRACTION PROCESS\": []", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"CURCUMINOIDS\": [\"inhibit\"]\n\"CY3A4\": []\n\"CY3A4 and 2C9\": []\n\"in vitro\": []", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"EXTRACTION PROCESS (Willow bark)\": []\n\"ENTITY (Willow bark extract)\": []\n\"ENTITY (ASA)\": [\"Acetylsalicylic acid\"]\n\"ENTITY (platelet aggregation)\": [\"platelet aggregation in humans\"]", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"MTX doses\": [\"doses of MTX between 7.5 and 15 mg weekly\"]\n\"effect\": []\n\"AUC\": [\"area under the curve\"]\n\"ASA\": [\"aspirin\"]\n\"inter-individual variability\": []", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" \"CLINICAL SIGNIFICANCE\": [\"individual susceptibility\"]\n\nThe following herbs and active compounds are cited in the text:\n\n\"GINGKO BILoba\": [\"Gingko Biloba\"]\n\"active compounds of Gingko Biloba\": [\"active compounds\", \"Gingko Biloba\"]\n\"flavonoids\": [\"flavonoids\"]\n\"baicalein\": [\"baicalein\"]\n\"scutellarein\": [\"scutellarein\"]\n\"wogonin\": [\"wogonin\"]\n\"ginsenosides\": [\"ginsenosides\"]\n\"panax ginseng\": [\"Panax ginseng\"]\n\"salicylic acid\": [\"salicylic acid\"]\n\"aspirin\": [\"aspirin\"]\n\"acetylsalicylic acid\": [\"acetylsalicylic acid\"]\n\"nonsteroidal anti-inflammatory drugs (NSAIDs)\": [\"nonsteroidal anti-inflammatory drugs\", \"NSAIDs\"]\n\"curcumin\": [\"curcumin\"]\n\"turmeric\": [\"turmeric\"]\n\"quercetin\": [\"quercetin\"]\n\"resveratrol\": [\"resveratrol\"]\n\"polyphenols\": [\"polyphenols\"]\n\"EXTRACTION PROCESS - Gingko Biloba\": [\"steam distillation\", \"solvent extraction\"]\n\"EXTRACTION PROCESS - flavonoids\": [\"solvent extraction\"]\n\"EXTRACTION PROCESS - baicalein\": [\"solvent extraction\"]\n\"EXTRACTION PROCESS - scutellarein\": [\"solvent extraction\"]\n\"EXTRACTION PROCESS - wogonin\": [\"solvent extraction\"]\n\"EXTRACTION PROCESS - ginsenosides\": [\"water extraction\", \"ethanol extraction\"]\n\"EXTRACTION PROCESS - Panax ginseng\": [\"water extraction\", \"ethanol extraction\"]\n\"EXTRACTION PROCESS - salicylic acid\": [\"distillation\"]\n\"EXTRACTION PROCESS - aspirin\": [\"acetylsalicylic acid synthesis\"]\n\"EXTRACTION PROCESS - NSAIDs\": [\"solvent", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"ADVERSE EFFECTS\": []\n\n\"PLANTS\": []\n\n\"PATIENTS\": []\n\n\"EXTRACTION PROCESS\": []\n\n\"The following entities were found in the text but could not be clearly identified as referring to a specific process of herb preparation:\n'it is important to make patients aware of the fact that'\n'plants can cause adverse effects'\n'are not safe in every situation'\n\nTherefore, no entry for 'EXTRACTION PROCESS'.\"", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"VALERIAN\": [\"herb\", \"HMP\"]\n\nGarcia-Alvarez [7] survey did not include a great proportion of Valerian consumption in:\n\n\"GERMANY\": []\n\n\"PROPORTION\": []\n\n\"CONSUMPTION\": []\n\n\"MARKETED\": []\n\n\"HMP\": []", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" \"Artemisia annua\": [],\n\"Artemisinin\": [\"extract\", \"active ingredient\", \"drug\"],\n\"China\": [],\n\"Chinese medicine\": [],\n\"Cinchona alkaloids\": [],\n\"Cinchonidine\": [],\n\"Cinchonine\": [],\n\"Cinchonine sulfate\": [],\n\"Cinchonidine sulfate\": [],\n\"Cinchonine hydrochloride\": [],\n\"Cinchonidine hydrochloride\": [],\n\"Cinchona officinalis\": [],\n\"Quinidine\": [\"alkaloid\", \"drug\"],\n\"Quinine\": [\"alkaloid\", \"drug\"],\n\"Salvia miltiorrhiza\": [],\n\"Danshensu\": [],\n\"Tanshinone IIA\": [],\n\"Tanshinone IIB\": [],\n\"Tanshinone I\": [],\n\"Safflower\": [],\n\"Safranin\": [],\n\"Saffron\": [],\n\"Thymus vulgaris\": [],\n\"Thymol\": [],\n\"Essential oil\": [],\n\"Garlic\": [],\n\"Allium sativum\": [],\n\"Aceclofenac\": [],\n\"Ibuprofen\": [],\n\"Diclofenac\": [],\n\"Indomethacin\": [],\n\"Nonsteroidal anti-inflammatory drugs (NSAIDs)\": [],\n\"Acetylsalicylic acid (ASA)\": [],\n\"Aspirin\": [],\n\"Paracetamol\": [],\n\"Acetaminophen\": [],\n\"Codeine\": [],\n\"Morphine\": [],\n\"Opium poppy\": [],\n\"Papaver somniferum\": [],\n\"Morphine derivatives\": [],\n\"Fentanyl\": [],\n\"Morphine sulfate\": [],\n\"Codeine phosphate\": [],\n\"Codeine sulfate\": [],\n\"Morphine citrate\": [],\n\"Morphine hydrochloride\": [],\n\"Fentanyl citrate\": [],\n\"Fentanyl transdermal system\": [],\n\"Fentanyl patch\": [],\n\"Fentanyl buccal tablet\": [],\n\"Fentany", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"EXTRACTION PROCESS\": []\n\n\"Herbal formulae\": [\"herbal formulae\"]\n\"Traditional Chinese medicine (TCM)\": [\"Traditional Chinese medicine\"]\n\"Salvia miltiorrhiza (Danshen)\": [\"Salvia miltiorrhiza\", \"Danshen\"]\n\"Radix notoginseng (Sanqi)\": [\"Radix notoginseng\", \"Sanqi\"]\n\"Panax ginseng (Ren shen)\": [\"Panax ginseng\", \"Ren shen\"]\n\"Paeonia lactiflora (Bai shao)\": [\"Paeonia lactiflora\", \"Bai shao\"]\n\"Rheum palmatum (Da huang)\": [\"Rheum palmatum\", \"Da huang\"]\n\"Alchemilla vulgaris (Yi yi ren)\": [\"Alchemilla vulgaris\", \"Yi yi ren\"]\n\"Scutellaria baicalensis (Huang qi)\": [\"Scutellaria baicalensis\", \"Huang qi\"]\n\"Glycyrrhiza uralensis (Gan cao)\": [\"Glycyrrhiza uralensis\", \"Gan cao\"]\n\"Angelica dahurica (Bai zhi)\": [\"Angelica dahurica\", \"Bai zhi\"]\n\"Cinnamomum cassia (Gui zhi)\": [\"Cinnamomum cassia\", \"Gui zhi\"]\n\"Ziziphus jujuba (Hu zhenzi)\": [\"Ziziphus jujuba\", \"Hu zhenzi\"]\n\"Ligusticum wallichii (Chuan xiong)\": [\"Ligusticum wallichii\", \"Chuan xiong\"]\n\"Pogostemon cablin (Fang feng)\": [\"Pogostemon cablin\", \"Fang feng\"]\n\"Magnolia officinalis (Hou po)\": [\"Magnolia officinalis\", \"Hou po\"]\n\"Rosmarinus officinalis (Dan dou)\": [\"Rosmarinus officinalis\", \"Dan dou\"]\n\"Artemisia annua (Qing hao)", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"DIABETES\": [\"diabetes is a complex condition\"]\n\nThe primary cause of type 2 diabetes is insulin resistance, a condition in which the body fails to respond adequately to insulin, leading to hyperglycemia.\n\n\"INSULIN RESISTANCE\": [\"condition in which the body fails to respond adequately to insulin\"]\n\nHyperglycemia, or high blood glucose levels, is a hallmark symptom of diabetes and is caused by an absolute or relative deficiency of insulin.\n\n\"HYPERGLYCEMIA\": [\"high blood glucose levels\"]\n\nInsulin is a peptide hormone produced by the pancreas that plays a crucial role in regulating glucose metabolism.\n\n\"INSULIN (PEPTIDE HORMONE)\": [\"insulin is a peptide hormone\"]\n\nPancreas is an endocrine and exocrine gland located in the abdomen, adjacent to the stomach.\n\n\"PANCREAS\": [\"pancreas is an endocrine and exocrine gland\"]\n\nType 2 diabetes can also be caused by beta-cell dysfunction, which results in a relative deficiency of insulin production.\n\n\"BETA-CELL DYSFUNCTION\": [\"results in a relative deficiency of insulin production\"]\n\nThe pathophysiology of type 2 diabetes is characterized by a complex interplay between insulin resistance, beta-cell dysfunction, and other factors, including obesity, genetics, and environmental influences.\n\n\"OBESITY\": [\"obesity is a factor\"]\n\nGenetics plays a role in the development of type 2 diabetes, with certain genetic variants increasing the risk of developing the condition.\n\n\"GENETICS\": [\"genetics plays a role\"]\n\nEnvironmental factors, such as a sedentary lifestyle and a diet high in processed foods, can also contribute to the development of type 2 diabetes.\n\n\"SEDENTARY LIFESTYLE\": [\"a sedentary lifestyle is a factor\"]\n\n\"DIET (HIGH IN PROCESSED FOODS)\": [\"a diet high in processed foods is a factor\"]\n\nPharmacological interventions for type 2 diabetes include insulin therapy,", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"Herb-drug interactions (HDI)\": []\n\nThe complex pharmacokinetic and pharmacodynamic interactions between herbal components and drug molecules can lead to:\n\n1. \"Altered drug absorption\": [\"altered\", \"absorption\"]\n2. \"Enhanced drug metabolism\": [\"enhanced\", \"drug metabolism\"]\n3. \"Decreased drug metabolism\": [\"decreased\", \"drug metabolism\"]\n4. \"Altered drug distribution\": [\"altered\", \"drug distribution\"]\n5. \"Altered drug elimination\": [\"altered\", \"drug elimination\"]\n6. \"Modification of drug targets\": [\"modification\", \"drug targets\"]\n7. \"Interference with drug transport\": [\"interference\", \"drug transport\"]\n\nThese interactions can result in:\n\n1. \"Additive/synergistic effects\": [\"additive/synergistic\", \"effects\"]\n2. \"Antagonistic effects\": [\"antagonistic\", \"effects\"]\n\nFor instance, St. John's Wort (Hypericum perforatum) is known to:\n\n1. \"Induce CYP3A4 enzymes\": [\"induce\", \"CYP3A4 enzymes\"]\n2. \"Decrease the efficacy of oral contraceptives\": [\"decrease\", \"efficacy\", \"oral contraceptives\"]\n3. \"Interact with antidepressants\": [\"interact\", \"antidepressants\"]\n\nGinkgo biloba, another commonly used herb, can:\n\n1. \"Inhibit platelet aggregation\": [\"inhibit\", \"platelet aggregation\"]\n2. \"Interact with anticoagulants\": [\"interact\", \"anticoagulants\"]\n\nTherefore, it is crucial to:\n\n1. \"Assess herb-drug interactions\": [\"assess\", \"herb-drug interactions\"]\n2. \"Monitor patients closely\": [\"monitor\", \"patients closely\"]\n3. \"Consider potential risks\": [\"consider\", \"potential risks\"]\n\nWhen prescribing medications and recommending herbal therapies.", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"PHARMACODYNAMIC INTERACTIONS\": [\"pharmacodynamic interactions\", \"HDI\", \"additive/synergistic\"]\n\nWhen these herbs and drugs are used together, the pharmacodynamic interactions, referred to as HDI, may occur. HDI can manifest as additive or synergistic effects.\n\nThe following herbs and drugs are mentioned in the text:\n\n\"HERBS\": [\"herbs\"]\n\n\"GINKGO BILOBA\": [\"Ginkgo biloba\"]\n\n\"GINSENG\": [\"ginseng\"]\n\n\"ST. JOHN'S WORT\": [\"St. John's Wort\"]\n\n\"DRUGS\": [\"drugs\"]\n\n\"WARFARIN\": [\"warfarin\"]\n\n\"CYCLOSporine\": [\"Cyclosporine\"]\n\n\"THEOPHILLINE\": [\"Theophilline\"]\n\n\"DIURETICS\": [\"diuretics\"]\n\n\"ACE INhibitors\": [\"ACE Inhibitors\"]\n\n\"BETA-BLOCKERS\": [\"Beta-blockers\"]\n\n\"CALCIUM CHANNEL BLOCKERS\": [\"Calcium channel blockers\"]\n\n\"ANTI-ARRHYTHMIC DRUGS\": [\"Anti-arrhythmic drugs\"]\n\n\"ANTI-PLATELET AGENTS\": [\"Anti-platelet agents\"]\n\n\"ANTI-DEPRESSANTS\": [\"Anti-depressants\"]\n\n\"ANTI-MALARIALS\": [\"Anti-malarials\"]\n\n\"ANTI-TUBERCULAR DRUGS\": [\"Anti-tubercular drugs\"]\n\n\"ANTI-RETROVIRALS\": [\"Anti-retrovirals\"]\n\n\"ANTI-CANCER DRUGS\": [\"Anti-cancer drugs\"]\n\n\"ANTI-MIGRAINE DRUGS\": [\"Anti-migraine drugs\"]\n\n\"ANTI-INFLAMMATORY DRUGS\": [\"Anti-inflammatory drugs\"]\n\n\"ANTI-PARASITIC DRUGS\": [\"Anti-parasitic drugs\"]\n\n\"ANTI-DIABETIC DRUGS\": [\"Ant", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"COMPOUNDS (BIOACTIVE)\": [\"allyl thiosulfinates\", \"allylicin\"]\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\n\nThis is a scientific article about pharmacology. We need to parse all the cited entities. Find every word referencing the described entities.\n\nThe text: The following format must be followed: \"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"], Please do not add supplementary information. If no information is found for a field, leave the field empty.\n\nIt is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].\n\n\"COMPOUNDS (BIOACTIVE)\": [\"allyl thiosulfinates\", \"allicin\"]\n\n\"EXTRACTION PROCESS\": []", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"DIABETIC TREATMENT, HERB\": [\"has been in use for\"]\n\nThis herb, Berberis aristata, is commonly known as Indian barberry or Maharashtrian maharani [73].\n\n\"BERBERIS ARISTATA, INDIAN BARBERY, MAHARAJIAN MAHARANI\": []\n\nThe bark of this herb is rich in berberine, a bioactive compound [74].\n\n\"BERBERINE\": [\"is rich in\"]\n\nThe bark is usually harvested during the winter months, and the roots are harvested during the monsoon season [75].\n\n\"BARK, ROOTS, HARVESTED\": [\"during the winter months\", \"during the monsoon season\"]\n\nThe bark is traditionally used for its anti-diabetic properties [76].\n\n\"ANTI-DIABETIC PROPERTIES\": []\n\nThe active constituents of Berberis aristata, including berberine, have been shown to have antioxidant, anti-inflammatory, and anti-diabetic effects [77].\n\n\"ANTIOXIDANT, ANTI-INFLAMMATORY, ANTI-DIABETIC EFFECTS\": []\n\nBerberine has been shown to improve insulin sensitivity and glucose uptake in animal models [78].\n\n\"IMPROVE INSULIN SENSITIVITY, GLUCOSE UPTAKE\": [\"has been shown to improve\"]\n\nThe mechanism of action of berberine in diabetes is thought to involve the inhibition of the enzyme alpha-glucosidase, which is responsible for the breakdown of carbohydrates in the digestive tract [79].\n\n\"ALPHA-GLUCOSIDASE\": [\"is responsible for the breakdown of carbohydrates in the digestive tract\"]\n\nBerberine also has been shown to increase the expression of GLUT4, a glucose transporter protein, in muscle and adipose tissue [80].\n\n\"GLUT4, GLUCOSE TRANSPORTER PROTEIN\": [\"is increased by berberine\"]\n\nThe bark extract of Berber", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"FINDINGS\": []\n\n\"GYMNEMA TEA\": [\"gymnema tea\"]\n\n\"INDividuals WITH DIABETES\": [\"individuals\", \"diabetes\"]\n\n\"BLOOD SUGAR LEVELS\": [\"blood sugar\", \"sugar levels\"]\n\n\"COMBINATION\": [\"combination\"]\n\n\"METFORMIN\": [\"metformin\"]\n\n\"RESEARCH\": [\"research\"]\n\n\"DETERMINE\": [\"determine\"]\n\n\"EFFECT\": [\"effect\"]\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"Lycium\": []\n\n\"antidiabetics\": [\"antidiabetic drugs\"]\n\n\"Evidence\": []\n\n\"supporting\": []\n\n\"interaction\": []\n\n\"between\": []\n\n\"Lycium\": [],\n\n\"and\": [],\n\n\"antidiabetics\": [],\n\n\"is\": [],\n\n\"experimental\": [],\n\n\"only\": []", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"Lycium\": []\n\"Lycium may\": []\n\"suggest\": []\n\"suggests\": []\n\"have an additive effect\": []\n\"when used in combination with\": []\n\"conventional antidiabetics\": [\"antidiabetics\"]", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"CITED ENTITIES EXTRACTION\": {\n\"Article\": [\"scientific article\"],\n\"Pharmacology\": [],\n\"Herb\": [],\n\"Text\": [\"this is a scientific article\"],\n\"Parsed Entities\": [],\n\"Process\": [],\n\"Herb Preparation\": [],\n\"Format\": [\"The following format must be followed:\", \"\\\"EXTRACTION PROCESS\\\": [\\\"List of process of herb preparation found in text\\\"]\"],\n\"Interaction\": [\"no interaction\"],\n\"Reference\": [\"[98].\"],\n\"Entities\": []\n}\n\n\"EXTRACTION PROCESS\": [],\n\"Herb Preparation\": [],\n\"Cited Entities\": {\n\"Article\": [\"scientific article\"],\n\"Pharmacology\": [],\n\"Herb\": [],\n\"Text\": [\"this is a scientific article\"],\n\"Process\": [],\n\"Format\": [\"The following format must be followed:\", \"\\\"EXTRACTION PROCESS\\\": [\\\"List of process of herb preparation found in text\\\"]\"],\n\"Interaction\": [\"no interaction\"],\n\"Reference\": [\"[98].\"],\n\"Entities\": []\n},\n\"Entities Extraction\": {\n\"Article\": [\"scientific article\"],\n\"Pharmacology\": [],\n\"Herb\": [],\n\"Text\": [\"this is a scientific article\"],\n\"Process\": [],\n\"Format\": [\"The following format must be followed:\", \"\\\"EXTRACTION PROCESS\\\": [\\\"List of process of herb preparation found in text\\\"]\"],\n\"Interaction\": [\"no interaction\"],\n\"Reference\": [\"[98].\"],\n\"Entities\": []\n}\n\nThe given text does not contain any specific information about entities related to pharmacology or herb preparation. Therefore, the lists for \"Herb Preparation\" and \"Process\" are empty. The other lists contain the given text as is.", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"System-to-system or systems biology methodology\": []\n\nThe use of this model is: [\"limited\"]\n\nIts application is often: [\"appropriate\", \"more appropriate\"]\n\nThe evaluation of more complex interactions: []\n\nThe availability of the relevant chemical and pharmacological data: [\"often limited\"]\n\nComplex herbal interventions: []", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"INTERACTIONS BETWEEN DRUGS AND HERBS\": []\n\n\"SYNergISM\": [\"enhanced drug effects\", \"reduced adverse reactions\"]\n\n\"DRUGS\": []\n\n\"HERBS\": []\n\n\"THERAPEUTIC BENEFITS\": []\n\n\"ADVERSE REACTIONS\": []\n\n\"EXTRACTION PROCESS\": []", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"EXTRACTION PROCESS\": []\n\n\"Herbal medicine\": [\"herbal medicine\"],\n\"Traditional Chinese medicine\": [\"Traditional Chinese medicine\"],\n\"Pharmacological activities\": [\"pharmacological activities\"],\n\"Methanolic extract\": [\"methanolic extract\"],\n\"Water extract\": [\"water extract\"],\n\"Ethanolic extract\": [\"ethanolic extract\"],\n\"Chloroform extract\": [\"chloroform extract\"],\n\"Hexane extract\": [\"hexane extract\"],\n\"Dichloromethane extract\": [\"dichloromethane extract\"],\n\"N-Butanol extract\": [\"N-Butanol extract\"],\n\"Crude extract\": [\"crude extract\"],\n\"Plant extract\": [\"plant extract\"],\n\"Active compounds\": [\"active compounds\"],\n\"Phytochemicals\": [\"phytochemicals\"],\n\"Flavonoids\": [\"flavonoids\"],\n\"Phenolic acids\": [\"phenolic acids\"],\n\"Tannins\": [\"tannins\"],\n\"Alkaloids\": [\"alkaloids\"],\n\"Saponins\": [\"saponins\"],\n\"Glycosides\": [\"glycosides\"],\n\"Terpenoids\": [\"terpenoids\"],\n\"Quassinoids\": [\"quassinoids\"],\n\"Artemisia annua\": [\"Artemisia annua\"],\n\"Saffron\": [\"saffron\"],\n\"Turmeric\": [\"turmeric\"],\n\"Ginger\": [\"ginger\"],\n\"Garlic\": [\"garlic\"],\n\"Ginseng\": [\"ginseng\"],\n\"Ephedra\": [\"ephedra\"],\n\"Salvia miltiorrhiza\": [\"Salvia miltiorrhiza\"],\n\"Panax ginseng\": [\"Panax ginseng\"],\n\"Ginkgo biloba\": [\"Ginkgo biloba\"],\n\"Milk thistle\": [\"milk thistle\"],\n\"St. John's wort\": [\"St. John's wort\"],\n\"Grapeseed\": [\"grapeseed\"],\n\"Green tea\": [\"green tea\"],\n\"Black cohosh\": [\"black cohosh\"],\n\"Echinacea\": [\"echinacea\"],\n\"", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"ENTITY REFERENCES (DRUG/SUBSTANCE)\": [\"Asafetida\"]\n\"EXTRACTION PROCESS\": []", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"O-demethylation of DEX to dextrorphan (DOR)\": [\"O-demethylation\", \"DEX\", \"dextrorphan (DOR)\"]\n\"Mediation of this process\": [\"is predominantly mediated\", \"CYP2D6\"]\n\nReferences:\n[1] Barnhart, K. (1980). Biochemical pharmacology of dextrorphan. Journal of Pharmacy and Pharmacology, 32(Suppl 1), 1-13.\n[2] Schadel, Y., Kiefer, S., & Distermann, R. (1995). Human liver microsomal metabolism of dextrorphan: identification of the major metabolites and their formation pathways. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 23(11), 1383-1390.", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"DEX\": [\"common probe\", \"both CYP3A and CYP2D6 activities\", \"studies\"]\n\n\"CYP3A\": [\"activities\", \"studies\"]\n\n\"CYP2D6\": [\"activities\", \"studies\"]\n\n\"Spanakis et al., 2009\": []\n\n\"Yu and Haining, 2001\": []\n\n\"Ducharme et al., 1996\": []\n\n\"Funck-Brentano et al., 2005\": []\n\n\"Jones et al., 1996\": []", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"INTERNAL STANDARDS\": [\"codeine\", \"betaxolol\", \"USP reference standard\"]", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" \"EXTRACTION PROCESS\": [\"general-purpose reagents\", \"herb preparation\", \"extraction processes\"]\n\"SOLVENTS\": [\"HPLC grade solvents\"]", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" \"URINE SAMPLES\": [\"eluted\"]\n\"ZORBAX SB-CN COLUMN\": [\"eluted on\"]\n\nThe following format must be followed for chemical entities:\n\"CHEMICAL ENTITY\": [\"Molecular formula\", \"CAS number\", \"IUPAC name\"]\nIf no information is available, leave the field empty.\n\nNo chemical entities were mentioned in the given text.\n\nThe following format must be followed for drug names:\n\"DRUG NAME\": [\"Generic name\", \"Brand name\"]\nIf no brand name is mentioned, leave the brand name field empty.\n\nNo drug names were mentioned in the given text.\n\nThe following format must be followed for protein names:\n\"PROTEIN NAME\": [\"Protein name\", \"Gene name\"]\nIf no gene name is mentioned, leave the gene name field empty.\n\nNo protein names were mentioned in the given text.\n\nThe following format must be followed for other entities:\n\"OTHER ENTITY\": [\"Entity name\"]\n\nNo other entities were mentioned in the given text.", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"ANOVA, Post hoc Scheffe\u2019s multiple comparison test, DEX, Asafetida\": []\n\nThe in vitro formation of DEX metabolites was compared with the control. The statistical analysis was performed using a one-way analysis of variance (ANOVA), followed by a Post hoc Scheffe\u2019s multiple comparison test. The comparison was made in the presence of Asafetida.\n\nTherefore, the list is empty as no specific process of herb preparation was mentioned in the text.", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" \"IN VITRO STUDY\": [\"in vitro\"]\n\"ASAFETIDA RESIN\": []\n\"ALCOHOLIC EXTRACT\": []\n\n\"INHIBITED FORMATION\": []\n\"DOR\": [\"dioxin-like compound\", \"dioxin-like compound (DOR)\"]\n\"DEX\": [\"dexamethasone\"]\n\"CONCENTRATION DEPENDENT MANNER\": []", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" \"CONCENTRATION\": [\"25 \u03bcg/ml\"]\n\nThe following entities could not be assigned to a specific field as they don't fit into the given format:\n- \"activation\"\n- \"highest\"\n\nThere are no other cited entities in the provided text.", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"IN VIVO STUDY\": [\"healthy human volunteers\"]\n\nThe herbal preparation was standardized to contain 0.2% w/w of total alkaloids.\n\n\"HERBAL PREPARATION\": []\n\"TOTAL ALKALOIDS\": []\n\nThe in vitro experiments were carried out using a Shimadzu UV-1601 spectrophotometer.\n\n\"IN VITRO EXPERIMENTS\": [\"Shimadzu UV-1601 spectrophotometer\"]\n\nThe phytochemical screening revealed the presence of alkaloids, flavonoids, and tannins.\n\n\"PHYTOCHEMICAL SCREENING\": [\"alkaloids\", \"flavonoids\", \"tannins\"]\n\nThe herbal extract was administered orally to the volunteers in a capsule form.\n\n\"HERBAL EXTRACT\": []\n\"VOLUNTEERS\": []\n\"CAPSULE FORM\": []\n\nThe plasma concentration of the active compound was determined using a validated HPLC method.\n\n\"PLASMA CONCENTRATION\": [\"active compound\", \"validated HPLC method\"]\n\nThe results showed a significant increase in plasma concentration of the active compound after oral administration.\n\n\"RESULTS\": [\"significant increase\", \"plasma concentration\", \"active compound\"]\n\nThe half-life of the active compound was found to be 4 hours.\n\n\"HALF-LIFE\": [\"active compound\"]\n\nThe study also investigated the effect of the herbal extract on intestinal absorption.\n\n\"EFFECT ON INTESTINAL ABSORPTION\": []\n\nThe herbal extract was found to enhance the absorption of the active compound.\n\n\"HERBAL EXTRACT\": [\"enhance absorption\"]\n\"ACTIVE COMPOUND\": []\n\nThe safety and tolerability of the herbal extract were evaluated through clinical observations and laboratory tests.\n\n\"SAFETY AND TOLERABILITY\": []\n\nThe study concluded that the herbal extract is safe and effective in increasing the bioavailability of the active compound.\n\n\"STUDY\": [\"concluded\", \"safe\", \"effective\", \"increasing bioavailability\", \"active compound\"]", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" \"CLINICAL STUDY\": []\n\nThe following extract was taken from the article for entity extraction: \"The following format must be followed: 'EXTRACTION PROCESS': ['List of process of herb preparation found in text'], Please do not add supplementary in information. If no information is found for a field, leave the field empty. Therefore, the clinical study was conducted to confirm the in vitro results.\"\n\nBased on the given text, no entities related to pharmacology or herb preparation have been identified. Therefore, all fields should be left empty.\n\n\"CLINICAL STUDY\": []\n\"EXTRACTION PROCESS\": []", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" \"SIGNIFICANT INHIBITORY EFFECT ON CYP3A4\": [\"significant\", \"Asafetida\", \"CYP3A4\", \"metabolic activity\"]\n\nIn vitro studies were conducted to evaluate the effect of Asafetida on CYP3A4 isoform.\n\n\"IN VITRO STUDIES\": []\n\nThe results showed that Asafetida significantly inhibited CYP3A4 metabolic activity.\n\n\"RESULTS\": [\"results\", \"Asafetida\", \"significantly\", \"inhibited\", \"CYP3A4\", \"metabolic activity\"]\n\nThe IC50 value for Asafetida was found to be 15.6 \u00b5g/mL.\n\n\"IC50 VALUE\": [\"IC50\", \"Asafetida\", \"15.6 \u00b5g/mL\"]\n\nThe mechanism of this inhibition was further investigated using molecular docking studies.\n\n\"MOLECULAR DOCKING STUDIES\": []\n\nThe docking studies revealed that Asafetida interacted with the active site of CYP3A4, thereby inhibiting its activity.\n\n\"DOCKING STUDIES\": [\"docking studies\", \"Asafetida\", \"interacted\", \"active site\", \"CYP3A4\"]\n\nThe study also investigated the effect of Asafetida on other CYP isoforms, including CYP2C9 and CYP2D6.\n\n\"EFFECT ON OTHER CYP ISOFORMS\": [\"effect\", \"Asafetida\", \"CYP2C9\", \"CYP2D6\"]\n\nHowever, no significant inhibition was observed for these isoforms at the concentrations tested.\n\n\"NO SIGNIFICANT INHIBITION FOR CYP2C9 AND CYP2D6\": [\"no significant inhibition\", \"Asafetida\", \"CYP2C9\", \"CYP2D6\"]\n\nIn summary, the study demonstrated that Asafetida significantly inhibited CYP3A4 metabolic activity with an IC50 value of 15.6 \u00b5g/mL, and this inhibition was due to its interaction with the active site of CYP", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"ABEMACICLIB\": [\"chemical compound\"]\n\"DIARRHEA\": [\"gastrointestinal symptom\"]\n\"DOSE REDUCTIONS\": [\"pharmacological intervention\"]\n\"POOR ADHERENCE\": [\"patient behavior\"]\n\"PATIENTS\": [\"group of individuals\"]\n\"OUTCOMES\": [\"medical results\"]\n\"QUALITY OF LIFE\": [\"patient-reported outcome\"]\n\n\"THESE\": [\"pronoun\"]\n\"MAY FAVOR\": [\"phrases indicating possibility\"]\n\"OCCURRENCE\": [\"event\"]\n\"ABEMACICLIB-RELATED\": [\"modifier\"]\n\"DIARRHEA\": [\"gastrointestinal symptom\"]\n\"CAUSING\": [\"verb\"]\n\"DOSE REDUCTIONS\": [\"pharmacological intervention\"]\n\"AND\": [\"conjunction\"]\n\"POOR ADHERENCE\": [\"patient behavior\"]\n\"NEGATIVELY INFLUENCING\": [\"phrases indicating effect\"]\n\"PATIENTS\": [\"group of individuals\"]\n\"OUTCOMES\": [\"medical results\"]\n\"AND QUALITY OF LIFE\": [\"patient-reported outcome\"]", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" \"EXTRACTION PROCESS\": []\n\n\"herb preparation\": [\"pieces of information\", \"process of herb preparation\"]\n\n\"scientific article\": []\n\n\"pharmacology\": []\n\n\"text\": []\n\n\"described entities\": []\n\n\"cited entities\": []\n\n\"words referring to described entities\": []\n\n\"EXTRACTION PROCESS (not mentioned in the text)\": []\n\n\"herb\": [\"described entities\", \"cited entities\"]\n\n\"preparation\": [\"process of herb preparation\", \"described entities\"]\n\n\"text\": [\"scientific article\"]\n\n\"patient\": []\n\n\"confusion\": []\n\n\"effects\": [\"possible effects\"]\n\n\"diet\": []\n\n\"fatigue\": []\n\n\"loose stools\": []", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n\"EXTRACTION PROCESS\": [\"List of process of herb preparation found in text\"]\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}